

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 22, 2004, 19:17:58 : Search time 919.412 Seconds

(without alignments)  
3343.258 Million cell updates/sec

Title: US-09-898-616A-1

Perfect score: 65

Sequence: 1 gatcatggaatctgcgcg.....tgctgatggaaccgcgtcc 65

Scoring table:

Gapop 60.0, Gapext 60.0

Searched: 4526723 seqs, 2364849745 residues

Word size: 0

Total number of hits satisfying chosen parameters: 9053458

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Listing first 45 summaries

Database: GenEmbl:

1: gb\_ba:\*  
2: gb\_hig:\*  
3: gb\_in:\*  
4: gb\_om:\*  
5: gb\_ov:\*  
6: gb\_pal:\*  
7: gb\_ph:\*  
8: gb\_pl:\*  
9: gb\_pr:\*  
10: gb\_ro:\*  
11: gb\_seg:\*  
12: gb\_sy:\*  
13: gb\_un:\*  
14: gb\_vl:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	65	100.0	65	AR160915	Sequence
2	65	100.0	65	AR160922	Sequence
3	65	100.0	65	AR160921	Sequence
4	65	100.0	65	AR160921	Sequence
5	65	100.0	65	AR160921	Sequence
6	65	100.0	65	AR160921	Sequence
7	65	100.0	65	AR160921	Sequence
8	65	100.0	65	AR160921	Sequence
9	65	100.0	65	AR160921	Sequence
10	65	100.0	65	AR160921	Sequence
11	65	100.0	65	AR160921	Sequence
12	65	100.0	65	AR160921	Sequence
13	65	100.0	65	AR160921	Sequence
14	65	100.0	65	AR160921	Sequence
15	65	100.0	65	AR160921	Sequence
16	65	100.0	65	AR160921	Sequence
17	65	100.0	65	AR160921	Sequence
18	65	100.0	65	AR160921	Sequence
19	65	100.0	65	AR160921	Sequence
20	65	100.0	65	AR160921	Sequence
21	65	100.0	65	AR160921	Sequence
22	65	100.0	65	AR160921	Sequence
23	65	100.0	65	AR160921	Sequence
24	65	100.0	65	AR160921	Sequence
25	65	100.0	65	AR160921	Sequence
26	65	100.0	65	AR160921	Sequence
27	65	100.0	65	AR160921	Sequence
28	65	100.0	65	AR160921	Sequence
29	65	100.0	65	AR160921	Sequence
30	65	100.0	65	AR160921	Sequence
31	65	100.0	65	AR160921	Sequence
32	65	100.0	65	AR160921	Sequence
33	65	100.0	65	AR160921	Sequence
34	65	100.0	65	AR160921	Sequence
35	65	100.0	65	AR160921	Sequence
36	65	100.0	65	AR160921	Sequence
37	65	100.0	65	AR160921	Sequence
38	65	100.0	65	AR160921	Sequence
39	65	100.0	65	AR160921	Sequence
40	65	100.0	65	AR160921	Sequence
41	65	100.0	65	AR160921	Sequence
42	65	100.0	65	AR160921	Sequence
43	65	100.0	65	AR160921	Sequence
44	65	100.0	65	AR160921	Sequence
45	65	100.0	65	AR160921	Sequence

20	17	26.2	3579	7	BPH298563	AU298563 Bacterioph
21	17	26.2	3592	7	BPH298557	AU298557 Bacterioph
22	17	26.2	12111	1	AE004545	AE004545 Pseudomon
23	17	26.2	65674	5	EX936427	EX936427 Zebrafish
24	17	26.2	81299	2	AC140044	AC140044 Mus muscu
25	17	26.2	110000	1	EX897699	Continuation (11 c
26	17	26.2	149146	10	AC134848	AC134848 Mus muscu
27	17	26.2	157321	9	AC068811	AC068811 Homo sapi
28	17	26.2	158219	9	AC005534	AC005534 Homo sapi
29	17	26.2	163884	2	AC145388	AC145388 Pan trogl
30	17	26.2	164302	2	AC145691	AC145691 Mus muscu
31	17	26.2	164423	2	CR361552	CR361552 Dario rer
32	17	26.2	165540	10	AC107673	AC107673 Mus muscu
33	17	26.2	169328	2	AC112659	AC112659 Mus muscu
34	17	26.2	171548	2	AC024732	AC024732 Homo sapi
35	17	26.2	175631	9	AC023511	AC023511 Homo sapi
36	17	26.2	177655	10	AC132288	AC132288 Mus muscu
37	17	26.2	179576	1	EX294156	EX294156 Pirellula
38	17	26.2	181862	10	AC127262	AC127262 Mus muscu
39	17	26.2	182107	10	AC083915	AC083915 Mus muscu
40	17	26.2	185761	9	AC098974	AC098974 Homo sapi
41	17	26.2	185929	10	AC090657	AC090657 Mus muscu
42	17	26.2	193627	2	AC091427	AC091427 Mus muscu
43	17	26.2	204632	2	AC097583	AC097583 Rattus no
44	17	26.2	219405	2	AC118096	AC118096 Rattus no
45	17	26.2	227595	2	AC093396	AC093396 Bos tauru

## ALIGNMENTS

RESULT 1	AR160915	Sequence 6 from patent US 6255281.	65 bp	DNA	linear	PAT 17-OCT-2001
LOCUS	AR160915	Sequence 6 from patent US 6255281.	65 bp	DNA	linear	PAT 17-OCT-2001
DEFINITION	AR160915	Sequence 6 from patent US 6255281.	65 bp	DNA	linear	PAT 17-OCT-2001
ACCESSION	AR160915	Sequence 6 from patent US 6255281.	65 bp	DNA	linear	PAT 17-OCT-2001
VERSION	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
KEYWORDS	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
SOURCE	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
ORGANISM	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
REFERENCE	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
AUTHORS	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
TITLE	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
JOURNAL	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
FEATURES	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
source	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
ORIGIN	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Query Match	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Best Local Similarity	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Matches	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q1	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q2	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q3	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q4	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q5	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q6	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q7	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q8	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q9	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q10	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q11	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q12	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q13	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q14	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q15	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q16	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q17	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q18	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q19	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q20	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q21	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q22	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q23	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q24	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q25	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q26	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q27	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q28	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q29	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q30	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q31	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q32	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q33	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q34	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q35	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q36	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q37	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q38	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q39	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q40	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q41	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q42	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q43	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q44	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001
Q45	AR160915.1	GI:16225978	65 bp	DNA	linear	PAT 17-OCT-2001

ORGANISM Unknown.  
Unclassified.  
1 (bases 1 to 42)  
REFERENCE  
AUTHORS Pilon,A.V., Mukherjee,A.B. and Zhang,Z.  
TITLE Use of recombinant human uteroglobin in treatment of inflammatory  
JOURNAL and fibrotic conditions  
Patent: US 6255281-A 13 03-JUL-2001;  
FEATURES  
source 1. .42  
/organism="unknown"  
/mol\_type="unassigned DNA"

ORIGIN  
Query Match 64.6%; Score 42; DB 6; Length 42;  
Best Local Similarity 100.0%; Pred.No. 2.9e-13;  
Matches 42; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GATCCATGGAATCTGCCGCTTTTCAGCGCTATCGAAA 42  
DB 42 GATCCATGGAATCTGCCGCTTTTCAGCGCTATCGAAA 1

RESULT 3  
ARI60921/c AR:60921 60 bp DNA linear PAT 17-OCT-2001  
LOCUS Sequence 12 from patent US 6255281.  
DEFINITION ARI60921  
ACCESSION ARI60921  
VERSION ARI60921.1 GI:16225996  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE  
AUTHORS 1 (bases 1 to 60)  
TITLE Pilon,A.V., Mukherjee,A.B. and Zhang,Z.  
JOURNAL Use of recombinant human uteroglobin in treatment of inflammatory  
and fibrotic conditions  
Patent: US 6255281-A 12 03-JUL-2001;  
FEATURES  
source 1. .60  
/organism="unknown"  
/mol\_type="unassigned DNA"

ORIGIN  
Query Match 35.4%; Score 23; DB 6; Length 60;  
Best Local Similarity 100.0%; Pred.No. 0.033; 0; Indels 0; Gaps 0;  
Matches 23; Conservative 0; Mismatches 0;

QY 43 CCTGTGATGACACCCCGCTCC 65  
DB 60 CCTGTGATGACACCCCGCTCC 38

RESULT 4  
AC122438 AC122438 193659 bp DNA linear ROD 05-NOV-2003  
LOCUS Mus musculus BAC clone RP24-216W6 from 5, complete sequence.  
DEFINITION AC122438  
ACCESSION AC122438  
VERSION AC122438.2 GI:22296783  
KEYWORDS  
SOURCE Mus musculus (house mouse)  
ORGANISM Mus musculus.  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
REFERENCE  
AUTHORS 1 (bases 1 to 193659)  
TITLE Vanbrunt,A., Creason,K. and Van,Brunt.  
JOURNAL The sequence of Mus musculus BAC clone RP24-216W6  
Unpublished (2001)  
REFERENCE  
AUTHORS 2 (bases 1 to 193659)  
TITLE Wilson,R.  
JOURNAL Sequencing of Mus musculus  
Unpublished (2001)  
REFERENCE  
AUTHORS 3 (bases 1 to 193659)  
TITLE McPherson,J.D. and Waterston,R.H.

TITLE Direct Submission  
JOURNAL Submitted (23-MAY-2002) Genome Sequencing Center, 4444 Forest Park  
REFERENCE  
AUTHORS Parkway, St. Louis, MO 63108, USA  
TITLE 4 (bases 1 to 193659)  
JOURNAL McPherson,J.D. and Waterston,R.H.  
TITLE Direct Submission  
REFERENCE  
AUTHORS Submitted (17-AUG-2002) Genome Sequencing Center, 4444 Forest Park  
TITLE 5 (bases 1 to 193659)  
JOURNAL Parkway, St. Louis, MO 63108, USA  
TITLE Wilson,R.  
JOURNAL Direct Submission  
COMMENT Submitted (05-NOV-2003) Department of Genetics, Washington  
University, 4444 Forest Park Avenue, St. Louis, Missouri 63108, USA  
On Aug 17, 2002 this sequence version replaced gi:21105899.  
----- Genome Center  
Center: Washington University Genome Sequencing Center  
Center code: WUGSC  
Web site: <http://genome.wustl.edu>  
Contact: [submissions@wustl.wustl.edu](mailto:submissions@wustl.wustl.edu)  
----- Summary Statistics  
Center project name: W\_BB0216X06

NOTICE: This sequence may not represent the entire insert of this  
clone. It may be shorter because we only sequence overlapping  
clone sections once, or longer because we provide a small overlap  
between neighboring data submissions.

This sequence was finished as follows unless otherwise noted:  
all regions were double stranded, sequenced with an alternate  
chemistry, or covered by high quality data (i.e., phred quality >=  
30); an attempt was made to resolve all sequencing problems, such  
as compressions and repeats; all regions were covered by sequence  
from more than one subclone; and the assembly was confirmed by  
restriction digest.

MAPPING INFORMATION:  
Mapping information for this clone was provided by Dr. Wes Warren,  
Department of Genetics, Washington University, St. Louis MO. For  
additional information about the map position of this sequence, see  
<http://genome.wustl.edu>

SOURCE INFORMATION:  
The RP24-216 BAC library has been constructed by Pieter de Jong and  
coworkers (<http://www.chori.org>) from male C57BL/6J mouse spleen  
and/or brain genomic DNA. The clone and detailed information can be  
obtained from Pieter de Jong and coworkers at <http://www.chori.org>

NEIGHBORING SEQUENCE INFORMATION:  
This sequence is the entire insert of the clone.

FEATURES  
source 1. 193659  
Location/Qualifiers  
/organism="Mus musculus"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:10090"  
/chromosome="5"  
/map="5"  
/clone="RP24-216W6"  
/clone\_1id="RP24-216W6"  
/clone\_1id="RP24-216W6"  
/clone\_1id="RP24-216W6"  
/rpt\_family="ID"  
2822..3615  
/note="CGP\_island (86C=72.2, o/e=0.86, #CGs=87)"  
4426..4591  
/rpt\_family="L2"  
6139..6322  
/rpt\_family="B2"  
6144..6216  
/product="RNA-Seq"  
/note="Likely pseudogene (HMM Sc=33.90 / Sec struct  
Sc=11.21)"  
6385..6621  
/rpt\_family="MER1\_type"

```

repeat_region 6923..7072
/rpc_family="B4"
repeat_region 7131..7183
/rpc_family="ID"
repeat_region 7263..7443
/rpc_family="B2"
complement(7366..7438)
/product="RNA-Ren"
/note="Likely pseudogene (MM Sc=37.14 / Sec struct
Sc=-11.21)"
repeat_region 7452..7548
/rpc_family="Alu"
repeat_region 7992..8324
/rpc_family="MALR"
repeat_region 8343..8501
/rpc_family="L2"
repeat_region 8640..8784
/rpc_family="Alu"
repeat_region 8821..8999
/rpc_family="B2"
repeat_region 9048..9094
/rpc_family="Alu"
repeat_region 9298..9522
/rpc_family="B2"
repeat_region 9523..9728
/rpc_family="MALR"
repeat_region 9729..9842
/rpc_family="Y-chromosomal"
repeat_region 9732..9884
/rpc_family="B4"
repeat_region 10020..10059
/rpc_family="B4"
repeat_region 10060..10128
/rpc_family="B4"
repeat_region 10206..10339
/rpc_family="Alu"
repeat_region 10476..10613
/rpc_family="B4"
repeat_region 10665..10864
/rpc_family="B2"
repeat_region 11129..11323
/rpc_family="B2"
repeat_region 11878..11944
/rpc_family="ID"
repeat_region 12389..12717
/rpc_family="MALR"
repeat_region 12879..13035
/rpc_family="B4"
repeat_region 13066..13174
/rpc_family="Alu"
repeat_region 14406..14610
/rpc_family="B2"
repeat_region 14626..14705
/rpc_family="ID"
repeat_region 15013..15152
/rpc_family="Alu"
repeat_region 15177..15346
/rpc_family="B2"
repeat_region 15438..15709
/rpc_family="L1"
repeat_region 15730..15871
/rpc_family="Alu"
repeat_region 16035..16247
/rpc_family="B2"
repeat_region 16263..16487
/rpc_family="B2"
repeat_region 16711..16734
/rpc_family="Alu"
repeat_region 16735..16829
/rpc_family="B4"
repeat_region 16936..16999
/rpc_family="ID"
repeat_region 17216..17329

```

```

repeat_region 17568..17630
/rpc_family="Alu"
repeat_region 17631..17645
/rpc_family="B4"
repeat_region 18027..18228
/rpc_family="B2"
repeat_region 18364..18450
/rpc_family="Alu"
repeat_region 18478..18612
/rpc_family="Alu"
repeat_region 18625..18723
/rpc_family="Alu"
repeat_region 18705..18863
/rpc_family="B2"
repeat_region 18864..19010
/rpc_family="Alu"
repeat_region 19011..19024
/rpc_family="B2"
repeat_region 19083..19156
/rpc_family="Alu"
repeat_region 19415..19511
/rpc_family="L2"
repeat_region 19747..19926
/rpc_family="B2"
repeat_region 20128..20303
/rpc_family="B2"
repeat_region 20542..20647
/rpc_family="Alu"
repeat_region 20653..20793
/rpc_family="B2"
repeat_region 20848..20996
/rpc_family="Alu"
repeat_region 21587..21766
/rpc_family="B2"

```

Query Match 29.2%; Score 19; DB 10; Length 193659;  
 Best Local Similarity 100.0%; Pred. No. 4.8;  
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 40 AAACCTGCTGATGACAC 58  
 DB 95628 AAACCTGCTGATGACAC 95646

RESULT 5  
 LOCUS AC141530 215983 bp DNA linear HTG 17-MAR-2003  
 DEFINITION Rattus norvegicus clone CH230-517N11, WORKING DRAFT SEQUENCE, 47  
 uncloned pieces.  
 ACCESSION AC141530  
 VERSION AC141530.1 GI:28975794  
 KEYWORDS HTG; HTGS PHASE1; HTGS DRAFT.  
 SOURCE Rattus norvegicus (Norway rat)  
 ORGANISM Rattus norvegicus  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;  
 Rattus.

#### REFERENCE

1 (bases 1 to 215983)  
 Muzny D, Marie M, Metzker M, Lee S, Abramson S, Adams C, Alder J, Allen C, Allen H, Alsbrooke S, Amin A, Anguiano D, Anyalbechi V, Ayoyagi A, Ayodeji M, Baca E, Baden H, Baldwin D, Bandaranaike D, Barber M, Barnstead M, Benhammed F, Biswas K, Blair D, Blankenburg K, Blyth P, Brown M, Bryant N, Buhay C, Burch P, Burrell K, Calderon E, Cardenas V, Carter K, Cavazos I, Caesar H, Center A, Chacko J, Chavez D, Chen G, Chen R, Chen Y, Chen Z, Chu J, Cleveland C, Cockrell R, Cox C, Coyle M, Cree A, D'Souza L, Davila M, Davis C, Davy-Carroll L, De Anda C, Dedrich D, Delgado O, Denison S, Deramo C, Ding Y, Dinh H, Divya K, Draper H, Dugan-Rocha S, Dunn A, Durbin K, Duval B, Evans K, Egan A, Escoto M, Eugene C, Evans C, Falls T, Fan G, Fernandez S, Finley M, Flagg N, Forbes L, Foster M, Foster P,

Fraser, C.M., Gabisi, A., Ganta, R., Garcia, A., Garner, T., Garza, M.,  
 Gergeogis, E., Geer, K., Gell, R., Grady, M., Guerra, W., Guevara, M.,  
 Gunaratne, P., Haaland, W., Hamill, C., Hamilton, C., Hamilton, K.,  
 Harvey, Y., Havlak, P., Hawes, A., Henderson, N., Hernandez, J.,  
 Hernandez, R., Hines, S., Hladun, S.L., Hodgson, A., Hughes, M.,  
 Hollins, E., Howell, S., Hulyk, S., Hume, J., Idlebird, D., Jackson, A.,  
 Jackson, L., Jacob, J., Jiang, H., Johnson, B., Johnson, R., Jolivet, A.,  
 Karachay, S., Kelly, S., Kelly, S., Khan, Z., Kang, L., Kovar, C.,  
 Kowalski, C., Kraft, C.L., Ledow, H., Levan, J., Lewis, L., Li, Z., Liu, J.,  
 Liu, J., Liu, Y., London, P., Longacre, S., Lopez, J.,  
 Lorenshewa, L., Louisedge, H., Lozano, R.J., Lu, X., Ma, J.,  
 Maheshwari, M., Mahindrasekaran, M., Mahmood, M., Malloy, K., Mangun, A.,  
 Mangun, B., Mapa, P., Martin, K., Martin, R., Martinez, E.,  
 Manthey, S., McLeod, M., McNeill, T., Meenan, E., Milosavljevic, A.,  
 Miner, G., Minja, E., Montemayor, J., Moore, S., Morgan, M., Morris, K.,  
 Morris, S., Mundasa, M., Murphy, M., Nair, L., Nankervis, C., Neal, D.,  
 Newton, N., Nguyen, N., Norris, S., Nwaelelemeh, O., Okunnu, G.,  
 Olarunmugbon, A., Pal, S., Parke, C., Pasternak, S., Paul, H.,  
 Perez, A., Perez, L., Pfankuch, C., Plopper, F., Poldrecker, A.,  
 Povolac, D., Primus, E., Pu, L.-L., Puzo, M., Quirroz, J., Rachlin, E.,  
 Reeves, K., Regier, M.A., Reigh, R., Reilly, B., Reilly, M., Ren, Y.,  
 Reuter, M., Richards, S., Riggs, F., Rivers, C., Rodery, T., Rojas, A.,  
 Rose, M., Rose, R., Ruiz, S.J., Sanders, W., Saverly, G., Scherer, S.,  
 Scott, G., Slatman, S., Shen, H., Shetty, J., Shvartsbeyn, A.,  
 Slason, I., Sitter, C.D., Sma, J., Sneed, A., Sodergren, E.,  
 Song, X.-Z., Sorrell, R., Sosa, J., Steinle, M., Strong, R., Sutton, A.,  
 Svatek, A., Taber, P., Taylor, C., Taylor, T., Thomas, N., Thomas, S.,  
 Tingey, A., Trejos, Z., Usmani, K., Valas, R., Vera, V., Villalana, D.,  
 Waldron, L., Walker, B., Wang, J., Wang, Q., Wang, S., Warren, J.,  
 Warren, R., Wei, X., White, F., Williams, G., Willson, R., Wleczek, R.,  
 Woodson, H., Worley, K., Wright, D., Wright, R., Wu, J., Yakub, S.,  
 Yen, J., Yoon, L., Yoon, V., Yu, F., Zhang, J., Zhou, J., Zhou, X.,  
 Zhao, S., Dunn, D., von Niederhausern, A., Weiss, R., Smith, D.R.,  
 Holt, R.A., Smith, H.C., Weinstock, G. and Gibbs, R.A.

Direct Submission  
 Submitted (17-MAR-2003) Human Genome Sequencing Center, Department  
 of Molecular and Human Genetics, Baylor College of Medicine, One  
 Baylor Plaza, Houston, TX 77030, USA

----- Genome Center  
 Center: Baylor College of Medicine  
 Center code: BCM  
 Web site: <http://www.hgsc.bcm.tmc.edu/>  
 Contact: [hgsc-help@bcm.tmc.edu](mailto:hgsc-help@bcm.tmc.edu)  
 ----- Project Information  
 Center project name: KERP  
 Center clone name: CH230-517N11  
 ----- Summary Statistics  
 Sequencing vector: Plasmid  
 Chemistry: Dye-terminator Big Dye 100% of reads  
 Assembly program: Phrap, version 0.990329  
 Consensus quality: 200142 bases at least Q40  
 Consensus quality: 204905 bases at least Q30  
 Consensus quality: 208606 bases at least Q20  
 Estimated insert size: 2045.6; sum-of-contigs estimation  
 Quality coverage: 3x in Q20 bases; sum-of-contigs estimation

NOTE: Estimated insert size may differ from sequence length  
 (see [http://www.hgsc.bcm.tmc.edu/gcsc/genbank\\_draft\\_data.html](http://www.hgsc.bcm.tmc.edu/gcsc/genbank_draft_data.html)).  
 NOTE: This is a 'working draft' sequence. It currently  
 consists of 47 contigs. The true order of the pieces  
 is not known and their order in this sequence record is  
 arbitrary. Gaps between the contigs are represented as  
 runs of N, but the exact sizes of the gaps are unknown.  
 This record will be updated with the finished sequence  
 as soon as it is available and the accession number will  
 be preserved.

1 1367: contig of 1367 bp in length  
 \* 1368 1467: gap of unknown length  
 \* 1468 2579: contig of 1112 bp in length

2580 2679: gap of unknown length  
 \* 2680 4117: contig of 1438 bp in length  
 \* 4118 4218: gap of unknown length  
 \* 4218 5365: contig of 1148 bp in length  
 \* 5365 5465: gap of unknown length  
 \* 5465 6816: contig of 1351 bp in length  
 \* 6816 6916: gap of unknown length  
 \* 6916 7947: contig of 1030 bp in length  
 \* 7947 8047: gap of unknown length  
 \* 8047 9569: contig of 1523 bp in length  
 \* 9569 9670: gap of unknown length  
 \* 9670 11197: contig of 1527 bp in length  
 \* 11197 11296: gap of unknown length  
 \* 11296 12515: contig of 1319 bp in length  
 \* 12515 12616: gap of unknown length  
 \* 12616 14440: contig of 1725 bp in length  
 \* 14440 14540: gap of unknown length  
 \* 14540 15603: contig of 1063 bp in length  
 \* 15603 15703: gap of unknown length  
 \* 15703 15704: contig of 2247 bp in length  
 \* 15704 17951: contig of 2247 bp in length  
 \* 17951 18050: gap of unknown length  
 \* 18050 20114: contig of 2064 bp in length  
 \* 20114 20214: gap of unknown length  
 \* 20214 21578: contig of 1364 bp in length  
 \* 21578 21678: gap of unknown length  
 \* 21678 24453: contig of 2775 bp in length  
 \* 24453 24554: gap of unknown length  
 \* 24554 26291: contig of 1738 bp in length  
 \* 26291 26391: gap of unknown length  
 \* 26391 27338: contig of 1247 bp in length  
 \* 27338 27738: gap of unknown length  
 \* 27738 30093: contig of 2355 bp in length  
 \* 30093 30193: gap of unknown length  
 \* 30193 33157: contig of 2964 bp in length  
 \* 33157 33257: gap of unknown length  
 \* 33257 33258: contig of 2907 bp in length  
 \* 33258 36264: gap of unknown length  
 \* 36264 36265: gap of unknown length  
 \* 36265 39483: contig of 3219 bp in length  
 \* 39483 39583: gap of unknown length  
 \* 39583 42511: contig of 2528 bp in length  
 \* 42511 42611: gap of unknown length  
 \* 42611 46973: contig of 4362 bp in length  
 \* 46973 47073: gap of unknown length  
 \* 47073 50898: contig of 3825 bp in length  
 \* 50898 50998: gap of unknown length  
 \* 50998 54616: contig of 3618 bp in length  
 \* 54616 54716: gap of unknown length  
 \* 54716 58819: contig of 4103 bp in length  
 \* 58819 58919: gap of unknown length  
 \* 58919 64062: contig of 5143 bp in length  
 \* 64062 64162: gap of unknown length  
 \* 64162 67669: contig of 3507 bp in length  
 \* 67669 67769: gap of unknown length  
 \* 67769 72693: contig of 4924 bp in length  
 \* 72693 72793: gap of unknown length  
 \* 72793 76521: contig of 3859 bp in length  
 \* 76521 76752: gap of unknown length  
 \* 76752 83329: contig of 6577 bp in length  
 \* 83329 83429: gap of unknown length  
 \* 83429 88560: contig of 5131 bp in length  
 \* 88560 88660: gap of unknown length  
 \* 88660 94968: contig of 6308 bp in length  
 \* 94968 95068: gap of unknown length  
 \* 95068 100869: contig of 5801 bp in length  
 \* 100869 100969: gap of unknown length  
 \* 100969 108995: contig of 8026 bp in length  
 \* 108995 109095: gap of unknown length  
 \* 109095 116371: contig of 7276 bp in length  
 \* 116371 116471: gap of unknown length  
 \* 116471 121822: contig of 5351 bp in length  
 \* 121822 121922: gap of unknown length  
 \* 121922 127516: contig of 5594 bp in length  
 \* 127516 127616: gap of unknown length



127617 135246: contig of 7630 bp in length  
 \* 135247 135246: gap of unknown length  
 \* 135347 142259: contig of 6913 bp in length  
 \* 142260 142359: gap of unknown length  
 \* 142360 152844: contig of 10585 bp in length  
 \* 152945 153044: gap of unknown length  
 \* 153045 160462: contig of 7418 bp in length  
 \* 160463 160562: gap of unknown length  
 \* 160563 168267: contig of 7705 bp in length  
 \* 168268 168367: gap of unknown length  
 \* 168368 177703: contig of 9335 bp in length  
 \* 177704 177803: gap of unknown length  
 \* 177804 187092: contig of 9289 bp in length  
 \* 187093 187192: gap of unknown length  
 \* 187193 201446: contig of 14254 bp in length  
 \* 201447 201546: gap of unknown length  
 \* 201547 215983: contig of 14437 bp in length.

Location/Qualifiers  
 1. 215983  
 /organism="Rattus norvegicus"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:10116"  
 /clone="CH230-517N11"

ORIGIN  
 Query Match 29.2% Score 19; DB 2; Length 215983;  
 Best Local Similarity 100.0%; Pred. No. 4.7;  
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 12 ATCTGCCCCCTTTTCAGC 30  
 Db 119509 ATCTGCCCCCTTTTCAGC 119527

RESULT 6  
 AC141151  
 LOCUS Rattus norvegicus clone CH230-114H6, WORKING DRAFT SEQUENCE, 67  
 DEFINITION  
 AC141151  
 AC141151.2 GI:28951124  
 HTG: HTGS PHASE1; HTGS\_DRAFT.  
 KEYWORDS Rattus norvegicus (Norway rat)  
 SOURCE Rattus norvegicus  
 ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;  
 Rattus.  
 1 (bases 1 to 220434)  
 Muzny D, Marie, Metzker M, Lee, Abramson S, Adams C, Alder J, Allen C, Allen H, Alshrooke S, Arin A, Arguliano D, Aryaladechi V, Ayodeji A, Ayodeji M, Baca B, Baden H, Baldwin D, Bandaranaike D, Barber M, Barnstead M, Benahmed F, Biewald K, Blair J, Blankenburg K, Blyth P, Brown M, Bryant N, Buhay C, Burch P, Butrell K, Calderon E, Cardenas V, Carter K, Cavazos I, Cessari H, Chen Z, Chacko J, Chavez D, Chen R, Chen Y, Chen Y, Chent Z, Chu J, Cleveland C, Cockrell R, Cox C, Coyle M, Cree A, D'Souza L, Davila M, Davis C, Davy-Carroll L, De Anda C, Dedrich D, Delgado O, Denson S, Detamo C, Ding Y, Dinh H, Diya K, Draper H, Dugan-Rocha S, Dunn A, Durbin K, Duval B, Eaves K, Egan A, Escotto M, Eugene C, Evans C, Falls T, Fan G, Fernandez S, Finley M, Flaeg N, Forbes L, Foster M, Foster P, Fraser C, Gabisi A, Ganta R, Garcia A, Garner T, Garza M, Gebregorjisi B, Geer K, Gill R, Grady M, Guerra M, Guevara W, Gunaratne P, Haaland W, Hamill C, Hamilton C, Hamilton K, Harvey Y, Havlak P, Hawes A, Henderson N, Hernandez J, Hernandez R, Hines S, Hladun S, Hodgson A, Hogues M, Hollins B, Howells S, Huliy S, Hume J, Idelberg D, Jackson A, Jackson L, Jacob L, Jiang H, Johnson B, Johnson R, Jolivet A, Karachy S, Kelly S, Kelly S, Khan Z, King L, Kovar C, Kows C, Kraft C, Lebow H, Levan D, Lewis L, Li Z, Liu J, Liu J, Liu W, Liu Y, London P, Longacre S, Lopez J, Lornshewer L, Louisedge H, Lozano R, Lu X, Ma J,

Maneshwari M, Mahindartine M, Mahmud M, Malloy K, Mangum A, Mangum B, Mapua P, Martin K, Martin R, Martinez E, Marthiny S, McLeod M, McNeill T, Meenen E, Milosavljevic A, Minier G, Mirza E, Montemayor U, Moore S, Morgan M, Morris K, Morris S, Munilla M, Murphy M, Nait L, Nankervis C, Neal D, Newton N, Nguyen N, Norris S, Nwankwelu O, Okwodu G, Olatunmbi A, Pal S, Parks K, Pasternak S, Paul H, Perez A, Perez L, Pfannkuch C, Plopper F, Poindeexter A, Poveic D, Primus E, Pu L, Plazo M, Quiroz J, Rachlin E, Reeves K, Regier M, Reich R, Reilly B, Reilly M, Ren Y, Reuter M, Richards S, Riggs F, Rives C, Rodery T, Rojas A, Rose M, Rose R, Ruiz S, Sanders W, Savery G, Scherer S, Scott G, Shatsman S, Shen H, Shetty J, Shvartsbeyn A, Sisson I, Sitter C, Smaj D, Sheed A, Sodergren B, Song X, Z, Sorrell R, Sosa J, Steidle M, Strong R, Sutton A, Sytek A, Taber P, Taylor C, Taylor T, Thomas N, Thomas S, Tingey A, Trejos Z, Usmani K, Valae R, Vera V, Villaseana D, Waldron L, Walker B, Wang J, Wang O, Wang S, Warren J, Warren R, Wei X, White F, Williams G, Willson R, Wlezyk R, Wooden H, Worley K, Wright D, Wright R, Wu J, Yakub S, Yen J, Yoon L, Yoon V, Yu F, Zhang J, Zhou J, Zhou X, Zhao S, Zoon D, von Niederhausern A, Weiss R, Smith D, R, Holt R, A, Smith H, O, Weinstock G, and Gibbs R, A.

Direct Submission  
 Unpublished  
 2 (bases 1 to 220434)  
 Submitted (10-MAR-2003) Human Genome Sequencing Center, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA  
 3 (bases 1 to 220434)  
 Worley K, C.

Direct Submission  
 Submitted (27-MAR-2003) Human Genome Sequencing Center, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA  
 On Mar 14, 2003 this sequence version replaced gi:2894506.

----- genome center  
 Center: Baylor College of Medicine  
 Center code: BCM  
 Web site: <http://www.hgsc.bcm.tmc.edu/>  
 Contact: hgsc-help@bcm.tmc.edu  
 ----- Project Information  
 Center project name: KERT  
 Center clone name: CH230-114H6  
 ----- Summary Statistics  
 Sequencing vector: plasmid;  
 Chemistry: Dye-terminator Big Dye; 100% of reads  
 Assembly program: Phrap; version 0.990329  
 Consensus quality: 197818 bases at least Q40  
 Consensus quality: 201911 bases at least Q30  
 Consensus quality: 208432 bases at least Q20  
 Estimated insert size: 18182; sum-of-coverage estimation  
 Quality coverage: 3x in Q20 bases; sum-of-coverage estimation

NOTE: Estimated insert size may differ from sequence length  
 (see [http://www.hgsc.bcm.tmc.edu/docs/genbank\\_draft\\_data.html](http://www.hgsc.bcm.tmc.edu/docs/genbank_draft_data.html)).  
 NOTE: This is a 'working draft' sequence. It currently  
 consists of 67 contigs. The true order of the pieces  
 is not known and their order in this sequence record is  
 arbitrary. Gaps between the contigs are represented as  
 runs of N, but the exact sizes of the gaps are unknown.  
 This record will be updated with the finished sequence  
 as soon as it is available and the accession number will  
 be preserved.

1 1220: contig of 1220 bp in length  
 \* 1221 1320: gap of unknown length  
 \* 1321 2711: contig of 1391 bp in length  
 \* 2712 2811: gap of unknown length  
 \* 2812 4302: contig of 1491 bp in length  
 \* 4303 4403: gap of unknown length  
 \* 4403 5435: contig of 1033 bp in length

```

* 5436 5535: gap of unknown length
* 5536 6682: contig of 1147 bp in length
* 6683 6782: gap of unknown length
* 6783 8125: contig of 1343 bp in length
* 8126 8225: gap of unknown length
* 8226 9654: contig of 1428 bp in length
* 9654 9753: gap of unknown length
* 9754 10893: contig of 1139 bp in length
* 10893 10993: gap of unknown length
* 10993 12420: contig of 1427 bp in length
* 12420 12520: gap of unknown length
* 12520 13792: contig of 1273 bp in length
* 13792 13892: gap of unknown length
* 13893 15227: contig of 1335 bp in length
* 15228 15328: gap of unknown length
* 15328 16824: contig of 1496 bp in length
* 16824 16923: gap of unknown length
* 16923 18594: contig of 1671 bp in length
* 18594 18694: gap of unknown length
* 18694 20057: contig of 1363 bp in length
* 20057 20157: gap of unknown length
* 20158 21205: contig of 1048 bp in length
* 21206 21306: gap of unknown length
* 21306 22447: contig of 1142 bp in length
* 22448 22548: gap of unknown length
* 22548 24158: contig of 1611 bp in length
* 24159 24258: gap of unknown length
* 24259 25928: contig of 1671 bp in length
* 25930 26028: gap of unknown length
* 26030 27224: contig of 1195 bp in length
* 27225 27325: gap of unknown length
* 27325 28721: contig of 1397 bp in length
* 28722 28822: gap of unknown length
* 28822 29840: contig of 1019 bp in length
* 29841 29940: gap of unknown length
* 29941 31548: contig of 1609 bp in length
* 31550 31650: gap of unknown length
* 31650 33452: contig of 1803 bp in length
* 33453 33552: gap of unknown length
* 33553 35257: contig of 1705 bp in length
* 35258 37459: gap of unknown length
* 37460 37559: contig of 2102 bp in length
* 37560 38810: gap of unknown length
* 38811 38910: contig of 1251 bp in length
* 38911 39979: contig of 1069 bp in length
* 39980 40079: gap of unknown length
* 40080 41615: contig of 1536 bp in length
* 41616 41715: gap of unknown length
* 41716 44028: contig of 2313 bp in length
* 44029 44128: gap of unknown length
* 44129 45435: contig of 1308 bp in length
* 45436 45537: gap of unknown length
* 45537 48041: contig of 2505 bp in length
* 48042 48141: gap of unknown length
* 48142 50554: contig of 2413 bp in length
* 50555 50654: gap of unknown length
* 50655 52760: contig of 2106 bp in length
* 52761 52861: gap of unknown length
* 52862 54582: contig of 1722 bp in length
* 54583 54682: gap of unknown length
* 54683 57043: contig of 2361 bp in length
* 57044 57143: gap of unknown length
* 57144 59095: contig of 1952 bp in length
* 59096 59195: gap of unknown length
* 59196 62500: contig of 3305 bp in length
* 62501 62600: gap of unknown length
* 62601 64620: contig of 2020 bp in length
* 64621 64720: gap of unknown length
* 64721 67094: contig of 2374 bp in length
* 67095 68971: gap of unknown length
* 68972 69071: contig of 1777 bp in length
* 69072 69171: gap of unknown length

```

```

* 69072 71750: contig of 2679 bp in length
* 71751 71850: gap of unknown length
* 71851 74352: contig of 2502 bp in length
* 74353 74452: gap of unknown length
* 74453 77263: contig of 2811 bp in length
* 77264 77363: gap of unknown length
* 77364 80267: contig of 2903 bp in length
* 80268 80366: gap of unknown length
* 80367 83477: contig of 3111 bp in length
* 83478 83577: gap of unknown length
* 83578 86160: contig of 2583 bp in length
* 86161 86260: gap of unknown length
* 86261 88294: contig of 2034 bp in length
* 88295 88394: gap of unknown length
* 88395 93403: contig of 5009 bp in length
* 93404 93503: gap of unknown length
* 93504 98849: contig of 5346 bp in length

Query Match      29.2% Score 19; DB 2; Length 220434;
Best Local Similarity 100.0%; Pred. No. 4.7;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      12 ATCTGCCGCTCTTTCACG 30
Db      26915 ATCTGCCGCTCTTTCACG 26933

RESULT 7
AL445257
LOCUS      Homo sapiens chromosome 1 clone RP5-1175N1, 14 unordered pieces.
DEFINITION
AL445257.1 GI:10716509
ACCESSION
VERSION
KEYWORDS   HTG; HTGS PHASE1; HTGS_CANCELLED.
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
1 Burton, J.
  Direct Submission
  Submitted (12-JUN-2001) Sanger Centre, Hinxton, Cambridgeshire,
  CB10 1SA, UK. E-mail enquiries: humquery@sanger.ac.uk
  requests: clonerequests@sanger.ac.uk
  ----- Genome Center
  Center: Sanger Centre
  Center code: SC
  Web site: http://www.sanger.ac.uk
  Contact: humquery@sanger.ac.uk
  ----- Project Information
  Center project name: d11175N1
  ----- Summary Statistics
  Assembly program: XAPI; Version 4.5
  Sequencing vector: plasmid; 108752, 100% of reads
  Chemistry: Dye-terminator Big Dye; 100% of reads
  Consensus quality: 28716 bases at least Q40
  Consensus quality: 32676 bases at least Q30
  Consensus quality: 35450 bases at least Q20
  Insert size: 38286; sum-of-contigs
  Insert size: 138118; 12.9% error; agarose-fp
  Quality coverage: 1.51x in Q20 bases; sum-of-contigs Quality
  coverage: 0.97x in Q20 bases; agarose-fp
  -----
  * NOTE: This is a 'working draft' sequence. It currently
  * consists of 14 contigs. The true order of the pieces
  * is not known and their order in this sequence record is
  * arbitrary. Gaps between the contigs are represented as
  * runs of N, but the exact sizes of the gaps are unknown.
  * This record will be updated with the finished sequence
  * as soon as it is available and the accession number will
  * be preserved.
  * 1 2942: contig of 2942 bp in length
  * 2943 3042: gap of 100 bp

```

```
FEATURES      Location/Qualifiers
source        1. .39596
```

ORIGIN

Age Group	Percentage
18-24	15
25-34	35
35-44	25
45-54	15
55-64	10
65-74	5
75-84	2
85-94	1
95-104	0

LOCUS	AW557113	103513 bp	DNA	linear	FRI 01-MAR-2001
DEFINITION	Human DNA sequence from clone RP11-3J23 on chromosome 1, complete				

VERSION AL357713.11 GI:13234918  
KEYWORDS HTG.

*Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Dalmatians; Canidae; Felidae; Hom*

AUTHORS	TITLE
Williams, S.	Direct Submission

COMMENT  
On or before May 15 2001 this sequence version renjaced  
requests: clonerequest@sanger.ac.uk

During sequence assembly data is compared from overlapping clones. Where differences are found these are annotated as variations

variation annotation may not be found in the sequence submission together with a note of the overlapping clone name. Note that the

corresponding to the overlapping clone, as we submit sequences with only a small overlap as described above.

This sequence was finished as follows unless otherwise noted: all regions were either double-stranded or sequenced with an alternate

chemistry or covered by high quality data (i.e., phred quality >= 20). an attempt was made to resolve all sequencing problems such

as compressions and repeats; all regions were covered by at least 50% an attempt was made to resolve all sequencing problems, such as compressions and repeats; all regions were covered by at least

one plasmid subclone or more than one missubclone, and the assembly was confirmed by restriction digest. The following

abbreviations are used to associate primary accession numbers given in the feature table with their source databases: Em; EMBL; Sw;

SWISSPROT; Tr; TREMBL; Wp; WORMPEP; Information on the WORMPEP database can be found at

[http://www.sanger.ac.uk/Projects/C\\_elegans/wormpep](http://www.sanger.ac.uk/Projects/C_elegans/wormpep) This sequence was generated from part of bacterial clone conf103 of human

chromosome 1, constructed by the Sanger Centre Chromosome 1 Mapping Group. Further information can be found at

Group. Further information can be found at <http://www.sanger.ac.uk/HGP/Chr1>

RP11-3023 is from the library RP1-11.1 constructed by the group of Pieter de Jong. For further details see

http://www.chori.org/bacpac/home.htm  
VECTOR: pBACE3.6

**IMPORTANT:** This sequence is not the entire insert of clone RP1-3723. It may be shorter because we sequence overlapping

sections only once, except for a 100 base overlap. The true left end of clone pPA-63318 is at 103414 in this sequence

The true right end of clone RP5-115A15 is at 100 in this sequence.

FEATURES	location/qualifiers
source	1. .103513

```
/organism="Homo sapiens"  
/mol_type="genomic DNA"
```

```
/db_xref="taxon:9606"  
/chromosome="1"
```

```

/clone="RP11-3J23"
/clone_11b="BPCT-11 1"

```

```
repeat_region      870.  .941
/extra-llsc region 3 max to 65% compressed"
```

```
repeat_region      877. .921      /nucleoside copies 2 iter aa 60% conserved
```

```
repeat_region 1178.1469 /note="5 copies 9 mer attaatcaa 86% conserved"
```

```

/note="146 copies 2 mer aa 55% conserved"
repeat region 1477. .1752

```

```
repeat region 2069..2365
/note="AluI repeat: matches 3..285 of consensus"
```

```

repeat region      3599   3429
/note="AluX repeat: matches 3. .300 of consensus"

```

```
repeat_region /note="L1MCS repeat: matches 6643. .7530 of consensus"
4398. .4517
/note="MIR repeat: matches 23. .150 of consensus"
repeat_region 5208. .5327
/note="L2 repeat: matches 2630. .2750 of consensus"
repeat_region 6043. .6348
/note="AluX repeat: matches 1. .306 of consensus"
repeat_region 6359. .6657
/note="AluX repeat: matches 1. .299 of consensus"
repeat_region 6741. .6832
/note="L2 repeat: matches 2606. .2710 of consensus"
repeat_region 6869. .7317
/note="L2 repeat: matches 7. .470 of consensus"
repeat_region 7332. .7527
/note="L2 repeat: matches 2424. .2621 of consensus"
repeat_region 9468. .9772
/note="AluX repeat: matches 1. .299 of consensus"
repeat_region 9806. .9927
/note="FLAM_C repeat: matches 6. .127 of consensus"
repeat_region 10303. .10364
/note="MLT1J repeat: matches 1. .61 of consensus"
repeat_region 10464. .10832
/note="THE1B repeat: matches 1. .364 of consensus"
repeat_region 11305. .11465
/note="MIR repeat: matches 44. .197 of consensus"
repeat_region 12077. .12376
/note="AluX repeat: matches 1. .299 of consensus"
repeat_region 12649. .12774
/note="L63 copies 2 mer tt 65% conserved"
repeat_region 12654. .12789
/note="L8 copies 17 mer 64% conserved"
repeat_region 12687. .12767
/note="L9 copies 9 mer ttatttta 70% conserved"
repeat_region 13172. .13395
/note="MER38A repeat: matches 1. .224 of consensus"
repeat_region 13731. .14012
/note="AluX repeat: matches 1. .277 of consensus"
repeat_region 14282. .14592
/note="AluX repeat: matches 1. .297 of consensus"
repeat_region 17149. .17504
/note="THE1B repeat: matches 3. .364 of consensus"
repeat_region 17952. .18217
/note="AluX repeat: matches 38. .303 of consensus"
repeat_region 18219. .18518
/note="AluX repeat: matches 1. .302 of consensus"
repeat_region 18828. .18871
/note="L11 copies 4 mer caca 100% conserved"
repeat_region 18938. .18997
/note="L30 copies 2 mer ac 96% conserved"
repeat_region 19312. .19615
/note="AluX repeat: matches 3. .303 of consensus"
repeat_region 20942. .21167
/note="AluX repeat: matches 72. .310 of consensus"
repeat_region 21262. .21333
/note="MER5A repeat: matches 36. .104 of consensus"
repeat_region 21479. .21559
/note="L1MCA repeat: matches 7897. .7977 of consensus"
repeat_region 21778. .21877
/note="L25 copies 4 mer gaag 94% conserved"
repeat_region 22337. .22632
/note="AluX repeat: matches 1. .299 of consensus"
repeat_region 22662. .22972
/note="AluX repeat: matches 1. .309 of consensus"
repeat_region 23047. .23316
/note="AluX repeat: matches 1. .299 of consensus"
repeat_region 24280. .24579
/note="AluX repeat: matches 1. .299 of consensus"
repeat_region 24745. .24926
/note="AluX repeat: matches 180. .308 of consensus"
repeat_region 24927. .25226
/note="AluX repeat: matches 1. .300 of consensus"
repeat_region 25227. .25388
/note="AluX repeat: matches 2. .180 of consensus"
repeat_region 25427. .25721
/note="AluX repeat: matches 1. .299 of consensus"
repeat_region 26005. .26137
/note="AluX repeat: matches 1. .136 of consensus"
repeat_region 26138. .26443
/note="AluX repeat: matches 1. .307 of consensus"
repeat_region 27061. .27268
/note="AluX repeat: matches 3. .209 of consensus"
repeat_region 27510. .27820
/note="AluX repeat: matches 1. .305 of consensus"
repeat_region 27854. .28032
/note="MIR repeat: matches 85. .261 of consensus"
repeat_region 28116. .28415
/note="AluX repeat: matches 3. .301 of consensus"
repeat_region 28423. .28731
/note="AluX repeat: matches 1. .309 of consensus"
repeat_region 32979. .33020
/note="L21 copies 2 mer ac 78% conserved"
repeat_region 34272. .34561
/note="AluX repeat: matches 9. .300 of consensus"
repeat_region 35277. .35362
/note="L2 repeat: matches 2666. .2749 of consensus"
repeat_region 35420. .35620
/note="MIR repeat: matches 16. .223 of consensus"
repeat_region 37090. .37219
/note="L2 repeat: matches 2571. .2701 of consensus"
repeat_region 38314. .38413
/note="MER94 repeat: matches 2. .100 of consensus"
repeat_region 39688. .39711
/note="L12 copies 2 mer aa 100% conserved"
repeat_region 40371. .40654
/note="AluX repeat: matches 6. .285 of consensus"
repeat_region 42365. .42459
/note="AluX repeat: matches 1. .90 of consensus"
repeat_region 42684. .42806
/note="FLAM_C repeat: matches 1. .123 of consensus"
repeat_region 43618. .44082
/note="L19A repeat: matches 1. .486 of consensus"
repeat_region 44567. .44813
/note="AluX repeat: matches 44. .297 of consensus"
repeat_region 47807. .47918
/note="AluX repeat: matches 169. .280 of consensus"
repeat_region 47922. .47965
/note="L11 copies 4 mer cata 86% conserved"
repeat_region 48455. .48618
/note="FRAM repeat: matches 1. .160 of consensus"
repeat_region 50339. .50623
/note="AluX repeat: matches 1. .282 of consensus"
repeat_region 50626. .50677
/note="L26 copies 2 mer ac 84% conserved"
repeat_region 50629. .50680
/note="L13 copies 4 mer caca 84% conserved"
repeat_region 50846. .51151
/note="AluX repeat: matches 1. .306 of consensus"
repeat_region 51947. .52235
/note="AluX repeat: matches 1. .289 of consensus"
repeat_region 52994. .53120
/note="L2 repeat: matches 2565. .2703 of consensus"
repeat_region 53182. .53488
```

```
Query Match 27.7% Score 18; DB 9; Length 103513;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2 ATCCATGGAAATCTGCC 19
DB 80412 ATCCATGGAAATCTGCC 80412
```

```
RESULT 9
LMFLCHR36 11/c
WPCOMMENT
Sequence split into 36 fragments LOCUS LMFLCHR36 Accession AL499624
```

Fragment Name Begin End  
 LMFCHR36\_00 1 110000  
 LMFCHR36\_01 100001 210000  
 LMFCHR36\_02 200001 310000  
 LMFCHR36\_03 300001 410000  
 LMFCHR36\_04 400001 510000  
 LMFCHR36\_05 500001 610000  
 LMFCHR36\_06 600001 710000  
 LMFCHR36\_07 700001 810000  
 LMFCHR36\_08 800001 910000  
 LMFCHR36\_09 900001 1010000  
 LMFCHR36\_10 1000001 1110000  
 LMFCHR36\_11 1100001 1210000  
 LMFCHR36\_12 1200001 1310000  
 LMFCHR36\_13 1300001 1410000  
 LMFCHR36\_14 1400001 1510000  
 LMFCHR36\_15 1500001 1610000  
 LMFCHR36\_16 1600001 1710000  
 LMFCHR36\_17 1700001 1810000  
 LMFCHR36\_18 1800001 1910000  
 LMFCHR36\_19 1900001 2010000  
 LMFCHR36\_20 2000001 2110000  
 LMFCHR36\_21 2100001 2210000  
 LMFCHR36\_22 2200001 2310000  
 LMFCHR36\_23 2300001 2410000  
 LMFCHR36\_24 2400001 2510000  
 LMFCHR36\_25 2500001 2610000  
 LMFCHR36\_26 2600001 2710000  
 LMFCHR36\_27 2700001 2810000  
 LMFCHR36\_28 2800001 2910000  
 LMFCHR36\_29 2900001 3010000  
 LMFCHR36\_30 3000001 3110000  
 LMFCHR36\_31 3100001 3210000  
 LMFCHR36\_32 3200001 3310000  
 LMFCHR36\_33 3300001 3410000  
 LMFCHR36\_34 3400001 3510000  
 LMFCHR36\_35 3500001 352982

Continuation (12 of 36) of LMFCHR36 from base 1100001 (AL499624 Tetrahymena major chromo

Query Match 27.7%; Score 18; DB 2; Length 110000;  
 Best Local Similarity 100.0%; Pred. No. 19;  
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 14 CTTCCCGTCTTTCACGC 31  
 DB 66513 CTTCCCGTCTTTCACGC 66496

RESULT 10  
 AC079838 156481 bp DNA linear HTG 01-APR-2001  
 LOCUS AC079838  
 DEFINITION Homo sapiens chromosome 2 clone RP11-257N14, WORKING DRAFT  
 ACCESSION AC079838  
 VERSION AC079838.3 GI:13493151  
 KEYWORDS HTG; HTGS\_PHASE1; HTGS\_DRAFT; HTGS\_FULLTOP.  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 REFERENCE 1 (bases 1 to 156481)  
 AUTHORS Waterston,R.H.  
 TITLE The sequence of Homo sapiens clone  
 JOURNAL Unpublished  
 REFERENCE 2 (bases 1 to 156481)  
 AUTHORS Waterston,R.H.  
 TITLE Direct Submission  
 JOURNAL Submitted (12-SEP-2000) Genome Sequencing Center, Washington  
 University School of Medicine, 4444 Forest Park Parkway, St. Louis,  
 MO 63108, USA  
 COMMENT On Apr 1, 2001 this sequence version replaced gi:10799482.

Genome Center -----

Center: Washington University Genome Sequencing Center  
 Center code: WUGSC  
 Web site: <http://genome.wustl.edu/gsc/index.shtml>  
 Project information -----  
 Project name: H.NH0257N14  
 Summary Statistics -----  
 Sequencing vector: M13, 68%  
 Sequencing vector: plasmid, 32%  
 Chemistry: Dye-primer ET; 68% of reads  
 Chemistry: Dye-terminator Big Dye; 32% of reads  
 Assembly program: Phrap, version 0.99019  
 Consensus quality: 15481 bases at least Q40  
 Consensus quality: 155806 bases at least Q30  
 Consensus quality: 155806 bases at least Q20  
 Insert size: 139000; agarose-fp  
 Quality coverage: 6.40 in Q20 bases; sum-of-contigs  
 Quality coverage: 6.28 in Q20 bases; sum-of-contigs

\* NOTE: This is a 'working draft' sequence. It currently  
 \* consists of 2 contigs. The true order of the pieces  
 \* is not known and their order in this sequence record is  
 \* arbitrary. Gaps between the contigs are represented as  
 \* runs of N, but the exact sizes of the gaps are unknown.  
 \* This record will be updated with the finished sequence  
 \* as soon as it is available and the accession number will  
 \* be preserved.

1 6178: contig of 6178 bp in length  
 \* 6179 6278: gap of unknown length  
 \* 6279 156481: contig of 150203 bp in length.  
 Location/Qualifiers  
 1. 156481  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 /chromosome="2"  
 /clone="RP11-257N14"  
 1. 6178  
 /note="assembly\_name:Contig7  
 clone\_end:T7  
 vector\_side:right"  
 6279. 156481  
 /note="assembly\_name:Contig8  
 clone\_end:SP6  
 vector\_side:left"

misc\_feature  
 misc\_feature

Query Match 27.7%; Score 18; DB 2; Length 156481;  
 Best Local Similarity 100.0%; Pred. No. 18;  
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 43 CCTGCTGATGACACCC 60  
 DB 11249 CCTGCTGATGACACCC 11266

RESULT 11  
 AC007098 157650 bp DNA linear PRI 09-MAY-2001  
 LOCUS AC007098  
 DEFINITION Homo sapiens BAC clone RP11-43F16 from 2, complete sequence.  
 ACCESSION AC007098  
 VERSION AC007098.4 GI:11038585  
 KEYWORDS HTG.  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 REFERENCE 1 (bases 1 to 157650)  
 AUTHORS Sulston,J.E. and Waterston,R.  
 TITLE Toward a complete human genome sequence  
 JOURNAL Genome Res. 8 (11), 1097-1108 (1998)  
 MEDLINE 99063792  
 PUBMED 9847074

REFERENCE 2 (bases 1 to 157650)  
 AUTHORS Kallunki, J., Johnson, D. and Harris, A.  
 TITLE The sequence of Homo sapiens BAC clone RP11-443F16  
 JOURNAL Unpublished  
 REFERENCE 3 (bases 1 to 157650)  
 AUTHORS Waterston, R.H.  
 TITLE Direct Submission  
 JOURNAL Submitted (16-MAR-1999) Genome Sequencing Center, Washington University School of Medicine, 4444 Forest Park Parkway, St. Louis, MO 63108, USA

REFERENCE 4 (bases 1 to 157650)  
 AUTHORS Waterston, R.H.  
 TITLE Direct Submission  
 JOURNAL Submitted (30-OCT-2000) Genome Sequencing Center, Washington University School of Medicine, 4444 Forest Park Parkway, St. Louis, MO 63108, USA

REFERENCE 5 (bases 1 to 157650)  
 AUTHORS Waterston, R.  
 TITLE Direct Submission  
 JOURNAL Submitted (09-MAY-2001) Department of Genetics, Washington University, 4444 Forest Park Avenue, St. Louis, Missouri 63108, USA  
 On Oct 30, 2000 this sequence version replaced gi:8570191.

COMMENT  
 Center: Washington University Genome Sequencing Center  
 Center code: WUGSC  
 Web site: <http://genome.wustl.edu/gsc>  
 Contact: [sapient@wustl.edu](mailto:sapient@wustl.edu)  
 Summary Statistics  
 Center project name: H\_NH0443F16

NOTICE: This sequence may not represent the entire insert of this clone. It may be shorter because we only sequence overlapping clone sections once, or longer because we provide a small overlap between neighboring data submissions.

This sequence was finished as follows unless otherwise noted:  
 all regions were double stranded, sequenced with an alternate chemistry, or covered by high quality data (i.e., phred quality >= 30); an attempt was made to resolve all sequencing problems, such as compressions and repeats; all regions were covered by sequence from more than one subclone; and the assembly was confirmed by restriction digest.

MAPPING INFORMATION:  
 Mapping information for this clone was provided by Dr. John D. McPherson, Department of Genetics, Washington University, St. Louis MO. For additional information about the map position of this sequence, see <http://genome.wustl.edu/gsc>

SOURCE INFORMATION:  
 The RFL1-11 human BAC library was made from the blood of one male donor, as described by Osogawa, K., Woon, P.Y., Zhao, B., Frenken, E., Tateo, M., Catanesi, J.J., and de Jong, P.J. (1998) An improved approach for construction of bacterial artificial chromosome libraries. Genomics 51:1-8. The clone may be obtained either from Research Genetics, Inc. (<http://www.rgsen.com>) or Pieter de Jong and coworkers at the Roswell Park Cancer Institute (<http://pacpac.med.buffalo.edu>)  
 VECTOR: pBAC3.6

NEIGHBORING SEQUENCE INFORMATION:  
 The clone sequenced to the right is RP11-511I11, 200 bp overlap. Actual start of this clone is at base position 1 of RP11-443F16; actual end is at base position 157456 of RP11-443F16.

## FEATURES

source  
 1. 157650  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 /chromosome="2"  
 /map="2"  
 /clone="RP11-443F16"  
 /clone\_1b="RP11-11"

misc_feature	75..449	/note="similar to EST H66784 (NID:g1025524) YR84h10.r1"
repeat_region	181..425	/rpt_family="L1"
repeat_region	422..1348	/rpt_family="L1"
repeat_region	1349..1476	/rpt_family="L1"
repeat_region	1477..1870	/rpt_family="Alu"
repeat_region	1871..2176	/rpt_family="L1"
repeat_region	2177..2455	/rpt_family="Alu"
repeat_region	2228..2698	/rpt_family="L1"
repeat_region	2800..3357	/rpt_family="L1"
repeat_region	3497..3582	/rpt_family="MALR"
repeat_region	3599..3949	/rpt_family="L2"
repeat_region	4875..4907	/rpt_family="L2"
repeat_region	5004..5103	/rpt_family="L2"
repeat_region	5348..5454	/rpt_family="L2"
repeat_region	6944..7100	/rpt_family="L2"
repeat_region	7099..7878	/rpt_family="MER2_type"
repeat_region	7912..8544	/rpt_family="MER2_type"
repeat_region	8545..10505	/rpt_family="MER2_type"
repeat_region	10510..10614	/rpt_family="ERV1"
repeat_region	10619..10995	/rpt_family="MER2_type"
repeat_region	11078..11306	/rpt_family="MALR"
repeat_region	12958..13086	/rpt_family="L2"
misc_feature	12958..13086	/note="similar to EST AA456682 (NID:g2179258) aal3e01.r1"
misc_feature	12958..13086	/note="similar to EST A1150782 (NID:g3679251) qc06g03.x1"
misc_feature	12958..13086	/note="similar to EST A1675083 (NID:g4875563) wc23c03.x1"
misc_feature	12965..13086	/note="similar to EST AA721648 (NID:g2736631) ny87f02.s1"
misc_feature	13045..13086	/note="similar to EST AM102800 (NID:g6073413) xd38c10.x1"
repeat_region	14003..14303	/rpt_family="Alu"
repeat_region	14920..15821	/rpt_family="Alu"
repeat_region	15257..15864	/rpt_family="Alu"
repeat_region	16122..16425	/rpt_family="Alu"
repeat_region	16796..17077	/rpt_family="Alu"
repeat_region	17109..17251	/rpt_family="Alu"
repeat_region	17636..17941	/rpt_family="Alu"
repeat_region	17948..18103	/rpt_family="Alu"
misc_feature	18324..18766	/note="similar to EST Z21249 (NID:g279922)"
misc_feature	18526..18766	/note="similar to EST AM102800 (NID:g6073413) xd38c10.x1"
misc_feature	18526..18699	

```

misc_feature      /note="similar to EST A1675083 (NID:g4875563) wc23c03.x1"
18526..18691
misc_feature      /note="similar to EST AA721648 (NID:g2736631) ny87f02.s1"
18526..18691
misc_feature      /note="similar to EST A1150782 (NID:g3679251) qc06g03.x1"
18526..18691
misc_feature      /note="similar to EST AA456682 (NID:g2179258) aa13e01.r1"
18583..18700
misc_feature      /note="similar to EST A1806986 (NID:g5393552) wf24g10.x1"
19222..19284
repeat_region     /ftc_family="CRI"
19385..20704
repeat_region     /ftc_family="L1"
20717..20783
repeat_region     /ftc_family="L1"
20832..21073
repeat_region     /ftc_family="L1"
21093..21887
repeat_region     /ftc_family="L1"
21885..22187
repeat_region     /ftc_family="Alu"
22188..22460
repeat_region     /ftc_family="L1"
22461..22755
repeat_region     /ftc_family="Alu"
22756..23600
repeat_region     /ftc_family="L1"
23981..24250
repeat_region     /ftc_family="CRI"
24287..24530
repeat_region     /ftc_family="Alu"
25833..25891
misc_feature      /note="similar to EST AA868764 (NID:g2964209) akc2f09.s1"
26383..26640
repeat_region     /ftc_family="L1"
26645..27084
repeat_region     /ftc_family="L1"
27124..27556
repeat_region     /ftc_family="L1"

Query Match      27.7% Score 18; DB 9; Length 16771;
Best Local Similarity 100.0%; Pred. No. 18;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 43 CCTGCTGATGACACCC 60
Db 28647 CCTGCTGATGACACCC 28664

RESULT 12
AC007629/c 16771 bp DNA linear HTG 07-OCT-2000
LOCUS Homo sapiens clone NH0443B15a, *** SEQUENCING IN PROGRESS ***. 5
DEFINITION
AC007629
UNPUBLISHED
AC007629
AC007629.9 GI:10716584
VERSION HTG; HTGS PHASE1.
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1 (bases 1 to 16771)
AUTHORS McCombie,W.R.
TITLE Human Genomic Sequence
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 16771)
AUTHORS McCombie,W.R.
TITLE Direct Submision
JOURNAL Submitted (21-MAY-1999) Lita Annenberg Hazen Genome Sequencing
Center, Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring
Harbor, NY 11724, USA
On Oct 7, 2000 this sequence version replaced gi:9972279.
* NOTE: This is a 'working draft' sequence. It currently

```

```

* consists of 6 contigs. The true order of the pieces
* is not known and their order in this sequence record is
* arbitrary. Gaps between the contigs are represented as
* runs of N, but the exact sizes of the gaps are unknown.
* This record will be updated with the finished sequence
* as soon as it is available and the accession number will
* be preserved.
* 1 142198: contig of 142198 bp in length
* 142199 142298: gap of unknown length
* 142299 157945: contig of 15647 bp in length
* 157946 158045: gap of unknown length
* 158046 160827: contig of 2782 bp in length
* 160828 160928: gap of unknown length
* 160928 163434: contig of 2507 bp in length
* 163435 163534: gap of unknown length
* 163535 165854: contig of 2320 bp in length
* 165855 165954: gap of unknown length
* 165955 167711: contig of 1757 bp in length.

FEATURES
source
1..16771
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/clone="NH0443B15a"

ORIGIN
Query Match      27.7% Score 18; DB 2; Length 16771;
Best Local Similarity 100.0%; Pred. No. 18;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 43 CCTGCTGATGACACCC 60
Db 128804 CCTGCTGATGACACCC 128787

RESULT 13
AE017156 191854 bp DNA linear BCT 15-AUG-2003
LOCUS Haemophilus ducreyi strain 35000HP section 6 of 6 of the complete
genome.
DEFINITION
AE017156 AE017143
AE017156.1 GI:33149035
ACCESSION
AE017156
VERSION
AE017156
KEYWORDS
SOURCE Haemophilus ducreyi 35000HP
ORGANISM Haemophilus ducreyi 35000HP
Bacteria; Proteobacteria; Gammaproteobacteria; Pasteurellales;
Pasteurellaceae; Haemophilus.
REFERENCE 1 (bases 1 to 191854)
AUTHORS Munson,R.S., Jr., Ray,W.C., Mahairas,G., Sabo,P., Mungur,R.,
Johnson,L., Nguyen,D., Wang,J., Forst,C. and Hood,L.
TITLE The Complete Genome Sequence of Haemophilus ducreyi
JOURNAL Unpublished
JOURNAL 2 (bases 1 to 191854)
AUTHORS Munson,R.S., Jr., Ray,W.C., Mahairas,G., Sabo,P., Mungur,R.,
Johnson,L., Nguyen,D., Wang,J., Forst,C. and Hood,L.
TITLE Direct Submision
JOURNAL Submitted (04-JUN-2003) Pediatrics, Columbus Children's Research
Institute and The Ohio State University, 700 Children's Drive,
Columbus, OH 43205 USA

FEATURES
source
1..191854
/organism="Haemophilus ducreyi 35000HP"
/mol_type="genomic DNA"
/strain="35000HP"
/db_xref="taxon:233412"
complement(142..2073)
/gene="hrs"
/locus_tag="HD1803"
complement(142..2073)
/gene="hrs"
/locus_tag="HD1803"
/codon_start=1
/transl_table=1

```



/product="threonyl-tRNA synthetase"  
/protein\_id="AAP96553.1"  
/db\_xref="GI:33149036"  
/translation="MPIITLPDGSQRNEDNPVSVIEVAQSIGTGLAKATLAGRVNGER  
RDACIIIEOSTLEITAKDEDELEIIRSCAMHGAIKQLFPTVKALIGPTIENF  
YVVDRLTODDLAIERKMLELAKTNVNVKPKVMOQAROTFEKRGPKYALIL  
DENIETAPALVHEEYIDMCRGPPMVRCPHFKLOKAVAGVWEDSKNKLOST  
YGTAAADKCOLTEYLRLLEAKAPRRATGKALDIYHMOEARPGVPMHNDKILPFE  
LETPVTKLEYDYGVCKPPMMDRYMRGCHQNVADLMFTTOSREBAITKPNK  
ISEVYACIMVYDIYSTGFNTIPVKLSTRDNRIGADMDRDAEAGLSALSTNGE  
EYQIQGEGAFYQPKLEFALRDCLEHMQCGVQDLPALPSRLASVYTESHNTY  
MIRRALIGSIERIGITTEYAGFPVWLAPIOAVVNIITDSQADYVQVQVCKLSDG  
LRYVADIRNEKVFYKREHTRRVPYMLVCGDKETEGKSVRTKGGEDLTENIEAF  
VENLKVQVREKILGSEA"  
/gene="pnrk"  
/locus\_tag="HD1804"  
2343..3242  
/gene="pnrk"  
/locus\_tag="HD1804"  
/codon\_start=1  
/transl\_table=11  
/product="probable inorganic polyphosphate/ATP-NAD kinase"  
/protein\_id="AAP96554.1"  
/db\_xref="GI:33149037"  
/translation="MNTMKVYTKRSPOTIATYGRPRHNALETHLAVYNTKDNHYSY  
LVEKIAEQQLFNGRIEIQIADLVITIGDDNMLGARSILAKTOVPLIGNRGN  
LGFLTIAPQSAFEOQLSEKGEPIEQRFLLEQIBONGKILSANNALVAVIHT  
QVARIIEFEYVIDSKEAFQSRSDGLIATPTSTIYASAGPILTPMNAIAVPH  
PHALSPPVITDSDSHSLRFAQYQNPNIESCDDODLPPTPEDRITVRKSDILHL  
LHKDNYFTVLSGSKLGSXLF"  
/complement(3274..3867)  
/locus\_tag="HD1805"  
/complement(3274..3867)  
/locus\_tag="HD1805"  
/codon\_start=1  
/transl\_table=11  
/product="putative MAP protein"  
/protein\_id="AAP96555.1"  
/db\_xref="GI:33149038"  
/translation="MAKKIYILANSRFRWALLQNGLLPLASRIDETANAMAD  
YCSRIAREKQAQAVRIRONIAEYPTIADTWISIDGILSKRPHQOAVEMLSKLS  
GRHOYVTAQVANSQOLPECHSSSVTKRLESEAIYAVIATGEPMDKAGAYIQAL  
GGIFLOHLAGSPFGVGLPIFEVVALKKVNTLPS"  
/complement(3940..5394)  
/gene="thi1"  
/locus\_tag="HD1806"  
/complement(3940..5394)  
/gene="thi1"  
/locus\_tag="HD1806"  
/codon\_start=1  
/transl\_table=11  
/product="thiamine biosynthesis protein Thi1"  
/protein\_id="AAP96556.1"  
/db\_xref="GI:33149039"  
/translation="MKRTIKLPEIMIKSDSVKRPKITINSIRNVLTREQAVY  
RNDPTEVRAKVAHEPILIDILKRTPGHLLLEVOMPTSTHIDPEPRAXONL  
LVKTRHGLGYPYIGTQEDVLSISGGPDSGVSTWFKRSRVHYCFNIGASHEI  
GKQWMAHYMSRYSISHKRVAVINFSVAGIILEKVDGQGVVLKMKMARASQIA  
ERPALQAVTGALGVSSQTLTNLRLIDKADSVLPLITHDKETIALAKOIGTD  
DIKASPEFCGVSKNPTVAIESKIVEEGHEDPVLKAVONATYDIEELIOTE  
KDYVAVATGALTENKIDILDIRSEEMDEKPLVLAQAVIELPYKLSGTQPAHDSQK  
NYLLCBRGWMSLQALYLKRGYQVAKVFNLPK"  
/complement(5519..6817)  
/gene="pura"  
/locus\_tag="HD1807"  
/complement(5519..6817)  
/gene="pura"  
/locus\_tag="HD1807"  
/codon\_start=1  
/transl\_table=11

/product="adenylosuccinate synthetase"  
/protein\_id="AAP96557.1"  
/db\_xref="GI:33149040"  
/translation="WGSVALILGQWDESKGIVDLLIDRYKATVTRYGCHNAGHTL  
IINSGKVALRILPGLIRENVTLIGGVVLSSEALMKEMKELACGINVERKLISE  
ACPLILPVHVMHAREALGAKNKIGTGGIIPAAVEDKARGLGVSDLPKKEAAT  
KLKOLLIDNQLVHYKVEVPFQKTLDPVAVAVIKMVADVTTLHOKRKEVN  
ILPEAQETMDIDHGTYPFPTSNTAGGAVAGAGPANTLYVIGIKACCTRGS  
GPFTTELMERGETIARKNGEGAVTGPARGCMPAVAVRAVAVINSISGCMTKLD  
VLDEGETIKCTAYKMPGELVEYAPMAADMGVSPRIYETPMGSENFQVIXEAL  
PQALDIYKRIEELVGVVVDILSTGPRIETMLRDPFA"  
/complement(6953..7840)  
/locus\_tag="HD1808"  
/complement(6953..7840)  
/gene="hflC"  
/locus\_tag="HD1808"  
/codon\_start=1  
/transl\_table=11  
/product="HflC protein"  
/protein\_id="AAP96558.1"  
/db\_xref="GI:33149041"  
/translation="MKLLPFLVSLVMMALISCLVIVPEBGRCIMLRFKVORDADOK  
VYVYEPGLHVPFIDSKILDSRIQMLDQEDRFYVEKDLVDSYVKMRISFGK  
FYTAGGVKASDILRRKVDRLRSIGRTIKDLYSGRGLMAGQALNAGSG  
AEKIGIEVDYRVKQINLPKVSSTIYORBARDAVARHROGGEKAEFTIRAEYDK  
KVILIEAKKKKXKILLGEGDALAKTYANAPKADRFYSFVNSLAVENSFTKQDN  
MKLLKSDSEFRPKAPTK"  
/complement(7843..9048)  
/gene="hflK"  
/locus\_tag="HD1809"  
/complement(7843..9048)  
/gene="hflK"  
/locus\_tag="HD1809"  
/codon\_start=1  
/transl\_table=11  
/product="HflK protein"  
/protein\_id="AAP96559.1"  
/db\_xref="GI:33149042"  
/translation="MSWNESGQODPWPGRQKKPEQGEPSGQGNODPNRPASAQNP  
PLBEAPFKLLKMGQGNKSNORPASLKEFTIATYFALVWAGSGFTVDEARG  
VYTRGKHQIVPGLMKKPTFDQVPIETIERSEIKTGSMNLTODEMNVQEMTVO  
YVREGRPAKYKESVYNSADSLKOATDSALRYVIGISMDDITLGRATVEKTELR  
IKTIDGSLTVDNFGQARPEEYKAPFDAIKQSDERLIREANAYARGSEPAR  
GQAGRIEQAVAYEQVLEAQDIDRFKSLPEYQAPAVMERLITETEKYMKRT  
KQIWDSSNVAVPLPEKFLGKTASVACKPLATVQOPVSHOLASVYEDNR  
EQPIRRGRF"  
/complement(9247..9564)  
/gene="trxA"  
/locus\_tag="HD1810"  
/complement(9247..9564)  
/gene="trxA"  
/locus\_tag="HD1810"  
/codon\_start=1  
/transl\_table=11  
/product="thioredoxin"  
/protein\_id="AAP96560.1"  
/db\_xref="GI:33149043"  
/translation="MTRGVDTATFEQVLSKDLPVLLDEWAPMGCPRTIAPVDELA  
QEFARAVAKYVNDENDQIAQCGTISPIILLFKRGVVALQVGLPSCSLYVILE  
QAL"  
/complement(9663..10955)  
/locus\_tag="HD1811"  
/complement(9663..10955)  
/locus\_tag="HD1811"  
/codon\_start=1  
/transl\_table=11  
/product="putative xanthine permease"  
/protein\_id="AAP96561.1"  
/db\_xref="GI:33149044"  
/translation="MKNLRYPIDSKRPFGLSVLLAVGHLAALGIIIVAVTVGNVVK  
LPTSDTIVAVNALVSGIVTIIQCRGIGPIGLPLPMVGSTFTFAAALATPSESG  
VAGINGSSLISGLVWISFPMYVRKLPFVVTGIVVMVIGSLIPVAVDMFAGQCK







[illegible]

/gene="pcoa"  
/locus\_tag="NE0279"  
6979 .8820  
/gene="pcoa"

Query Match 27.7% Score 18; DB 1; Length 313050;  
Best Local Similarity 100.0%; Pred. No. 18;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 37 TCGAACCCTGCTGATGG 54  
|||||  
Db 81964 TCGAACCCTGCTGATGG 81947

Search completed: December 22, 2004, 23:36:25  
Job time : 929.412 secs



CC codon usage was optimised for expression in bacteria. In an example from  
CC the invention, the synthetic gene was cloned into plasmid pCG12 (see  
CC AB583378) and recombinant rhug (see ABP72259) was produced in *Escherichia*  
CC coli strain CG12. The invention relates generally to the production of  
CC recombinant rhug by bacterial expression, protein purification and scaled-  
CC up production according to current good manufacturing practices. The  
CC recombinant rhug is useful for the treatment of inflammatory and fibrotic  
CC conditions, such as neonatal respiratory distress syndrome and  
CC bronchopulmonary dysplasia. It may also be used to treat conditions  
CC associated with elevated phospholipase A2 levels such as pancreatitis,  
CC acute renal failure, rheumatoid arthritis and asthma  
CC  
SQ Sequence 65 BP; 13 A; 22 C; 14 G; 16 T; 0 U; 0 Other;  
Query Match 100.0%; Score 65; DB 9; Length 65;  
Best Local Similarity 100.0%; Pred. No. 2e-25;  
Matches 65; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 GATCCATGGAATCTGCCCGCTTTCCAGCGCTTATCGAAACCCCTGATGACACCC 60  
DB 1 GATCCATGGAATCTGCCCGCTTTCCAGCGCTTATCGAAACCCCTGATGACACCC 60  
QY 61 CGTCC 65  
DB 61 CGTCC 65  
RESULT 2  
ADL27626  
ID ADL27626 standard; DNA; 65 BP.  
XX ADL27626;  
AC 20-MAY-2004 (first entry)  
DT 20-MAY-2004 (first entry)  
XX  
DE Recombinant human uteroglobin, rhug, coding oligonucleotide #1.  
XX  
KM Human; ss; recombinant human uteroglobin; rhug;  
KM Bacterial expression system; rhug master cell bank;  
KM rhug research seed bank; anti-inflammatory; secretory phospholipase A 2;  
KM fibronectin; respiratory distress; inflammation; fibrotic disease.  
XX  
OS Homo sapiens.  
OS Synthetic.  
OS  
XX US2003207795-A1.  
PN 06-NOV-2003.  
PD 02-JUL-2002; 2002US-00187498.  
PF 28-MAY-1997; 97US-00864357.  
PR 02-JUL-2001; 2001US-00898616.  
XX  
PA (PILON) PILON A L.  
PA (WELCH) WELCH R W.  
XX  
PI Pilon AL, Welch RW;  
XX  
DR WPI; 2004-051527/05.  
PT Bacterial expression system for production of recombinant human  
XX uteroglobin comprising synthetic gene or human cDNA sequence which codes  
XX for human uteroglobin.  
PS Claim 1; SEQ ID NO 1; 64p; English.  
XX  
CC The invention relates to a bacterial expression system for the production  
CC of recombinant human uteroglobin (rhug) comprising a synthetic gene or  
CC human cDNA sequence which codes for human uteroglobin, constructed from the  
CC oligonucleotides appearing as ADL27626-ADL27629, and which further  
CC comprises Met-Ala-Ala at the N-terminus of the sequence. Also included  
CC are producing an rhug master cell bank (comprising inoculating a suitable

CC incubating broth with an aliquot portion of a rhug research seed bank to  
CC form a bacterial culture, incubating the bacterial culture, adding a  
CC cryoprotective to the bacterial culture to form a cryopreserved  
CC solution, transferring a portion of the cryopreserved solution to a  
CC cryovial and storing the cryovial at a temperature below -60 degrees C).  
CC expressing rhug (comprising providing a production seed cell bank culture  
CC comprising an expression vector capable of expressing rhug; inoculating a  
CC broth medium with the production seed cell bank culture to form an  
CC inoculum, incubating the bacterial culture formed in step (b),  
CC inoculating a large scale fermenter with the inoculum formed from the  
CC step (c) to form a fermentation culture, incubating the fermentation  
CC culture within the large scale fermenter, adding an induction agent to  
CC the fermentation culture to induce the expression of rhug and harvesting  
CC of rhug in a sample, measuring in vitro anti-inflammatory effect arising  
CC from inhibition or blocking of secretory phospholipase A 2 enzymes by  
CC rhug, measuring in vitro binding of rhug to fibronectin, determining the  
CC purity of rhug, and a pharmaceutical composition comprising a purified  
CC rhug and a carrier or diluent. The bacterial expression system is useful  
CC for producing a rhug research seed bank or a pharmaceutical grade rhug  
CC drug substance. rhug is safe to administer to a patient in respiratory  
CC distress. The rhug is useful for treating inflammation and fibrotic  
CC diseases. The present sequence is a coding strand oligonucleotide used to  
CC construct the synthetic rhug gene.  
XX  
SQ Sequence 65 BP; 13 A; 22 C; 14 G; 16 T; 0 U; 0 Other;  
Query Match 100.0%; Score 65; DB 12; Length 65;  
Best Local Similarity 100.0%; Pred. No. 2e-25;  
Matches 65; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 GATCCATGGAATCTGCCCGCTTTCCAGCGCTTATCGAAACCCCTGATGACACCC 60  
DB 1 GATCCATGGAATCTGCCCGCTTTCCAGCGCTTATCGAAACCCCTGATGACACCC 60  
QY 61 CGTCC 65  
DB 61 CGTCC 65  
RESULT 3  
ABZ58376/c  
ID ABZ58376 standard; DNA; 60 BP.  
XX ABZ58376;  
AC 28-APR-2003 (first entry)  
DT 28-APR-2003 (first entry)  
XX  
DE Human uteroglobin synthetic gene oligonucleotide 7.  
XX  
KM Human; uteroglobin; respiratory distress; anti-inflammatory; antifibrotic;  
KM anti-inflammatory; antiaesthetic; nephroretropic; antirheumatic;  
KM antiarthritic; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
OS  
XX WO2003003979-A2.  
PN 16-JAN-2003.  
PD 02-JUL-2002; 2002WO-US020836.  
PF 02-JUL-2001; 2001US-00898616.  
XX  
PA (CIAR-) CIARAGEN INC.  
XX  
PI Pilon AL, Welch RE;  
XX  
DR WPI; 2003-221527/21.  
PT Bacterial expression system for producing recombinant human uteroglobin  
XX for treating inflammatory and fibrotic conditions, comprises a synthetic

PT gene which codes for human uteroglobin.

XX Example 1; Page 33; 127pp; English.

XX The present sequence is that of oligonucleotide 7, which was used in the  
CC construction of a synthetic gene for the production of human uteroglobin  
CC (hUG) in bacteria. Oligonucleotides 1-4 (see ABZ58370-73) were used to  
CC assemble the coding strand and oligonucleotides 5-8 (see ABZ58374-77) the  
CC complementary strand. The gene was assembled by annealing and ligation of  
CC the oligonucleotides. Because mature native hUG has glutamic acid at its  
CC N-terminus, an initiator methionine was added to the N-terminus, and  
CC codon usage was optimised for expression in bacteria. In an example from  
CC the invention, the synthetic gene was cloned into plasmid pCG12 (see  
CC ABZ58378) and recombinant hUG (see ABP72259) was produced in *Escherichia*  
CC coli strain CG12. The invention relates generally to the production of  
CC recombinant hUG by bacterial expression, protein purification and scaled-  
CC up production according to current good manufacturing practices. The  
CC recombinant hUG is useful for the treatment of inflammatory and fibrotic  
CC conditions, such as neonatal respiratory distress syndrome and  
CC bronchopulmonary dysplasia. It may also be used to treat conditions  
CC associated with elevated phospholipase A2 levels such as pancreatitis,  
CC acute renal failure, rheumatoid arthritis and asthma

XX Sequence 60 BP; 12 A; 14 C; 22 G; 12 T; 0 U; 0 Other;

Query Match 35.4%; Score 23; DB 9; Length 60;  
Best Local Similarity 100.0%; Pred. No. 0.014;

Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 43 CCTGCTGATGACACCCCGTCC 65

DB 60 CCTGCTGATGACACCCCGTCC 38

RESULT 4  
ABZ58377/c  
ID ABZ58377 standard; DNA; 60 BP.

XX AC ABZ58377;

XX DT 28-APR-2003 (first entry)

XX DB Human uteroglobin synthetic gene oligonucleotide 8.

XX KW Human; uteroglobin; respiratory distress; antiinflammatory; antifibrotic;

XX KW antiinflammatory; antiasthmatic; nephrotropic; antirheumatic;

XX OS Homo sapiens.

XX OS Synthetic.

XX PN WO2003003979-A2.

XX PD 16-JAN-2003.

XX PF 02-JUL-2002; 2002WC-US020836.

XX PR 02-JUL-2001; 2001US-00898616.

XX PA (CLAR-) CLARAGEN INC.

XX PI Pilon AL, Welch RE;

XX DR WPI; 2003-221527/21.

XX Bacterial expression system for producing recombinant human uteroglobin  
PT for treating inflammatory and fibrotic conditions, comprises a synthetic  
PT gene which codes for human uteroglobin.

XX Example 1; Page 33; 127pp; English.

XX The present sequence is that of oligonucleotide 8, which was used in the  
CC construction of a synthetic gene for the production of human uteroglobin

CC (hUG) in bacteria. Oligonucleotides 1-4 (see ABZ58370-73) were used to  
CC assemble the coding strand and oligonucleotides 5-8 (see ABZ58374-77) the  
CC complementary strand. The gene was assembled by annealing and ligation of  
CC the oligonucleotides. Because mature native hUG has glutamic acid at its  
CC N-terminus, an initiator methionine was added to the N-terminus, and  
CC codon usage was optimised for expression in bacteria. In an example from  
CC the invention, the synthetic gene was cloned into plasmid pCG12 (see  
CC ABZ58378) and recombinant hUG (see ABP72259) was produced in *Escherichia*  
CC coli strain CG12. The invention relates generally to the production of  
CC recombinant hUG by bacterial expression, protein purification and scaled-  
CC up production according to current good manufacturing practices. The  
CC recombinant hUG is useful for the treatment of inflammatory and fibrotic  
CC conditions, such as neonatal respiratory distress syndrome and  
CC bronchopulmonary dysplasia. It may also be used to treat conditions  
CC associated with elevated phospholipase A2 levels such as pancreatitis,  
CC acute renal failure, rheumatoid arthritis and asthma

XX Sequence 60 BP; 12 A; 14 C; 22 G; 12 T; 0 U; 0 Other;

Query Match 35.4%; Score 23; DB 9; Length 60;  
Best Local Similarity 100.0%; Pred. No. 0.014;

Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 43 CCTGCTGATGACACCCCGTCC 65

DB 60 CCTGCTGATGACACCCCGTCC 38

RESULT 5  
ADL27633/c  
ID ADL27633 standard; DNA; 60 BP.

XX AC ADL27633;

XX DT 20-MAY-2004 (first entry)

XX DB Recombinant human uteroglobin, rhUG, non-coding oligonucleotide #4.

XX KW Human; ss; recombinant human uteroglobin; rhUG;

XX KW bacterial expression system; rhUG master cell bank;

XX KW rhUG research seed bank; anti-inflammatory; secretory phospholipase A 2;

XX KW fibronectin; respiratory distress; inflammation; fibrotic disease.

XX OS Homo sapiens.

XX OS Synthetic.

XX PN US2003207795-A1.

XX PD 06-NOV-2003.

XX PF 02-JUL-2002; 2002US-00187498.

XX PR 28-MAY-1997; 9TUS-00864357.

XX PR 02-JUL-2001; 2001US-00898616.

XX PA (PILO/) PILON A L.

XX PA (WELC/) WELCH R W.

XX PI Pilon AL, Welch RW;

XX DR WPI; 2004-051527/05.

XX Bacterial expression system for production of recombinant human  
PT uteroglobin comprising synthetic gene or human cDNA sequence which codes  
PT for human uteroglobin.

XX Example 1; SEQ ID NO 8; 64pp; English.

XX The invention relates to a bacterial expression system for the production  
CC of recombinant human uteroglobin (rhUG) comprising a synthetic gene or  
CC human cDNA sequence which codes for human hUG constructed from the  
CC oligonucleotides appearing as ADL27626-ADL27629, and which further  
CC comprises Met-Ala-Ala at the N-terminus of the sequence. Also included

are producing an rhUG master cell bank (comprising inoculating a suitable incubating broth with an aliquot portion of a rhUG research seed bank to form a bacterial culture, incubating the bacterial culture, adding a cryopreservative to the bacterial culture to form a cryopreserved solution, transferring the cryopreserved solution to a cryovial and storing the cryovial at a temperature below -60 degrees C), expressing rhUG (comprising providing a production seed cell bank culture comprising an expression vector capable of expressing rhUG, inoculating a broth medium with the production seed cell bank culture to form an inoculum, incubating the bacterial culture formed in step (b), inoculating a large scale fermenter with the inoculum formed from the step (c) to form a fermentation culture, adding an induction agent to the fermentation culture to induce the expression of rhUG and harvesting the above fermentation culture), purifying rhUG, determining the potency of rhUG in a sample, measuring in vitro anti-inflammatory effect arising from inhibition or blocking of secretory phospholipase A 2 enzymes by rhUG, measuring in vitro binding of rhUG to fibronectin, determining the purity of rhUG, and a pharmaceutical composition comprising a purified rhUG and a carrier or diluent. The bacterial expression system is useful for producing a rhUG research seed bank or a pharmaceutical grade rhUG drug substance. rhUG is safe to administer to a patient in respiratory distress. The rhUG is useful for treating inflammation and fibrotic diseases. The present sequence is a non-coding strand oligonucleotide used to construct the synthetic rhUG gene.

Sequence 60 BP, 12 A, 14 C, 22 G, 12 T, 0 U, 0 Other;

Query Match 35.4%; Score 23; DB 12; Length 60;  
Best Local Similarity 100.0%; Pred. No. 0.014;  
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

43 CCTGCTGATGACACCCCGTCC 65  
60 CCTGCTGATGACACCCCGTCC 38

RESULT 6  
ADL27632/C  
ID ADL27632 standard; DNA; 60 BP.  
XX  
XX  
AC ADL27632;  
XX  
DT 20-MAY-2004 (first entry)  
XX  
DE Recombinant human uteroglobin, rhUG, non-coding oligonucleotide #3.  
XX  
DE Human; ss; recombinant human uteroglobin; rhUG;  
KW bacterial expression system; rhUG master cell bank;  
KW rhUG research seed bank; anti-inflammatory; secretory phospholipase A 2;  
KW fibronectin; respiratory distress; inflammation; fibrotic disease.  
XX  
XX Homo sapiens.  
OS Synthetic.  
XX  
XX US2003207795-A1.  
XX  
XX PD 06-NOV-2003.  
XX  
XX PF 02-JUL-2002; 2002US-00187498.  
XX  
XX PR 28-MAY-1997; 97US-00864357.  
XX  
XX PR 02-JUL-2001; 2001US-00898616.  
XX  
XX PA (PILCO) PILON A L.  
XX (WELC) WELCH R W.  
XX  
XX PI Pilon AL, Welch RW;  
XX  
XX DR WPI, 2004-051527/05.  
XX  
XX PT Bacterial expression system for production of recombinant human  
PT uteroglobin comprising synthetic gene or human cDNA sequence which codes

for human uteroglobin.

XX  
XX Example 1; SEQ ID NO 7; 64bp; English.

XX  
XX The invention relates to a bacterial expression system for the production  
XX of recombinant human uteroglobin (rhUG), comprising a synthetic gene or  
XX human cDNA sequence which codes for human UG, constructed from the  
XX oligonucleotides appearing as ADL27626-ADL27629, and which further  
XX comprises Met-Ala-Ala at the N-terminus of the sequence. Also included  
XX are producing an rhUG master cell bank (comprising inoculating a suitable  
XX incubating broth with an aliquot portion of a rhUG research seed bank to  
XX form a bacterial culture, incubating the bacterial culture, adding a  
XX cryopreservative to the bacterial culture to form a cryopreserved  
XX solution, transferring the cryovial at a temperature below -60 degrees C),  
XX cryovial and storing the cryovial at a temperature below -60 degrees C),  
XX expressing rhUG (comprising providing a production seed cell bank culture  
XX comprising an expression vector capable of expressing rhUG, inoculating a  
XX broth medium with the production seed cell bank culture to form an  
XX inoculum, incubating the bacterial culture formed in step (b),  
XX inoculating a large scale fermenter with the inoculum formed from the  
XX step (c) to form a fermentation culture, adding an induction agent to  
XX culture within the large scale fermenter, adding an induction agent to  
XX the fermentation culture to induce the expression of rhUG and harvesting  
XX the above fermentation culture), purifying rhUG, determining the potency  
XX of rhUG in a sample, measuring in vitro anti-inflammatory effect arising  
XX from inhibition or blocking of secretory phospholipase A 2 enzymes by  
XX rhUG, measuring in vitro binding of rhUG to fibronectin, determining the  
XX purity of rhUG, and a pharmaceutical composition comprising a purified  
XX rhUG and a carrier or diluent. The bacterial expression system is useful  
XX for producing a rhUG research seed bank or a pharmaceutical grade rhUG  
XX drug substance. rhUG is safe to administer to a patient in respiratory  
XX distress. The rhUG is useful for treating inflammation and fibrotic  
XX diseases. The present sequence is a non-coding strand oligonucleotide  
XX used to construct the synthetic rhUG gene.

Sequence 60 BP, 12 A, 14 C, 22 G, 12 T, 0 U, 0 Other;

Query Match 35.4%; Score 23; DB 12; Length 60;  
Best Local Similarity 100.0%; Pred. No. 0.014;  
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

43 CCTGCTGATGACACCCCGTCC 65  
60 CCTGCTGATGACACCCCGTCC 38

RESULT 7  
ABK10937  
ID ABK10937 standard; DNA; 36 BP.  
XX  
XX  
AC ABK10937;  
XX  
DT 20-MAY-2002 (first entry)  
XX  
DE Primer IRAP5 relating to modified retroviral vector invention.  
XX  
XX Human; retrovirus vector; elongation factor 1-alpha; gene therapy;  
KW EF 1alpha; Murine Leukemia Virus; MLV; multi-cloning site; MCS; primer;  
KW IRAP5; ss.  
XX  
XX Unidentified.  
OS  
XX  
XX KR2001069245-A.  
XX  
XX PD 25-JUL-2001.  
XX  
XX PF 08-SEP-2000; 2000KR-00053613.  
XX  
XX PR 08-SEP-2000; 2000KR-00053613.  
XX  
XX PA (VIRRO-) VIRRO MED LTD.  
XX  
XX PI Kim SY, Lee JT, Yoo SS;



XX	WPI; 2002-065240/09.
DR	
XX	
PT	Retroviral vectors useful in gene therapy, containing no viral coding
PT	sequences but which includes a human elongation factor 1 alpha non-coding
PT	fragment.
XX	
XX	
PS	Disclosure; Page 31; 32pp; Korean.
XX	
CC	The present invention relates to a retrovirus vector containing modified
CC	non-coding sequences derived from the human elongation factor 1-alpha
CC	gene (EF 1alpha, bases +773 to +1006), which can be effectively used in
CC	gene therapy due to it's high stability and expression. The Murine
CC	Leukemia Virus (MLV)-derived retrovirus vector is modified by complete
CC	removal of the gag, env and pol genes to improve gene expression and
CC	virus producibility. It is also modified to contain the non-coding
CC	portion of the EF 1alpha gene upstream of a multi-cloning site (MCS). The
CC	present sequence represents a primer used in the methods of the present
CC	invention
XX	
SC	Sequence 36 BP; 9 A; 11 C; 10 G; 6 T; 0 U; 0 Other;
Query Match	26.2%; Score 17; DB 6; Length 36;
Best Local Similarity	100.0%; Pred. No. 27;
Matches 17; Conservative	0; Mismatches 0; Indels 0; Gaps 0;
Qy	1 GATCCATGGAAATCTGC 17
Db	2 GATCCATGGAAATCTGC 18
RESULT 8	
ABK47610	
ID	ABK47610 standard; DNA; 36 BP.
XX	
AC	ABK47610;
XX	
DT	
XX	24-SEP-2002 (first entry)
DE	Interleukin-1 receptor antagonist (IL-1ra), PCR primer IRAP5'.
XX	
KW	Human; elongation factor 1-alpha; retroviral vector; EF1a;
KW	murine leukemia virus vector; MLV; elongation factor 1 alpha;
KW	gene therapy; interleukin-1 receptor antagonist; IL-1ra; PCR; primer; ss.
OS	Homo sapiens.
XX	
WO200220810-A1.	
PN	14-MAR-2002.
XX	
PF	08-SEP-2001; 2001WO-KR001515.
XX	
PR	08-SEP-2000; 2000KR-00053613.
XX	
PA	(VIRO-) VIROMED LTD.
XX	
PI	Kim SY, Yu SS, Lee JT;
XX	
DR	WPI; 2002-065240/41.
XX	
PT	Retroviral vectors useful in gene therapy, containing no viral coding
PT	sequences but which includes a human elongation factor 1 alpha non-coding
PT	fragment.
XX	
PS	Example 5; Page 45; 47pp; English.
XX	

CC gene therapy vectors. They are safe, i.e. they can not form replication  
CC competent retroviruses by homologous recombination; the heterologous  
CC hitron ensures efficient expression of foreign genes and the specified  
CC mutation means that a proper balance between splicing efficiency and  
CC viral titre is maintained. Also a heterologous promoter can be inserted  
CC to increase viral titre in packaging lines derived from human cells. An  
CC additional promoter (or internal ribosome entry site) can be provided to  
CC allow expression of two or more genes. The present sequence represents a  
CC PCR primer used to make the retroviral vector of the invention  
XX

XX Sequence 36 BP; 9 A; 11 C; 10 G; 6 T; 0 U; 0 Other;

Query Match 26.2%; Score 17; DB 6; Length 36;  
Best Local Similarity 100.0%; Pred. No. 27;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Caps 0

Qy 1 GATCCATGGAAATCTGC 17  
Db 2 GATCCATGGAAATCTGC 18

RESULT 9  
AAH66339/c  
AAH66339 standard; DNA; 990 BP.

AC AAH66339;  
XX  
XX  
XX 26-SEP-2001 (first entry)  
XX  
XX C glutamicum coding sequence fragment SEQ ID NO: 1374.  
XX  
XX Coryneform bacterium; amino acid synthesis; vitamin; saccharide;  
XX organic acid synthesis; ds.  
XX  
XX Corynebacterium glutamicum.  
XX  
XX BP1108790-A2.  
XX  
XX 20-JUN-2001.  
XX  
XX 18-DEC-2000; 2000EP-00127688.  
XX  
XX 16-DEC-1999; 993P-00377484.  
XX 07-APR-2000; 2000UP-00159162.  
XX 03-AUG-2000; 2000UP-00280958.  
XX  
XX (KYOM ) KYOMA HAKKO KOGYO KK.  
XX  
XX Nakagawa S, Mizoguchi H, Ando S, Hayashi M, Ochiai K, Yokoi H;  
XX Tateshi N, Senoh A, Ikeda M, Ozaki A;  
XX  
XX WPI, 2001-376931/40.  
XX P-PSDB; AAG91120.  
XX  
XX Novel polynucleotides derived from Coryneform bacteria, for identifying  
XX mutation point of a gene, measuring expression of a gene, analyzing  
XX expression profile or pattern of a gene and identifying homologous gene.  
XX  
XX Claim 8; SEQ ID NO 1374; 246bp + Sequence Listing; English.

PS The present invention provides a number of nucleotide and protein  
CC sequences from the Coryneform bacterium Corynebacterium glutamicum. These  
CC are useful for identifying the mutation point of a gene derived from a  
CC mutant of coryneform bacterium, measuring expression amount and analyzing  
CC the expression profile or expression pattern of a gene derived from  
CC Coryneform bacterium, and identifying a homologue of a gene derived from  
CC coryneform bacterium. Coryneform bacteria are useful for producing amino  
CC acids, nucleic acids, vitamins, saccharides and organic acids,  
CC particularly L-lysine. The present sequence is a nucleic acid described  
CC in the exemplification of the invention. Note, the sequence data for this  
CC patent did not form part of the printed specification, but was obtained  
CC in electronic format directly from the European Patent Office  
XX

Sequence 990 BP; 196 A; 239 C; 310 G; 245 T; 0 U; 0 Other;  
 Query Match 26.2%; Score 17; DB 5; Length 990;  
 Best Local Similarity 100.0%; Pred. No. 26;  
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GATCCATGGAATCTGC 17  
 |||||  
 DB 688 GATCCATGGAATCTGC 672

RESULT 10  
 AAF71853/c  
 ID AAF71853 standard; DNA; 1113 BP.  
 XX AAF71853;  
 AC  
 XX  
 DT 30-APR-2001 (first entry)  
 XX  
 DE Corynebacterium glutamicum MP protein nucleotide sequence SEQ ID NO:201.  
 XX  
 KW Corynebacterium glutamicum; metabolic pathway protein; MP protein;  
 KW fine chemical production; microorganism; organic acid; nucleoside;  
 KW nonproteogenic amino acid; purine base; pyrimidine base; nucleotide;  
 KW lipid; saturated fatty acid; unsaturated fatty acid; diol; vitamin;  
 KW carbohydrate; aromatic compound; cofactor; polypeptide; enzyme; ds.  
 XX  
 OS Corynebacterium glutamicum.  
 XX  
 PN W0200100843-A2.  
 XX  
 PD 04-JAN-2001.  
 XX  
 PF 23-JUN-2000; 2000MO-IB000923.  
 XX  
 PR 25-JUN-1999; 99US-0141031P  
 PR 01-JUL-1999; 99DE-01030736  
 PR 02-JUL-1999; 99US-0142101P  
 PR 08-JUL-1999; 99DE-01031415  
 PR 08-JUL-1999; 99DE-01031418  
 PR 08-JUL-1999; 99DE-01031419  
 PR 08-JUL-1999; 99DE-01031420  
 PR 08-JUL-1999; 99DE-01031424  
 PR 08-JUL-1999; 99DE-01031428  
 PR 08-JUL-1999; 99DE-01031434  
 PR 08-JUL-1999; 99DE-01031435  
 PR 08-JUL-1999; 99DE-01031443  
 PR 08-JUL-1999; 99DE-01031453  
 PR 08-JUL-1999; 99DE-01031457  
 PR 08-JUL-1999; 99DE-01031465  
 PR 08-JUL-1999; 99DE-01031478  
 PR 08-JUL-1999; 99DE-01031510  
 PR 08-JUL-1999; 99DE-01031541  
 PR 08-JUL-1999; 99DE-01031573  
 PR 08-JUL-1999; 99DE-01031592  
 PR 08-JUL-1999; 99DE-01031632  
 PR 08-JUL-1999; 99DE-01031634  
 PR 08-JUL-1999; 99DE-01031636  
 PR 09-JUL-1999; 99DE-01032125  
 PR 09-JUL-1999; 99DE-01032126  
 PR 09-JUL-1999; 99DE-01032130  
 PR 09-JUL-1999; 99DE-01032186  
 PR 09-JUL-1999; 99DE-01032206  
 PR 09-JUL-1999; 99DE-01032227  
 PR 09-JUL-1999; 99DE-01032228  
 PR 09-JUL-1999; 99DE-01032229  
 PR 09-JUL-1999; 99DE-01032230  
 PR 14-JUL-1999; 99DE-01032822  
 PR 14-JUL-1999; 99DE-01032826  
 PR 14-JUL-1999; 99DE-01032828  
 PR 14-JUL-1999; 99DE-01033004  
 PR 14-JUL-1999; 99DE-01033005  
 PR 14-JUL-1999; 99DE-01033006

PR 12-AUG-1999; 99US-0148613P  
 PR 27-AUG-1999; 99DE-01040764  
 PR 27-AUG-1999; 99DE-01040765  
 PR 27-AUG-1999; 99DE-01040766  
 PR 27-AUG-1999; 99DE-01040832  
 PR 31-AUG-1999; 99DE-01041378  
 PR 31-AUG-1999; 99DE-01041379  
 PR 31-AUG-1999; 99DE-01041380  
 PR 31-AUG-1999; 99DE-01041394  
 PR 31-AUG-1999; 99DE-01041396  
 PR 03-SEP-1999; 99DE-01042076  
 PR 03-SEP-1999; 99DE-01042077  
 PR 03-SEP-1999; 99DE-01042079  
 PR 03-SEP-1999; 99DE-01042086  
 PR 03-SEP-1999; 99DE-01042087  
 PR 03-SEP-1999; 99DE-01042088  
 PR 03-SEP-1999; 99DE-01042095  
 PR 03-SEP-1999; 99DE-01042124  
 PR 03-SEP-1999; 99DE-01042129  
 PR 09-MAR-2000; 2000US-0187970P  
 XX  
 PA (BAD) BASF AG.  
 XX  
 PI Pompejus M, Kroeger B, Schroeder H, Zelder O, Haberhauer G;  
 XX  
 DR MPI; 2001-137957/14.  
 DR P-PSDB; AAB79734.  
 XX  
 PS Claim 3; Page 446-447; 1737pp; English.  
 XX  
 CC AAF71753 to AAF72330 encode the Corynebacterium glutamicum metabolic  
 CC pathway (MP) proteins given in AAB79634 to AAB80211. The C. glutamicum MP  
 CC nucleic acids are useful for the production of fine chemicals in  
 CC microorganisms, including organic acids, nonproteogenic amino acids,  
 CC purine and pyrimidine bases, nucleosides, nucleotides, lipids, saturated  
 CC and unsaturated fatty acids, diols, carbohydrates, aromatic compounds,  
 CC vitamins, cofactors, polypeptides and enzymes  
 XX  
 SQ Sequence 1113 BP; 220 A; 271 C; 348 G; 274 T; 0 U; 0 Other;  
 Query Match 26.2%; Score 17; DB 4; Length 1113;  
 Best Local Similarity 100.0%; Pred. No. 26;  
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GATCCATGGAATCTGC 17  
 |||||  
 DB 788 GATCCATGGAATCTGC 772

RESULT 11  
 AAS96115/c  
 ID AAS96115 standard; DNA; 1113 BP.  
 XX AAS96115;  
 AC  
 XX  
 DT 26-FEB-2002 (first entry)  
 XX  
 DE C. glutamicum gene #40 encoding metabolic pathway protein.  
 XX  
 KW Metabolic pathway protein; MP; lysine biosynthesis pathway;  
 KW methionine biosynthesis pathway; large-scale production of fine chemical;  
 KW Corynebacterium diptheriae; diptheria; ds.  
 XX  
 OS Corynebacterium glutamicum.  
 XX  
 PN W0200166573-A2.  
 XX  
 PD 13-SEP-2001.

XX 22-DEC-2000; 2000WO-1B002035.  
 PF 09-MAR-2000; 2000US-0187970P.  
 PR 23-JUN-2000; 2000US-00606740.  
 XX  
 PA (BADI) BASF AG.  
 XX  
 PI Pompejus M, Kroeger B, Schroeder H, Zelder O, Habernauer G;  
 PI Kim U, Lee H, Hwang B;  
 XX  
 DR WPI; 2001-582869/65.  
 DR P-PSDB; AAU71905.  
 XX  
 PT Nucleic acids encoding metabolic pathway proteins from *Corynebacterium*  
 PT glutamicum, useful for producing methionine and lysine in *Corynebacterium*  
 PT and *Brevibacterium*.  
 XX  
 PS Disclosure; Page 256-257; 316pp; English.  
 XX  
 CC The present invention relates to the isolation of novel *Corynebacterium*  
 CC glutamicum genes encoding metabolic pathway (MP) proteins (AAU71863-  
 CC AAU71922). The metabolic pathway proteins of the invention include  
 CC enzymes involved in the lysine and methionine biosynthetic pathways. The  
 CC polynucleotide sequences of the invention can be used for the large-scale  
 CC production and/or modulation of expression of fine chemicals such as  
 CC lysine and methionine. The sequences of the invention may be used to  
 CC identify *C. glutamicum* and related organisms e.g. *C. diphtheriae* in a  
 CC subject to detect diphtheria. AAS96073-AAS96132 represent *C. glutamicum*  
 CC genes encoding the novel metabolic pathway proteins of the invention  
 XX  
 SQ Sequence 113 BP; 220 A; 271 C; 348 G; 274 T; 0 U; 0 Other;  
 Query Match 26.2%; Score 17; DB 4; Length 113;  
 Best Local Similarity 100.0%; Pred. No. 26;  
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 GATCCATGGAATCTGC 17  
 Db 788 GATCCATGGAATCTGC 772  
 XX  
 RESULT 12  
 ID AAS74960 standard; CDNA; 2055 BP.  
 AC AAS74960;  
 XX  
 DT 13-FEB-2002 (first entry)  
 XX  
 DE DNA encoding novel human diagnostic protein #10764.  
 XX  
 KW Human; chromosome mapping; gene mapping; gene therapy; forensic;  
 KW food supplement; medical imaging; diagnostic; genetic disorder; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200175067-A2.  
 XX  
 PD 11-OCT-2001.  
 XX  
 PF 30-MAR-2001; 2001WO-US008631.  
 XX  
 PR 31-MAR-2000; 2000US-00540217.  
 PR 23-AUG-2000; 2000US-00649167.  
 XX  
 PA (HYSE-) HYSEQ INC.  
 XX  
 PI Drmanac RT, Liu C, Tang YT;  
 XX  
 DR WPI; 2001-639362/73.  
 DR P-PSDB; ABG10773.  
 XX

PT New isolated polynucleotide and encoded polypeptides, useful in  
 PT diagnostics, forensics, gene mapping, identification of mutations  
 PT responsible for genetic disorders or other traits and to assess  
 PT biodiversity.  
 XX  
 PS Claim 1; SEQ ID NO 10764; 103pp; English.  
 XX  
 CC The invention relates to isolated polynucleotide (I) and polypeptide (II)  
 CC sequences. (I) is useful as hybridisation probes, polymerase chain  
 CC reaction (PCR) primers, oligomers, and for chromosome and gene mapping,  
 CC and in recombinant production or (II). The polynucleotides are also used  
 CC in diagnostics as expressed sequence tags for identifying expressed  
 CC genes. (I) is useful in gene therapy techniques to restore normal  
 CC activity of (II) or to treat disease states involving (II). (II) is  
 CC useful for generating antibodies against it, detecting or quantitating a  
 CC polypeptide in tissue, as molecular weight markers and as a food  
 CC supplement. (II) and its binding partners are useful in medical imaging  
 CC of sites expressing (II). (I) and (II) are useful for treating disorders  
 CC involving aberrant protein expression or biological activity. The  
 CC polypeptide and polynucleotide sequences have applications in  
 CC diagnostics, forensics, gene mapping, identification of mutations  
 CC responsible for genetic disorders or other traits to assess biodiversity  
 CC and to produce other types of data and products dependent on DNA and  
 CC amino acid sequences. AAS6197-AAS94564 represent novel human diagnostic  
 CC coding sequences of the invention. Note: The sequence data for this  
 CC patent did not appear in the printed specification, but was obtained in  
 CC electronic format directly from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences  
 XX  
 SQ Sequence 2055 BP; 469 A; 581 C; 604 G; 401 T; 0 U; 0 Other;  
 Query Match 26.2%; Score 17; DB 5; Length 2055;  
 Best Local Similarity 100.0%; Pred. No. 26;  
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 40 AAACCTGCTGATGAGAC 56  
 Db 98 AAACCTGCTGATGAGAC 114  
 XX  
 RESULT 13  
 ID ACA43988 standard; DNA; 2877 BP.  
 AC ACA43988;  
 XX  
 DT 19-JUN-2003 (first entry)  
 XX  
 DE Prokaryotic essential gene #25645.  
 XX  
 KW Antisense; ds; prokaryotic essential gene; cell proliferation;  
 KW drug design; gene.  
 XX  
 OS *Pseudomonas putida*.  
 XX  
 PN WO200277133-A2.  
 XX  
 PD 03-OCT-2002.  
 XX  
 PF 21-MAR-2002; 2002WO-US009107.  
 XX  
 PR 21-MAR-2001; 2001US-00815242.  
 PR 06-SEP-2001; 2001US-00948993.  
 PR 25-OCT-2001; 2001US-0342923P.  
 PR 08-FEB-2002; 2002US-00072851.  
 PR 06-MAR-2002; 2002US-0362699P.  
 XX  
 PA (ELIT-) ELITRA PHARM INC.  
 XX  
 PI Wang L, Zamudio C, Malone C, Haselbeck R, Ohlsen KL, Zyskind JW;  
 PI Wall D, Trawick JD, Carr GT, Yamamoto R, Foreyth RA, Xu HH;  
 XX  
 DR WPI; 2003-029926/02.  
 XX

DR P-PSDB; AEU40118.

XX New antisense nucleic acids, useful for identifying proteins or screening  
PT for homologous nucleic acids, required for cellular proliferation to  
PT isolate candidate molecules for rational drug discovery programs.

PS Claim 14; SEQ ID NO 31858; 1766pp; English.

XX The invention relates to an isolated nucleic acid comprising any one of  
CC the 6213 antisense sequences given in the specification where expression  
CC of the nucleic acid inhibits proliferation of a cell. Also included are:  
CC (1) a vector comprising a promoter operably linked to the nucleic acid  
CC encoding a polypeptide whose expression is inhibited by the antisense  
CC nucleic acid; (2) a host cell containing the vector; (3) an isolated  
CC polypeptide or its fragment whose expression is inhibited by the  
CC antisense nucleic acid; (4) an antibody capable of specifically binding  
CC the polypeptide; (5) producing the polypeptide; (6) inhibiting cellular  
CC proliferation or the activity of a gene in an operon required for  
CC proliferation; (7) identifying a compound that influences the activity of  
CC the gene product or that has an activity against a biological pathway  
CC required for proliferation, or that inhibits cellular proliferation; (8)  
CC identifying a gene required for cellular proliferation or the biological  
CC pathway in which a proliferation-regulated gene or its gene product lies  
CC or a gene on which the test compound that inhibits proliferation of an  
CC organism acts; (9) manufacturing an antibiotic; (10) profiling a  
CC compound's activity; (11) a culture comprising strains in which the gene  
CC product is overexpressed or underexpressed; (12) determining the extent  
CC to which each of the strains is present in a culture or collection of  
CC strains; or (13) identifying the target of a compound that inhibits the  
CC proliferation of an organism. The antisense nucleic acids are useful for  
CC identifying proteins or screening for homologous nucleic acids required  
CC for cellular proliferation to isolate candidate molecules for rational  
CC drug discovery programs, or for screening homologous nucleic acids  
CC required for proliferation in cells other than *S. aureus*, *S. typhimurium*,  
CC *K. pneumoniae* or *P. aeruginosa*. The present sequence is one of the target  
CC prokaryotic essential genes. Note: The sequence data for this patent did  
CC not form part of the printed specification, but was obtained in  
CC electronic format directly from WIPO at  
CC [ftp://wipo.int/pub/published\\_pct\\_sequences](http://wipo.int/pub/published_pct_sequences)

SQ Sequence 2877 BP; 629 A; 981 C; 802 G; 465 T; 0 U; 0 Other;

Query Match 26.2%; Score 17; DB 8; Length 2877;  
Best Local Similarity 100.0%; Pred. No. 26;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 44 CCTGCTGATGACACCC 60  
DB 675 CCTGCTGATGACACCC 691

## RESULT 14

AAS34085 AAS54085 standard; DNA; 2892 BP.

AC AAS54085;

DT 13-FEB-2002 (first entry)

DE Pseudomonas aeruginosa DNA for cellular proliferation protein #216.

XX Antisense; ds; prokaryotic cellular proliferation gene; antibiotic;  
KM antibacterial; drug design.

OS Pseudomonas aeruginosa.

PN W0200170955-A2.

PD 27-SEP-2001.

PF 21-MAR-2001; 2001WO-US009180.

PR 21-MAR-2000; 2000US-0191078P.

PR 23-MAY-2000; 2000US-0206848P.  
PR 26-MAY-2000; 2000US-0207272P.  
PR 23-OCT-2000; 2000US-0242578P.  
PR 27-NOV-2000; 2000US-0253625P.  
PR 22-DEC-2000; 2000US-0257531P.  
PR 16-FEB-2001; 2001US-0269308P.

PA (ELIT-) ELITRA PHARM INC.

XX Haselbeck R, Ohlsen KL, Zyskind JW, Wall D, Trawick JD, Carr GJ;

PI Yamamoto RT, Xu HH;

XX WPI, 2001-611495/70.

DR P-PSDB; AEU36226.

XX New polynucleotides for the identification and development of  
PT antibiotics, comprise sequences of antisense nucleic acids.

PS Claim 27; SEQ ID NO 7722; 511pp; English.

XX The invention relates to antisense inhibitors of genes essential to  
CC prokaryotic cellular proliferation, their use in identifying the genes,  
CC their use in the discovery of novel antibiotics, the essential genes  
CC themselves and the encoded proteins. The prokaryotes used are *Escherichia*  
CC coli, *Staphylococcus aureus*, *Salmonella typhi*, *Klebsiella pneumoniae*,  
CC *Pseudomonas aeruginosa* and *Enterococcus faecalis*. The invention is also  
CC useful for the identification of potential new targets for antibiotic  
CC development. The antisense nucleic acids can also be used to identify  
CC proteins used in proliferation, to express these proteins, and to obtain  
CC antibodies capable of binding to the expressed proteins. The proteins can  
CC be used to screen compounds in rational drug discovery programmes. The  
CC antisense nucleic acid sequence is also useful to screen for homologous  
CC nucleic acids which are required for cell proliferation in a wide variety  
CC of organisms. The present sequence encodes an essential prokaryotic  
CC cellular proliferation protein. Note: The sequence data for this patent  
CC did not form part of the printed specification, but was obtained in  
CC electronic format directly from WIPO at  
CC [ftp://wipo.int/pub/published\\_pct\\_sequences](http://wipo.int/pub/published_pct_sequences)

SQ Sequence 2892 BP; 594 A; 1063 C; 824 G; 411 T; 0 U; 0 Other;

Query Match 26.2%; Score 17; DB 4; Length 2892;  
Best Local Similarity 100.0%; Pred. No. 26;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 44 CCTGCTGATGACACCC 60  
DB 675 CCTGCTGATGACACCC 691

## RESULT 15

ACA42189 ACA42189 standard; DNA; 2892 BP.

AC ACA42189;

DT 19-JUN-2003 (first entry)

DE Prokaryotic essential gene #23856.

XX Antisense; ds; prokaryotic essential gene; cell proliferation;  
KM drug design; gene.

OS Pseudomonas aeruginosa.

PN W0200277183-A2.

PD 03-OCT-2002.

PF 21-MAR-2002; 2002WO-US009107.

PR 21-MAR-2001; 2001US-00815242.

PR 06-SEP-2001; 2001US-00948993.

PR 25-OCT-2001; 2001US-0342923P.  
 PR 08-FEB-2002; 2002US-0007285P.  
 PR 06-MAR-2002; 2002US-0362699P.  
 XX  
 XX (ELIT-) ELITRA PHARM INC.  
 PA  
 PI Wang L, Zamudio C, Malone C, Haselbeck R, Ohlsen KL, Zyskind JW;  
 PI Wall D, Trawick JD, Carr GT, Yamamoto R, Forsyth RA, Xu HH;  
 XX  
 DR MPI; 2003-029926/02.  
 DR P-PDB; AB038329.  
 XX  
 PT New antisense nucleic acids, useful for identifying proteins or screening  
 PT for homologous nucleic acids required for cellular proliferation to  
 PT isolate candidate molecules for rational drug discovery programs.  
 XX  
 PS Claim 14; SEQ ID NO 30069; 1766bp; English.  
 XX  
 CC The invention relates to an isolated nucleic acid comprising any one of  
 CC the 6213 antisense sequences given in the specification where expression  
 CC of the nucleic acid inhibits proliferation of a cell. Also included are:  
 CC (1) a vector comprising a promoter operably linked to the nucleic acid  
 CC encoding a polypeptide whose expression is inhibited by the antisense  
 CC nucleic acid; (2) a host cell containing the vector; (3) an isolated  
 CC polypeptide or its fragment whose expression is inhibited by the  
 CC antisense nucleic acid; (4) an antibody capable of specifically binding  
 CC the polypeptide; (5) producing the polypeptide; (6) inhibiting cellular  
 CC proliferation or the activity of a gene in an operon required for  
 CC proliferation; (7) identifying a compound that influences the activity of  
 CC the gene product or that has an activity against a biological pathway  
 CC required for proliferation, or that inhibits cellular proliferation; (8)  
 CC identifying a gene required for cellular proliferation or the biological  
 CC pathway in which a proliferation-required gene or its gene product lies  
 CC or a gene on which the test compound that inhibits proliferation of an  
 CC organism acts; (9) manufacturing an antibiotic; (10) profiling a  
 CC compound's activity; (11) a culture comprising strains in which the gene  
 CC product is overexpressed or underexpressed; (12) determining the extent  
 CC to which each of the strains is present in a culture or collection of  
 CC strains; or (13) identifying the target of a compound that inhibits the  
 CC proliferation of an organism. The antisense nucleic acids are useful for  
 CC identifying proteins or screening for homologous nucleic acids required  
 CC for cellular proliferation to isolate candidate molecules for rational  
 CC drug discovery programs, or for screening homologous nucleic acids  
 CC required for proliferation in cells other than *S. aureus*, *S. typhimurium*,  
 CC *K. pneumoniae* or *P. aeruginosa*. The present sequence is one of the target  
 CC prokaryotic essential genes. Note: The sequence data for this patent did  
 CC not form part of the printed specification, but was obtained in  
 CC electronic format directly from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences  
 XX  
 SQ Sequence 2892 BP; 594 A; 1063 C; 824 G; 411 T; 0 U; 0 Other;  
 XX  
 Query Match 26.2%; Score 17; DB 8; Length 2892;  
 Best Local Similarity 100.0%; Pred. No. 26;  
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 44 CCTGCTGATGACACCC 60  
 DB 675 CCTGCTGATGACACCC 691

Search completed: December 22, 2004, 22:44:07  
 Job time : 234.662 secs

**This Page Blank (uspto)**



ORGANISM: artificial  
FEATURE:  
OTHER INFORMATION: primer sequence  
US-08-864-357F-13

Query Match 64.6%; Score 42; DB 3; Length 42;  
Best Local Similarity 100.0%; Pred. No. 5,6e-14;  
Matches 42; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GATCCATGGAATCTGCCCTCTTCCAGCGCTTATCATAA 42  
DB 42 GATCCATGGAATCTGCCCTCTTCCAGCGCTTATCATAA 1

RESULT 3  
US-08-864-357F-12/c  
Sequence 12, Application US/08864357F  
Patent No. 6255281  
GENERAL INFORMATION:  
APPLICANT: Clargen, Inc. & NIH  
TITLE OF INVENTION: Use of Recombinant Human Uteroglobulin in Treatment of Inflammac  
FILE REFERENCE: 116142/2  
CURRENT APPLICATION NUMBER: US/08/864,357F  
CURRENT FILING DATE: 1997-05-28  
NUMBER OF SEQ ID NOS: 22  
SOFTWARE: Patent version 3.0  
SEQ ID NO 12  
LENGTH: 60  
TYPE: DNA  
ORGANISM: artificial  
FEATURE:  
OTHER INFORMATION: primer sequence  
US-08-864-357F-12

Query Match 35.4%; Score 23; DB 3; Length 60;  
Best Local Similarity 100.0%; Pred. No. 0.0016;  
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 43 CCTGCTGATGACACCCCGCTCC 65  
DB 60 CCTGCTGATGACACCCCGCTCC 38

RESULT 4  
US-09-252-991A-2879  
Sequence 2879, Application US/09252991A  
Patent No. 6551795  
GENERAL INFORMATION:  
APPLICANT: Marc J. Rubenfield et al.  
TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS  
FILE REFERENCE: 107196.136  
CURRENT APPLICATION NUMBER: US/09/252,991A  
CURRENT FILING DATE: 1999-02-18  
PRIOR APPLICATION NUMBER: US 60/074,788  
PRIOR FILING DATE: 1998-02-18  
PRIOR APPLICATION NUMBER: US 60/094,190  
PRIOR FILING DATE: 1998-07-27  
NUMBER OF SEQ ID NOS: 33142  
SEQ ID NO 2879  
LENGTH: 2997  
TYPE: DNA  
ORGANISM: Pseudomonas aeruginosa  
US-09-252-991A-2879

Query Match 26.2%; Score 17; DB 4; Length 2997;  
Best Local Similarity 100.0%; Pred. No. 3.1;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 44 CCTGCTGATGACACCC 60  
DB 780 CCTGCTGATGACACCC 756

RESULT 5  
US-09-252-991A-3091/c  
Sequence 3091, Application US/09252991A  
Patent No. 6551795  
GENERAL INFORMATION:  
APPLICANT: Marc J. Rubenfield et al.  
TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS  
FILE REFERENCE: 107196.136  
CURRENT APPLICATION NUMBER: US/09/252,991A  
CURRENT FILING DATE: 1999-02-18  
PRIOR APPLICATION NUMBER: US 60/074,788  
PRIOR FILING DATE: 1998-02-18  
PRIOR APPLICATION NUMBER: US 60/094,190  
PRIOR FILING DATE: 1998-07-27  
NUMBER OF SEQ ID NOS: 33142  
SEQ ID NO 3091  
LENGTH: 3009  
TYPE: DNA  
ORGANISM: Pseudomonas aeruginosa  
US-09-252-991A-3091

Query Match 26.2%; Score 17; DB 4; Length 3009;  
Best Local Similarity 100.0%; Pred. No. 3.1;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 44 CCTGCTGATGACACCC 60  
DB 2428 CCTGCTGATGACACCC 2412

RESULT 6  
US-09-489-039A-1155  
Sequence 1155, Application US/09489039A  
Patent No. 6610836  
GENERAL INFORMATION:  
APPLICANT: Gary Breton et. al  
TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO KLEBSIELLA  
FILE REFERENCE: 2709.2004001  
CURRENT APPLICATION NUMBER: US/09/489,039A  
CURRENT FILING DATE: 2000-01-27  
PRIOR APPLICATION NUMBER: US 60/117,747  
PRIOR FILING DATE: 1999-01-29  
NUMBER OF SEQ ID NOS: 14342  
SEQ ID NO 1155  
LENGTH: 894  
TYPE: DNA  
ORGANISM: Klebsiella pneumoniae  
US-09-489-039A-1155

Query Match 24.6%; Score 16; DB 4; Length 894;  
Best Local Similarity 100.0%; Pred. No. 11;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 40 AAACCTGCTGATGGA 55  
DB 527 AAACCTGCTGATGGA 542

RESULT 7  
US-09-489-039A-3704  
Sequence 3704, Application US/09489039A  
Patent No. 6610836  
GENERAL INFORMATION:  
APPLICANT: Gary Breton et. al  
TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO KLEBSIELLA  
FILE REFERENCE: 2709.2004001  
CURRENT APPLICATION NUMBER: US/09/489,039A  
CURRENT FILING DATE: 2000-01-27



PRIOR APPLICATION NUMBER: US 60/117,747  
 PRIOR FILING DATE: 1999-01-29  
 NUMBER OF SEQ ID NOS: 14342  
 SEQ ID NO 3704  
 LENGTH: 1119  
 TYPE: DNA  
 ORGANISM: Klebsiella pneumoniae  
 US-09-489-039A-3704

Query Match  
 Best Local Similarity 100.0%; Pred. No. 11;  
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 45 CTGCTGATGACACCC 60  
 DB 937 CTGCTGATGACACCC 952

RESULT 8  
 US-08-858-207A-101  
 Sequence 101, Application US/08858207A  
 Patent No. 6348328

GENERAL INFORMATION:  
 APPLICANT: Black, Michael  
 APPLICANT: Hodgson, John  
 APPLICANT: Knowles, David  
 APPLICANT: Nicholas, Richard  
 APPLICANT: Stedola, Robert  
 TITLE OF INVENTION: No. 6348328e1 Compounds  
 NUMBER OF SEQUENCES: 552  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: SmithKline Beecham Corporation  
 STREET: 709 Swedeland Road  
 CITY: King of Prussia  
 STATE: PA

COUNTRY: USA  
 ZIP: 19406-0939  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: Diskette  
 COMPUTER: IBM Compatible  
 OPERATING SYSTEM: DOS  
 SOFTWARE: FastSeq for Windows Version 2.0  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/08/858,207A  
 FILING DATE: 09-MAY-1997  
 CLASSIFICATION: 435  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: 60/017670  
 FILING DATE: 14-MAY-1996  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Gimm, Edward R  
 REGISTRATION NUMBER: 38,891  
 REFERENCE/DOCKET NUMBER: P50475  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 610-270-4478  
 TELEFAX: 610-270-5090  
 TELEX:

INFORMATION FOR SEQ ID NO: 101:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 1155 base pairs  
 TYPE: nucleic acid  
 STRANDEDNESS: single  
 TOPOLOGY: linear  
 US-08-858-207A-101

Query Match  
 Best Local Similarity 100.0%; Pred. No. 11;  
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 TCCATGGAATCTGCC 18  
 DB 1011 TCCATGGAATCTGCC 1026

RESULT 9  
 US-09-023-655-481/c  
 Sequence 481, Application US/09023655  
 Patent No. 6607879

GENERAL INFORMATION:  
 APPLICANT: Cocks, Benjamin G.  
 APPLICANT: Susan G. Stuart  
 APPLICANT: Jeffrey J. Seilhamer  
 TITLE OF INVENTION: COMPOSITION FOR THE DETECTION OF BLOOD CELL GENE  
 TITLE OF INVENTION: EXPRESSION  
 NUMBER OF SEQUENCES: 1508  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: INCYTE PHARMACEUTICALS, INC.  
 STREET: 3174 PORTER DRIVE  
 CITY: PALO ALTO  
 STATE: CALIFORNIA  
 COUNTRY: USA

ZIP: 94304  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: Floppy disk  
 COMPUTER: IBM PC compatible  
 OPERATING SYSTEM: PC-DOS/MS-DOS  
 SOFTWARE: Word Perfect 6.1 for Windows/MS-DOS 6.2  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/09/023,655  
 FILING DATE: HEREMITH  
 CLASSIFICATION:  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER:  
 FILING DATE:

ATTORNEY/AGENT INFORMATION:  
 NAME: Zeller, Karen J  
 REGISTRATION NUMBER: 37,071  
 REFERENCE/DOCKET NUMBER: PA-0001 US  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: (650) 845-4166  
 TELEFAX: (650) 855-0555  
 INFORMATION FOR SEQ ID NO: 481:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 1434 base pairs  
 TYPE: nucleic acid  
 STRANDEDNESS: single  
 TOPOLOGY: linear  
 IMMEDIATE SOURCE:  
 LIBRARY: CONNUT01  
 CLONE: 1908804  
 US-09-023-655-481

Query Match  
 Best Local Similarity 100.0%; Pred. No. 11;  
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 14 CTGCCCGCTTCCAG 29  
 DB 26 CTGCCCGCTTCCAG 11

RESULT 10  
 US-09-566-921-61/c  
 Sequence 61, Application US/09566921  
 Patent No. 6682888  
 GENERAL INFORMATION:  
 APPLICANT: Loring, Jeanne F.  
 APPLICANT: Tingley, Debora W.  
 APPLICANT: Edwards, Carla M.  
 TITLE OF INVENTION: GENES EXPRESSED IN ALZHEIMER'S DISEASE  
 FILING DATE: PA-0024 US  
 CURRENT APPLICATION NUMBER: US/09/566,921  
 CURRENT FILING DATE: 2000-05-05  
 NUMBER OF SEQ ID NOS: 138  
 SOFTWARE: PERL Program

SEQ ID NO 61  
LENGTH: 3911  
TYPE: DNA  
ORGANISM: Homo sapiens  
FEATURE:  
NAME/KEY: misc\_feature  
OTHER INFORMATION: Incyte ID No. 6682888 166400.9  
US-09-566-921-61

Query Match 24.6%; Score 16; DB 4; Length 3911;  
Best Local Similarity 100.0%; Pred. No. 11;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 14 CTGCCCGCTTTCCAG 29  
Db 2494 CTGCCCGCTTTCCAG 2479

RESULT 11  
US-09-166-350-32  
Sequence 32, Application US/09166350A  
Patent No. 6440663  
GENERAL INFORMATION:  
APPLICANT: Scanlan, Matthew  
APPLICANT: Chen, Yao  
APPLICANT: Stockert, Elisabeth  
APPLICANT: Old, Lloyd  
APPLICANT: Uager, Elke  
APPLICANT: Knuth, Alex  
TITLE OF INVENTION: Renal Cancer Associated Antigens and  
FILE REFERENCE: L0461/7051  
CURRENT APPLICATION NUMBER: US/09/166,350A  
CURRENT FILING DATE: 1998-10-05  
EARLIER APPLICATION NUMBER: US 09/166,350  
EARLIER FILING DATE: 1998-10-05  
NUMBER OF SEQ ID NOS: 35  
SOFTWARE: FastSeq for Windows Version 3.0  
SEQ ID NO 32  
LENGTH: 4169  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-166-350-32

Query Match 24.6%; Score 16; DB 4; Length 4169;  
Best Local Similarity 100.0%; Pred. No. 11;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 43 CCTGCTGATGACAC 58  
Db 3093 CCTGCTGATGACAC 3108

RESULT 12  
US-09-513-999C-11687/c  
Sequence 11687, Application US/09513999C  
Patent No. 6783961  
GENERAL INFORMATION:  
APPLICANT: Dumas Milne Edwards, J.B.  
APPLICANT: Duclert, A.Y.  
TITLE OF INVENTION: Expressed Sequence Tags and Encoded Human Proteins.  
Patent No. 6783961  
FILE REFERENCE: 59, US2, REG  
CURRENT APPLICATION NUMBER: US/09/513,999C  
CURRENT FILING DATE: 2000-02-24  
PRIOR APPLICATION NUMBER: US 60/122,487  
PRIOR FILING DATE: 1999-02-26  
NUMBER OF SEQ ID NOS: 36681  
SOFTWARE: Patent.pm  
SEQ ID NO 11687  
LENGTH: 301  
TYPE: DNA

ORGANISM: Homo sapiens  
FEATURE:  
NAME/KEY: misc\_feature  
LOCATION: 244  
OTHER INFORMATION: n=a, g, c or t  
FEATURE:  
NAME/KEY: misc\_feature  
LOCATION: 274  
OTHER INFORMATION: r=a or g  
US-09-513-999C-11687

Query Match 23.1%; Score 15; DB 4; Length 301;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 17 CCGGCTTTCCAGCG 31  
Db 32 CCGGCTTTCCAGCG 18

RESULT 13  
US-09-702-705-1590  
Sequence 1590, Application US/09702705  
Patent No. 6504010  
GENERAL INFORMATION:  
APPLICANT: Wang, Tongtong  
APPLICANT: Bangur, Chaitanya S.  
APPLICANT: Lodes, Michael A.  
APPLICANT: Fanger, Gary  
APPLICANT: Vedvick, Tom  
APPLICANT: Carter, Darrick  
APPLICANT: Retter, Marc  
APPLICANT: Mannion, Jane  
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY AND  
FILE REFERENCE: 210121.4/78C14  
CURRENT APPLICATION NUMBER: US/09/702,705  
CURRENT FILING DATE: 2000-10-30  
NUMBER OF SEQ ID NOS: 1833  
SOFTWARE: FastSeq for Windows Version 3.0  
SEQ ID NO 1590  
LENGTH: 434  
TYPE: DNA  
ORGANISM: Homo sapiens  
FEATURE:  
NAME/KEY: misc\_feature  
LOCATION: (1)...(434)  
OTHER INFORMATION: n = A,T,C or G  
US-09-702-705-1590

Query Match 23.1%; Score 15; DB 4; Length 434;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 39 GAACCCCTGCTGATG 53  
Db 20 GAACCCCTGCTGATG 34

RESULT 14  
US-09-736-457-1590  
Sequence 1590, Application US/09736457  
Patent No. 6509448  
GENERAL INFORMATION:  
APPLICANT: Wang, Tongtong  
APPLICANT: Bangur, Chaitanya S.  
APPLICANT: Lodes, Michael A.  
APPLICANT: Fanger, Gary  
APPLICANT: Vedvick, Tom  
APPLICANT: Carter, Darrick  
APPLICANT: Retter, Marc  
APPLICANT: Mannion, Jane

```

1  APPLICANT:  Fan, Liqun
2  APPLICANT:  Wang, Aijun
3  TITLE OF INVENTION:  COMPOSITIONS AND METHODS FOR THE THERAPY AND
4  TITLE OF INVENTION:  DIAGNOSIS OF LUNG CANCER
5  FILE REFERENCE:  210121.478615
6  CURRENT APPLICATION NUMBER:  US/09/736,457
7  CURRENT FILING DATE:  2000-12-13
8  NUMBER OF SEQ ID NOS:  1864
9  SOFTWARE:  FastSeq for Windows Version 3.0
10 SEQ ID NO 1590
11 LENGTH: 434
12 TYPE: DNA
13 ORGANISM: Homo sapiens
14 FEATURE:
15 NAME/KEY: misc feature
16 LOCATION: (1)...(434)
17 OTHER INFORMATION: n = A,T,C or G
18 OS-09-736-457-1590

```

Query Match	23.1%;	Score 15;	DB 4;	Length 434;
Best Local Similarity	100.0%;	Pred No. 39;		
Matches 15;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;

QY	39	GAAACCCCTGCTGATG	53
Db	20	GAAACCCCTGCTGATG	34

```

RESULT 15
US-09-614-124B-1590
Sequence 1590, Application US/09614124B
Patent No. 6630574
GENERAL INFORMATION:
APPLICANT: Wang, Tonglong
APPLICANT: Bangur, Chantanya S.
APPLICANT: Lodes, Michael A.
APPLICANT: Fanger, Gary
APPLICANT: Vedvick, Tom
APPLICANT: Carter, Darlick
APPLICANT: Reltter, Marc
APPLICANT: Mannion, Jane
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THERAPY AND
TITLE OF INVENTION: DIAGNOSIS OF LUNG CANCER
FILE REFERENCE: 210121.478C9
CURRENT APPLICATION NUMBER: US/09/614,124B
CURRENT FILING DATE: 2001-07-11
NUMBER OF SEQ. ID NOS: 1668
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 1590
LENGTH: 434
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: misc feature
LOCATION: (1)_(434)
OTHER INFORMATION: n = A,T,C or G
US-09-614-124B-1590

```

```
Query Match      23.1%; Score 15; DB 4; Length 434;
Best Local Similarity 100.0%; Pred. NO. 39;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 39 GAAACCTGCTGATG 53  
|||  
Db 20 GAAACCTGCTGATG 34

Search completed: December 23, 2004, 01:33:34  
Job time : 55.3529 secs

**This Page Blank (uspto)**

OM nucleic - nucleic search, using sw model

397.214 Million cell updates/sec

Title: US-09-898-616A-1

Sequence: 1 gatccatgnaatctgccg.....tgctgatgnaaaccccgctcc 65

Scoring table: OLIGO\_NUC

Searched: 4105333 seqs, 2784095677 residues

Word size

Total number of hits satisfying chosen parameters: 8210666

```
Minimum DB seq length: 0
Maximum DB seq length: 2000000000
```

Post-processing: Listing first 45 summaries

Database : Published Applications NA:\*

1: /cgn2\_6/prodataa1/pubnpa/US07\_PUBCOMB.seq.\*  
2: /cgn2\_6/prodataa1/pubnpa/Pct\_NEM\_PUB.seq.\*  
3: /cgn2\_6/prodataa1/pubnpa/US06\_NEM\_PUB.seq.\*  
4: /cgn2\_6/prodataa1/pubnpa/US06\_PUBCOMB.seq.\*  
5: /cgn2\_6/prodataa1/pubnpa/US07\_NEM\_PUB.seq.\*  
6: /cgn2\_6/prodataa1/pubnpa/PCTUS\_PUBCOMB.seq.\*  
7: /cgn2\_6/prodataa1/pubnpa/US08\_NEM\_PUB.seq.\*  
8: /cgn2\_6/prodataa1/pubnpa/US08\_PUBCOMB.seq.\*  
9: /cgn2\_6/prodataa1/pubnpa/US09\_PUBCOMB.seq.\*  
10: /cgn2\_6/prodataa1/pubnpa/US09\_PUBCOMB.seq.\*  
11: /cgn2\_6/prodataa1/pubnpa/US09\_PUBCOMB.seq.\*  
12: /cgn2\_6/prodataa1/pubnpa/US10\_PUBCOMB.seq.\*  
13: /cgn2\_6/prodataa1/pubnpa/US10\_PUBCOMB.seq.\*  
14: /cgn2\_6/prodataa1/pubnpa/US10\_PUBCOMB.seq.\*  
15: /cgn2\_6/prodataa1/pubnpa/US10\_PUBCOMB.seq.\*  
16: /cgn2\_6/prodataa1/pubnpa/US10\_PUBCOMB.seq.\*  
17: /cgn2\_6/prodataa1/pubnpa/US10\_PUBCOMB.seq.\*  
18: /cgn2\_6/prodataa1/pubnpa/US10\_NEM\_PUB.seq.\*  
19: /cgn2\_6/prodataa1/pubnpa/US10\_NEM\_PUB.seq.\*  
20: /cgn2\_6/prodataa1/pubnpa/US10\_NEM\_PUB.seq.\*  
21: /cgn2\_6/prodataa1/pubnpa/US60\_PUBCOMB.seq.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	65	100.0	65	9	US-09-861-688-6	Sequence 6, Appl
2	65	100.0	65	10	US-09-898-616A-1	Sequence 1, Appl
3	65	100.0	65	15	US-10-187-498A-1	Sequence 1, Appl
4	65	100.0	65	16	US-10-647-371-5	Sequence 5, Appl
5	42	64.6	42	9	US-09-861-688-13	Sequence 13, Appl
6	42	65.6	42	16	US-10-647-371-12	Sequence 12, Appl
7	23	35.4	60	9	US-09-861-688-12	Sequence 12, Appl
8	23	35.4	60	10	US-09-898-616A-7	Sequence 7, Appl
9	23	35.4	60	10	US-09-898-616A-8	Sequence 8, Appl
10	23	35.4	60	15	US-10-187-498A-7	Sequence 7, Appl
11	23	35.4	60	15	US-10-187-498A-8	Sequence 8, Appl
12	23	35.4	60	16	US-10-647-371-11	Sequence 11, Appl

## ALIGNMENTS

```

RESULT 1
US-09-661-688-6
; Sequence 6, Application US/09661668
; Patent No. US20020173460A1
GENERAL INFORMATION:
; APPLICANT: ClariaGen, Inc. & NIH
; TITLE OF INVENTION: Use of Recombinant Human Uteroglobulin in Treatment of
; TITLE OF INVENTION: Inflammatory and
; TITLE OF INVENTION: Fibrotic Conditions
; FILE REFERENCE: 116142/2
; CURRENT APPLICATION NUMBER: US/09/661,668
; CURRENT FILING DATE: 2001-05-21
; PRIOR APPLICATION NUMBER: 08/664,357
; PRIOR FILING DATE: 1997-05-28
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 6
; LENGTH: 65
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer sequence
; US-09-661-688-6

```

```

Query Match      100.0%; Score 65; DB 9; Length 65;
Best Local Similarity 100.0%; P-adj. 1.3e-27;
Matches 65; Conservative 0; Mismatches 0; Indels 0; Gaps
QY      1 GATTCATGGAATCTGCGCGCTCTTCCAGCGTGTTATGGAACCTGCTGATGACACCC 65
Db       1 GATTCATGGAATCTGCGCGCTCTTCCAGCGTTATGGAACCTGCTGATGACACCC 65
QY      61 CGTCC 65
Db       61 CGTCC 65

```

## RESULT 2

US-09-898-616A-1  
Sequence 1, Application US/09898616A  
Publication No. US20030109429A1  
GENERAL INFORMATION:  
APPLICANT: Clargen, Inc.  
APPLICANT: Pilon, Apple L  
APPLICANT: Weich, Richard W  
TITLE OF INVENTION: Method for the Production of Purified rhug for the Treatment of  
TITLE OF INVENTION: Inflammatory and Fibrotic Conditions  
FILE REFERENCE: 116142/00170  
CURRENT APPLICATION NUMBER: US/09/898,616A  
PRIOR FILING DATE: 2002-10-15  
PRIOR APPLICATION NUMBER: US 08/864,357  
PRIOR FILING DATE: 1997-05-28  
NUMBER OF SEQ ID NOS: 10  
SOFTWARE: PatentIn version 3.1  
SEQ ID NO 1  
LENGTH: 65  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte  
FEATURE:  
NAME/KEY: misc feature  
OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte  
OTHER INFORMATION: d sequence maximized for expression in E. coli.  
US-09-898-616A-1

Query Match 100.0%; Score 65; DB 10; Length 65;  
Best Local Similarity 100.0%; Pred. No. 1.3e-27;  
Matches 65; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GATCCATGGAATCTGCGCTTTTCCAGCGTGTATCGAAACCGTGTATGACACCC 60  
DB 1 GATCCATGGAATCTGCGCTTTTCCAGCGTGTATCGAAACCGTGTATGACACCC 60

QY 61 CGTCC 65  
DB 61 CGTCC 65

## RESULT 3

US-10-187-498A-1  
Sequence 1, Application US/10187498A  
Publication No. US20030207795A1  
GENERAL INFORMATION:  
APPLICANT: Clargen, Inc.  
APPLICANT: Pilon, Apple L  
APPLICANT: Weich, Richard W  
TITLE OF INVENTION: Method for the Production of Purified rhug for the Treatment of  
TITLE OF INVENTION: Inflammatory and Fibrotic Conditions  
FILE REFERENCE: 116142/00260  
CURRENT APPLICATION NUMBER: US/10/187,498A  
PRIOR FILING DATE: 2001-07-02  
PRIOR APPLICATION NUMBER: US 08/864,357  
PRIOR FILING DATE: 1997-05-28  
NUMBER OF SEQ ID NOS: 10  
SOFTWARE: PatentIn version 3.1  
SEQ ID NO 1  
LENGTH: 65  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte  
OTHER INFORMATION: d sequence maximized for expression in E. coli.  
NAME/KEY: misc feature  
OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte  
OTHER INFORMATION: d sequence maximized for expression in E. coli.

## US-10-187-498A-1

Query Match 100.0%; Score 65; DB 15; Length 65;  
Best Local Similarity 100.0%; Pred. No. 1.3e-27;  
Matches 65; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GATCCATGGAATCTGCGCTTTTCCAGCGTGTATCGAAACCGTGTATGACACCC 60  
DB 1 GATCCATGGAATCTGCGCTTTTCCAGCGTGTATCGAAACCGTGTATGACACCC 60

QY 61 CGTCC 65  
DB 61 CGTCC 65

## RESULT 4

US-10-647-371-5  
Sequence 5, Application US/10647371  
Publication No. US20040047857A1  
GENERAL INFORMATION:  
APPLICANT: Clargen, Inc. & NIH  
TITLE OF INVENTION: Use of Recombinant Human Uteroglobulin in Treatment of Inflammatory  
FILE REFERENCE: 116142-85  
CURRENT APPLICATION NUMBER: US/10/647,371  
PRIOR FILING DATE: 2003-08-25  
PRIOR APPLICATION NUMBER: 09/549,926  
PRIOR FILING DATE: 2000-04-14  
NUMBER OF SEQ ID NOS: 12  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 5  
LENGTH: 65  
TYPE: DNA  
ORGANISM: Artificial  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: primer sequence  
US-10-647-371-5

Query Match 100.0%; Score 65; DB 15; Length 65;  
Best Local Similarity 100.0%; Pred. No. 1.3e-27;  
Matches 65; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GATCCATGGAATCTGCGCTTTTCCAGCGTGTATCGAAACCGTGTATGACACCC 60  
DB 1 GATCCATGGAATCTGCGCTTTTCCAGCGTGTATCGAAACCGTGTATGACACCC 60

QY 61 CGTCC 65  
DB 61 CGTCC 65

## RESULT 5

US-09-861-688-13/c  
Sequence 13, Application US/09861688  
Patent No. US2002017460A1  
GENERAL INFORMATION:  
APPLICANT: Clargen, Inc. & NIH  
TITLE OF INVENTION: Use of Recombinant Human Uteroglobulin in Treatment of  
TITLE OF INVENTION: Inflammatory and  
TITLE OF INVENTION: Fibrotic Conditions  
FILE REFERENCE: 116142/2  
CURRENT APPLICATION NUMBER: US/09/861,688  
PRIOR FILING DATE: 2001-05-21  
PRIOR APPLICATION NUMBER: 08/864,357  
PRIOR FILING DATE: 1997-05-28  
NUMBER OF SEQ ID NOS: 22  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 13  
LENGTH: 42  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: primer sequence

US-09-861-688-13

Query Match 64.6%; Score 42; DB 9; Length 42;  
Best Local Similarity 100.0%; Pred. No. 3.1e-14;  
Matches 42; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GATCCATGGAATCTGCCCGCTTTTCAGCGCTTTATCGAAA 42  
DB 42 GATCCATGGAATCTGCCCGCTTTTCAGCGCTTTATCGAAA 1

RESULT 6

US-10-647-371-12/c  
Sequence 12, Application US/10647371  
Publication No. US20040047857A1  
GENERAL INFORMATION:  
APPLICANT: Clargen, Inc. & NIH  
TITLE OF INVENTION: Use of Recombinant Human Uteroglobin in Treatment of Inflammatory  
FILE REFERENCE: 116142-85  
CURRENT FILING DATE: 2003-08-25  
PRIOR APPLICATION NUMBER: 09/549,926  
PRIOR FILING DATE: 2000-04-14  
NUMBER OF SEQ ID NOS: 12  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 12  
LENGTH: 42  
TYPE: DNA  
ORGANISM: Artificial  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: primer sequence  
US-10-647-371-12

Query Match 64.6%; Score 42; DB 16; Length 42;  
Best Local Similarity 100.0%; Pred. No. 3.1e-14;  
Matches 42; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GATCCATGGAATCTGCCCGCTTTTCAGCGCTTTATCGAAA 42  
DB 42 GATCCATGGAATCTGCCCGCTTTTCAGCGCTTTATCGAAA 1

RESULT 7

US-09-861-688-12/c  
Sequence 12, Application US/09861688  
Patent No. US20020173460A1  
GENERAL INFORMATION:  
APPLICANT: Clargen, Inc. & NIH  
TITLE OF INVENTION: Use of Recombinant Human Uteroglobin in Treatment of  
FILE REFERENCE: 116142/2  
CURRENT FILING DATE: 2001-05-21  
PRIOR APPLICATION NUMBER: 08/864,357  
PRIOR FILING DATE: 1997-05-28  
NUMBER OF SEQ ID NOS: 22  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 12  
LENGTH: 60  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: primer sequence  
US-09-861-688-12

Query Match 35.4%; Score 23; DB 9; Length 60;  
Best Local Similarity 100.0%; Pred. No. 0.0034;  
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 43 CCTGCTGATGACACCCCGTCC 65  
DB 43 CCTGCTGATGACACCCCGTCC 65

DB 60 CCTGCTGATGACACCCCGTCC 38

RESULT 8  
US-09-898-616A-7/c  
Sequence 7, Application US/09896616A  
Publication No. US20030109429A1  
GENERAL INFORMATION:  
APPLICANT: Clargen Inc.  
APPLICANT: Pilon, Apple L.  
TITLE OF INVENTION: Method for the Production of Purified rhNG for the Treatment of  
FILE REFERENCE: 116142/00170  
CURRENT FILING DATE: 2002-10-15  
PRIOR APPLICATION NUMBER: US 08/864,357  
PRIOR FILING DATE: 1997-05-28  
NUMBER OF SEQ ID NOS: 10  
SOFTWARE: PatentIn version 3.1  
SEQ ID NO 7  
LENGTH: 60  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte  
OTHER INFORMATION: d sequence maximized for expression in E. coli.  
US-09-898-616A-7

Query Match 35.4%; Score 23; DB 10; Length 60;  
Best Local Similarity 100.0%; Pred. No. 0.0034;  
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 43 CCTGCTGATGACACCCCGTCC 65  
DB 60 CCTGCTGATGACACCCCGTCC 38

RESULT 9

US-09-898-616A-8/c  
Sequence 8, Application US/09896616A  
Publication No. US20030109429A1  
GENERAL INFORMATION:  
APPLICANT: Clargen Inc.  
APPLICANT: Pilon, Apple L.  
TITLE OF INVENTION: Method for the Production of Purified rhNG for the Treatment of  
FILE REFERENCE: 116142/00170  
CURRENT FILING DATE: 2002-10-15  
PRIOR APPLICATION NUMBER: US 08/864,357  
PRIOR FILING DATE: 1997-05-28  
NUMBER OF SEQ ID NOS: 10  
SOFTWARE: PatentIn version 3.1  
SEQ ID NO 8  
LENGTH: 60  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte  
OTHER INFORMATION: d sequence maximized for expression in E. coli.  
NAME/KEY: misc feature  
OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte  
OTHER INFORMATION: d sequence maximized for expression in E. coli.  
US-09-898-616A-8

Query Match 35.4%; Score 23; DB 10; Length 60;

Best Local Similarity 100.0%; Pred. No. 0.0034;  
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 43 CCTGCTGATGAGACCCCGTCC 65  
DB 60 CCTGCTGATGAGACCCCGTCC 38

## RESULT 10

US-10-187-498A-7/C

Sequence 7, Application US/10187498A  
Publication No. US2003020795A1

GENERAL INFORMATION:

APPLICANT: Clargen Inc.

APPLICANT: Pilon, Aprile L

APPLICANT: Welch, Richard W

TITLE OF INVENTION: Method for the Production of Purified rhug for the Treatment of

TITLE OF INVENTION: Inflammatory and Fibrotic Conditions

FILE REFERENCE: 116142/00260

CURRENT FILING DATE: 2001-07-02

PRIOR APPLICATION NUMBER: US 08/864,357

PRIOR FILING DATE: 1997-05-28

NUMBER OF SEQ ID NOS: 10

SOFTWARE: PatentIn version 3.1

SEQ ID NO 7

LENGTH: 60

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE: OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte

FEATURE: OTHER INFORMATION: d sequence maximized for expression in E. coli.

NAME/KEY: misc\_feature

OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte

OTHER INFORMATION: d sequence maximized for expression in E. coli.

US-10-187-498A-7

Query Match 35.4%; Score 23; DB 15; Length 60;

Best Local Similarity 100.0%; Pred. No. 0.0034;

Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 43 CCTGCTGATGAGACCCCGTCC 65

DB 60 CCTGCTGATGAGACCCCGTCC 38

## RESULT 11

US-10-187-498A-8/C

Sequence 8, Application US/10187498A  
Publication No. US2003020795A1

GENERAL INFORMATION:

APPLICANT: Clargen Inc.

APPLICANT: Pilon, Aprile L

APPLICANT: Welch, Richard W

TITLE OF INVENTION: Method for the Production of Purified rhug for the Treatment of

TITLE OF INVENTION: Inflammatory and Fibrotic Conditions

FILE REFERENCE: 116142/00260

CURRENT FILING DATE: 2001-07-02

PRIOR APPLICATION NUMBER: US 08/864,357

PRIOR FILING DATE: 1997-05-28

NUMBER OF SEQ ID NOS: 10

SOFTWARE: PatentIn version 3.1

SEQ ID NO 8

LENGTH: 60

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE: OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte

FEATURE: OTHER INFORMATION: d sequence maximized for expression in E. coli.

NAME/KEY: misc\_feature

OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte  
OTHER INFORMATION: d sequence maximized for expression in E. coli.

Query Match 35.4%; Score 23; DB 15; Length 60;  
Best Local Similarity 100.0%; Pred. No. 0.0034;  
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 43 CCTGCTGATGAGACCCCGTCC 65  
DB 60 CCTGCTGATGAGACCCCGTCC 38

## RESULT 12

US-10-647-371-11/C

Sequence 11, Application US/10647371  
Publication No. US20040047857A1

GENERAL INFORMATION:

APPLICANT: Clargen, Inc. &amp; NIH

TITLE OF INVENTION: Use of Recombinant Human Uteroglobulin in Treatment of Inflammatory

TITLE OF INVENTION: and Fibrotic Conditions

FILE REFERENCE: 116142-85

CURRENT FILING DATE: 2003-08-25

PRIOR APPLICATION NUMBER: 09/549,926

PRIOR FILING DATE: 2000-04-14

NUMBER OF SEQ ID NOS: 12

SOFTWARE: PatentIn version 3.2

SEQ ID NO 11

LENGTH: 60

TYPE: DNA

ORGANISM: Artificial

FEATURE: OTHER INFORMATION: Description of Artificial Sequence: primer sequence

US-10-647-371-11

Query Match 35.4%; Score 23; DB 16; Length 60;

Best Local Similarity 100.0%; Pred. No. 0.0034;

Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 43 CCTGCTGATGAGACCCCGTCC 65

DB 60 CCTGCTGATGAGACCCCGTCC 38

## RESULT 13

US-10-129-422-10

Sequence 10, Application US/10129422  
Publication No. US2003016251A1

GENERAL INFORMATION:

APPLICANT: KTM, Sun Young et al.; Wyomed Ltd.

TITLE OF INVENTION: High efficiency retroviral vector which contains genetically engi

TITLE OF INVENTION: non-coding sequence harboring splice acceptor

FILE REFERENCE: PCA10935/VML/PCT

CURRENT FILING DATE: 2002-10-16

NUMBER OF SEQ ID NOS: 15

SOFTWARE: KOPATIN 1.5

SEQ ID NO 10

LENGTH: 36

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE: OTHER INFORMATION: primer IRAP5'

US-10-129-422-10

Query Match 26.2%; Score 17; DB 15; Length 36;

Best Local Similarity 100.0%; Pred. No. 10; Indels 0; Gaps 0;

Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GATCCATGGAATCTGC 17

|||||





**This Page Blank (uspio)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 22, 2004, 19:17:58 ; Search time 848.688 Seconds  
(without alignments)  
3343.258 Million cell updates/sec

Title: US-09-898-616A-2

Perfect score: 60

Sequence: 1 agctacgaagcagctatgta.....acatgcgtgaagcagtgct 60

Scoring table: OLIGO\_NUC  
Gapop 60.0 , Gapext 60.0

Searched: 4526729 seqs, 23644849745 residues

Word size : 0

Total number of hits satisfying chosen parameters: 3053458

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Listing first 45 summaries

Database :

GenEmbl1:  
1: gb\_ba:\*  
2: gb\_hgt:\*  
3: gb\_in:\*  
4: gb\_om:\*  
5: gb\_ov:\*  
6: gb\_pat:\*  
7: gb\_ph:\*  
8: gb\_pl:\*  
9: gb\_pr:\*  
10: gb\_ro:\*  
11: gb\_sts:\*  
12: gb\_sy:\*  
13: gb\_un:\*  
14: gb\_vi:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	60	100.0	60	6	AR160916
2	37	61.7	60	6	AR160916 Sequence
3	19	31.7	89959	8	AP004967
4	19	31.7	200849	2	AC026895
5	18	30.0	59	6	AR160920
6	18	30.0	201	11	BV203590
7	18	30.0	201	11	BV203591
8	18	30.0	201	11	BV203592
9	18	30.0	432	6	AX397069
10	18	30.0	1428	6	BD094070
11	18	30.0	1428	9	HUMSF2P33
12	18	30.0	1618	5	BC042354
13	18	30.0	1717	9	HUMASF
14	18	30.0	1860	5	BC056752
15	18	30.0	2002	5	BC055511
16	18	30.0	2055	5	BC075558
17	18	30.0	2059	9	BC033785
18	18	30.0	2369	5	BC046679
19	18	30.0	2583	9	AB000463

20	18	30.0	2708	9	BC010264
21	18	30.0	2731	5	BC076945
22	18	30.0	2765	6	BD189938
23	18	30.0	2765	9	AB062124
24	18	30.0	2900	5	BC066682
25	18	30.0	22970	9	HS1247F6
26	18	30.0	35240	2	AC040987
27	18	30.0	69023	2	AC087445
28	18	30.0	110000	2	BX827305_0
29	18	30.0	119974	9	AC018763
30	18	30.0	135259	9	AC091857
31	18	30.0	142801	2	AC079206
32	18	30.0	149969	9	HSJ323A24
33	18	30.0	154462	2	AC036136
34	18	30.0	160111	2	AP000780
35	18	30.0	160415	2	AC140961
36	18	30.0	164404	2	AC127149
37	18	30.0	165726	2	AC143663
38	18	30.0	168651	9	AC009474
39	18	30.0	169403	9	AL445929
40	18	30.0	176310	2	BX897686
41	18	30.0	176879	5	AL929224
42	18	30.0	177314	9	AC022209
43	18	30.0	181275	2	BS111308
44	18	30.0	181494	9	AC015813
45	18	30.0	196476	2	AC055890

## ALIGNMENTS

RESULT 1  
AR160916  
LOCUS AR160916  
DEFINITION Sequence 7 from patent US 6255281.  
ACCESSION AR160916  
VERSION AR160916.1 GI:16225981  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 60)  
AUTHORS Pilon A.L., Mukherjee, A.B. and Zhang, Z.  
TITLE Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions  
JOURNAL Patent: US 6255281-A 7 03-JUN-2001;  
FEATURES  
source location/Qualifiers  
1..60  
/organism="Unknown"  
/mol\_type="unassigned DNA"

ORIGIN  
Query Match 100.0%; Score 60; DB 6; Length 60;  
Best Local Similarity 100.0%; Pred. No. 1.4e-22;  
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 AGCTACGAAGCAGCTATGTAAGCTGCTCCCGACGACGATCGCTGAAGCAGTGCT 60  
DB 1 AGCTACGAAGCAGCTATGTAAGCTGCTCCCGACGACGATCGCTGAAGCAGTGCT 60  
RESULT 2  
AR160921/c  
LOCUS AR160921  
DEFINITION Sequence 12 from patent US 6255281.  
ACCESSION AR160921  
VERSION AR160921.1 GI:16225996  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 60)  
AUTHORS Pilon, A.L., Mukherjee, A.B. and Zhang, Z.

TITLE Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions  
JOURNAL Patent: US 6255281-A 12-03-JUL-2001;  
FEATURES Location/Qualifiers  
source 1..60  
/organism="unknown"  
/mol\_type="unassigned DNA"

ORIGIN  
Query Match 61.7%; Score 37; DB 6; Length 60;  
Best Local Similarity 100.0%; Pred. No. 1.1e-09;  
Matches 37; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGCTGAGAGCAGCTATGAACTGTTCTCCGAGAC 37  
37 AGCTGAGAGCAGCTATGAACTGTTCTCCGAGAC 1

Db

RESULT 3  
AP004967/c 89959 bp DNA linear PLN 22-JUL-2003  
LOCUS Lotus corniculatus var. japonicus genomic DNA, chromosome 1,  
DEFINITION clone:UJT7L02, TM0144, complete sequence.  
ACCESSION AP004967 GI:21907985  
VERSION AP004967  
KEYWORDS HTG.  
SOURCE Lotus corniculatus var. japonicus (Lotus japonicus)  
ORGANISM Lotus corniculatus var. japonicus  
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;  
Rosids; eurosids I; Fabales; Fabaceae; Papilionoideae; Leguminales;  
Lotus.

REFERENCE  
AUTHORS 1  
TITLE Kaneko, T., Nakamura, Y., Asamizu, E., Kato, T., Sato, S. and Tabata, S.  
JOURNAL Structural Analysis of a Lotus japonicus Genome. I. Sequence  
REFERENCE Features and Mapping of Sixty-six TAC clones which cover the 6.7 Mb  
JOURNAL Regions of the Genome  
AUTHORS 2 (bases 1 to 89959)  
JOURNAL Unpublished  
TITLE Nakamura, Y.  
JOURNAL Direct Submission  
JOURNAL Submitted (26-MAR-2002) Yasukazu Nakamura, Kazusa DNA Research  
JOURNAL Institute, Department of Plant Gene Research; 1532-3, Yata,  
JOURNAL Kisarazu, Chiba 292-0812, Japan (E-mail: ynakazusa.or.jp,  
JOURNAL URL: http://www.kazusa.or.jp; Tel: 81-438-52-3935,  
JOURNAL Fax: 81-438-52-3934)

FEATURES  
source 1..89959  
Location/Qualifiers  
1..89959  
/organism="Lotus corniculatus var. japonicus"  
/mol\_type="genomic DNA"  
/variety="japonicus"  
/db\_xref="taxon:34305"  
/chromosome="1"  
/clone="UJT7L02"  
/clone\_lib="UJT Library"  
/note="TAC clone: TM0144-synonym: Lotus japonicus"

ORIGIN  
Query Match 31.7%; Score 19; DB 8; Length 89959;  
Best Local Similarity 100.0%; Pred. No. 6;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 AACGAGTATGAACTGTT 26  
Db 87202 AACGAGTATGAACTGTT 87184

RESULT 4  
AC026895 200849 bp DNA linear HTG 20-APR-2000  
LOCUS Homo sapiens chromosome 2 clone RP11-396J2 map 2, WORKING DRAFT  
DEFINITION  
SEQUENCE 22 unordered pieces.  
ACCESSION AC026895

VERSION AC026895.2 GI:7596820  
KEYWORDS HTG, HTGS PHASE1, HTGS\_DRAFT.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE  
AUTHORS 1 (bases 1 to 200849)  
JOURNAL Birren, B., Linton, L., Nusbaum, C. and Lander, E.  
JOURNAL Homo sapiens chromosome 2, clone RP11-396J2  
JOURNAL Unpublished  
JOURNAL 2 (bases 1 to 200849)  
JOURNAL Birren, B., Linton, L., Nusbaum, C., Lander, E., Abraham, H., Allen, N.,  
JOURNAL Anderson, S., Baldwin, J., Barna, N., Bastien, V., Bedalov, F.,  
JOURNAL Boguski, M., Brown, A., Brown, A., Burkett, G.,  
JOURNAL Campione, A., Castle, A., Chao, Y., Collins, S.,  
JOURNAL Collymore, A., Cooke, P., DeRubeis, K., Dewar, K., Diaz, J., S.,  
JOURNAL Dodge, S., Domingo, M., Doyle, M., Fereira, P., Fitzhugh, W., Gage, D.,  
JOURNAL Galagan, J., Garavito, S., Glendon, S., Goyette, M., Graham, L.,  
JOURNAL Grand, P., Grant, G., Hagos, B., Heaford, A., Horton, L.,  
JOURNAL Howland, J., Iley, I., Johnson, R., Jones, C., Kan, L., Karas, A.,  
JOURNAL Klein, J., Lacroix, K., Lamazares, R., Landers, T., Lech, J.,  
JOURNAL Levine, R., Liu, C., Liu, G., Locke, K., MacDonald, P., Margulis, N.,  
JOURNAL McCarthy, M., McEwan, P., McGuire, A., McKernan, K., McPherson, R.,  
JOURNAL Meltzer, J., Meneses, L., Mihov, T., Miranda, C., Miska, V., Morrow, J.,  
JOURNAL Murphy, T., Naylor, J., Norman, C., O'Connor, T., O'Donnell, P.,  
JOURNAL O'Neill, D., Oliver, T., Oliver, J., Peterson, K., Pierre, N.,  
JOURNAL Pisan, C., Pollara, V., Raymond, C., Riley, R., Rogov, P., Rothman, D.,  
JOURNAL Roy, A., Santos, R., Schauer, S., Severy, P., Spencer, B.,  
JOURNAL Stange, Thomas, N., Stojanovic, N., Subramanian, A., Talama, J.,  
JOURNAL Teste, S., Theodore, J., Tirrell, A., Travers, M., Triggillo, J.,  
JOURNAL Vassiliev, H., Viel, R., Vo, A., Wilson, B., Wu, X., Wyman, D., Ye, W., J.,  
JOURNAL Young, G., Zainoun, J., Zimmer, A. and Zody, M.

Direct Submission  
Submitted (25-MAR-2000) Whitehead Institute/MIT Center for Genome  
Research, 320 Charles Street, Cambridge, MA 02141, USA  
On Apr 19, 2000 this sequence version replaced gi:7328755.  
All repeats were identified using RepeatMasker:  
Smit, A.F.A. & Green, P. (1996-1997)  
http://ftp.genome.washington.edu/JM/RepeatMasker.html

Genome Center  
Center: Whitehead Institute/ MIT Center for Genome Research  
Center code: WIBR  
Web site: http://www-seg.wi.mit.edu  
Contact: sequence\_submissions@genome.wi.mit.edu  
Project Information  
Center project name: L6461  
Center clone name: 396 J 2  
Summary Statistics  
Sequencing vector: M13, M7815, 100% of reads  
Chemistry: Dye-terminator Big Dye, 100% of reads  
Assembly program: Phrap, version 0.960731  
Consensus quality: 188437 bases at least Q40  
Consensus quality: 194805 bases at least Q30  
Consensus quality: 197132 bases at least Q20  
Insert size: 210000; agarose-ff  
Insert size: 198749; sum-of-covs  
Quality coverage: 4.6 in Q20 bases; agarose-ff  
Quality coverage: 4.8 in Q20 bases; sum-of-covs

NOTE: This is a 'working draft' sequence. It currently  
consists of 22 contigs. The true order of the pieces  
is not known and their order in this sequence record is  
arbitrary. Gaps between the contigs are represented as  
runs of N, but the exact sizes of the gaps are unknown.  
This record will be updated with the finished sequence  
as soon as it is available and the accession number will  
be preserved.

1 1067: contig of 1067 bp in length  
\* 1 1068 1167: gap of 100 bp  
\* 1 1168 2886: contig of 1689 bp in length  
\* 1 2887 2956: gap of 100 bp  
\* 1 2957 5983: contig of 3027 bp in length  
\* 1 5984 6083: gap of 100 bp

```

* 6084 7783: contig of 1700 bp in length
* 7784 7883: gap of 100 bp
* 7884 10615: contig of 2732 bp in length
* 10616 10715: gap of 100 bp
* 10716 12692: contig of 1977 bp in length
* 12693 12792: gap of 100 bp
* 12793 14959: contig of 2167 bp in length
* 14960 15059: gap of 100 bp
* 15060 19764: contig of 4705 bp in length
* 19765 19864: gap of 100 bp
* 19865 22666: contig of 2802 bp in length
* 22667 27132: contig of 4366 bp in length
* 27133 31434: contig of 4202 bp in length
* 31435 31534: gap of 100 bp
* 31535 39440: contig of 7906 bp in length
* 39441 46513: contig of 6973 bp in length
* 46514 55509: contig of 8896 bp in length
* 55510 66257: contig of 10647 bp in length
* 66258 77020: contig of 10664 bp in length
* 77021 77120: gap of 100 bp
* 77121 88050: contig of 10930 bp in length
* 88051 88150: gap of 100 bp
* 88151 98020: contig of 9870 bp in length
* 98021 98120: gap of 100 bp
* 98121 108280: contig of 10160 bp in length
* 108281 108380: gap of 100 bp
* 108381 126228: contig of 17848 bp in length
* 126229 126328: gap of 100 bp
* 126329 165333: contig of 38905 bp in length
* 165334 200849: contig of 35516 bp in length.
* 165334 200849: contig of 35516 bp in length.

```

```

FEATURES
source 1..200849

```

```

/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/chromosome="2"
/map="2"
/clone="RP11-396J2"
/clone_id="RPC1-11 Human Male BAC"
1..1067
/note="assembly_fragment"
misc_feature /note="assembly_fragment"
1168..2856
/note="assembly_fragment"
misc_feature /note="assembly_fragment"
2957..5983
/note="assembly_fragment"
misc_feature /note="assembly_fragment"
6084..7783
/note="assembly_fragment"
misc_feature /note="assembly_fragment"
7884..10615
/note="assembly_fragment"
misc_feature /note="assembly_fragment"
10716..12692
/note="assembly_fragment"
misc_feature /note="assembly_fragment"
12793..14959
vector_side:right"
15060..19764
/note="assembly_fragment"
misc_feature /note="assembly_fragment"
19865..22666
/note="assembly_fragment"
misc_feature /note="assembly_fragment"
22767..27132
/note="assembly_fragment"
misc_feature /note="assembly_fragment"
27233..31434
/note="assembly_fragment"
misc_feature /note="assembly_fragment"
31535..39440
/note="assembly_fragment"
misc_feature /note="assembly_fragment"
39541..46513

```

```

/note="assembly_fragment"
46614..55509
/note="assembly_fragment"
55610..66256
/note="assembly_fragment"
66357..77020
/note="assembly_fragment"
77121..88050
/note="assembly_fragment"
clone_end:left"
vector_side:right"
88151..98020
/note="assembly_fragment"
98121..108280
/note="assembly_fragment"
108381..126228
/note="assembly_fragment"
126329..165333
/note="assembly_fragment"
165334..200849
/note="assembly_fragment"

```

```

ORIGIN
Query Match 31.7%; Score 19; DB 2; Length 200849;
Best Local Similarity 100.0%; Pred.No. 5.5;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 9 AGCAGCTATGAGACTGTTTC 27
Db 114115 AGCAGCTATGAGACTGTTTC 114133

```

```

RESULT 5
LOCUS AR160920/c 59 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 11 from patent US 6255281.
ACCESSION AR160920
VERSION AR160920.1 GI:16225993
KEYWORDS
SOURCE unknown.
ORGANISM unknown.
REFERENCE 1 (bases 1 to 59)
AUTHORS Pilon,A.L., Mukherjee,A.B. and Zhang,Z.
TITLE Use of recombinant human uteroglobin in treatment of inflammatory
and fibrotic conditions
JOURNAL Patent: US 6255281-A 11 03-JUL-2001;
FEATURES
source Location/Qualifiers
1..59
/organism="unknown"
/mol_type="unassigned DNA"

```

```

ORIGIN
Query Match 30.0%; Score 18; DB 6; Length 59;
Best Local Similarity 100.0%; Pred.No. 4.7;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 38 AGACATCGTGAAGCAG 55
Db 59 AGACATCGTGAAGCAG 42

```

```

RESULT 6
LOCUS BV203590 201 bp DNA linear STS 10-JUN-2004
DEFINITION sqm212590 Human DNA (sequenom) Homo sapiens STS genomic sequence
tagged site.
ACCESSION BV203590
VERSION BV203590.1 GI:48173010
KEYWORDS STS.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

```

REFERENCE  
1 (bases 1 to 201)  
AUTHORS  
Nelson,R.M., Marnellos,G., Kammerer,S., Hoyal,C.R., Shi,M.M.,  
Cantor,C.R. and Braun,A.  
TITLE  
Large-Scale Validation of Single Nucleotide Polymorphisms in Gene  
Regions  
JOURNAL  
Genome Res. (2004) In press

COMMENT  
Contact: Andreas Braun  
Pharmaceuticals division  
Sequenom, Inc.  
3595 John Hopkins Court, San Diego, CA 92121, USA  
Tel: 18582029018  
Fax: 18582029020  
Email: abraun@sequenom.com  
Primer A: No primer sequence submitted  
Primer B: No primer sequence submitted  
STS size: 201.

FEATURES  
source  
1..201  
Location/Qualifiers  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
/clone\_lib="Human DNA (Sequenom)"  
<1..>201

ORIGIN  
STS  
Query Match  
Best Local Similarity 100.0%; Pred.No.42;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY  
41 ACATGCGTGAAGCAGGTG 58  
130 ACATGCGTGAAGCAGGTG 147

RESULT 7  
BV203591 201 bp DNA linear STS 10-JUN-2004  
DEFINITION  
sqm212591 Human DNA (Sequenom) Homo sapiens STS genomic, sequence  
tagged site.

ACCESSION  
BV203591  
VERSION  
BV203591.1 GI:48173011  
KEYWORDS  
STS.  
SOURCE  
Homo sapiens (human)  
ORGANISM  
Homo sapiens  
Bakayota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

REFERENCE  
1 (bases 1 to 201)  
Nelson,R.M., Marnellos,G., Kammerer,S., Hoyal,C.R., Shi,M.M.,  
Cantor,C.R. and Braun,A.  
TITLE  
Large-Scale Validation of Single Nucleotide Polymorphisms in Gene  
Regions  
JOURNAL  
Genome Res. (2004) In press

COMMENT  
Contact: Andreas Braun  
Pharmaceuticals division  
Sequenom, Inc.  
3595 John Hopkins Court, San Diego, CA 92121, USA  
Tel: 18582029018  
Fax: 18582029020  
Email: abraun@sequenom.com  
Primer A: No primer sequence submitted  
Primer B: No primer sequence submitted  
STS size: 201.

FEATURES  
source  
1..201  
Location/Qualifiers  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
/clone\_lib="Human DNA (Sequenom)"  
<1..>201

ORIGIN  
STS  
Query Match  
Best Local Similarity 100.0%; Pred.No.42;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY  
41 ACATGCGTGAAGCAGGTG 58  
121 ACATGCGTGAAGCAGGTG 138

RESULT 8  
BV203592 201 bp DNA linear STS 10-JUN-2004  
DEFINITION  
sqm212593 Human DNA (Sequenom) Homo sapiens STS genomic, sequence  
tagged site.

ACCESSION  
BV203592  
VERSION  
BV203592.1 GI:48173012  
KEYWORDS  
STS.  
SOURCE  
Homo sapiens (human)  
ORGANISM  
Homo sapiens  
Bakayota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

REFERENCE  
1 (bases 1 to 201)  
Nelson,R.M., Marnellos,G., Kammerer,S., Hoyal,C.R., Shi,M.M.,  
Cantor,C.R. and Braun,A.  
TITLE  
Large-Scale Validation of Single Nucleotide Polymorphisms in Gene  
Regions  
JOURNAL  
Genome Res. (2004) In press

COMMENT  
Contact: Andreas Braun  
Pharmaceuticals division  
Sequenom, Inc.  
3595 John Hopkins Court, San Diego, CA 92121, USA  
Tel: 18582029018  
Fax: 18582029020  
Email: abraun@sequenom.com  
Primer A: No primer sequence submitted  
Primer B: No primer sequence submitted  
STS size: 201.

FEATURES  
source  
1..201  
Location/Qualifiers  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
/clone\_lib="Human DNA (Sequenom)"  
<1..>201

ORIGIN  
STS  
Query Match  
Best Local Similarity 100.0%; Pred.No.42;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY  
41 ACATGCGTGAAGCAGGTG 58  
112 ACATGCGTGAAGCAGGTG 129

RESULT 9  
AX397069 432 bp DNA linear PAT 18-MAY-2002  
LOCUS  
Sequence 1284 from Patent WO0212328.  
DEFINITION  
AX397069  
ACCESSION  
AX397069.1 GI:21067816  
VERSION  
AX397069.1  
KEYWORDS  
STS.  
SOURCE  
Homo sapiens (human)  
ORGANISM  
Homo sapiens  
Bakayota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

REFERENCE  
1  
King,G.E., Meagher,M.J., Xu,J. and Secrist,H.  
Compositions and methods for the therapy and diagnosis of colon  
cancer  
Patent: WO 0212328-A 1284 14-FEB-2002;



Amphibia; Batrachia; Anura; Mesobatrachia; Pipidae; Pipidae;  
Xenopodinae; Xenopus; Xenopus.  
1 (bases 1 to 1618)  
Klein, S.L., Strausberg, R.L., Wagner, L., Pontius, J., Clifton, S.W.,  
and Richardson, P.  
Genetic and genomic tools for Xenopus research: The NIH Xenopus  
initiative  
Dev. Dyn. 225 (4), 384-391 (2002)

JOURNAL  
PUBMED  
1454917  
2 (bases 1 to 1618)  
Strausberg, R.L., Feingold, E.A., Grouse, L.H., Derge, J.G.,  
Klausner, R.D., Collins, P.S., Wagner, L., Shenmen, C.M., Schuler, G.D.,  
Altschul, S.F., Zeeberg, B., Buetow, K.H., Schaefer, C.F., Bat, N.K.,  
Hopkins, R.F., Jordan, H., Moore, T., Max, S.I., Wang, J., Hsieh, F.,  
Dietzen, L., Marnasing, K., Farmer, A.A., Rubin, G.M., Hong, L.,  
Sapich, M., Soares, M.B., Bonaldo, M.F., Casavant, T.L.,  
Schaefer, T.E., Brownstein, M.J., Ustin, T.B., Toshimichi, S.,  
Carninci, P., Prange, C., Raha, S.S., Loggiano, N.A., Peters, G.J.,  
Abramson, R.D., Mullahy, S.J., Bosak, S.A., McSwan, P.J.,  
McKernan, K.J., Malek, J.A., Gunatane, P.H., Richards, S.,  
Morley, K.C., Hale, S., Garcia, A.M., Gay, L.J., Hult, K.S.W.,  
Villalón, D.K., Muzny, D.M., Sodergren, E.J., Lu, X., Gibbs, R.A.,  
Raeey, J., Helton, E., Kettman, M., Madan, A., Rodriguez, S.,  
Sanchez, A., Whiting, M., Madan, A., Young, A.C., Shevchenko, Y.,  
Bouffard, G.G., Blakesley, R.W., Touchman, J.W., Green, E.D.,  
Dickson, M.C., Rodriguez, A.C., Grimwood, J., Schmutz, J., Myers, R.M.,  
Butterfield, Y.S., Krzywinski, M.I., Skalska, U., Smal, D.E.,  
Scherer, A., Schein, J.E., Jones, S.J. and Marra, M.A.  
Generation and initial analysis of more than 15,000 full-length  
human and mouse cDNA sequences  
Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)

JOURNAL  
PUBMED  
1477932  
3 (bases 1 to 1618)  
Klein, S. and Strausberg, R.  
Direct Submission  
Submitted (02-JAN-2003) National Institutes of Health, Xenopus Gene  
Collection (XGC), National Institute of Child Health and Human  
Development, 6100 Executive Boulevard, Room 4B01, Rockville, MD  
20892-7510, USA  
NIH-XGC Project  
Contact: XGC help desk  
Email: gcraps-remail.nih.gov  
Tissue Procurement: Dr. Igor David  
cDNA Library Preparation: Life Technologies, Inc.  
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
DNA Sequencing by: Institute for Systems Biology  
http://www.systemsbio.org  
Contact: amadasystemsbio.org  
Anup Madan, Jessica Fahey, Erin Helton, Mark Kettman, Anuradha  
Madan, Stephanie Rodrigues, Amy Sanchez and Michelle Whiting

FEATURES  
source  
1. 1618  
/organism="Xenopus laevis"  
/mol\_type="mRNA"  
/db\_xref="taxon:8355"  
/clone="IMAGE:4681465"  
/tissue\_type="Embryo, stage 31/32, Xenopus"  
/clone\_lib="NICHD\_XGC\_Emb4"  
/lab\_host="DH10B"  
/note="Vector: pCMV-SPORT6"  
1. 1618  
/gene="Sfrs1"  
/db\_xref="LOCUS:ID:399226"  
1. 853  
/gene="Sfrs1"  
/codon\_start=2

gene  
CDS  
/db\_xref="LOCUS:ID:399226"  
1. 853  
/gene="Sfrs1"  
/codon\_start=2

misc\_feature  
107..271  
/gene="Sfrs1"  
/note="RBM: Region: RNA recognition motif"  
/db\_xref="CDD:smat00360"  
476..658  
/gene="Sfrs1"  
/note="RBM: 1; Region: RNA recognition motif. (a.x.a. RBM,  
RBD, or RNP domain). The RBM motif is probably diagnostic  
of an RNA binding protein. RBMs are found in a variety of  
RNA binding proteins, including various hnRNP proteins,  
protein implicated in regulation of alternative splicing,  
and protein components of snRNPs. The motif also appears  
in a few single stranded DNA binding proteins. The RBM  
structure consists of four strands and two helices  
arranged in an alpha/beta sandwich, with a third helix  
present during RNA binding in some cases. The C-terminal  
beta strand (4th strand) and final helix are hard to align  
and have been omitted in the SEED alignment. The LA  
protein have a N terminus rim which is included in the  
seed. There is a second region towards the C terminus that  
has some features of a rim but does not appear to have the  
important structural core of a rim. The LA proteins are  
one of the main autoantigens in Systemic lupus  
erythematosus (SLE), an autoimmune disease"  
/db\_xref="CDD:pfam00076"

## ORIGIN

Query Match 30.0%; Score 18; DB 5; Length 1618;  
Best Local Similarity 100.0%; Pred. No. 33;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 41 ACATGCGTGAAGACAGTG 58  
Db 525 ACATGCGTGAAGACAGTG 542

RESULT 13  
HUMAN  
LOCUS 1717 bp mRNA linear PRI 27-APR-1993  
DEFINITION Human alternative splicing factor mRNA, complete cds.  
ACCESSION M72709.1 GI:179073  
VERSION M72709.1 GI:179073  
KEYWORDS alternative splicing factor.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
1 (bases 1 to 1717)  
Ge, H., Zuo, P. and Manley, J.L.  
Primary structure of the human splicing factor ASF reveals  
similarities with Drosophila regulators  
Cell 66 (2), 373-382 (1991)

REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
PUBMED  
91309149  
185257  
Original  
source text: Homo sapiens cDNA to mRNA.  
location/Qualifiers  
1. 1717  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/cell\_line="HeLa"  
/joinI..648,831..1717  
/note="alternative"

misc\_feature  
107..271  
/gene="Sfrs1"  
/note="RBM: Region: RNA recognition motif"  
/db\_xref="CDD:smat00360"  
476..658  
/gene="Sfrs1"  
/note="RBM: 1; Region: RNA recognition motif. (a.x.a. RBM,  
RBD, or RNP domain). The RBM motif is probably diagnostic  
of an RNA binding protein. RBMs are found in a variety of  
RNA binding proteins, including various hnRNP proteins,  
protein implicated in regulation of alternative splicing,  
and protein components of snRNPs. The motif also appears  
in a few single stranded DNA binding proteins. The RBM  
structure consists of four strands and two helices  
arranged in an alpha/beta sandwich, with a third helix  
present during RNA binding in some cases. The C-terminal  
beta strand (4th strand) and final helix are hard to align  
and have been omitted in the SEED alignment. The LA  
protein have a N terminus rim which is included in the  
seed. There is a second region towards the C terminus that  
has some features of a rim but does not appear to have the  
important structural core of a rim. The LA proteins are  
one of the main autoantigens in Systemic lupus  
erythematosus (SLE), an autoimmune disease"  
/db\_xref="CDD:pfam00076"



```

mRNA
  join(1..648,848..1717)
  /note="alternative"
  1..648
  /number=1
  1..96
  join(97..648,831..1157)
  /note="alternative"
  /number=2
  /codon_start=1
  /protein_id="AA35564.1"
  /db_xref="GI:179074"
  /translation="MSGGVRGPGANNDCRIYGNLPDIRTKIDVYKKAIRD
  IDLKRGGPPPAVEFEDPRDAEDAVYGRGYDGRLEVEPRSGRGGGGG
  GGGAAPRGYRYPSPRSRSENRYVSGLPSPSGMODLKHMRAGVCAVDYRDGTGV
  EFKEDMTYAVRKLDTKFRSHGEGTAYIRKVDGPRSPSGRSRSGRSRSGR
  ABAVATAGVAVTPOGEADHHA1LPVIALALVHKLIGTPTHTVYVSFPLSTI
  FSPFNSCFVONGKIC"
  join(97..648,848..1042)
  /note="alternative"
  /number=1
  /codon_start=1
  /protein_id="AA35565.1"
  /db_xref="GI:179075"
  /translation="MSGGVRGPGANNDCRIYGNLPDIRTKIDVYKKAIRD
  IDLKRGGPPPAVEFEDPRDAEDAVYGRGYDGRLEVEPRSGRGGGGG
  GGGAAPRGYRYPSPRSRSENRYVSGLPSPSGMODLKHMRAGVCAVDYRDGTGV
  EFKEDMTYAVRKLDTKFRSHGEGTAYIRKVDGPRSPSGRSRSGRSRSGR
  SNRSRSGYSPRSRSGSPRYSPRSRSGRST"
  649..847
  /number=1
  /label=1a
  649..830
  /number=1
  /label=1b
  831..1717
  /number=2
  /label=2b
  848..1717
  /number=2
  /label=2a
  1043..1717

ORIGIN
3'UTR
Query Match      30.0%; Score 18; DB 9; Length 1717;
Best Local Similarity 100.0%; Pred. No. 33;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CY
41 ACATGCGTGAAGCAGGTG 58
|||||
515 ACATGCGTGAAGCAGGTG 532

RESULT 14
LOCUS BC056752 1860 bp mRNA linear VRT 25-MAY-2004
DEFINITION Danio rerio cDNA clone MGC:65898 IMAGE:6801570, complete cds.
ACCESSION BC056752
VERSION BC056752.1 GI:34785173
KEYWORDS MGC.
SOURCE Danio rerio (zebrafish)
ORGANISM Danio rerio
  Chordata; Chordata; Craniata; Vertebrata; Euteleostomi;
  Actinopterygii; Neopterygii; Teleostei; Ostariophysi;
  Cypriniformes; Cyprinidae; Danio.
  1 (bases 1 to 1860)
  Straussberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
  Klausner R.D., Collins F.S., Wagner L., Shennan C.M., Schuler G.D.,
  Altschul S.F., Zeeberg B., Buetow K.H., Scheffer C.F., Bat N.K.,
  Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
  Datchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
  Stajich M., Soares M.B., Bonaldo M.F., Casavant T.L.,
  Scheetz T.E., Brownstein M.J., Ustin T.B., Toshiyuki S.,
  Carninci P., Prange C., Raha S.S., Loggiano N.A., Peters G.J.,

```

```

TITLE
JOURNAL
PUBMED
REFERENCE
AUTHORS
JOURNAL
TITLE
2 (bases 1 to 1860)
Straussberg R.
Direct Submission
Submitted (25-AUG-2003) National Institutes of Health, Mammalian
Gene Collection (MGC), Cancer Genomics Office, National Cancer
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
USA
NIH-MGC Project URL: http://mgc.nci.nih.gov
Contact: MGC help desk
Email: cgabs-r@mail.nih.gov
Tissue Procurement: Dr. Chi-Bin Chien
CDNA Library Preparation: Invitrogen Corp
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)
DNA Sequencing by: National Institutes of Health Intramural
Sequencing Center (NISC),
Gaithersburg, Maryland;
Web site: http://www.nisc.nih.gov/
Contact: nisc.mgc@nih.gov
Aklter N., Ayle K., Beckstrom-Sternberg S.M., Benjamin B.,
Blakesley R.W., Bouffard G.G., Bren K., Brinkley C., Brooks S.,
Dietrich N.L., Granate S., Guan X., Gupta V., Haghighi P.,
Hansen N., Ho S.-L., Karlins E., Kwong P., Latic P., Legaspi R.,
Maduro Q.L., Masello C., Maskeri B., Mastrian S.D., McCloskey J.C.,
McDowell J., Pearson R., Stancijop S., Thomas P.D., Touchman J.W.,
Tsurgenc C., Vogt J.L., Walker M.A., Wetherby K.D., Wiggins L.,
Young A., Zhang L.-H. and Green E.D.
Clone distribution: MGC clone distribution information can be found
through the I.M.A.G.E. Consortium/LNL at: http://image.llnl.gov
Series: IRX Plate: 121 Row: P Column: 12
This clone was selected for full length sequencing because it
passed the following selection criteria: Hexamer frequency ORF
analysis, Similarity but not identity to protein.
Location/Qualifiers
1..1860
/organism="Danio rerio"
/mol_type="mRNA"
/db_xref="taxon:7955"
/clone="MGC:65898 IMAGE:6801570"
/tissue_type="Embryo, zebrafish whole embryo 72 hpf"
/clone_lib="NCI CGAP_Zemb3"
/lab_host="DH10B"
/note="vector: pCMV-SPORT6.1"
196..762
/codon_start=1
/product="Unknown (protein for MGC:65898)"
/protein_id="AAH56752.1"
/db_xref="GI:34785174"
/translation="MSGGVRGPGANNDCRIYGNLPDIRTKIDVYKKAIRD
IDLKRGGPPPAVEFEDPRDAEDAVYGRGYDGRLEVEPRSGRGGGGG
GGGAAPRGYRYPSPRSRSENRYVSGLPSPSGMODLKHMRAGVCAVDYRDGTGV
EFKEDMTYAVRKLDTKFRSHGEGTAYIRKVDGPRSPSGRSRSGRSRSGR
ST"
FEATURES
source
1..1860

```

```

ORIGIN
Query Match      30.0%; Score 18; DB 5; Length 1860;
Best Local Similarity 100.0%; Pred. No. 33;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CY
41 ACATGCGTGAAGCAGGTG 58

```

Db 611 ACATGCGTGAACGAGGTG 628

# RESULT 15 BC055511

LOCUS BC055511  
DEFINITION Danio rerio zgc:66146, mRNA (cDNA clone MGC:66146 IMAGE:5410436), complete cds.

ACCESSION BC055511  
VERSION BC055511.1 GI:33416586  
KEYWORDS MGC.  
SOURCE Danio rerio (zebrafish)  
ORGANISM Danio rerio

Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes; Cyprinidae; Danio.  
1 (bases 1 to 2002)  
Strausberg, R.L., Feingold, E.A., Grouse, L.H., Derge, J.G., Klausner, R.D., Collins, F.S., Wagner, L., Shenmen, C.M., Schuler, G.D., Altschul, S.F., Zeeberg, B., Buetow, K.H., Schaefer, C.F., Bhat, N.K., Hopkins, R.F., Jordan, H., Moore, T., Max, S.I., Wang, J., Hsieh, F., Dietzeno, L., Mansina, K., Farmer, A.A., Rubin, G.M., Hong, L., Stuplton, M., Soares, M.B., Ronald, M.F., Casavant, T.L., Scheetz, T.E., Brownstein, W.D., Usdin, T.B., Toshiyuki, S., Carninci, P., Prange, C., Raha, S.S., Loguelli, N.A., Peters, G.J., Abramson, R.D., Mullahy, S.J., Bosak, S.A., McEwan, P.J., McKernan, K.J., Malek, J.A., Gunaratne, P.H., Richards, S., Worley, K.C., Hale, S., Garcia, A.M., Gay, L.J., Hult, S.W., Villalón, D.K., Muzny, D.M., Sodergren, E.J., Lu, X., Gibbs, R.A., Fahey, J., Helton, E., Kettelman, M., Madan, A., Rodriguez, S., Sanchez, A., Whiting, M., Madan, A., Young, A.C., Shevchenko, Y., Bouffard, G.G., Blakesley, R.W., Touchman, J.W., Green, E.D., Dickson, M.C., Rodriguez, A.C., Grimwood, J., Schmutz, J., Myers, R.M., Butlerfield, Y.S., Krzywinski, M.I., Skalska, J., Smalins, D.E., Scherch, A., Schein, J.E., Jones, S.J., and Marra, M.A.

Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences  
Proc Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)

JOURNAL 12477932  
PUBMED 2 (bases 1 to 2002)  
REFERENCE Strausberg, R.

TITLE Direct Submission  
Submitted (01-AUG-2003) National Institutes of Health, Mammalian Gene Collection (MGC), Cancer Genomics Office, National Cancer Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590, USA

REMARK NIH-MGC Project URL: <http://mgc.nci.nih.gov>  
COMMENT Contact: MGC help desk  
Email: [cgaps-remail.nih.gov](mailto:cgaps-remail.nih.gov)

Tissue Procurement: Dr. Sumio Sugano  
CDNA Library Preparation: Dr. Sumio Sugano  
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LITL)  
DNA Sequencing by: Sequencing Group at the Stanford Human Genome Center, Stanford University School of Medicine, Stanford, CA 94305  
Web site: <http://www.shgc.stanford.edu>  
Contact: (Dickson, Mark) [mcd@paxil.stanford.edu](mailto:mcd@paxil.stanford.edu)  
Dickson, M., Schmutz, J., Grimwood, J., Rodriguez, A., and Myers, R. M.

Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LITL at: <http://image.llnl.gov>  
Series: IRAX Plate: 122 Row: f Column: 6  
This clone was selected for full length sequencing because it passed the following selection criteria: Hexamer frequency ORF analysis, similarity but not identity to protein.

FEATURES  
Location/Qualifiers  
1..2002

/organism="Danio rerio"  
/mol\_type="mRNA"  
/db\_xref="taxon:7955"  
/clone="MGC:66146 IMAGE:5410436"  
/tissue\_type="Whole body, adult male"

gene  
CDS  
/clone\_lib="Sugano SJD adult male"  
/lab\_host="DH10B"  
/note="Vector: pME188-FL3"  
1..2002  
/gene="zgc:66146"  
/db\_xref="LOCUSID:406288"  
80..817  
/gene="zgc:66146"  
/codon\_start=1  
/product="zgc:66146"  
/protein\_id="AAH5511.1"  
/db\_xref="GI:33416587"  
/translation="MSGGVRGAPAGSNDRCIVGNLPPDIRTKOVDEPFKVAIBDI  
DKNRGGRPPAFVFRPPDPAAYARQYDGYRLTEPRPSRGGRGFRGG  
GGGGGGGGGGGAFRRYCPFRSRIRIVSGLPSSGMDLKHMRADGVCA  
DVFRDGTGVVEVRKEDYIVAKLDNTPKSHGEGTAYILRVYDGRSPSYGRSRR  
SRSRSRSRSRNNRSYSPPRSRGGSP"

ORIGIN  
Query Match 30.0%; Score 18; DB 5; Length 2002;  
Best Local Similarity 100.0%; Pred. No. 33;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CY 41 ACATGCGTGAACGAGGTG 58  
DB 528 ACATGCGTGAACGAGGTG 545

Search completed: December 22, 2004, 23:36:31  
Job time: 854.668 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd

OM nucleic - nucleic search, using sw model

Run on: December 22, 2004, 19:14:28 ; Search time 211.765 Seconds  
(without 31:50 minutes)

Title: US-09-898-616A-2

Sequence: 1 agctacgaaagcagctatcga.....acatgcgtcgaagcaggtgct 60

scoring table: OLIGO\_NUC      Capext 60 0  
Garot 60 0

Searched: 4134886 seqs, 2624710521 residues

Word size : 0

Total number of hits satisfying chosen parameters: 8269772

```
Minimum DB seq length: 0
Maximum DB seq length: 20000000000
```

Maximum DB seq length: 200000000000

Post-processing: Listing first 45 summaries

Database : N\_GeneSeq\_23Sep04:

- 1: geneseqn19305: \*  
2: geneseqn19305: \*  
3: geneseqn20005: \*  
4: geneseqn2001a: \*  
5: geneseqn2001a: \*  
6: geneseqn2002a: \*  
7: geneseqn2002b: \*  
8: geneseqn2003a: \*  
9: geneseqn2003b: \*  
10: geneseqn2003c: \*  
11: geneseqn2004a: \*  
12: geneseqn2004a: \*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed and is derived by analysis of the total score distribution.

## SUMMARIES

Result	Query	Score	Match	Length	DB	ID	Description
No.	No.						
1	60	100.0	60	9	ABZ58371	Human ute	ABZ58371 Human ute
2	60	100.0	60	12	AD127627	Recombina	AD127627 Recombina
3	37	61.7	60	9	ABZ58376	Human ute	ABZ58376 Human ute
4	37	61.7	60	9	ABZ58377	Human ute	ABZ58377 Human ute
5	37	61.7	60	12	AD127633	Recombina	AD127633 Recombina
6	37	61.7	60	12	AD127632	Recombina	AD127632 Recombina
7	18	30.0	59	9	ABZ58375	Human ute	ABZ58375 Human ute
8	18	30.0	59	12	AD127631	Recombina	AD127631 Recombina
9	18	30.0	432	6	ABK45733	cDNA enco	ABK45733 cDNA enco
10	18	30.0	489	9	ACH35932	Human end	ACH35932 Human end
11	18	30.0	1438	4	AAH02904	Human she	AAH02904 Human she
12	18	30.0	1438	10	AA160055	Human PC	AA160055 Human PC
13	18	30.0	1717	10	ADH28741	Human chr	ADH28741 Human chr
14	18	30.0	1926	12	ADP07658	Human sec	ADP07658 Human sec
15	18	30.0	2765	10	ADD22452	H1A-B46 T	Add22452 H1A-B46 T
16	18	30.0	2765	10	AD115992	Human PP	AD115992 Human PP
17	18	30.0	3252	12	ADQ22406	Human scot	ADQ22406 Human scot
18	18	30.0	3299	10	AD122703	Human 113	AD122703 Human 113
19	18	30.0	22970	10	ADK70082	Mutant h	ADK70082 Mutant h
20	18	30.0	22970	10	ADK70081	Mild type	ADK70081 Mild type
21	17	28.3	29	6	AA518797	PCR prime	AA518797 PCR prime

C	22	17	28.3	1978	6	AEN59992	Novel hum
C	23	16	28.3	65	6	ABN56135	Abn56135 Mouse spl
C	24	16	26.7	300	2	AAZ14356	AAz14356 Human gen
C	25	16	26.7	351	12	ADL85790	Adl85790 DNA up-tr
C	26	16	26.7	351	12	ADL85789	Adl85789 DNA up-tr
C	27	16	26.7	373	8	ABX50810	Abx50810 Bovine ES
C	28	16	26.7	624	9	ADA30641	Ada30641 DNA encod
C	29	16	26.7	732	2	AAZ17762	AAz17762 Human gen
C	30	16	26.7	802	2	AAZ16289	AAz16289 Human gen
C	31	16	26.7	830	11	ADJ13178	Adj13178 Human cdb
C	32	16	26.7	846	3	AAc49282	Aac49282 Arabidops
C	33	16	26.7	889	6	ABK13152	ABk13152 Transcript
C	34	16	26.7	1019	4	AA559766	AA559766 Propionib
C	35	16	26.7	1019	8	ACF64695	Acf64695 Propionib
C	36	16	26.7	1820	7	ADM18824	Add18824 Human dci
C	37	16	26.7	1919	11	ADM03518	Adm03518 Human cdb
C	38	16	26.7	1959	11	ABD09379	Abd09379 Pseudomoc
C	39	16	26.7	2010	11	ABD09565	Abd09565 Pseudomoc
C	40	16	26.7	2402	4	AAx81667	Aax81667 Human imm
C	41	16	26.7	3602	8	ACF12861	Acf12861 Human cer
C	42	16	26.7	3803	2	AAx76396	Aax76396 Human sec
C	43	16	26.7	3803	2	ADC38821	Adc38821 Human cdb
C	44	16	26.7	5333	10	ADD47032	Add47032 Human gen
C	45	16	26.7	5333	10	ADD47860	Add47860 Human gen

RESULT 1  
 ID ABZ58371 standard; DNA; 60 BP.  
 XX ABZ58371  
 AC  
 XX ABZ58371;  
 DT 28-Apr-2003 (first entry)  
 DE  
 XX Human uteroglobin synthetic gene oligonucleotide 2.  
 DE  
 XX Human, uteroglobin; respiratory distress; antiinflammatory; antifibrotic;  
 KW antiinflammatory; antiasthmatic; nephrotropic; antirheumatic;  
 KW antiarthritic; ss.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 XX MO2003003979-A2.  
 XX  
 XX 16-JAN-2003.  
 XX  
 XX 02-JUL-2002; 2002WC-US020835.  
 XX  
 XX 02-JUL-2001; 2001US-00898616.  
 XX  
 XX (CLAR-) CLARAGEN INC.  
 XX  
 XX Pilon AL, Welch RE;  
 XX  
 XX WPI; 2003-221527/21.  
 XX  
 XX Bacterial expression system for producing recombinant human uteroglobin  
 XX for treating inflammatory and fibrotic conditions, comprises a synthetic  
 XX gene which codes for human uteroglobin.  
 XX  
 XX Claim 1; Page 33; 127pb; English.  
 XX  
 XX The present sequence is that of oligonucleotide 2, which was used in the  
 XX construction of a synthetic gene for the production of human uteroglobin  
 XX (hUG) in bacteria. Oligonucleotides 1-4 (see ABZ58370-73) were used to  
 XX assemble the coding strand and oligonucleotides 5-8 (see ABZ58374-77) the  
 XX complementary strand. The gene was assembled by annealing and ligation of  
 XX the oligonucleotides. Because mature native hUG has glutamic acid at its  
 XX N-terminus, an initiator methionine was added to the N-terminus, and

CC	codon usage was optimised for expression in bacteria. In an example from
CC	the invention, the synthetic gene was cloned into plasmid pCG32 (see
CC	ABP58378) and recombinant hUG (see ABP72259) was produced in Escherichia
CC	coli strain CG12. The invention relates generally to the production of
CC	recombinant hUG by bacterial expression, protein purification and scaled-
CC	up production according to current good manufacturing practices. The
CC	recombinant hUG is useful for the treatment of inflammatory and fibrotic
CC	conditions, such as neonatal respiratory distress syndrome and
CC	bronchopulmonary dysplasia. It may also be used to treat conditions
CC	associated with elevated phospholipase A2 levels such as pancreatitis,
CC	acute renal failure, rheumatoid arthritis and asthma
XX	
SQ	Sequence 60 BP; 15 A; 15 C; 18 G; 12 T; 0 U; 0 Other;
OY	
Dd	
Query Match	100.0%; Score 60; DB 9; Length 60;
Best Local Similarity	100.0%; Pred. No. 5.2e-23;
Matches	60; Conservative 0; Mismatches 0; Indels 0; Gaps 0
1	AGCAGCACACACCTATGGAACTGTTCTCTCCGACACAGACATGCCGTGAAGAGGTC
1	AGCTTCAACACACTATTGACACTGTTCTCTCCGACACAGACATCTGTAAACAGTGCT
60	
RESULT 2	
ID	ADL27627 standard; DNA; 60 BP.
AC	ADL27627;
XX	
XX	20-MAY-2004 (first entry)
DT	
DE	Recombinant human uteroglobin, rhUG, coding oligonucleotide #2.
XX	
KW	Human; ss; recombinant human uteroglobin, rhUG;
KM	bacterial expression system; rhUG master cell bank;
XN	rhUG research seed bank; anti-inflammatory; secretory phospholipase A 2;
XX	fibrinectin; respiratory distress; inflammation; fibrotic disease.
OS	Homo sapiens.
OS	Synthetic.
PN	US2003207795-A1.
XX	
PD	06-NOV-2003.
XX	
PE	02-JUL-2002; 2002US-00187498.
XX	
PR	28-MAY-1997; 97US-00864357.
PR	02-JUL-2001; 2001US-00898616.
PA	(PILO/) PILON A L.
PA	(WELC/) WELCH R W.
PI	Pilon AL, Welch RW;
XX	
DR	WPI; 2004-051527/05.
PT	Bacterial expression system for production of recombinant human
PT	uteroglobin comprising synthetic gene or human cDNA sequence which codes
PT	for human uteroglobin.
PS	Claim 1; SEQ ID NO 2; 6app; English.
CC	The invention relates to a bacterial expression system for the production
CC	of recombinant human uteroglobin (rhUG), comprising a synthetic gene or
CC	human cDNA sequence which codes for human UG, constructed from the
CC	oligonucleotides appearing as ADL27626-ADL27629, and which further
CC	comprises Met-Ala-Ala at the N-terminus of the sequence. Also included
CC	are producing an rhUG master cell bank (comprising inoculating a suitable
CC	inoculating broth with an aliquot portion of a rhUG research seed bank to
CC	form a bacterial culture, incubating the bacterial culture, adding a
CC	cryopreservative to the bacterial culture to form a cryopreserved
CC	solution, transferring a portion of the cryopreserved solution to a

CC cryovial and storing the cryovial at a temperature below -60 degrees C),  
CC expressing rhG (comprising providing a production seed cell bank culture  
CC comprising an expression vector capable of expressing rhG; inoculating a  
CC broth medium with the production seed cell bank culture to form an  
CC inoculum; incubating the bacterial culture formed in step (b) with the  
CC inoculum; incubating the bacterial culture with the inoculum formed from the  
CC step (c) to form a fermentation culture; incubating the fermentation  
CC culture within the large scale fermenter, adding an induction agent to  
CC the fermentation culture to induce the expression of rhG and harvesting  
CC the above fermentation culture), purifying rhG, determining the potency  
CC of rhG in a sample, measuring in vitro anti-inflammatory effect arising  
CC from inhibition or blocking of secretory phospholipase A 2 enzymes by  
CC rhG, measuring in vitro binding of rhG to fibronectin, determining the  
CC purity of rhG, and a pharmaceutical composition comprising a purified  
CC rhG and a carrier or diluent. The bacterial expression system is useful  
CC for producing a rhG research seed bank or a pharmaceutical grade rhG  
CC drug substance. rhG is safe to administer to a patient in respiratory  
CC distress. The rhG is useful for treating inflammation and fibrotic  
CC diseases. The present sequence is a coding strand oligonucleotide used to  
CC construct the synthetic rhG gene.

XX  
XX  
XX Sequence 60 BP; 15 A; 15 C; 18 G; 12 T; 0 U; 0 Other;

XX  
XX  
XX Query Match 100.0%; Score 60; DB 12; Length 60;  
XX  
XX Best Local Similarity 100.0%; Pred. No. 5.2e-23;  
XX  
XX Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0

XX  
XX  
XX 1 AGCTAGGAAGACGCTATGGACTGTTCTCTCCGAGCAGGACATGCGTGAAGAGGTGCT 60  
XX  
XX 1 AGCTAGGAAGACGCTATGGACTGTTCTCTCCGAGCAGGACATGCGTGAAGAGGTGCT 60

XX  
XX  
XX Db

XX  
XX  
XX RESULT 3  
XX  
XX ABZ58376/C  
XX  
XX ID ABZ58376 standard; DNA; 60 BP.  
XX  
XX AC  
XX  
XX ABZ58376;  
XX  
XX DT 28-APR-2003 (first entry)  
XX  
XX DX Human uteroglobin synthetic gene oligonucleotide 7.  
XX  
XX XX Human; uteroglobin; respiratory distress; antiinflammatory; antifibrotic;  
XX  
XX KW antiinflammatory; antiasthmatic; nephrotropic; antipneumatic;  
XX  
XX XX antiasthmatic; ss.  
XX  
XX OS Homo sapiens.  
XX  
XX OS Synthetic.  
XX  
XX PN WO2003003979-A2.  
XX  
XX XX 16-JAN-2003.  
XX  
XX PD 02-JUL-2002; 2002MO-US020836.  
XX  
XX PF 02-JUL-2001; 2001US-00898616.  
XX  
XX PR 02-JUL-2001; 2001US-00898616.  
XX  
XX PA (CIAR-) CLARAGEN INC.  
XX  
XX PI Pilon AL, Welch RB;  
XX  
XX DR WPI; 2003-221527/21.  
XX  
XX PT Bacterial expression system for producing recombinant human uteroglobin  
XX  
XX PT for treating inflammatory and fibrotic conditions, comprises a synthetic  
XX  
XX PT gene which codes for human uteroglobin.  
XX  
XX PS Example 1; Page 33; 127p; English.  
XX  
XX  
XX The present sequence is that of oligonucleotide 7, which was used in the  
XX  
XX CC construction of a synthetic gene for the production of human uteroglobin  
XX  
XX (rhG) in bacteria. Oligonucleotides 1-4 (see ABZ58370-73) were used to  
XX  
XX CC assemble the coding strand and oligonucleotides 5-8 (see ABZ58374-77) the

complementary strand. The gene was assembled by annealing and ligation of the oligonucleotides. Because mature native hUG has glutamic acid at its N-terminus, an initiator methionine was added to the N-terminus, and codon usage was optimised for expression in bacteria. In an example from the invention, the synthetic gene was cloned into plasmid pCG12 (see AB258378) and recombinant hUG (see ABP72259) was produced in *Escherichia coli* strain CG12. The invention relates generally to the production of recombinant hUG by bacterial expression, protein purification and scaled-up production according to current good manufacturing practices. The recombinant hUG is useful for the treatment of inflammatory and fibrotic conditions, such as neonatal respiratory distress syndrome and bronchopulmonary dysplasia. It may also be used to treat conditions associated with elevated phospholipase A2 levels such as pancreatitis, acute renal failure, rheumatoid arthritis and asthma.

Sequence 60 BP; 12 A; 14 C; 22 G; 12 T; 0 U; 0 Other;

Query Match 61.7%; Score 37; DB 9; Length 60;  
Best Local Similarity 100.0%; Pred. No. 2.1e-10;  
Matches 37; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGCTACGAGCAGCTATGGAAGTCTCTCCGAGAC 37  
DB 37 AGCTACGAGCAGCTATGGAAGTCTCTCCGAGAC 1

RESULT 4  
AB258377/c  
ID AB258377 standard; DNA; 60 BP.  
XX  
AC AB258377;  
XX  
DT 28-APR-2003 (first entry)  
XX  
DE Human uteroglobin synthetic gene oligonucleotide 8.  
XX  
XX Human; uteroglobin; respiratory distress; antiinflammatory; antifibrotic;  
KM antiinflammatory; antiasthmatic; nephroprotective; antirheumatic;  
KM antiarthritic; ss.  
XX  
OS Homo sapiens.  
XX Synthetic.  
XX  
PN WC003003979-A2.  
XX  
PD 16-JAN-2003.  
XX  
PF 02-JUL-2002; 2002WC-US020836.  
XX  
PR 02-JUL-2001; 2001US-00898616.  
XX  
PA (CLAR-) CLARAGEN INC.  
XX  
PI Pilon AL, Welch RE;  
XX  
DR WPI; 2003-221527/21.  
XX  
PT Bacterial expression system for producing recombinant human uteroglobin  
PT for treating inflammatory and fibrotic conditions, comprises a synthetic  
PT gene which codes for human uteroglobin.  
XX  
PS Example 1; Page 33; 127pp; English.  
XX  
CC The present sequence is that of oligonucleotide 8, which was used in the  
CC construction of a synthetic gene for the production of human uteroglobin  
CC (hUG) in bacteria. Oligonucleotides 1-4 (see AB258370-73) were used to  
CC assemble the coding strand and oligonucleotides 5-8 (see AB258374-77) the  
CC complementary strand. The gene was assembled by annealing and ligation of  
CC the oligonucleotides. Because mature native hUG has glutamic acid at its  
CC N-terminus, an initiator methionine was added to the N-terminus, and  
CC codon usage was optimised for expression in bacteria. In an example from  
CC the invention, the synthetic gene was cloned into plasmid pCG12 (see  
CC AB258378) and recombinant hUG (see ABP72259) was produced in *Escherichia*

*coli* strain CG12. The invention relates generally to the production of recombinant hUG by bacterial expression, protein purification and scaled-up production according to current good manufacturing practices. The recombinant hUG is useful for the treatment of inflammatory and fibrotic conditions, such as neonatal respiratory distress syndrome and bronchopulmonary dysplasia. It may also be used to treat conditions associated with elevated phospholipase A2 levels such as pancreatitis, acute renal failure, rheumatoid arthritis and asthma.

Sequence 60 BP; 12 A; 14 C; 22 G; 12 T; 0 U; 0 Other;

Query Match 61.7%; Score 37; DB 9; Length 60;  
Best Local Similarity 100.0%; Pred. No. 2.1e-10;  
Matches 37; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGCTACGAGCAGCTATGGAAGTCTCTCCGAGAC 37  
DB 37 AGCTACGAGCAGCTATGGAAGTCTCTCCGAGAC 1

RESULT 5  
ADL27633/c  
ID ADL27633 standard; DNA; 60 BP.  
XX  
AC ADL27633;  
XX  
DT 20-MAY-2004 (first entry)  
XX  
DE Recombinant human uteroglobin, rhUG, non-coding oligonucleotide #4.  
XX  
XX Human; ss; recombinant human uteroglobin; rhUG;  
KM bacterial expression system; rhUG master cell bank;  
KM rhUG research seed bank; anti-inflammatory; secretory phospholipase A 2;  
KM fibronectin; respiratory distress; inflammation; fibrotic disease.  
XX  
OS Homo sapiens.  
XX Synthetic.  
XX  
PN US2003207795-A1.  
XX  
PD 06-NOV-2003.  
XX  
PF 02-JUL-2002; 2002US-00187498.  
XX  
PR 28-MAY-1997; 97US-00864357.  
XX  
PR 02-JUL-2001; 2001US-00898616.  
XX  
PA (PILLO) PILON A L.  
XX (WELC/) WELCH R W.  
XX  
PI Pilon AL, Welch RW;  
XX  
DR WPI; 2004-051527/05.  
XX  
PT Bacterial expression system for production of recombinant human  
PT uteroglobin comprising synthetic gene or human cDNA sequence which codes  
PT for human uteroglobin.  
XX  
PS Example 1; SEQ ID NO 8; 64pp; English.  
XX  
CC The invention relates to a bacterial expression system for the production  
CC of recombinant human uteroglobin (rhUG), comprising a synthetic gene or  
CC human cDNA sequence which codes for human UG, constructed from the  
CC oligonucleotides appearing as ADL27626-ADL27629, and which further  
CC comprises Met-Ala-Ala at the N-terminus of the sequence. Also included  
CC are producing an rhUG master cell bank (comprising inoculating a suitable  
CC incubating broth with an aliquot portion of a rhUG research seed bank to  
CC form a bacterial culture, incubating the bacterial culture, adding a  
CC cryoprotective to the bacterial culture to form a cryopreserved  
CC solution, transferring a portion of the cryopreserved solution to a  
CC cryovial and storing the cryovial at a temperature below -60 degrees C),  
CC expressing rhUG (comprising providing a production seed cell bank culture  
CC comprising an expression vector capable of expressing rhUG, inoculating a

CC broth medium with the production seed cell bank culture to form an  
CC inoculum, incubating the bacterial culture formed in step (b)  
CC inoculating a large scale fermenter with the inoculum formed from the  
CC step (c) to form a fermentation culture, incubating the fermentation  
CC culture within the large scale fermenter, adding an induction agent to  
CC the fermentation culture to induce the expression of rhug and harvesting  
CC the above fermentation culture, purifying rhug, determining the potency  
CC of rhug in a sample, measuring in vitro anti-inflammatory effect arising  
CC from inhibition or blocking of secretory phospholipase A 2 enzymes by  
CC rhug, measuring in vitro binding of rhug to fibronectin, determining the  
CC purity of rhug, and a pharmaceutical composition comprising a purified  
CC rhug and a carrier or diluent. The bacterial expression system is useful  
CC for producing a rhug research seed bank or a pharmaceutical grade rhug  
CC drug substance. rhug is safe to administer to a patient in respiratory  
CC distress. The rhug is useful for treating inflammation and fibrotic  
CC diseases. The present sequence is a non-coding strand oligonucleotide  
CC used to construct the synthetic rhug gene.

SO Sequence 60 BP; 12 A; 14 C; 22 G; 12 T; 0 U; 0 Other;

Query Match 61.7%; Score 37; DB 12; Length 60;  
Best Local Similarity 100.0%; Pred. No. 2.1e-10;  
Matches 37; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 AGCTACGAGCAGCTATGGAAGTGTCTCTCCGAGCC 37  
Db 37 AGCTACGAGCAGCTATGGAAGTGTCTCTCCGAGCC 1

RESULT 6  
ADL27632/c  
ID ADL27632 standard; DNA; 60 BP.  
XX  
AC ADL27632;  
XX  
DT 20-MAY-2004 (first entry)  
XX  
DE Recombinant human uteroglobin, rhug, non-coding oligonucleotide #3.  
XX  
KW Human; ss; recombinant human uteroglobin; rhug;  
KW bacterial expression system; rhug master cell bank;  
KW rhug research seed bank; anti-inflammatory; secretory phospholipase A 2;  
KW fibronectin; respiratory distress; inflammation; fibrotic disease.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
PN US2003207795-A1.  
XX  
PD 06-NOV-2003.  
XX  
PF 02-JUL-2002; 2002US-00187498.  
XX  
PR 28-MAY-1997; 97US-00864357.  
PR 02-JUL-2001; 2001US-00898616.  
XX  
PA (PILLO/) PILON A L.  
PA (WELC/) WELCH R W.  
XX  
PI Pilon AL, Welch RW;  
XX  
DR WPI; 2004-051527/05.  
XX  
PT Bacterial expression system for production of recombinant human  
PT uteroglobin comprising synthetic gene or human cDNA sequence which codes  
PT for human uteroglobin.  
XX  
PS Example 1; SEQ ID NO 7; 64bp; English.  
XX  
CC The invention relates to a bacterial expression system for the production  
CC of recombinant human uteroglobin (rhug), comprising a synthetic gene or  
CC human cDNA sequence which codes for human ug, constructed from the  
CC oligonucleotides appearing as ADL27626-ADL27629, and which further

CC comprises Met-Ala-Ala at the N-terminus of the sequence. Also included  
CC are producing an rhug master cell bank (comprising inoculating a suitable  
CC incubating broth with an aliquot portion of a rhug research seed bank to  
CC form a bacterial culture, incubating the bacterial culture, adding a  
CC cryoprotective to the bacterial culture to form a cryopreserved  
CC solution, transferring a portion of the cryopreserved solution to a  
CC cryovial, and storing the cryovial at a temperature below -60 degrees C),  
CC expressing rhug (comprising providing a production seed cell bank culture  
CC comprising an expression vector capable of expressing rhug, inoculating a  
CC broth medium with the production seed cell bank culture to form an  
CC inoculum, incubating the bacterial culture formed in step (b),  
CC inoculating a large scale fermenter with the inoculum formed from the  
CC step (c) to form a fermentation culture, incubating the fermentation  
CC culture within the large scale fermenter, adding an induction agent to  
CC the fermentation culture to induce the expression of rhug and harvesting  
CC the above fermentation culture, purifying rhug, determining the potency  
CC of rhug in a sample, measuring in vitro anti-inflammatory effect arising  
CC from inhibition or blocking of secretory phospholipase A 2 enzymes by  
CC rhug, measuring in vitro binding of rhug to fibronectin, determining the  
CC purity of rhug, and a pharmaceutical composition comprising a purified  
CC rhug and a carrier or diluent. The bacterial expression system is useful  
CC for producing a rhug research seed bank or a pharmaceutical grade rhug  
CC drug substance. rhug is safe to administer to a patient in respiratory  
CC distress. The rhug is useful for treating inflammation and fibrotic  
CC diseases. The present sequence is a non-coding strand oligonucleotide  
CC used to construct the synthetic rhug gene.

SO Sequence 60 BP; 12 A; 14 C; 22 G; 12 T; 0 U; 0 Other;

Query Match 61.7%; Score 37; DB 12; Length 60;  
Best Local Similarity 100.0%; Pred. No. 2.1e-10;  
Matches 37; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 AGCTACGAGCAGCTATGGAAGTGTCTCTCCGAGCC 37  
Db 37 AGCTACGAGCAGCTATGGAAGTGTCTCTCCGAGCC 1

RESULT 7  
ABZ58375/c  
ID ABZ58375 standard; DNA; 59 BP.  
XX  
AC ABZ58375;  
XX  
DT 28-APR-2003 (first entry)  
XX  
DE Human uteroglobin synthetic gene oligonucleotide 6.  
XX  
KW Human; uteroglobin; respiratory distress; anti-inflammatory; antifibrotic;  
KW anti-inflammatory; antiaesthetic; nephroretropic; antineumatic;  
KW antiaesthetic; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
PN WO2003003979-A2.  
XX  
PD 16-JAN-2003.  
XX  
PF 02-JUL-2002; 2002WO-US020836.  
XX  
PR 02-JUL-2001; 2001US-00898616.  
XX  
PA (CLAR-) CLARAGEN INC.  
PA Pilon AL, Welch RE;  
XX  
DR WPI; 2003-221527/21.  
XX  
CC Bacterial expression system for producing recombinant human uteroglobin  
CC for treating inflammatory and fibrotic conditions, comprising a synthetic  
CC gene which codes for human uteroglobin.

PS Example 1, Page 33, 127pp; English.

XX The present sequence is that of oligonucleotide 6, which was used in the

CC construction of a synthetic gene for the production of human uteroglobin

CC (rhUG) in bacteria. Oligonucleotides 1-4 (see AB258370-73) were used to

CC assemble the coding strand and oligonucleotides 5-8 (see AB258374-77) the

CC complementary strand. The gene was assembled by annealing and ligation of

CC the oligonucleotides. Because mature native rhUG has glutamic acid at its

CC N-terminus, an initiator methionine was added to the N-terminus, and

CC codon usage was optimized for expression in bacteria. In an example from

CC the invention, the synthetic gene was cloned into plasmid pCG12 (see

CC AB258378) and recombinant rhUG (see ABP72259) was produced in *Escherichia*

CC coli strain CG12. The invention relates generally to the production of

CC recombinant rhUG by bacterial expression, protein purification and scaled-

CC up production according to current good manufacturing practices. The

CC recombinant rhUG is useful for the treatment of inflammatory and fibrotic

CC conditions, such as neonatal respiratory distress syndrome and

CC bronchopulmonary dysplasia. It may also be used to treat conditions

CC associated with elevated phospholipase A2 levels such as pancreatitis,

CC acute renal failure, rheumatoid arthritis and asthma

XX

SQ Sequence 59 BP; 9 A; 17 C; 15 G; 18 T; 0 U; 0 Other;

Query Match 30.0%; Score 18; DB 9; Length 59;

Best Local Similarity 100.0%; Pred. No. 5.5;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 38 AGGACATGCGTGAAGCAG 55

DB 59 AGGACATGCGTGAAGCAG 42

RESULT 8

ADL27631/c

ID ADL27631 standard; DNA; 59 BP.

XX

AC ADL27631;

XX

DT 20-MAY-2004 (first entry)

DE Recombinant human uteroglobin, rhUG, non-coding oligonucleotide #2.

XX

XX Human; ss; recombinant human uteroglobin; rhUG;

XX bacterial expression system; rhUG master cell bank;

XX rhUG research seed bank; anti-inflammatory; secretory phospholipase A 2;

XX fibronectin; respiratory distress; inflammation; fibrotic disease.

XX

OS Homo sapiens.

OS Synthetic.

XX

PN US20030207795-A1.

XX

PD 06-NOV-2003.

XX

PF 02-JUL-2002; 2002US-00187498.

XX

PR 28-MAY-1997; 97US-00864357.

PR 02-JUL-2001; 2001US-00898616.

XX

PA (PILO/) PILON A L.

PA (WELC/) WELCH R W.

XX

PI Pilon AL, Welch RW;

XX

DR WPI; 2004-051527/05.

XX

PT Bacterial expression system for production of recombinant human

PT uteroglobin comprising synthetic gene or human cDNA sequence which codes

PT for human uteroglobin.

XX

PS Example 1; SEQ ID NO 6; 64bp; English.

XX

CC The invention relates to a bacterial expression system for the production

CC of recombinant human uteroglobin (rhUG), comprising a synthetic gene or

CC human cDNA sequence which codes for human UG, constructed from the

CC oligonucleotides appearing as ADL27626-ADL27629, and which further

CC comprises Met-Ala-Ala at the N-terminus of the sequence. Also included

CC are producing an rhUG master cell bank (comprising inoculating a suitable

CC incubating broth with an aliquot portion of a rhUG research seed bank to

CC form a bacterial culture, incubating the bacterial culture, adding a

CC cryoprotective to the bacterial culture to form a cryopreserved

CC solution, transferring a portion of the cryopreserved solution to a

CC cryovial and storing the cryovial at a temperature below -60 degrees C),

CC expressing rhUG (comprising providing a production seed cell bank culture

CC comprising an expression vector capable of expressing rhUG; inoculating a

CC broth medium with the production seed cell bank culture to form an

CC inoculum, incubating the bacterial culture formed in step (b),

CC inoculating a large scale fermenter with the inoculum formed from the

CC step (c) to form a fermentation culture, incubating the fermentation

CC culture within the large scale fermenter, adding an induction agent to

CC the above fermentation culture) ; purifying rhUG, determining the potency

CC of rhUG in a sample, measuring in vitro anti-inflammatory effect arising

CC from inhibition or blocking of secretory phospholipase A 2 enzymes by

CC rhUG, measuring in vitro binding of rhUG to fibronectin, determining the

CC purity of rhUG, and a pharmaceutical composition comprising a purified

CC rhUG and a carrier or diluent. The bacterial expression system is useful

CC for producing a rhUG research seed bank or a pharmaceutical grade rhUG

CC drug substance. rhUG is safe to administer to a patient in respiratory

CC distress. The rhUG is useful for treating inflammation and fibrotic

CC diseases. The present sequence is a non-coding strand oligonucleotide

CC used to construct the synthetic rhUG gene.

XX

SQ Sequence 59 BP; 9 A; 17 C; 15 G; 18 T; 0 U; 0 Other;

Query Match 30.0%; Score 18; DB 12; Length 59;

Best Local Similarity 100.0%; Pred. No. 5.5;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 38 AGGACATGCGTGAAGCAG 55

DB 59 AGGACATGCGTGAAGCAG 42

RESULT 9

ABK45733

ID ABK45733 standard; cDNA; 432 BP.

XX

AC ABK45733;

XX

DT 05-JUN-2002 (first entry).

DE cDNA encoding colon tumour protein, SEQ ID NO 1284.

XX

XX Human; colon tumour; vaccine; colon cancer; immunogenic; immunotherapy;

XX gene; ss.

XX

OS Homo sapiens.

OS WO200212328-A2.

XX

PN WO200212328-A2.

XX

PD 14-FEB-2002.

XX

PF 31-JUL-2001; 2001WO-US024218.

XX

PR 03-AUG-2000; 2000US-0222283P.

PR 28-MAR-2001; 2001US-0279763P.

PR 29-JUN-2001; 2001US-0302051P.

XX

PA (CORI-) CORIXA CORP.

XX

PI King GE, Meagher MJ, Xu J, Secretist H;

XX

DR WPI; 2002-241739/29.

XX

PT New colon cancer polypeptides and polynucleotides, useful as vaccines,



PT for diagnosing, preventing, and treating colon cancer, and as markers for  
PT the progression of cancer.

PS Claim 1; SEQ ID NO 1284; 147bp; English.

CC The invention relates to polynucleotides encoding colon tumour proteins.  
CC The polynucleotides are encoded polypeptides are useful in pharmaceutical  
CC compositions, such as vaccines, for the diagnosis, prevention, and  
CC treatment of colon cancer. Polynucleotide sequences may be used as  
CC hybridisation probes or primers, and in the design and preparation of  
CC ribozyme molecules for inhibiting expression of tumour polypeptides and  
CC proteins in tumour cells. The compositions are useful for stimulating an  
CC immune response against cancer, particularly for the immunotherapy of  
CC colon cancer, and as markers for the progression of cancer. ABK4450  
CC ABK46237 represent coding sequences of human colon tumour proteins of the  
CC invention. Note: With the exception of SEQ ID No. 1 and 2, the sequence  
CC data for this patent did not form part of the printed specification but  
CC was supplied by the European Patent Office

CC Sequence 432 BP; 123 A; 85 C; 103 G; 121 T; 0 U; 0 Other;

Query Match 30.0%; Score 18; DB 6; Length 432;  
Best Local Similarity 100.0%; Pred. No. 5.6;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 41 ACATGCGTGAAGCAGGTG 58  
DB 9 ACATGCGTGAAGCAGGTG 26

RESULT 10  
ACH35932  
ID ACH35932 standard; cDNA; 489 BP.

AC ACH35932;

DT 13-OCT-2003 (first entry)

DE Human endothelial cell cDNA #4065.

XX Human; ss; sequencing by hybridisation; SBH; expressed sequence tag; EST;  
XX genome mapping; biodiversity; genetic disorder.

XX Homo sapiens.

XX US2003073623-A1.

XX 17-APR-2003.

XX 30-JUL-2001; 2001US-00918995.

XX 30-JUL-2001; 2001US-00918995.

XX (DRMA/) DRMANC R T.

XX (LABA/) LABAT I.

XX (STAC/) STACHE-CRAIN B.

XX (DICK/) DICKSON M C.

XX (JONE/) JONES L W.

XX Drmanac RT, Labat I, Stache-Crain B, Dickson MC, Jones LW;

XX WPI; 2003-615964/58.

XX New polynucleotide sequences obtained from various cDNA libraries, useful  
XX as hybridization probes, as oligomers for PCR, for chromosome and gene  
XX mapping, in the recombinant production of protein, or in generating  
XX antisense DNA or RNA.

XX Claim 1; SEQ ID NO 23144; 44bp; English.  
XX The invention relates to an isolated polynucleotide comprising any one of  
XX 38043 cDNA sequences, appearing as ACH12789-ACH50831, whose sequence was  
XX determined by the technique of SBH (sequencing by hybridisation). Also

CC included is a purified polypeptide comprising a sequence corresponding to  
CC a reading frame of the novel polynucleotide. The nucleic acid sequences  
CC are useful in diagnostics as expressed sequence tags (EST) for  
CC identifying expressed genes or for physical mapping of the human genome,  
CC in forensics, in assessing biodiversity, or in identifying mutations  
CC responsible for genetic disorders and other traits. The nucleotide  
CC sequences are also useful as hybridisation probes, as oligomers for PCR,  
CC for chromosome and gene mapping, in the recombinant production of  
CC protein, or in generating antisense DNA or RNA. The purified polypeptide  
CC is useful for generating antibodies specific for it. The present sequence  
CC is one of the 38043 isolated cDNA/EST sequences. Note: The sequence data  
CC for this patent did not form part of the printed specification, but was  
CC obtained in electronic format directly from USPTO at  
CC secdata.uspto.gov/sequence.html?docID=20030073623

XX Sequence 489 BP; 130 A; 103 C; 134 G; 119 T; 0 U; 3 Other;

Query Match 30.0%; Score 18; DB 9; Length 489;  
Best Local Similarity 100.0%; Pred. No. 5.6;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 41 ACATGCGTGAAGCAGGTG 58  
DB 122 ACATGCGTGAAGCAGGTG 139

RESULT 11  
AAH02904  
ID AAH02904 standard; DNA; 1428 BP.

AC AAH02904;

DT 15-JUN-2001 (first entry)

DE Human shear stress-response coding sequence SEQ ID NO: 61.

XX Human; shear stress-response protein; vascular disease; arteriosclerosis;  
XX de.

XX Homo sapiens.

XX WO200125427-A1.

XX 12-APR-2001.

XX 02-OCT-2000; 2000WO-0P006840.

XX 01-OCT-1999; 99JP-00280976.

XX (KYOM) KYOMA HAKKO KOGYO KK.

XX (NOJIT/) NOJIMA H.

XX Nojima H, Yoshitane H, Odayashi M, Ota T, Kawabata A, Sakurada K;

XX Kuga T, Sekine S, Nakamura Y, Sugano S;

XX WPI; 2001-266308/27.

XX P-P8DB; AAB90781.

XX DNA sequences, proteins encoded by them and antibodies against them  
XX useful in diagnosis and treatment of vascular disease caused by  
XX arteriosclerosis.

XX Claim 20; Page 386-388; 678bp; Japanese.

XX The present invention provides the protein and coding sequences of a  
XX number of human shear stress response proteins. These are useful in the  
XX diagnosis, treatment and screening of vascular diseases caused by  
XX arteriosclerosis, including heart failure, post-PTCA restenosis and  
XX hypertension

XX Sequence 1428 BP; 341 A; 296 C; 400 G; 391 T; 0 U; 0 Other;  
XX Query Match 30.0%; Score 18; DB 4; Length 1428;



Best Local Similarity 100.0%; Pred. No. 5.6;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 41 ACATGCGTGAAGCAGGTG 58  
DB 543 ACATGCGTGAAGCAGGTG 560

## RESULT 12

AA160055  
ID AA160055 standard; cDNA; 1428 BP.

XX AA160055;

DT 27-AUG-2003 (first entry)

XX Human PC036-2 cDNA.

XX Human; differentially regulated protein; prevention; therapy; vaccine;  
KM prostate cancer; gene therapy; pre-mRNA splicing factor; PC036-2;

XX chromosome 17q21.3-q22; gene; ss.

XX Homo sapiens.

XX Key Location/Qualifiers

FT CDS 125..871  
FT /tag= a  
FT /product= "Human PC036-2 protein"

XX MO2003040331-A2.

PD 15-MAY-2003.

XX 07-NOV-2002; 2002MO-US035563.

XX 07-NOV-2001; 2001US-0331041P.

XX 07-NOV-2001; 2001US-0331042P.

XX 18-DEC-2001; 2001US-0340251P.

XX 07-JUN-2002; 2002US-0344791P.

XX (ORIG-) ORIGENS TECHNOLOGIES INC.

XX Sun Z, Li X, Jay G, Kovacs KF, Fan W;

XX WPI; 2003-449451/42.

XX P-PSDB; AA029561.

XX New polynucleotide for diagnosing, staging, monitoring, prognosticating,  
PT preventing or treating, or determining the predisposition to, diseases or  
PT conditions such as prostate cancer, and for research or forensic science.

XX Claim 29; Page 127-128; 100bp; English.

XX The present invention relates to novel differentially regulated genes and  
XX polypeptides encoded by them. Sequences of the invention are useful in  
XX diagnosing, staging, monitoring, prognosticating, preventing, treating or  
XX determining the predisposition to diseases or conditions such as prostate  
XX cancer. They may be used as molecular markers, drug targets, vaccines, in  
XX gene therapy, research, clinical medicine or forensic science. The  
XX present sequence is a differentially regulated prostate cDNA, PC036-2  
XX which codes for a pre-mRNA splicing factor. PC036-2 gene is located on  
XX chromosome 17q21.3-q22

XX Sequence 1428 BP; 341 A; 296 C; 400 G; 391 T; 0 U; 0 Other;

XX Query Match 30.0%; Score 18; DB 10; Length 1428;

XX Best Local Similarity 100.0%; Pred. No. 5.6;

XX Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 41 ACATGCGTGAAGCAGGTG 58  
DB 543 ACATGCGTGAAGCAGGTG 560

## RESULT 13

ADH28741  
ID ADH28741 standard; DNA; 1717 BP.

XX ADH28741;

XX 11-MAR-2004 (first entry)

XX Human chronic myelogenous leukemia (CML) gene marker #9.

XX ds; chronic phase chronic myelogenous leukemia; CP-CML;

XX blast crisis CML; BC-CML; human; chronic myelogenous leukemia;

XX gene marker.

XX Homo sapiens.

XX US2003104426-A1.

XX 05-JUN-2003.

XX 14-JUN-2002; 2002US-00171561.

XX 18-JUN-2001; 2001US-0298914P.

XX (LINSLEY) LINSLEY P S.

XX (MAOM/) MAO M.

XX (DAIH/) DAI H.

XX (HEY/) HE Y.

XX (RAD/) RADICH J P.

XX Linsley PS, Mao M, Dai H, He Y, Radich JP;

XX WPI; 2003-787046/74.

XX Classifying cell sample as chronic phase chronic myelogenous leukemia or

XX blast crisis chronic myelogenous leukemia by detecting difference in

XX expression of genes corresponding to the markers such as X15415, U89436.

XX Disclosure; SEQ ID NO 9; 31pp; English.

XX The invention relates to a method of classifying a cell sample as chronic

XX phase chronic myelogenous leukemia (CP-CML) or blast crisis CML (BC-

XX CML). The method is useful for classifying a sample as CP-CML or BC-CML.

XX The present sequence represents a human chronic myelogenous leukemia

XX (CML) gene marker used to distinguish blast crisis CML from chronic phase

XX CML.

XX Sequence 1717 BP; 420 A; 343 C; 465 G; 489 T; 0 U; 0 Other;

XX Query Match 30.0%; Score 18; DB 10; Length 1717;

XX Best Local Similarity 100.0%; Pred. No. 5.6;

XX Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 41 ACATGCGTGAAGCAGGTG 58  
DB 515 ACATGCGTGAAGCAGGTG 532

## RESULT 14

ADP07658  
ID ADP07658 standard; DNA; 1926 BP.

XX ADP07658;

XX 12-AUG-2004 (first entry)

XX Human secreted protein encoding DNA, seq id 141.

XX Cytostatic; antidiabetic; anorectic; gynaecological; antiproliferative;

XX dermatological; antiarteriosclerotic; antihistaminic; neuroprotective;

XX neurotropic; antiparkinsonian; nephroprotective; human; secreted protein;

XX diagnostic; pharmaceutical; cancer; lung; oesophageal; liver; diabetes;

CM	Obesity; metabolic disorder; cardiovascular disorder;
KM	Reproductive disorder; psoriasis; eczema; bronchitis; cystic fibrosis;
KM	Atherosclerosis; benign prostatic hyperplasia; asthma;
KM	Alzheimer's disease; Parkinson's disease; renal disorder; gene; ds.
XX	
CS	Homo sapiens.
XX	
FN	MO2004042000-A2.
PD	21-MAY-2004.
XX	
PF	16-MAY-2003; 2003MO-US015439.
XX	
PR	17-MAY-2002; 2002US-0381592P.
PR	12-JUN-2002; 2002US-0388543P.
PR	08-AUG-2002; 2002US-00401757P.
PR	12-AUG-2002; 2002US-00402585P.
PR	13-AUG-2002; 2002US-0402799P.
PR	22-AUG-2002; 2002US-0404559P.
PR	04-OCT-2002; 2002US-0415902P.
XX	
PA	(HUMA-) HUMAN GENOME SCI INC.
PI	Rosen CA, Ruben SM, Olsen H, Baker KP, Fiscella M, Wei P;
PI	Blize CE, Komarsoullis G, Choi GH, Moore PA, Gupta R, Shi Y;
XX	
DR	WPI: 2004-400656/37.
XX	P-FSDB: ADP07840.
PT	New human secreted polypeptides and nucleic acid molecules for
PT	diagnosing, preventing or treating disorders associated with the secreted
PT	proteins, such as cancer, diabetes, obesity, cardiovascular disorders or
PT	renal disorders.
XX	
PS	Claim 7; SEQ ID NO 141; 1157bp; English.
XX	
CC	The invention relates to a human secreted polypeptide for diagnosing,
CC	preventing or treating disorders associated with the secreted proteins.
CC	The polypeptides and nucleic acid molecules of the invention are useful
CC	for preparing a diagnostic or pharmaceutical composition for diagnosing
CC	or treating a medical condition. These may be used for diagnosing,
CC	preventing or treating disorders related to the human secreted proteins,
CC	such as cancer (e.g. lung, oesophageal or liver cancer), reproductive
CC	obesity, metabolic disorders, cardiovascular disorders, diabetes,
CC	dermatitis, psoriasis, eczema, bronchitis, cystic fibrosis,
CC	atherosclerosis, benign prostatic hyperplasia, asthma, Alzheimer's
CC	disease, Parkinson's disease or renal disorders. Sequences given in
CC	records for ADP07558-ADP07709 represent human secreted protein encoding
CC	DNA's of the invention.
XX	
SO	Sequence 1926 BP; 479 A; 378 C; 568 G; 498 T; 0 U; 3 Other;
XX	
Query Match	30.0%; Score 18; DB 12; Length 1926;
Best Local Similarity	100.0%; Pred. NO. 5.6;
Matches 18; Conservative	0; Mismatches 0; Indels 0; Gaps 0;
Oy	41 ACATGCGTGAAGCAGGTG 58
Db	997 ACATGCGTGAAGCAGGTG 1014
XX	
RESULT 15	
ADD22452	
ID	ADD22452 standard; DNA; 2765 BP.
XX	
AC	ADD22452;
XX	
DT	15-JAN-2004 (first entry)
XX	
DE	H1A-Ba6 T cell recognised tumour antigenic polypeptide, SEQ No 102.
XX	
CM	tumour antigenic peptide; cancer; vaccine; cytostatic; cytotoxic T cell;
KM	colon; mouth; lung; prostatic; gynecological; human; gene; ds.

XX Homo sapiens.  
 XX JP2003111595-A.  
 PX 15-APR-2003.  
 PD 24-JUN-2002; 2002JP-00183603.  
 PF 25-JUN-2001; 2001JP-00191974.  
 PR (ITOX/) ITO Y.  
 PX WPI; 2003-611129/58.  
 DR Novel tumor antigenic peptide or polypeptide useful for inducing  
 PX cytotoxic T cells or for treating cancer such as colon, mouth, lung,  
 PT prostatic or gynecological cancer.  
 PT  
 XX Claim 10; SEQ ID NO 102; 98pp; Japanese.  
 PS  
 XX The invention relates to a novel tumour antigenic peptide or polypeptide  
 CC comprising a sequence selected from 99 sequences fully defined in the  
 CC specification. The tumour antigenic peptide or polypeptide comprises a  
 CC sequence selected from 99 sequences fully defined in the specification,  
 CC where the tumour antigenic peptide preferably has a sequence of Glu-Pro-  
 CC Pro-Leu-Ser-Glu-Glu-Thr-Phe, and the polypeptide preferably has a  
 CC sequence comprising 393 amino acids fully defined in the specification.  
 CC The invention further provides a cancer vaccine comprising a tumour  
 CC antigenic peptide or polypeptide, which has cytostatic activity. A tumour  
 CC antigenic peptide or polypeptide, its encoding polynucleotide, a  
 CC hybridising polynucleotide, a recombinant vector containing the  
 CC polynucleotide, a host transformed with the vector or an antibody are  
 CC useful for screening for compounds that interact with the tumour  
 CC antigenic peptide, the polypeptide or its encoding polynucleotide and  
 CC increases the expression of the tumour antigenic peptide, the polypeptide  
 CC or polynucleotide. The tumour antigenic peptide or the polypeptide is  
 CC useful for inducing cytotoxic T cells. The tumour antigenic peptide  
 CC vaccine is useful for treating cancer such as colon, mouth, lung,  
 CC prostatic or gynecological cancer. The invention also provides a  
 CC pharmaceutical composition useful for treating cancer. The tumour  
 CC antigenic peptide or the polypeptide is useful as an antigen to create  
 CC antibodies. This polynucleotide sequence represents the DNA encoding one  
 CC of the human tumour antigenic polypeptides of the invention.  
 XX  
 SQ Sequence 2765 BP; 759 A; 500 C; 652 G; 854 T; 0 U; 0 Other;  
 Query Match 30.0%; Score 18; DB 10; Length 2765;  
 Best Local Similarity 100.0%; Pred. No. 5.6;  
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0.  
 QY 41 ACATGCGGTGAAGCAGGTG 58  
 |||||  
 DB 509 ACATGCGGTGAAGCAGGTG 526  
 |||||

Search completed: December 22, 2004, 22:44:12  
 Job time : 217.015 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 22, 2004, 22:08:48 ; Search time 48.3258 Seconds

(without alignments)  
882.496 Million cell updates/sec

Title: US-09-898-616A-2

Perfect score: 60

Sequence: 1 agctacgaagcagctatgga.....acatgcctgaagcagctgct 60

Scoring table: OLIGO NUC

Gapop 60.0 , Gapext 60.0

Searched: 824507 seqs, 353394441 residues

Word size : 0

Total number of hits satisfying chosen parameters: 1649014

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Listing first 45 summaries

Database : Issued Patents, NA:

1: /cgn2\_6/ptodata/1/ina/5A.COMB.seq:\*  
2: /cgn2\_6/ptodata/1/ina/5B.COMB.seq:\*  
3: /cgn2\_6/ptodata/1/ina/6A.COMB.seq:\*  
4: /cgn2\_6/ptodata/1/ina/6B.COMB.seq:\*  
5: /cgn2\_6/ptodata/1/ina/PCUTUS.COMB.seq:\*  
6: /cgn2\_6/ptodata/1/ina/backfile1.seq:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	60	100.0	60	US-08-864-357F-7	Sequence 7, Appl1
2	37	61.7	60	US-08-864-357F-12	Sequence 12, Appl1
3	18	30.0	59	US-08-864-357F-11	Sequence 11, Appl1
4	16	26.7	624	US-09-328-352-1928	Sequence 1928, Ap
5	16	26.7	830	US-09-023-655-504	Sequence 504, App
6	16	26.7	1959	US-09-252-991A-7983	Sequence 7983, Ap
7	16	26.7	2010	US-09-252-991A-8169	Sequence 8169, Ap
8	16	26.7	26700	US-08-472-217-1	Sequence 1, Appl1
9	16	26.7	26700	US-08-488-199-5	Sequence 5, Appl1
10	16	26.7	26700	US-08-760-534A-1	Sequence 1, Appl1
11	16	26.7	26700	US-09-335-757-1	Sequence 1, Appl1
12	15	25.0	540	US-09-270-767-3339	Sequence 3339, A
13	15	25.0	540	US-09-270-767-18621	Sequence 18621, A
14	15	25.0	1089	US-08-978-589A-1	Sequence 1, Appl1
15	15	25.0	1089	US-09-335-601-2	Sequence 2, Appl1
16	15	25.0	1089	US-09-219-120-1	Sequence 1, Appl1
17	15	25.0	1651	US-09-975-594-598	Sequence 598, App
18	15	25.0	1913	US-08-588-258A-41	Sequence 41, Appl1
19	15	25.0	1913	US-09-016-434A-1078	Sequence 1078, Ap
20	15	25.0	1913	PCUTUS082935-41	Sequence 41, Appl1
21	15	25.0	1946	US-08-785-584-1	Sequence 1, Appl1
22	15	25.0	1946	US-09-192-611-1	Sequence 1, Appl1
23	15	25.0	1946	US-08-755-582A-5	Sequence 5, Appl1
24	15	25.0	1946	US-09-617-923-1	Sequence 1, Appl1
25	15	25.0	2432	US-09-799-451-5	Sequence 5, Appl1
26	15	25.0	2513	US-09-799-451-6	Sequence 6, Appl1
27	15	25.0	2900	US-08-034-650-9	Sequence 9, Appl1

28	15	25.0	2900	1	US-08-449-015-9	Sequence 9, Appl1
29	15	25.0	6151	4	US-09-799-451-528	Sequence 528, App
30	15	25.0	7194	4	US-09-601-326-76	Sequence 76, Appl1
31	15	25.0	15420	4	US-09-601-326-54	Sequence 54, Appl1
32	14	23.3	136	4	US-09-513-999C-19445	Sequence 19445, A
33	14	23.3	292	4	US-09-313-294A-957	Sequence 957, App
34	14	23.3	303	4	US-09-489-039A-4877	Sequence 4877, Ap
35	14	23.3	363	4	US-09-248-796A-2610	Sequence 2610, Ap
36	14	23.3	373	4	US-09-513-999C-9517	Sequence 9517, Ap
37	14	23.3	498	4	US-09-621-976-2381	Sequence 2381, Ap
38	14	23.3	575	4	US-09-270-767-2759	Sequence 2759, A
39	14	23.3	724	3	US-08-998-416-810	Sequence 810, App
40	14	23.3	798	4	US-09-489-039A-4894	Sequence 4894, Ap
41	14	23.3	836	2	US-08-698-805-7	Sequence 7, Appl1
42	14	23.3	872	4	US-09-270-767-29234	Sequence 29234, A
43	14	23.3	879	4	US-09-620-312D-87	Sequence 87, Appl1
44	14	23.3	1105	4	US-09-221-017B-108	Sequence 108, App
45	14	23.3	1176	4	US-09-270-767-12926	Sequence 12926, A

## ALIGNMENTS

RESULT 1  
US-08-864-357F-7  
Sequence 7, Application US/08864357F  
Patent No. 6255281  
GENERAL INFORMATION:  
APPLICANT: Claragen, Inc. & NIH  
TITLE OF INVENTION: Use of Recombinant Human Uteroglobulin in Treatment of Inflammato  
FILE REFERENCE: 116142/2  
CURRENT FILING DATE: 1997-05-28  
CURRENT APPLICATION NUMBER: US/08/864,357F  
NUMBER OF SEQ ID NOS: 22  
SOFTWARE: Patentin version 3.0  
SEQ ID NO 7  
LENGTH: 60  
TYPE: DNA  
ORGANISM: artificial  
FEATURE:  
OTHER INFORMATION: primer sequence  
US-08-864-357F-7  
Query Match 100.0%; Score 60; DB 3; Length 60;  
Best Local Similarity 100.0%; Pred. No. 2.5e-24;  
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 AGCTACGAAGCAGCTATGGAAGCTTTCTTCGCGACGACATGCGTGAAGCAGGTGCT 60  
DB 1 AGCTACGAAGCAGCTATGGAAGCTTTCTTCGCGACGACATGCGTGAAGCAGGTGCT 60  
RESULT 2  
US-08-864-357F-12/c  
Sequence 12, Application US/08864357F  
Patent No. 6255281  
GENERAL INFORMATION:  
APPLICANT: Claragen, Inc. & NIH  
TITLE OF INVENTION: Use of Recombinant Human Uteroglobulin in Treatment of Inflammato  
FILE REFERENCE: 116142/2  
CURRENT FILING DATE: 1997-05-28  
CURRENT APPLICATION NUMBER: US/08/864,357F  
NUMBER OF SEQ ID NOS: 22  
SOFTWARE: Patentin version 3.0  
SEQ ID NO 12  
LENGTH: 60  
TYPE: DNA  
ORGANISM: artificial  
FEATURE:  
OTHER INFORMATION: primer sequence  
US-08-864-357F-12

Query Match 61.7%; Score 37; DB 3; Length 60;  
Best Local Similarity 100.0%; Pred. No. 1.6e-11;  
Matches 37; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGCTACGAGCAGCTATGAGTCTCTCCGACC 37  
DB 37 AGCTACGAGCAGCTATGAGTCTCTCCGACC 1

## RESULT 3

US-08-864-357F-11/C  
Sequence 11, Application US/0864357F  
Patent No. 6255281

GENERAL INFORMATION:  
APPLICANT: Claretgen, Inc. & NIH

TITLE OF INVENTION: Use of Recombinant Human Uteroglobin in Treatment of Inflammato  
TITLE OF INVENTION: Fibrotic Conditions  
FILE REFERENCE: 116142/2

CURRENT APPLICATION NUMBER: US/08/864,357F

CURRENT FILING DATE: 1997-05-28

NUMBER OF SEQ ID NOS: 22

SOFTWARE: Patent version 3.0

SEQ ID NO 11

LENGTH: 59

TYPE: DNA

ORGANISM: artificial

FEATURE:

OTHER INFORMATION: primer sequence

US-08-864-357F-11

Query Match 30.0%; Score 18; DB 3; Length 59;  
Best Local Similarity 100.0%; Pred. No. 0.62;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 38 AGGACATGCGTGAAGCAG 55  
DB 59 AGGACATGCGTGAAGCAG 42

## RESULT 4

US-09-328-352-1928  
Sequence 1928, Application US/09328352

Patent No. 6562958

GENERAL INFORMATION:

APPLICANT: Gary L. Bretton et al.

TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO ACINETOBACTER

FILE REFERENCE: GTC09-03PA

CURRENT APPLICATION NUMBER: US/09/328,352

CURRENT FILING DATE: 1999-06-04

NUMBER OF SEQ ID NOS: 8252

SEQ ID NO 1928

LENGTH: 624

TYPE: DNA

ORGANISM: Acinetobacter baumannii

US-09-328-352-1928

Query Match 26.7%; Score 16; DB 4; Length 624;  
Best Local Similarity 100.0%; Pred. No. 8.3;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 42 CATCGGTGAAGCAGT 57  
DB 177 CATCGGTGAAGCAGT 192

## RESULT 5

US-09-023-655-504/C

Sequence 504, Application US/09023655

Patent No. 6607879

GENERAL INFORMATION:

APPLICANT: Cocks, Benjamin G.

APPLICANT: Susan G. Stuart  
APPLICANT: Jeffrey J. Seilhamer  
TITLE OF INVENTION: COMPOSITION FOR THE DETECTION OF BLOOD CELL GENE  
TITLE OF INVENTION: EXPRESSION  
NUMBER OF SEQUENCES: 1508  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: INCYTE PHARMACEUTICALS, INC.  
STREET: 3174 PORTER DRIVE  
CITY: PALO ALTO  
STATE: CALIFORNIA  
COUNTRY: USA  
ZIP: 94304

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Word Perfect 6.1 for Windows/MS-DOS 6.2

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/023,655

FILING DATE: HEREMITH

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER:

FILING DATE:

CLASSIFICATION:

ATTORNEY/AGENT INFORMATION:

NAME: Zeller, Karen J.

REGISTRATION NUMBER: 37,071

REFERENCE/DOCKET NUMBER: PA-0001 US

TELEPHONE: (650) 855-0555

TELEFAX: (650) 845-4166

INFORMATION FOR SEQ ID NO: 504:

SEQUENCE CHARACTERISTICS:

LENGTH: 830 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

IMMEDIATE SOURCE:

LIBRARY: TESTNOT03

CLONE: 2006402

US-09-023-655-504

Query Match 26.7%; Score 16; DB 4; Length 830;  
Best Local Similarity 100.0%; Pred. No. 8.3;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 45 GCGTGAAGCAGTGCT 60  
DB 195 GCGTGAAGCAGTGCT 180

## RESULT 6

US-09-252-991A-7983  
Sequence 7983, Application US/09252991A

Patent No. 6551795

GENERAL INFORMATION:

APPLICANT: Marc J. Rubenfield et al.

TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS

FILE REFERENCE: 107196.136

CURRENT APPLICATION NUMBER: US/09/252,991A

CURRENT FILING DATE: 1999-02-18

PRIOR APPLICATION NUMBER: US 60/074,788

PRIOR FILING DATE: 1998-02-18

PRIOR APPLICATION NUMBER: US 60/094,190

PRIOR FILING DATE: 1998-07-27

NUMBER OF SEQ ID NOS: 33142

SEQ ID NO 7983

LENGTH: 1959

TYPE: DNA

ORGANISM: Pseudomonas aeruginosa

US-09-252-991A-7983

Query Match 26.7%; Score 16; DB 4; Length 1959;  
Best Local Similarity 100.0%; Pred. No. 8.4;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 45 GCGTGAGCAGGTGCT 60  
DB 1913 GCGTGAGCAGGTGCT 1928

RESULT 7  
US-09-252-991A-8169/C  
; Sequence 8169, Application US/09252991A  
; Patent No. 6551795  
; GENERAL INFORMATION:  
; APPLICANT: Marc J. Rubenfield et al.  
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS  
; FILE REFERENCE: 107196.136  
; CURRENT APPLICATION NUMBER: US/09/252,991A  
; PRIOR FILING DATE: 1999-02-18  
; PRIOR APPLICATION NUMBER: US 60/074,788  
; PRIOR FILING DATE: 1998-02-18  
; PRIOR APPLICATION NUMBER: US 60/094,190  
; PRIOR FILING DATE: 1998-07-27  
; NUMBER OF SEQ ID NOS: 33142  
; SEQ ID NO 8169  
; LENGTH: 2010  
; TYPE: DNA  
; ORGANISM: Pseudomonas aeruginosa  
US-09-252-991A-8169

Query Match 26.7%; Score 16; DB 4; Length 2010;  
Best Local Similarity 100.0%; Pred. No. 8.4;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 45 GCGTGAGCAGGTGCT 60  
DB 134 GCGTGAGCAGGTGCT 119

RESULT 8  
US-08-472-217-1  
; Sequence 1, Application US/08472217  
; Patent No. 5726058  
; GENERAL INFORMATION:  
; APPLICANT: Alanen-Kurki, Leena  
; APPLICANT: Auvinen, Petri  
; APPLICANT: Jaakkola, Panu  
; APPLICANT: Jaakkola, Markku  
; APPLICANT: Lepp, Sirpa  
; APPLICANT: Maki, Markku  
; APPLICANT: Vihtinen, Tapani  
; APPLICANT: Wrti, Anni  
; TITLE OF INVENTION: Syndecan Stimulation Of Cellular  
; TITLE OF INVENTION: Differentiation  
; NUMBER OF SEQUENCES: 4  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Sterne, Kessler, Goldstein & Fox  
; STREET: 1100 New York Avenue, Suite 600  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: U.S.A.  
; ZIP: 20005  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; OPERATING SYSTEM: IBM PC compatible  
; SOFTWARE: Patentin Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/472,217  
; FILING DATE: 07-JUN-1995  
; CLASSIFICATION: 514

PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/206,186  
; FILING DATE: 07-MAR-1994  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/988,427  
; FILING DATE: 01-DEC-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Cimballa, Michele A.  
; REGISTRATION NUMBER: 33,851  
; REFERENCE/DOCKET NUMBER: 1102,0050003  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 371-2600  
; TELEFAX: (202) 371-2540  
; INFORMATION FOR SEQ ID NO: 1:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 26700 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: both  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA (genomic)  
; HYPOTHEICAL: NO  
; ANTI-SENSE: NO  
; FEATURE:  
; NAME/KEY: CDS  
; LOCATION: join(4378..4443, 22026..22106, 23001..23483,  
; ; LOCATION: 23905..24039, 24251..24418)  
US-08-472-217-1

Query Match 26.7%; Score 16; DB 1; Length 26700;  
Best Local Similarity 100.0%; Pred. No. 8.7;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 29 CTCGGAGCAGGACAT 44  
DB 3800 CTCGGAGCAGGACAT 3815

RESULT 9  
US-08-488-199-5  
; Sequence 5, Application US/08488199  
; Patent No. 5851993  
; GENERAL INFORMATION:  
; APPLICANT: Talkanen, Markku  
; APPLICANT: Maki, Markku  
; TITLE OF INVENTION: Suppression of Tumor Cell Growth By  
; TITLE OF INVENTION: Syndecan-1 Ectodomain  
; NUMBER OF SEQUENCES: 8  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: STERNE, KESSLER, GOLDSTEIN & FOX  
; STREET: 1100 New York Ave., NW  
; CITY: Washington  
; STATE: DC  
; COUNTRY: USA  
; ZIP: 20005  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; OPERATING SYSTEM: IBM PC compatible  
; SOFTWARE: Patentin Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/488,199  
; FILING DATE: 07-JUN-1995  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/258,862  
; FILING DATE: 13-JUN-1994  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Cimballa, Michele A.  
; REGISTRATION NUMBER: 33,851  
; REFERENCE/DOCKET NUMBER: 1102,0130001  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 202-371-2600  
; TELEFAX: 202-371-2540

INFORMATION FOR SEQ ID NO: 5:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 26700 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
FEATURE:  
NAME/KEY: CDS  
LOCATION: 4378..4443  
FEATURE:  
NAME/KEY: CDS  
LOCATION: 22026..22107  
FEATURE:  
NAME/KEY: CDS  
LOCATION: 23002..23483  
FEATURE:  
NAME/KEY: CDS  
LOCATION: 23905..24040  
FEATURE:  
NAME/KEY: CDS  
LOCATION: 24252..24418  
US-08-488-199-5

Query Match: 26.7%; Score 16; DB 2; Length 26700;  
Best Local Similarity 100.0%; Pred. No. 8.7;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 29 CTCGGACCCAGGACAT 44  
DB 3800 CTCGGACCCAGGACAT 3815

RESULT 10  
US-08-760-534A-1  
Sequence 1, Application US/08760534A  
Patent No. 6017727  
GENERAL INFORMATION:  
APPLICANT: JALKANEN, MARKKU  
APPLICANT: JAAKKOLA, PANU  
APPLICANT: VIHINEN, TAPANI  
TITLE OF INVENTION: SYNDACAN ENHANCER ELEMENT AND SYNDACAN  
TITLE OF INVENTION: STIMULATION OF CELLULAR DIFFERENTIATION  
NUMBER OF SEQUENCES: 14  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: STERN, KESSLER, GOLDSTEIN & FOX P.L.L.C.  
STREET: 1100 NEW YORK AVENUE, SUITE 600  
CITY: WASHINGTON  
STATE: DC  
COUNTRY: US  
ZIP: 20005-3934  
COMPUTER READABLE FORM:  
MEDIUM TYPE: floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/760,534A  
FILING DATE: 02-DEC-1996  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/206,186  
FILING DATE: 07-MAR-1994  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: PCT/FI93/00514  
FILING DATE: 01-DEC-1993  
ATTORNEY/AGENT INFORMATION:  
NAME: CIMBALA, MICHELE A.  
REGISTRATION NUMBER: 33,851  
REFERENCE/DOCKET NUMBER: 1708, 0050004/MAC  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202) 371-2600  
TELEFAX: (202) 371-2540  
INFORMATION FOR SEQ ID NO: 1:

SEQUENCE CHARACTERISTICS:  
LENGTH: 26700 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: double  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
FEATURE:  
NAME/KEY: CDS  
LOCATION: join(4378..4443, 22026..22106, 23001..23483, 23905..24039, 24251..24418)  
US-08-760-534A-1

Query Match: 26.7%; Score 16; DB 3; Length 26700;  
Best Local Similarity 100.0%; Pred. No. 8.7;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 29 CTCGGACCCAGGACAT 44  
DB 3800 CTCGGACCCAGGACAT 3815

RESULT 11  
US-09-336-757-1  
Sequence 1, Application US/09336757  
Patent No. 6492344  
GENERAL INFORMATION:  
APPLICANT: JALKANEN, MARKKU  
APPLICANT: JAAKKOLA, PANU  
APPLICANT: VIHINEN, TAPANI  
TITLE OF INVENTION: SYNDACAN ENHANCER ELEMENT AND SYNDACAN  
TITLE OF INVENTION: STIMULATION OF CELLULAR DIFFERENTIATION  
NUMBER OF SEQUENCES: 14  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: STERN, KESSLER, GOLDSTEIN & FOX P.L.L.C.  
STREET: 1100 NEW YORK AVENUE, SUITE 600  
CITY: WASHINGTON  
STATE: DC  
COUNTRY: US  
ZIP: 20005-3934  
COMPUTER READABLE FORM:  
MEDIUM TYPE: floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/336,757  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/760,534  
FILING DATE:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: PCT/FI93/00514  
FILING DATE: 01-DEC-1993  
ATTORNEY/AGENT INFORMATION:  
NAME: CIMBALA, MICHELE A.  
REGISTRATION NUMBER: 33,851  
REFERENCE/DOCKET NUMBER: 1708, 0050004/MAC  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202) 371-2600  
TELEFAX: (202) 371-2540  
INFORMATION FOR SEQ ID NO: 1:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 26700 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: double  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
FEATURE:  
NAME/KEY: CDS  
LOCATION: join(4378..4443, 22026..22106, 23001..23483, 23905..24039, 24251..24418)  
US-09-336-757-1

Query Match 26.7%; Score 16; DB 4; Length 26700;  
Best Local Similarity 100.0%; Pred. No. 87;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 29 CTCGACGACGACACT 44  
DB 3800 CTCGACGACGACACT 3815

RESULT 12  
US-09-270-767-3339  
; Sequence 3339; Application US/09270767  
; Patent No. 6703491  
; GENERAL INFORMATION:  
; APPLICANT: Homburger et al.  
; TITLE OF INVENTION: Nucleic acids and proteins of *Drosophila melanogaster*  
; FILE REFERENCE: File Reference: 7326-094  
; CURRENT APPLICATION NUMBER: US/09/270,767  
; CURRENT FILING DATE: 1999-03-17  
; NUMBER OF SEQ ID NOS: 62517  
; SOFTWARE: Patent In Ver. 2.0  
; SEQ ID NO 3339  
; LENGTH: 540  
; TYPE: DNA  
; ORGANISM: *Drosophila melanogaster*  
; FEATURE:  
; OTHER INFORMATION: n means any nucleotide  
US-09-270-767-3339

Query Match 25.0%; Score 15; DB 4; Length 540;  
Best Local Similarity 100.0%; Pred. No. 30;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 10 GCAGCTATGGAAGT 24  
DB 134 GCAGCTATGGAAGT 148

RESULT 13  
US-09-270-767-18621  
; Sequence 18621; Application US/09270767  
; Patent No. 6703491  
; GENERAL INFORMATION:  
; APPLICANT: Homburger et al.  
; TITLE OF INVENTION: Nucleic acids and proteins of *Drosophila melanogaster*  
; FILE REFERENCE: File Reference: 7326-094  
; CURRENT APPLICATION NUMBER: US/09/270,767  
; CURRENT FILING DATE: 1999-03-17  
; NUMBER OF SEQ ID NOS: 62517  
; SOFTWARE: Patent In Ver. 2.0  
; SEQ ID NO 18621  
; LENGTH: 540  
; TYPE: DNA  
; ORGANISM: *Drosophila melanogaster*  
; FEATURE:  
; OTHER INFORMATION: n means any nucleotide  
US-09-270-767-18621

Query Match 25.0%; Score 15; DB 4; Length 540;  
Best Local Similarity 100.0%; Pred. No. 30;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 10 GCAGCTATGGAAGT 24  
DB 134 GCAGCTATGGAAGT 148

RESULT 14  
US-08-978-589A-1  
; Sequence 1; Application US/08978589A  
; Patent No. 6087145  
; GENERAL INFORMATION:

APPLICANT: ISHII, Takeshi  
APPLICANT: MITSUDA, Satoshi  
TITLE OF INVENTION: ESTERASE GENE AND ITS USE  
NUMBER OF SEQUENCES: 4  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: BIRCH, STEWART, KOLASCH & BIRCH, LLP  
STREET: P.O. BOX 747  
CITY: FALLS CHURCH  
STATE: VIRGINIA  
COUNTRY: UNITED STATES OF AMERICA  
ZIP: 22040

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/978,589A  
FILING DATE: 26-NOV-1997

CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: Murphy Jr., Gerald M.  
REGISTRATION NUMBER: 28,377  
REFERENCE/DOCKET NUMBER: 20-4336P  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (703) 205-8000  
TELEFAX: (703) 205-8050  
INFORMATION FOR SEQ ID NO: 1:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1089 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: double  
TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)  
ORGANISM: *Burkholderia cepacia*  
STRAIN: SC-20  
FEATURE:  
NAME/KEY: CDS  
LOCATION: 1..1089  
US-08-978-589A-1

Query Match 25.0%; Score 15; DB 3; Length 1089;  
Best Local Similarity 100.0%; Pred. No. 30;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 46 CGTGAAGCAGGTGCT 60  
DB 336 CGTGAAGCAGGTGCT 350

RESULT 15  
US-09-336-601-2  
; Sequence 2; Application US/09336601  
; Patent No. 6184008  
; GENERAL INFORMATION:  
; APPLICANT: OHTA, Hiromichi  
; APPLICANT: SUGAI, Takeshi  
; APPLICANT: ISHII, Takeshi  
; APPLICANT: MITSUDA, Satoshi  
; TITLE OF INVENTION: PRODUCTION OF OPTICALLY ACTIVE SPHINGOID COMPOUND  
; FILE REFERENCE: 2185-349P  
; CURRENT APPLICATION NUMBER: US/09/336,601  
; CURRENT FILING DATE: 1999-06-21  
; EARLIER APPLICATION NUMBER: 09/034,007  
; EARLIER FILING DATE: 1998-03-03  
; NUMBER OF SEQ ID NOS: 2  
; SOFTWARE: Patent In Ver. 2.0  
; SEQ ID NO 2  
; LENGTH: 1089  
; TYPE: DNA  
; ORGANISM: *E. coli* JM 109/pAL 612 strain  
US-09-336-601-2

Query Match 25.0%; Score 15; DB 3; Length 1089;  
 Best Local Similarity 100.0%; Pred. No. 30;  
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 46 CGTGAACGAGTGCT 50  
 |||||  
 Db 336 CGTGAACGAGTGCT 350

Search completed: December 23, 2004, 01:33:36  
 Job time : 50.3258 secs



GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using SW model

Run on: December 22, 2004, 23:36:53 ; Search time 841.086 Seconds  
(without alignments)  
397.214 Million cell updates/sec

Title: US-09-898-616A-2

Perfect score: 60  
Sequence: 1 agctacgaagcagctatgga.....acatgcgtgaagcagctgct 60

Scoring table: OLIGO\_NUC  
Gapop 60.0, Gapext 60.0

Searched: 4105333 seqs, 2784055677 residues

Word size: 0

Total number of hits satisfying chosen parameters: 8210666

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Listing first 45 summaries

Database:

Published Applications NA:\*

1: /cgn2\_6/ptodata/1/pubna/US07\_PUBCOMB.seq:\*

2: /cgn2\_6/ptodata/1/pubna/PC1\_NEW\_PUB.seq:\*

3: /cgn2\_6/ptodata/1/pubna/US06\_NEW\_PUB.seq:\*

4: /cgn2\_6/ptodata/1/pubna/US06\_PUBCOMB.seq:\*

5: /cgn2\_6/ptodata/1/pubna/US07\_NEW\_PUB.seq:\*

6: /cgn2\_6/ptodata/1/pubna/US07\_PUBCOMB.seq:\*

7: /cgn2\_6/ptodata/1/pubna/US08\_NEW\_PUB.seq:\*

8: /cgn2\_6/ptodata/1/pubna/US08\_PUBCOMB.seq:\*

9: /cgn2\_6/ptodata/1/pubna/US09\_PUBCOMB.seq:\*

10: /cgn2\_6/ptodata/1/pubna/US09\_PUBCOMB.seq:\*

11: /cgn2\_6/ptodata/1/pubna/US09C\_PUBCOMB.seq:\*

12: /cgn2\_6/ptodata/1/pubna/US09C\_NEW\_PUB.seq:\*

13: /cgn2\_6/ptodata/1/pubna/US10\_PUBCOMB.seq:\*

14: /cgn2\_6/ptodata/1/pubna/US10C\_PUBCOMB.seq:\*

15: /cgn2\_6/ptodata/1/pubna/US10C\_PUBCOMB.seq:\*

16: /cgn2\_6/ptodata/1/pubna/US10C\_PUBCOMB.seq:\*

17: /cgn2\_6/ptodata/1/pubna/US10C\_PUBCOMB.seq:\*

18: /cgn2\_6/ptodata/1/pubna/US10C\_PUBCOMB.seq:\*

19: /cgn2\_6/ptodata/1/pubna/US10C\_PUBCOMB.seq:\*

20: /cgn2\_6/ptodata/1/pubna/US10C\_PUBCOMB.seq:\*

21: /cgn2\_6/ptodata/1/pubna/US60\_PUBCOMB.seq:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match Length	ID	Description
1	60	100.0	9	US-09-861-688-7
2	60	100.0	10	US-09-898-616A-2
3	60	100.0	60	US-10-187-498A-2
4	60	100.0	16	US-10-647-371-6
5	37	61.7	60	US-09-861-688-12
6	37	61.7	9	US-09-898-616A-7
7	37	61.7	10	US-09-898-616A-8
8	37	61.7	60	US-10-187-498A-8
9	37	61.7	15	US-10-187-498A-8
10	37	61.7	60	US-10-647-371-11
11	18	30.0	9	US-09-861-688-11
12	18	30.0	59	US-09-898-616A-6

Result No.	Score	Query Match Length	ID	Description
13	18	30.0	59	US-10-187-498A-6
14	18	30.0	59	US-10-647-371-10
15	18	30.0	432	US-09-920-300A-1284
16	18	30.0	432	US-10-033-528-1284
17	18	30.0	432	US-10-099-926-1284
18	18	30.0	489	US-09-918-995-23144
19	18	30.0	1717	US-10-171-581-9
20	18	30.0	3252	US-10-723-860-5226
21	18	30.0	3299	US-10-006-285-513
22	17	28.3	467	US-10-027-632-59298
23	17	28.3	467	US-10-027-632-59299
24	17	28.3	467	US-10-027-632-59300
25	17	28.3	467	US-10-027-632-298628
26	17	28.3	467	US-10-027-632-298629
27	17	28.3	467	US-10-027-632-298630
28	17	28.3	467	US-10-027-632-59298
29	17	28.3	467	US-10-027-632-59299
30	17	28.3	467	US-10-027-632-59300
31	17	28.3	467	US-10-027-632-298628
32	17	28.3	467	US-10-027-632-298629
33	17	28.3	467	US-10-027-632-298630
34	17	28.3	534	US-10-027-632-50093
35	17	28.3	534	US-10-027-632-50093
36	17	28.3	555	US-10-027-632-321780
37	17	28.3	555	US-10-027-632-321780
38	16	26.7	65	US-09-908-975-28883
39	16	26.7	351	US-10-430-201-2182
40	16	26.7	351	US-10-430-201-2183
41	16	26.7	373	US-09-983-965-739
42	16	26.7	375	US-10-674-1244-22078
43	16	26.7	477	US-09-783-590-4830
44	16	26.7	492	US-10-425-115-102427
45	16	26.7	561	US-10-027-632-10327

#### ALIGNMENTS

RESULT 1

US-09-861-688-7

Sequence 7, Application US/09861688

Patent No. US020020173460A1

GENERAL INFORMATION:

APPLICANT: Chazgen, Inc. & NIH

TITLE OF INVENTION: Use of Recombinant Human Uteroglobin in Treatment of

TITLE OF INVENTION: Inflammatory and

FILE REFERENCE: 116142/2

CURRENT APPLICATION NUMBER: US/09/861,688

CURRENT FILING DATE: 2001-05-21

PRIOR APPLICATION NUMBER: 09/864,357

PRIOR FILING DATE: 1997-05-28

NUMBER OF SEQ ID NOS: 22

SOFTWARE: PatentIn version 3.0

SEQ ID NO 7

LENGTH: 60

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: primer sequence

US-09-861-688-7

Query Match 100.0%; Score 60; DB 9; Length 60;

Best Local Similarity 100.0%; Pred. No. 6.3e-24;

Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

DB 1

1 AGCTACGAAGCAGCTATGGAAGCTGCTCCCGGACGACATGCGTGAAGAGAGTGTCT 60

1 AGCTACGAAGCAGCTATGGAAGCTGCTCCCGGACGACATGCGTGAAGAGAGTGTCT 60

RESULT 2

US-09-898-616A-2

Sequence 2, Application US/09898616A  
Publication No. US20030109429A1  
GENERAL INFORMATION:  
APPLICANT: Clargen Inc.  
APPLICANT: Pilon, Aprile L  
APPLICANT: Welch, Richard W  
TITLE OF INVENTION: Method for the Production of Purified rhug for the Treatment of  
TITLE OF INVENTION: Inflammatory and Fibrotic Conditions  
FILE REFERENCE: 116142/00170  
CURRENT APPLICATION NUMBER: US/09/898,616A  
PRIOR FILING DATE: 2002-10-15  
PRIOR APPLICATION NUMBER: US 08/864,357  
NUMBER OF SEQ ID NOS: 10  
SOFTWARE: PatentIn version 3.1  
SEQ ID NO 2  
LENGTH: 60  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte  
OTHER INFORMATION: d sequence maximized for expression in E. coli.  
NAME/KEY: misc feature  
OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte  
OTHER INFORMATION: d sequence maximized for expression in E. coli.  
US-09-898-616A-2

Query Match 100.0%; Score 60; DB 10; Length 60;  
Best Local Similarity 100.0%; Pred. No. 6.3e-24;  
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGCTACGAGAGGATGTAAGTGTCTCTCCGACGAGACATGCGTGAAGCAGGTGCT 60  
DB 1 AGCTACGAGAGGATGTAAGTGTCTCTCCGACGAGACATGCGTGAAGCAGGTGCT 60

RESULT 3  
US-10-187-498A-2  
Sequence 2, Application US/10187498A  
Publication No. US2003020795A1  
GENERAL INFORMATION:  
APPLICANT: Clargen Inc.  
APPLICANT: Pilon, Aprile L  
APPLICANT: Welch, Richard W  
TITLE OF INVENTION: Method for the Production of Purified rhug for the Treatment of  
TITLE OF INVENTION: Inflammatory and Fibrotic Conditions  
FILE REFERENCE: 116142/00260  
CURRENT APPLICATION NUMBER: US/10/187,498A  
PRIOR FILING DATE: 2001-07-02  
PRIOR APPLICATION NUMBER: US 08/864,357  
NUMBER OF SEQ ID NOS: 10  
SOFTWARE: PatentIn version 3.1  
SEQ ID NO 2  
LENGTH: 60  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte  
OTHER INFORMATION: d sequence maximized for expression in E. coli.  
NAME/KEY: misc feature  
OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte  
OTHER INFORMATION: d sequence maximized for expression in E. coli.  
US-10-187-498A-2

Query Match 100.0%; Score 60; DB 15; Length 60;  
Best Local Similarity 100.0%; Pred. No. 6.3e-24;  
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGCTACGAGAGGATGTAAGTGTCTCTCCGACGAGACATGCGTGAAGCAGGTGCT 60  
DB 1 AGCTACGAGAGGATGTAAGTGTCTCTCCGACGAGACATGCGTGAAGCAGGTGCT 60

DB 1 AGCTACGAGAGGATGTAAGTGTCTCTCCGACGAGACATGCGTGAAGCAGGTGCT 60

RESULT 4  
US-10-647-371-6  
Sequence 6, Application US/10647371  
Publication No. US20040047857A1  
GENERAL INFORMATION:  
APPLICANT: Clargen, Inc. & NIH  
TITLE OF INVENTION: Use of Recombinant Human Uteroglobin in Treatment of Inflammatory  
TITLE OF INVENTION: and Fibrotic Conditions  
FILE REFERENCE: 116142-85  
CURRENT APPLICATION NUMBER: US/10/647,371  
PRIOR FILING DATE: 2003-08-25  
PRIOR APPLICATION NUMBER: 09/549,926  
NUMBER OF SEQ ID NOS: 12  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 6  
LENGTH: 60  
TYPE: DNA  
ORGANISM: Artificial  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: primer sequence  
US-10-647-371-6

Query Match 100.0%; Score 60; DB 15; Length 60;  
Best Local Similarity 100.0%; Pred. No. 6.3e-24;  
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGCTACGAGAGGATGTAAGTGTCTCTCCGACGAGACATGCGTGAAGCAGGTGCT 60  
DB 1 AGCTACGAGAGGATGTAAGTGTCTCTCCGACGAGACATGCGTGAAGCAGGTGCT 60

RESULT 5  
US-09-861-688-12/c  
Sequence 12, Application US/09861688  
Patent No. US20020173460A1  
GENERAL INFORMATION:  
APPLICANT: Clargen, Inc. & NIH  
TITLE OF INVENTION: Use of Recombinant Human Uteroglobin in Treatment of  
TITLE OF INVENTION: Inflammatory and  
FILE REFERENCE: 116142/2  
CURRENT APPLICATION NUMBER: US/09/861,688  
PRIOR FILING DATE: 2001-05-21  
PRIOR APPLICATION NUMBER: 08/864,357  
NUMBER OF SEQ ID NOS: 22  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 12  
LENGTH: 60  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: primer sequence  
US-09-861-688-12

Query Match 61.7%; Score 37; DB 9; Length 60;  
Best Local Similarity 100.0%; Pred. No. 6.3e-11;  
Matches 37; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGCTACGAGAGGATGTAAGTGTCTCTCCGACGAGAC 37  
DB 37 AGCTACGAGAGGATGTAAGTGTCTCTCCGACGAGAC 1

RESULT 6  
US-09-898-616A-7/c  
Sequence 7, Application US/09898616A  
Publication No. US20030109429A1  
GENERAL INFORMATION:

APPLICANT: Clargen Inc.  
APPLICANT: Pilon, Aprile L  
TITLE OF INVENTION: Method for the Production of Purified rhug for the Treatment of  
TITLE OF INVENTION: Inflammation and Fibrotic Conditions  
FILE REFERENCE: 116142/00170  
CURRENT APPLICATION NUMBER: US/09/898,616A  
PRIOR APPLICATION NUMBER: US 08/864,357  
PRIOR FILING DATE: 1997-05-28  
NUMBER OF SEQ ID NOS: 10  
SOFTWARE: PatentIn version 3.1  
SEQ ID NO 7  
LENGTH: 60  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte  
FEATURE:  
OTHER INFORMATION: d sequence maximized for expression in E. coli.  
NAME/KEY: misc feature  
OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte  
OTHER INFORMATION: d sequence maximized for expression in E. coli.  
US-09-898-616A-7

Query Match 61.7%; Score 37; DB 10; Length 60;  
Best Local Similarity 100.0%; Pred. No. 6.3e-11;  
Matches 37; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGCTACGAGCAGCTATGGAAGTCTTCTCCGAGCC 37  
DB 37 AGCTACGAGCAGCTATGGAAGTCTTCTCCGAGCC 1

RESULT 7  
US-09-898-616A-8/c  
Sequence 8, Application US/09898616A  
Publication No. US20030109429A1  
GENERAL INFORMATION:  
APPLICANT: Clargen Inc.  
APPLICANT: Pilon, Aprile L  
TITLE OF INVENTION: Method for the Production of Purified rhug for the Treatment of  
TITLE OF INVENTION: Inflammation and Fibrotic Conditions  
FILE REFERENCE: 116142/00170  
CURRENT APPLICATION NUMBER: US/09/898,616A  
PRIOR APPLICATION NUMBER: US 08/864,357  
PRIOR FILING DATE: 1997-05-28  
NUMBER OF SEQ ID NOS: 10  
SOFTWARE: PatentIn version 3.1  
SEQ ID NO 8  
LENGTH: 60  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte  
FEATURE:  
OTHER INFORMATION: d sequence maximized for expression in E. coli.  
NAME/KEY: misc feature  
OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte  
OTHER INFORMATION: d sequence maximized for expression in E. coli.  
US-09-898-616A-8

Query Match 61.7%; Score 37; DB 10; Length 60;  
Best Local Similarity 100.0%; Pred. No. 6.3e-11;  
Matches 37; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 8  
US-10-187-498A-7/c  
Sequence 7, Application US/10187498A  
Publication No. US20030207795A1  
GENERAL INFORMATION:  
APPLICANT: Clargen Inc.  
APPLICANT: Pilon, Aprile L  
TITLE OF INVENTION: Method for the Production of Purified rhug for the Treatment of  
TITLE OF INVENTION: Inflammation and Fibrotic Conditions  
FILE REFERENCE: 116142/00260  
CURRENT APPLICATION NUMBER: US/10/187,498A  
PRIOR APPLICATION NUMBER: 2001-07-02  
PRIOR FILING DATE: 1997-05-28  
NUMBER OF SEQ ID NOS: 10  
SOFTWARE: PatentIn version 3.1  
SEQ ID NO 7  
LENGTH: 60  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte  
FEATURE:  
OTHER INFORMATION: d sequence maximized for expression in E. coli.  
NAME/KEY: misc feature  
OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte  
OTHER INFORMATION: d sequence maximized for expression in E. coli.  
US-10-187-498A-7

Query Match 61.7%; Score 37; DB 15; Length 60;  
Best Local Similarity 100.0%; Pred. No. 6.3e-11;  
Matches 37; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGCTACGAGCAGCTATGGAAGTCTTCTCCGAGCC 37  
DB 37 AGCTACGAGCAGCTATGGAAGTCTTCTCCGAGCC 1

RESULT 9  
US-10-187-498A-8/c  
Sequence 8, Application US/10187498A  
Publication No. US20030207795A1  
GENERAL INFORMATION:  
APPLICANT: Clargen Inc.  
APPLICANT: Pilon, Aprile L  
TITLE OF INVENTION: Method for the Production of Purified rhug for the Treatment of  
TITLE OF INVENTION: Inflammation and Fibrotic Conditions  
FILE REFERENCE: 116142/00260  
CURRENT APPLICATION NUMBER: US/10/187,498A  
PRIOR APPLICATION NUMBER: 2001-07-02  
PRIOR FILING DATE: 1997-05-28  
NUMBER OF SEQ ID NOS: 10  
SOFTWARE: PatentIn version 3.1  
SEQ ID NO 8  
LENGTH: 60  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte  
FEATURE:  
OTHER INFORMATION: d sequence maximized for expression in E. coli.  
NAME/KEY: misc feature  
OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte  
OTHER INFORMATION: d sequence maximized for expression in E. coli.  
US-10-187-498A-8

Query Match 61.7%; Score 37; DB 15; Length 60;  
Best Local Similarity 100.0%; Pred. No. 6.3e-11;  
Matches 37; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTACGAGAGAGCTATGTAAGTGTCTCTCCGAGC 37  
DB 37 AGTACGAGAGAGCTATGTAAGTGTCTCTCCGAGC 1

RESULT 10  
US-10-647-371-11/c  
Sequence 11, Application US/10647371  
Publication No. US20040047857A1  
GENERAL INFORMATION:  
APPLICANT: Claragen, Inc. & NIH  
TITLE OF INVENTION: Use of Recombinant Human Uteroglobulin in Treatment of Inflammatory  
TITLE OF INVENTION: and Fibrotic Conditions  
FILE REFERENCE: 116142-85  
CURRENT APPLICATION NUMBER: US/10/647,371  
CURRENT FILING DATE: 2003-08-25  
PRIOR APPLICATION NUMBER: 09/549,926  
PRIOR FILING DATE: 2000-04-14  
NUMBER OF SEQ ID NOS: 12  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 11  
LENGTH: 60  
TYPE: DNA  
ORGANISM: Artificial  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: primer sequence  
US-10-647-371-11

Query Match 51.7%; Score 37; DB 16; Length 60;  
Best Local Similarity 100.0%; Pred. No. 6,3e-11;  
Matches 37; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTACGAGAGAGCTATGTAAGTGTCTCTCCGAGC 37  
DB 37 AGTACGAGAGAGCTATGTAAGTGTCTCTCCGAGC 1

RESULT 11  
US-09-861-688-11/c  
Sequence 11, Application US/09861688  
Patent No. US20020173460A1  
GENERAL INFORMATION:  
APPLICANT: Claragen, Inc. & NIH  
TITLE OF INVENTION: Use of Recombinant Human Uteroglobulin in Treatment of  
TITLE OF INVENTION: Inflammatory and  
TITLE OF INVENTION: Fibrotic Conditions  
FILE REFERENCE: 116142/2  
CURRENT APPLICATION NUMBER: US/09/861,688  
CURRENT FILING DATE: 2001-05-21  
PRIOR APPLICATION NUMBER: 08/864,357  
PRIOR FILING DATE: 1997-05-28  
NUMBER OF SEQ ID NOS: 22  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 11  
LENGTH: 59  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: primer sequence  
US-09-861-688-11

Query Match 30.0%; Score 18; DB 9; Length 59;  
Best Local Similarity 100.0%; Pred. No. 3.4;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 38 AGGACATGCGTGAAGCAG 55  
DB 59 AGGACATGCGTGAAGCAG 42

RESULT 12  
US-09-898-616a-6/c  
Sequence 6, Application US/09898616A

Publication No. US20030109429A1  
GENERAL INFORMATION:  
APPLICANT: Claragen Inc.  
APPLICANT: Pilon, Aprile L  
APPLICANT: Welch, Richard W  
TITLE OF INVENTION: Method for the Production of Purified rhNG for the Treatment of  
TITLE OF INVENTION: Inflammatory and Fibrotic Conditions  
FILE REFERENCE: 116142/00170  
CURRENT APPLICATION NUMBER: US/09/898,616A  
CURRENT FILING DATE: 2002-10-15  
PRIOR APPLICATION NUMBER: US 08/864,357  
PRIOR FILING DATE: 1997-05-28  
NUMBER OF SEQ ID NOS: 10  
SOFTWARE: PatentIn version 3.1  
SEQ ID NO 6  
LENGTH: 59  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte  
OTHER INFORMATION: d sequence maximized for expression in E. coli.  
FEATURE:  
NAME/KEY: misc.feature  
OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte  
OTHER INFORMATION: d sequence maximized for expression in E. coli.  
US-09-898-616a-6

Query Match 30.0%; Score 18; DB 10; Length 59;  
Best Local Similarity 100.0%; Pred. No. 3.4;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 38 AGGACATGCGTGAAGCAG 55  
DB 59 AGGACATGCGTGAAGCAG 42

RESULT 13  
US-10-187-498a-6/c  
Sequence 6, Application US/10187498A  
Publication No. US20030207795A1  
GENERAL INFORMATION:  
APPLICANT: Claragen Inc.  
APPLICANT: Pilon, Aprile L  
APPLICANT: Welch, Richard W  
TITLE OF INVENTION: Method for the Production of Purified rhNG for the Treatment of  
TITLE OF INVENTION: Inflammatory and Fibrotic Conditions  
FILE REFERENCE: 116142/00260  
CURRENT APPLICATION NUMBER: US/10/187,498A  
CURRENT FILING DATE: 2001-07-02  
PRIOR APPLICATION NUMBER: US 08/864,357  
PRIOR FILING DATE: 1997-05-28  
NUMBER OF SEQ ID NOS: 10  
SOFTWARE: PatentIn version 3.1  
SEQ ID NO 6  
LENGTH: 59  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte  
OTHER INFORMATION: d sequence maximized for expression in E. coli.  
FEATURE:  
NAME/KEY: misc.feature  
OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte  
OTHER INFORMATION: d sequence maximized for expression in E. coli.  
US-10-187-498a-6

Query Match 30.0%; Score 18; DB 15; Length 59;  
Best Local Similarity 100.0%; Pred. No. 3.4;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 38 AGGACATGCGTGAAGCAG 55  
DB 59 AGGACATGCGTGAAGCAG 42

## RESULT 14

US-10-647-371-10/C  
Sequence 10, Application US/10647371  
Publication No. US20040047857A1  
GENERAL INFORMATION:  
APPLICANT: Clargen, Inc. & NIH  
TITLE OF INVENTION: Use of Recombinant Human Uteroglobulin in Treatment of Inflammatory  
FILE REFERENCE: 116142-85  
CURRENT FILING DATE: 2003-08-25  
PRIORITY FILING DATE: 2000-04-14  
PRIORITY FILING DATE: 2000-04-14  
NUMBER OF SEQ ID NOS: 12  
SOFTWARE: Patent version 3.2  
SEQ ID NO 10  
LENGTH: 59  
TYPE: DNA  
ORGANISM: Artificial  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: primer sequence  
US-10-647-371-10

## Query Match

30.0%; Score 18; DB 16; Length 59;  
Best Local Similarity 100.0%; Pred. No. 3.4;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY

38 AGGACATGCGGTGAGACAG 55

Db

59 AGGACATGCGGTGAGACAG 42

## RESULT 15

US-09-920-300A-1284  
Sequence 1284, Application US/09920300A  
Patent No. US20020136728A1  
GENERAL INFORMATION:  
APPLICANT: King, Gordon E.  
APPLICANT: Meagher, Madeline Joy  
APPLICANT: Xu, Jianshun  
APPLICANT: Secrist, Heather  
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY  
FILE REFERENCE: 210121.547  
CURRENT FILING DATE: 2001-07-31  
PRIORITY FILING DATE: 2001-07-31  
NUMBER OF SEQ ID NOS: 1789  
SOFTWARE: FastSeq for Windows Version 4.0  
SEQ ID NO 1284  
LENGTH: 432  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-920-300A-1284

## Query Match

30.0%; Score 18; DB 9; Length 432;  
Best Local Similarity 100.0%; Pred. No. 3;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY

41 ACATGCGTGAAGCAGGTG 58

Db

9 ACATGCGTGAAGCAGGTG 26

Search completed: December 23, 2004, 05:19:26  
Job time : 843.086 secs

**This page blank (uspio)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 22, 2004, 19:17:58 ; Search time 834.543 Seconds  
(without alignments)  
3343.258 Million cell updates/sec

Title: US-03-898-616A-3

Perfect score: 59 1 cagctgaagaagaactgttga.....cgtgaatccatcataaactg 59

Sequence: OLIGO NUC  
Gapop 60.0 , Gapext 60.0

Scoring table: 4525729 seqs, 2364849745 residues

Searched: 0

Word size : 0

Total number of hits satisfying chosen parameters: 9053458

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: listing first 45 summaries

Database : GenEmbl:\*  
1: gb\_ba:\*  
2: gb\_hlg:\*  
3: gb\_in:\*  
4: gb\_cm:\*  
5: gb\_ov:\*  
6: gb\_pat:\*  
7: gb\_ph:\*  
8: gb\_pl:\*  
9: gb\_pr:\*  
10: gb\_ro:\*  
11: gb\_sts:\*  
12: gb\_sy:\*  
13: gb\_un:\*  
14: gb\_vl:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	59	100.0	59	6	ARI60917 Sequence
2	37	62.7	59	6	ARI60920 Sequence
3	19	32.2	62318	2	ACI35267 Rattus no
4	19	32.2	65394	2	ACI17645 Mus muscu
5	19	32.2	145825	8	OSJN00027
6	19	32.2	232344	2	ACI11782 Rattus no
7	19	32.2	246787	2	ACI28608 Rattus no
8	18	30.5	215	6	AI3577
9	18	30.5	215	6	AI3577
10	18	30.5	220	12	SYNBILRG
11	18	30.5	1234	8	AK073198 Oryza sat
12	18	30.5	2004	6	AX461306 Sequence
13	18	30.5	3176	8	AK065797 Oryza sat
14	18	30.5	7419	1	PSETPEDC
15	18	30.5	42499	8	AC004625 Arabidops
16	18	30.5	67388	9	ACI33476 Homo sapi
17	18	30.5	96066	8	AC005662 Arabidops
18	18	30.5	106057	8	ACI19796 Oryza sat
19	18	30.5	110000	1	RME591985_15 Continuation (16 o

c 20	18	30.5	150503	8	ACI22149 Oryza sat
c 21	18	30.5	159867	2	ACI30411 Homo sapi
c 22	18	30.5	166399	2	AC012584 Homo sapi
c 23	18	30.5	168199	2	ACI08292 Mus muscu
c 24	18	30.5	170064	8	AF003771 Oryza sat
c 25	18	30.5	193386	10	ACI17693 Arabidops
c 26	18	30.5	202920	10	AL929441 Mouse DNA
c 27	18	30.5	270725	2	ACI26948 Rattus no
c 28	17	28.8	195	6	AX435021 Mus muscu
c 29	17	28.8	993	13	AY487489 Unculture
c 30	17	28.8	2190	10	AF144255 Arabidops
c 31	17	28.8	3530	6	CO582203 Sequence
c 32	17	28.8	5568	6	AX571642 Sequence
c 33	17	28.8	10166	1	AE007324 Streptoco
c 34	17	28.8	11627	1	AE012368 Xanthomon
c 35	17	28.8	14736	6	CQ789080 Sequence
c 36	17	28.8	14736	6	AR218939 Sequence
c 37	17	28.8	14736	6	BD003851 Polynucle
c 38	17	28.8	19457	2	AC017722 Drosophila
c 39	17	28.8	62598	6	AX571767 Sequence
c 40	17	28.8	65904	2	ACI04954 Homo sapi
c 41	17	28.8	91803	9	AC092318 Homo sapi
c 42	17	28.8	95506	9	AC002407 Human Chr
c 43	17	28.8	100061	2	AC016551 Homo sapi
c 44	17	28.8	132164	9	AC098587 Homo sapi
c 45	17	28.8	144402	2	AC021854 Homo sapi

## ALIGNMENTS

RESULT 1	ARI60917	59 bp	DNA	linear	PAT 17-OCT-2001
LOCUS	Sequence 8 from patent US 6255281.				
DEFINITION	ARI60917				
ACCESSION	ARI60917.1	GI:16225984			
VERSION					
KEYWORDS					
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	Unclassified.				
AUTHORS	1 (bases 1 to 59)				
TITLE	Pilon A.L., Mukherjee, A.B. and Zhang, Z.				
JOURNAL	Use of recombinant human uteroglobin in treatment of inflammatory				
FEATURES	and fibrotic conditions				
ORIGIN	Patent: US 6255281-A 8 03-JUL-2001;				
	Location/Qualifiers				
	1..59				
	/organism="unknown"				
	/mol_type="unassigned DNA"				
Query Match	100.0%;	Score 59;	DB 6;	Length 59;	
Best Local Similarity	100.0%;	Pred. No. 3.3e-23;			
Matches	59;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
QY	1	CAGCTGAAGAAACGTTGACACCCCTGCCGAGAAACCGGTGAATCCATCAATAACTG 59			
Db	1	CAGCTGAAGAAACGTTGACACCCCTGCCGAGAAACCGGTGAATCCATCAATCACTG 59			
RESULT 2	ARI60920/c	59 bp	DNA	linear	PAT 17-OCT-2001
LOCUS	Sequence 11 from patent US 6255281.				
DEFINITION	ARI60920				
ACCESSION	ARI60920.1	GI:16225993			
VERSION					
KEYWORDS					
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	Unclassified.				
AUTHORS	1 (bases 1 to 59)				
	Pilon, A.L., Mukherjee, A.B. and Zhang, Z.				

TITLE Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions  
 JOURNAL Patent: US 6255281-A 11 03-JUL-2001;  
 FEATURES Location/Qualifiers  
 source 1..59  
 /organism="unknown"  
 /mol\_type="unassigned DNA"

ORIGIN

Query Match 62.7%; Score 37; DB 6; Length 59;  
 Best Local Similarity 100.0%; Pred. No. 2,2e-10;  
 Matches 37; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CY 1 CAGCTGAAGAACTGTTGACACCCGCGCAGAGAAC 37  
 37 CAGCTGAAGAACTGTTGACACCCGCGCAGAGAAC 1

DB 37 CAGCTGAAGAACTGTTGACACCCGCGCAGAGAAC 1

RESULT 3  
 AC135267 62318 bp DNA linear HTG 19-NOV-2002  
 LOCUS Rattus norvegicus clone CH230-416G11, WORKING DRAFT SEQUENCE.  
 AC135267 GI:25073198  
 DEFINITION HTG: HTGS\_PHASE2: HTGS\_DRAFT: HTGS\_FULLTOP.  
 AC135267  
 VERSION HTG: HTGS\_PHASE2: HTGS\_DRAFT: HTGS\_FULLTOP.  
 KEYWORDS Rattus norvegicus (Norway rat)  
 SOURCE Rattus norvegicus  
 ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus  
 1 (bases 1 to 62318)  
 Mueny,D.Marie, Metzker,M.Lee, Ambr,A., Anguita,C., Alder,J., Allen,C., Allen,H., Alsbrooks,S., Ambr,A., Anguita,C., Ambr,A., Ayodeji,M., Baca,E., Baden,H., Ayalebechi,V., Aoyagi,A., Ayodeji,M., Baca,E., Baden,H., Baldwin,D., Bandaranaike,D., Barber,M., Barnstead,M., Benahmed,F., Bawalo,K., Blat,J., Blankenburg,K., Blyth,P., Brown,M., Bryant,A., Buhay,C., Burch,P., Burrell,K., Calderon,E., Cardenas,V., Carter,K., Cavazos,I., Caesar,H., Center,A., Chacko,J., Chavez,D., Chen,G., Chen,R., Chen,Y., Chen,Z., Chu,D., Cleveland,C., Cockrell,R., Cox,C., Coyle,M., Cree,A., D'Souza,L., David,M.L., Davis,C., Davy-Carroll,L., De Anda,C., Dedetich,D., Delgado,O., Denison,S., Deramo,C., Ding,Y., Dinh,H., Divya,K., Draper,H., Dugan-Rocha,S., Dunn,A., Durbin,K., Duval,B., Eaves,K., Egan,A., Escotto,M., Eugene,C., Evans,C.A., Falls,T., Fan,G., Fernandez,S., Finley,M., Flagg,N., Forbes,L., Foster,M., Foster,P., Fraser,C.M., Gabris,A., Ganta,R., Garcia,A., Garner,T., Garza,M., Gebregeorgis,E., Geer,K., Gill,R., Grady,M., Guerra,W., Guevara,W., Gunaratne,P., Haaland,W., Hamill,C., Hamilton,C., Hamilton,K., Harvey,Y., Hayak,P., Hawes,A., Henderson,N., Hernandez,J., Hernandez,R., Hines,S., Hladun,S.L., Hodgson,A., Hogues,M., Hollins,B., Howells,S., Huix,S., Hume,J., Idelbitz,D., Jackson,A., Jackson,L., Jacob,L., Jiang,H., Johnson,B., Johnson,R., Jolivet,A., Kapathy,S., Kelly,S., Kelly,S., Khan,Z., King,J., Kovar,C., Kowis,C., Kraft,C.L., Lebow,H., Levan,J., Lewis,L., Li,Z., Liu,J., Liu,J., Liu,W., Liu,Y., London,P., Longacre,S., Lopez,J., Lorenshewa,L., Louisseg,H., Lozaco,R.J., Lu,X., Ma,J., Mageswar,M., Mahindaratne,M., Mahmoud,M., Malloy,K., Mangum,A., Mangum,B., Nagai,P., Martin,K., Martin,R., Martinez,E., Mawhney,S., McLeod,K.P., McNeill,T.Z., Meenen,E., Milosavljevic,A., Miner,G., Minja,E., Montemayor,U., Moore,S., Morgan,M., Morris,K., Morris,S., Munkasa,M., Murphy,M., Nair,D., Nankervis,C., Neal,D., Newton,N., Nguyen,N., Norris,S., Nwackeleneh,O., Okwono,G., Olarnpungoon,A., Pal,S., Parks,K., Pasternak,S., Paul,H., Perez,A., Perez,L., Pfankuch,C., Plopper,F., Polindexter,A., Popovic,C., Pritts,E., Pu,L., Pu,M., Puzo,M., Quiroz,U., Rachin,B., Reeves,K., Regier,M.A., Reigh,R., Reilly,B., Reilly,M., Ren,Y., Reuter,M., Richards,S., Riggs,F., Rivers,C., Rodkey,T., Rojas,A., Rose,M., Rose,R., Ritz,S.J., Sanders,W., Savary,G., Scherer,S., Scott,G., Shatsman,S., Shen,H., Shetty,J., Shvartsbeyn,A., Sisson,I., Sitter,C.D., Smajls,D., Sneed,A., Sodergren,E., Song,X.-Z., Sorrell,R., Sosa,J., Steimle,M., Strong,R., Sutton,A., Svatek,A., Tabor,P., Taylor,C., Taylor,T., Thomas,N., Thomas,S., Tingey,A., Trejos,Z., Umami,K.,

TITLE Valas,R., Vera,V., Villasana,D., Waidron,L., Walker,B., Wang,J., Wang,Q., Wang,S., Warren,U., Warren,R., Wei,X., White,F., Williams,G., Wilson,R., Wleczyk,R., Wooden,H., Worley,K., Wright,D., Wright,R., Wu,J., Yakub,S., Yen,J., Yoon,L., Yoon,V., Yu,F., Zhang,J., Zhou,J., Zhou,X., Zhao,S., Dunn,D., von Niederhausen,A., Weiss,R., Smith,D.R., Holt,R.A., Smith,H.O., Weinstock,G. and Gibbs,R.A.  
 Direct Submission  
 JOURNAL Unpublished  
 REFERENCE 2 (bases 1 to 62318)  
 AUTHORS Rat Genome Sequencing Consortium.  
 JOURNAL Direct Submission  
 SUBMITTED (11-OCT-2002) Human Genome Sequencing Center, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA  
 3 (bases 1 to 62318)  
 REFERENCE Rat Genome Sequencing Consortium.  
 JOURNAL Direct Submission  
 SUBMITTED (19-NOV-2002) Human Genome Sequencing Center, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA  
 On Nov 19, 2002 this sequence version replaced gi:23802942.  
 The sequence in this assembly is a combination of BAC based reads and whole genome shotgun sequencing reads assembled using Atlas (http://www.hgsc.bcm.tmc.edu/projects/rat/). Each contig described in the feature table below represents a scaffold in the Atlas assembly (a contig-scaffold). Within each contig-scaffold, individual sequence contigs are ordered and oriented, and separated by sized gaps filled with Ns to the estimated size. The sequence may extend beyond the ends of the clone and there may be sequence contigs within a contig-scaffold that consist entirely of whole genome shotgun sequence reads. Both end sequences and whole genome shotgun sequence only contigs will be indicated in the feature table.

----- Genome Center  
 Center: Baylor College of Medicine  
 Center code: BCM  
 Web site: http://www.hgsc.bcm.tmc.edu/  
 Contact: hgsc-help@bcm.tmc.edu  
 ----- Project Information  
 Center project name: KCVH  
 Center clone name: CH230-416G11  
 ----- Summary Statistics  
 Assembly program: Phrap; version 0.990329  
 Consensus quality: 52773 bases at least Q40  
 Consensus quality: 53668 bases at least Q30  
 Consensus quality: 54142 bases at least Q20  
 Estimated insert size: 52859; sum-of-contigs estimation  
 Quality coverage: 7x in Q20 bases; sum-of-contigs estimation

\* NOTE: Estimated insert size may differ from sequence length  
 \* (see http://www.hgsc.bcm.tmc.edu/docs/genbank\_draft\_data.html).  
 \* NOTE: This is a 'working draft' sequence. It currently  
 \* consists of 1 contigs. Gaps between the contigs  
 \* are represented as runs of N. The order of the pieces  
 \* is believed to be correct as given, however the sizes  
 \* of the gaps between them are based on estimates that have  
 \* provided by the submitter.  
 \* This sequence will be replaced  
 \* by the finished sequence as soon as it is available and  
 \* the accession number will be preserved.  
 \* 1 62318: contig of 62318 bp in length.  
 Location/Qualifiers  
 1..62318  
 /organism="Rattus norvegicus"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:10116"  
 /clone="CH230-416G11"  
 1..1459  
 /note="wgs end extension  
 clone end:Sp6"  
 complement(7376..8361)  
 /note="clone boundary"

FEATURES  
 source  
 misc\_feature  
 misc\_feature  
 misc\_feature



```

misc_feature      clone_end:sp6
                  site:
                  end_sequence:B2195618"
                  complement(54571..55515)
                  /note="Clone boundary
clone_end:T7
site:
end_sequence:B2195617"
60931..62318
/note="wgs_end_extension
clone_end:T7"

ORIGIN
Query Match      32.2% Score 19; DB 2; Length 62318;
Best Local Similarity 100.0%; Pred. No. 5.9;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY
4 CTGAAGAAACTGCTGACA 22
|||||
9891 CTGAAGAAACTGCTGACA 9909

RESULT 4
AC117645
LOCUS          AC117645      65394 bp      DNA      linear      HTG 30-AUG-2002
DEFINITION    Mus musculus clone RP23-238F4, LOW-PASS SEQUENCE SAMPLING.
ACCESSION     AC117645
VERSION       AC117645.5 GI:22549859
KEYWORDS      HTG; HTGS; PHASE0.
SOURCE        Mus musculus (house mouse)
ORGANISM      Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 65394)
Birren,B., Nusbäum,C. and Lander,E.
MUS musculus, clone RP23-238F4
Unpublished
2 (bases 1 to 65394)
Birren,B., Linton,L., Nusbäum,C., Lander,E., Ali,A., Allen,N.,
Anderson,S., Barra,N., Bastien,V., Bloom,T., Boguslavsky,L.,
Boukhgalter,B., Brown,A., Camarata,J., Campopiano,A., Chang,J.,
Chakarova,B., Choepel,Y., Colangelo,X., Collins,S., Collymore,A.,
Cook,A., Cooke,P., Dearellano,K., Dewar,K., Diaz,J.S., Dodge,S.,
Faro,S., Ferreira,P., Fitzhugh,W., Gage,D., Galagan,J., Gardyna,S.,
Ginde,S., Gord,S., Goyette,M., Graham,L., Grand-Pierre,N.,
Hagos,B., Horton,L., Hulme,W., Iliev,I., Johnson,R., Jones,C.,
Kamat,A., Karatas,A., Kells,C., Lafocque,K., Lamazares,R.,
Lander,E., Lehoczy,J., Levine,R., Lindblad-Toh,K., Liu,G.,
Maclean,C., Macdonald,P., Major,J., Marquis,N., Matthews,C.,
McCarthy,M., McEwan,P., McKernan,K., Meldrum,J., Meneses,L.,
Mihova,T., Mlenga,V., Murphy,T., Naylor,J., Nguyen,C., Nicol,R.,
Norbu,C., Norman,C.H., O'Connor,T., O'Donnell,P., O'Neill,D.,
O'Leary,J., Peterson,K., Phunkhang,P., Pierre,N., Pollara,V.,
Raymond,C., Retta,R., Ribbeck,M., Riley,R., Rise,C., Rogov,P.,
Roman,J., Rosetti,M., Roy,A., Santos,R., Schauer,N., Schupbach,R.,
Seaman,S., Severy,P., Spencer,B., Stange-Thomann,N., Stojanovic,N.,
Straus,N., Sudramanian,A., Talamas,J., Teiraye,S., Theodore,J.,
Topham,K., Travers,M., Travis,N., Triggillo,J., Vassiliev,H.,
Viel,R., Vo,A., Wilson,B., Wu,X., Wyman,D., Ye,W.J., Young,G.,
Zainoun,J., Zembek,L., Zimmer,A. and Zody,M.
Direct Submission
Submitted (10-APR-2002) Whitehead Institute/MIT Center for Genome
Research, 320 Charles Street, Cambridge, MA 02141, USA
3 (bases 1 to 65394)
Birren,B., Nusbäum,C., Lander,E., Ali,A., Allen,N., Anderson,S.,
Barra,N., Bastien,V., Bloom,T., Boguslavsky,L., Boukhgalter,B.,
Camarata,J., Chang,J., Chakarova,B., Choepel,Y., Collymore,A.,
Cook,A., Cooke,P., Dearellano,K., Dewar,K., Diaz,J.S., Dodge,S.,
Faro,S., Ferreira,P., Fitzgerald,M., Gage,D., Galagan,J.,
Gardyna,S., Gord,S., Graham,L., Grand-Pierre,N., Hagos,B.,
Horton,L., Hulme,W., Iliev,I., Johnson,R., Jones,C., Kamat,A.,
Karatas,A., Kells,C., Lander,E., Levine,R., Lindblad-Toh,K.,
Liu,G., Maclean,C., Macdonald,P., Major,J., Matthews,C.,

```

```

TITLE
JOURNAL
COMMENT
McCarthy,M., Meldrum,J., Meneses,L., Mihova,T., Mlenga,V.,
Murphy,T., Naylor,J., Nguyen,C., Nicol,R., Norbu,C., Norman,C.H.,
O'Connor,T., O'Donnell,P., O'Neill,D., Oliver,J., Peterson,K.,
Phunkhang,P., Pierre,N., Raymond,C., Retta,R., Rise,C., Rogov,P.,
Roman,J., Roy,A., Schauer,S., Schupbach,R., Seaman,S., Severy,P.,
Smith,C., Spencer,B., Stange-Thomann,N., Stojanovic,N., Talamas,J.,
Teiraye,S., Theodore,J., Topham,K., Travers,M., Vassiliev,H.,
Viel,R., Vo,A., Wilson,B., Wu,X., Wyman,D., Young,G., Zainoun,J.,
Zembek,L., Zimmer,A. and Zody,M.
Direct Submission
Submitted (30-AUG-2002) Whitehead Institute/MIT Center for Genome
Research, 320 Charles Street, Cambridge, MA 02141, USA
On Aug 30, 2002 this sequence version replaced gi:22474966.
All repeats were identified using RepeatMasker:
Smit, A.F.A. & Green, P. (1996-1997)
http://ftp.genome.washington.edu/RM/RepeatMasker.html

Genome Center
Center: Whitehead Institute/ MIT Center for Genome Research
Center code: WIBR
Web site: http://www-seq.wi.mit.edu
Contact: sequence_submissions@genome.wi.mit.edu
----- Project Information
Center project name: L23587
Center clone name: 238_F_4

* NOTE: This record contains 81 individual
* sequencing reads that have not been assembled into
* contigs. Runs of N are used to separate the reads
* and the order in which they appear is completely
* arbitrary. Low-pass sequence sampling is useful for
* identifying clones that may be gene-rich and allows
* overlap relationships among clones to be deduced.
* However, it should not be assumed that this clone
* will be sequenced to completion. In the event that
* the record is updated, the accession number will
* be preserved.

1
728 827: contig of 100 bp in length
828 827: gap of 100 bp
1549 1548: contig of 721 bp in length
1648 1648: gap of 100 bp
2370 2369: contig of 721 bp in length
2470 2469: gap of 100 bp
3185 3184: contig of 715 bp in length
3285 3284: gap of 100 bp
3978 3977: contig of 693 bp in length
4077 4077: gap of 100 bp
4296 4296: contig of 719 bp in length
4797 4797: gap of 100 bp
4897 4896: contig of 716 bp in length
5613 5612: contig of 716 bp in length
5713 5712: gap of 100 bp
6431 6431: contig of 719 bp in length
6532 6531: gap of 100 bp
7243 7243: contig of 712 bp in length
7343 7343: gap of 100 bp
8047 8046: contig of 703 bp in length
8147 8146: gap of 100 bp
8867 8866: contig of 720 bp in length
8967 8966: gap of 100 bp
9685 9684: contig of 718 bp in length
9785 9784: gap of 100 bp
10492 10492: contig of 708 bp in length
10592 10592: gap of 100 bp
10593 10592: contig of 726 bp in length
11319 11318: contig of 726 bp in length
11418 11418: gap of 100 bp
12131 12131: contig of 713 bp in length
12231 12231: gap of 100 bp
12938 12938: contig of 707 bp in length
13038 13038: gap of 100 bp
13748 13748: contig of 710 bp in length
13848 13848: gap of 100 bp
14557 14557: contig of 709 bp in length
14657 14657: gap of 100 bp
14658 15372: contig of 715 bp in length

```

```

* 15373 15472: gap of 100 bp
* 15473 16176: contig of 704 bp in length
* 16177 16276: gap of 100 bp
* 16277 16968: contig of 692 bp in length
* 16969 17068: gap of 100 bp
* 17069 17778: contig of 710 bp in length
* 17779 17878: gap of 100 bp
* 17879 18599: contig of 721 bp in length
* 18600 18699: gap of 100 bp
* 18700 19406: contig of 707 bp in length
* 19407 19506: gap of 100 bp
* 19507 20190: contig of 684 bp in length
* 20191 20290: gap of 100 bp
* 20291 20999: contig of 709 bp in length
* 21000 21099: gap of 100 bp
* 21100 21804: contig of 705 bp in length
* 21805 21904: gap of 100 bp
* 21905 22614: contig of 710 bp in length
* 22615 22714: gap of 100 bp
* 22715 23406: contig of 692 bp in length
* 23407 23506: gap of 100 bp
* 23507 24226: contig of 720 bp in length
* 24227 24326: gap of 100 bp
* 24327 25041: contig of 715 bp in length
* 25042 25141: gap of 100 bp
* 25142 25858: contig of 718 bp in length
* 25859 25959: gap of 100 bp
* 25960 26656: contig of 706 bp in length
* 26657 26756: gap of 100 bp
* 26757 27478: contig of 713 bp in length
* 27479 27578: gap of 100 bp
* 27579 28296: contig of 718 bp in length
* 28297 28397: gap of 100 bp
* 28398 29079: contig of 683 bp in length
* 29080 29179: gap of 100 bp
* 29180 29888: contig of 709 bp in length
* 29889 29988: gap of 100 bp
* 29989 30692: contig of 704 bp in length
* 30693 30792: gap of 100 bp
* 30793 31504: contig of 712 bp in length
* 31505 31604: gap of 100 bp
* 31605 32316: contig of 712 bp in length
* 32317 32416: gap of 100 bp
* 32417 33128: contig of 712 bp in length
* 33129 33228: gap of 100 bp
* 33229 33944: contig of 716 bp in length
* 33945 34044: gap of 100 bp
* 34045 34757: contig of 713 bp in length
* 34758 34857: gap of 100 bp
* 34858 35572: contig of 715 bp in length
* 35573 35672: gap of 100 bp
* 35673 36386: contig of 714 bp in length
* 36387 36486: gap of 100 bp
* 36487 37196: contig of 710 bp in length
* 37197 37296: gap of 100 bp
* 37297 37993: contig of 697 bp in length
* 37994 38093: gap of 100 bp
* 38094 38805: contig of 712 bp in length
* 38806 38905: gap of 100 bp
* 38906 39615: contig of 710 bp in length
* 39616 39715: gap of 100 bp
* 39716 40424: contig of 709 bp in length
* 40425 40524: gap of 100 bp
* 40525 41216: contig of 692 bp in length
* 41217 41316: gap of 100 bp
* 41317 42027: contig of 711 bp in length
* 42028 42127: gap of 100 bp
* 42128 42837: contig of 710 bp in length
* 42838 42937: gap of 100 bp
* 42938 43653: contig of 716 bp in length
* 43654 44461: gap of 100 bp
* 44462 44561: contig of 708 bp in length
* 44562 44561: gap of 100 bp

```

```

* 44562 45267: contig of 706 bp in length
* 45268 45368: gap of 100 bp
* 45369 46054: contig of 687 bp in length
* 46055 46154: gap of 100 bp
* 46155 46866: contig of 712 bp in length

```

```

Query Match 32.2% Score 19; DB 2; Length 65394;
Best Local Similarity 100.0%; Pred. No. 5.9;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Oy 17 TTGACACCTGCGCAGAA 35
Db 42513 TTGACACCTGCGCAGAA 42531

```

```

RESULT 5
OSJN00027 145825 bp DNA linear PLN 10-FEB-2004
LOCUS Oryza sativa genomic DNA, chromosome 4, BAC clone: OSJNB0067320,
DEFINITION complete sequence.
ACCESSION AL060600.3 GI:32479982
VERSION
KEYWORDS
ORIGIN

```

```

REFERENCE
AUTHORS
Feng, Q., Zhang, Y., Hao, P., Wang, S., Fu, G., Huang, Y., Li, Y., Zhu, J.,
Liu, Y., Hu, X., Jia, P., Zhang, Y., Zhao, Q., Ying, K., Yu, S., Tang, Y.,
Weng, Q., Zhang, L., Lu, Y., Mu, J., Lu, Y., Zhang, L. S., Yu, Z., Fan, D.,
Liu, X., Lu, T., Li, C., Wu, Y., Sun, T., Lai, H., Li, T., Hu, H., Guan, J.,
Wu, M., Zhang, R., Zhou, B., Chen, Z., Chen, L., Jin, Z., Wang, R.,
Yin, H., Cai, Z., Ren, S., Lv, G., Gu, W., Zhu, G., Tu, Y., Jia, D.,
Zhang, Y., Chen, T., Kang, H., Chen, X., Shao, C., Sun, Y., Hu, Q.,
Zhang, X., Zhang, W., Wang, L., Ding, C., Sheng, H., Gu, J., Chen, S.,
Ni, L., Zhu, F., Chen, W., Lan, L., Lai, Y., Cheng, Z., Gu, M., Jiang, J.,
Li, J., Hong, G., Xue, Y., and Han, B.
Sequence and analysis of rice chromosome 4
Nature 420 (6913), 316-320 (2002)
2237377
PUBMED
12447439

```

```

TITLE
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

```

```

AUTHORS

```

```

TITLE
JOURNAL

```

```

REMARK

```

```

COMMENT

```

This is a complete sequence. Genes were identified by a combination of several methods: Gene prediction programs including Egenes (http://www.softberry.com/), genescan (http://CCR-081.mit.edu/GENSCAN.html), GenemarkHM (http://genomebiology.gatech.edu/Genemark/), tRNAscan-SE (Sean Eddy, http://genome.wustl.edu/eddy/tRNAscan-SE/), searches of the complete sequence against NCBI non-redundant protein database (nr)

(ftp://ncbi.nlm.nih.gov/blast/db) and the EST database at NCGR.

FEATURES  
Source Location/Qualifiers

1.145825  
/organism="Oryza sativa (japonica cultivar-group)"  
/mol\_type="genomic DNA"  
/cultivar="Nipponbare"  
/sub\_species="japonica"  
/db\_xref="taxon:39947"  
/chromosome="4"  
/clone="OSJNBa0067g20.1"  
/clone\_1lb="CUGI-OSJNBa"  
40..2473  
/gene="OSJNBa0067g20.1"  
/join(40..679,759..883,951..1097,1204..1262,1330..1575,  
1766..1884,1983..2473)  
/gene="OSJNBa0067g20.1"  
/codon\_start=1  
/protein\_id="CAD40485.2"  
/db\_xref="GI:38345106"  
/db\_xref="EMBL:07X7P5"  
/translation="MEREAGGTPNPQVPLGRNVIEDYILCDFIPPSSEFLLVNFYGL  
LSLHLPNLSIAFLSI FSHLCAYIGVEPLDLRFYELRMEPNKNSQCVPRRLD  
GKSKRYTFQCCPSRSKRTWFLQIDSDPFIIVPEODPKIPSWTAPPLTSPD  
SFIDYIDLVKGLSRVEYADPVARRIQLOAPAHFADVSGPEDATRSPOGLNS  
TVRRGVGMISPTTASNTIIVPLCEKRAERDAINALPLNNIGPLADHOVAISIK  
EKVAREASDAAAATSGNVTARKGRKFSASPLPRRORLTVGSKARAVODE  
SGCTGAPMAASTDVYLAPRSREPTSGVSDAAGRFLLAVLTREDIQVEMKDL  
EKASRGIGDKSRVDDEVDQQRQPEFEFHASFDVDDTLATGPEWVTSIDLSA  
LGGQDRRIQWTKTFEVADLRITMLAVKKEQAVTLLGGEVENSYLKSCCTMARIC  
RELAVPHGDPEBSAGYISWLNCAQADGCGKRIIDALQOECHRSRSRAGGHVLA  
RLRGGFARSRTPAEIDHARSMAPFAKRIFGDMWRPMSW"  
complement(3453..6561)  
/gene="OSJNBa0067g20.2"  
complement(join(3453..4786,4844..5969,6199..6561))  
/gene="OSJNBa0067g20.2"  
/codon\_start=1  
/protein\_id="CAD40484.2"  
/db\_xref="GI:38345107"  
/db\_xref="EMBL:07X8E5"  
/translation="MAASHVAYOLYKNSGGPKTITIOGNTKLAOCDSKSLDVEOP  
SPDPTPEPKVSKNTKTKPKDGAIKIYPLSANDKTVKIGALISEKLEIALITLR  
DNADVAPQSDMGVPREAPKDPHPIARDQVDVSTACELISLIDANSCHOISM  
AKDEBKTFITIPGVFCYKMPFELLTAGTFRITQGLSDGLSGNVAVDVIV  
KIKTDSLIDLRTEFDNLRYHLMLNEKCTFEVSGKFLPLVSGRGVLEAPBEKIK  
ALEKNSPTRLKEVQKLGCMALSRFVARGSGOPELLKQDKFVITQAEBAEF  
VALKRYLNPPLVAPQMBELFLYIATPYVSSTIIIVREKORVYVSALDA  
KTRYPOIKRLVAVIMTSRLRHYFOAHRTVVSFPLGEVAKRVGRIAKMIVEL  
SQDYPAPRTAKGVLADPVAWMTNDSNQLNEMTMAFDQFGVHLNFR  
VMTNAYEGLIARATIGVRLTVKASSELVANOYKDKYCSKPELSKYLIVR  
KLERPDGIEVRYHRYKNTIELDLARASQBLEGTFLDITKRSVEVGEVSP  
VTLDSSKATKAEKAVADITTDTRFPPLIFINSELPEDDTAEKIKKATCIYV  
GNALYKAPNVLKSISSDNGRHLIDHIGIYSAAGACITLVGKAFRGSPPTTL  
KACDMVORCEACQPHSKRSLSAQALQITPLTFPSCWGLDIGPFRQGGYRQF  
VAIDFTKMIKAVPMGEIKAVNAIKFIIGFCRCYGLPHRIITDNGSQFIADQDCI  
GLGVKICFASVSHPSNGQVVERANGIYVGGIKTRYVRLMSHDKWVEELPSVLMAR  
TPTTCNKETTFEYVGSSEAMLPSEL"  
6833..9625  
/gene="OSJNBa0067g20.3"  
/join(6833..7754,7830..8701,8774..9625)  
/gene="OSJNBa0067g20.3"  
/codon\_start=1  
/protein\_id="CAD40483.1"  
/db\_xref="GI:21740600"  
/db\_xref="EMBL:07X655"  
/translation="MAANELAEVKQLEELKEKGYIRPSTPOGAPYIFVEKKDKR  
KGVDRALNEVITIKKPYLPRIIDLPOLKATIPSTCLDASGTHORIRIEEDPKTA  
ETTRIGLTFEYWSFGLTNAPAFERNLMLKFKMYLTKFVVRITDILVLSQSEBHQ  
QTLRLVLEKLRHQYLAKLRCEPLSEVKFLGVISAKGVAADPKVIVATLWKQPK  
TVTOVRSGLAGYRRRIENFSKIAQPMQDLKEKKEFWMSPOCEKAFQITLKKKPK  
SEVLLIPTRKDFLVCDASQGLRVLVMEQAAVHALKWRHLLIGNRCEIITDKS  
LKVIFTOGDLNFORMLLEIKDVRILHYHFGKAVYADPLSKRSKCNLTIGRGGLP  
ELNQGMEALNTSIVGRGLATLEAKPTLDDIRAGQNDPMYGILKNMGQGRGAAGFT  
EHEHGTLMNGNRVCVPDDDELKQILLQNAHSSVSIHPSGSKTYITLDLKEKYMTISMR

BIAPFVALCPVQCHVKAHORPARLLOPLQVPEKMKDEIGMDPITGLPKTQGGGSIW  
VYVDRITVAPRPVPIKTYTGKNTKLAETLOEELKLEIPSTNAPNAGDQGVDR  
LNQIITEDILRACVINFRTKNDKSLPYREFSNNSYQASIQMAYEALYKRCOTPLM  
DQVGSQVGFQGDILIREABVKRTIQENLKAQSRQKSYANRRRNAPFAVDNLYKLV  
TPELGVNRFQRTKLAARFVGPFRILIRRBVAIOLBPLSLNVHDFVFLSOLKCL  
REDSQADSQIEVEREDLYVERPVKILDMTERTRRVRIRFKVQWNSHBAEATWE  
REDELKAHPDLFASSESRGRDSV"  
complement(13199..15084)  
/gene="OSJNBa0067g20.4"  
complement(join(13199..13606,13767..14071,14133..15084))  
/gene="OSJNBa0067g20.4"  
/codon\_start=1  
/protein\_id="CAD40482.1"  
/db\_xref="GI:21740599"  
/db\_xref="EMBL:07X7S6"  
/translation="MSSSLVNSVNTNLQVFPASTYLVNTQYGEIYFPYTTPIST  
CPMTGNENAVATNRDSDMSKDPTEAKNGIISTTSLEKSDNSAKOCRSMMREPTKM  
TSEATRSKCPITKTSKTLQTCVPLNVAEISICERGIQRIISPREDYCCPIHKTK  
HDLSSCKVLSAKAPPPKVOQSHITPRLDQXERKATPTSDRVGVITDIPREPSVLH  
LLEDYGSSTISALREVLALIDVGSISARTNAEENQATPQAHIRAVANALIRTPYDFV  
LNDLARTALRESVTNLSTNEEAAHAPQPPGDMALSETSTIAERHDAE  
TMKTVPGWMSLHGAIMTKIEBTLQTKTEAVITATITTIANGGQTIIVEDVATLT  
TMETGAGTTGDDDRILIELOADILVIRFPFGAIEKXDGSTDEEFLQVFTLVLAG  
ADNNAVLVLTALKGSASWLMHLIPLYSISWADLMQCPVAFQGTGRHAIEDDLH  
ALTONSGESIIEVYRRFNECNTIPETITDASVIHAFKSGVDCYTT"  
complement(19850..20257)  
/gene="OSJNBa0067g20.5"  
complement(19850..20257)  
/gene="OSJNBa0067g20.5"  
/codon\_start=1  
/protein\_id="CAD40481.2"  
/db\_xref="GI:38345108"  
/db\_xref="EMBL:07X8D8"  
/translation="MAALLQAMGVAAPVPLPBEETPSYDVETIASPDQCHLAAAP  
SWAFPPPADSEEEBAVAVLGSFETCGSISESTIDETTRITTESMFTPTNGS  
NDVGRRRKRVMSRGSFLRGSGFVVEGITK"  
complement(21613..22857)  
/gene="OSJNBa0067g20.6"  
complement(join(21613..22296,22777..22857))  
/gene="OSJNBa0067g20.6"  
/codon\_start=1  
/protein\_id="CAD40480.1"  
/db\_xref="GI:21740597"  
/db\_xref="EMBL:07X7R8"  
/translation="MQNLPARKTRRNKTKAKGQCAEIVLVNADLFSFDIKYDPDET  
KEDTYSKALAVLSQDVRTLDDISHREASLSLIVDCGPISTRLHEVALIPBILA  
DVLPVAVLKQCKLEKAKRLAEERERKDIATIQANQLVHEEKAKLDQSEGIPI  
KSNIDRLKARITELIADQGNTELDMEHKIADLPQAVBQKARLKSATIKVADMTK  
SLKTYPGTDADAQATEVEQIQRAISAIQRILSQ"  
23570..24858  
/gene="OSJNBa0067g20.7"  
/join(23570..23705,23930..24120,24214..24858)  
/gene="OSJNBa0067g20.7"  
/codon\_start=1  
/protein\_id="CAE01610.1"  
/db\_xref="GI:32479983"  
/db\_xref="EMBL:07X796"  
/translation="MRQFGLKRETSIKRQYVPEFVPLPNAFKYLDPSKESQ  
DAIKRQDDEPYHEITQRFREMRNCRFLSLTDHQLADAFQKITAIFRRETSSEDS  
LSHLIQKQDSEIEAAEVAERSKVITSCQWKSFRKEKADYFQITKADKIFDLIRSKQ  
IQDPAGHILPSABELGKRRYCKMNSHSHSTNOCXVCRQOIQVAILGGKRIKFPDSGKKP  
MKVDNPPVPMVMTAQCIADRYAKSGFQVNSAKIINKYRKADKQKEXEYEDDGF  
DPHNGCEPFRCLNMGGRILCHAOKTFNFTYLCIKSSSRNQRYTN"  
complement(32437..41228)  
/gene="OSJNBa0067g20.8"  
complement(join(32437..33230,33273..33521,35840..35975,  
38583..38601,40070..40446,40988..41228))  
/gene="OSJNBa0067g20.8"  
/codon\_start=1  
/protein\_id="CAE01611.2"  
/db\_xref="GI:38345109"  
/db\_xref="EMBL:07X796"

Query Match

32.2% Score 19; DB 8; Length 145825;

Best Local Similarity 100.0%; Pred. No. 5.8;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

2 AGCTGAAGAACTGCTGA 20

101851 AGCTGAAGAACTGCTGA 101869

# RESULT 6

AC111782

AC111782 Rattus norvegicus clone CH230-22601, WORKING DRAFT SEQUENCE, 3

DEFINITION Rattus norvegicus clone CH230-22601, WORKING DRAFT SEQUENCE, 3

AC111782

HTG: HTGS PHASE1; HTGS DRAFT; HTGS FULLTOP.

Rattus norvegicus (Norway rat)

SOURCE

ORGANISM

Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.

1 (bases 1 to 232344)

REFERENCE

AUTHORS

Murphy, D., Maritz, Metzger, M., Lee, Abramson, S., Adams, C., Alder, J., Allen, C., Allen, H., Alsbrooks, S., Amin, A., Anguiano, D., Anyalebechi, V., Aoyagi, A., Ayodeji, M., Baca, E., Baden, H., Baldwin, D., Bandaranaike, D., Barber, M., Barnstead, M., Benahmed, F., Biewick, K., Blair, J., Blankenburg, K., Blyth, P., Brown, M., Bryant, N., Buhay, C., Burch, P., Butrell, K., Calderon, E., Cadenas, V., Carter, K., Cavazos, I., Caesar, H., Center, A., Chacko, J., Chavez, D., Chen, G., Chen, Y., Chen, Y., Chu, J., Cleveland, C., Cockrell, R., Cox, C., Coyle, M., Cree, A., D'Souza, L., Davila, M., Davis, C., Davy-Carroll, L., De Anda, C., Dederich, D., Delgado, O., Denison, S., Deramo, C., Ding, Y., Dinh, Y., Divya, K., Diaper, H., Dugan-Rocha, S., Dunn, A., Durbin, K., Duval, B., Eaves, K., Egan, A., Escoto, M., Eugene, C., Evans, C., Falls, T., Fan, G., Fernandez, S., Finley, M., Flagay, N., Forbes, L., Foster, M., Foster, P., Fraser, C., Gabler, A., Ganta, R., Garcia, A., Garner, T., Garra, M., Georgegeorgis, E., Geer, K., Giller, R., Grady, M., Guerra, W., Guevara, W., Gunaratne, P., Haaland, W., Hamill, C., Hamilton, C., Hamilton, K., Harvey, Y., Havlak, P., Hawes, A., Henderson, N., Hernandez, J., Hernandez, R., Hines, S., Hladun, S., Hume, J., Idelbird, D., Jackson, A., Hollins, B., Howell, S., Hulys, S., Hume, J., Johnson, B., Johnson, R., Jackson, A., Karapathy, S., Kelly, S., Kelly, S., Khan, Z., King, L., Kovar, C., Kovits, C., Kraft, C., Lepow, H., Levan, J., Lewis, L., Li, Z., Liu, J., Liu, J., Liu, W., Liu, Y., London, P., Longacre, S., Lopez, J., Lorenzshwa, L., Louised, H., Lozano, R., Lu, X., Ma, J., Maheshwari, M., Mahindaratne, M., Mahmoud, K., Malloy, K., Mangum, A., Mangum, B., Mapua, P., Martin, K., Martin, R., Martinez, E., Mawhinney, S., McLeod, M., McNeill, T., Meenen, E., Milosavljevic, A., Miner, G., Minja, E., Montemayor, J., Moore, S., Morgan, M., Morris, K., Morris, S., Muniz, M., Murphy, M., Nair, L., Nakervia, C., Neal, D., Newton, N., Nguyen, N., Norris, S., Nwokenkwen, O., Okwuonu, G., Olarnpunsagoon, A., Pal, S., Parks, K., Paternek, S., Paul, H., Perez, A., Perez, L., Pfannkuch, C., Plopper, F., Polidexter, A., Popovic, D., Pritts, E., Pu, L., Puzo, M., Quirio, J., Rachlin, E., Reeves, K., Regier, M., Reigh, R., Reilly, B., Reilly, M., Ren, Y., Reuter, R., Richards, S., Riggs, F., Rives, C., Rodkey, T., Rois, A., Rose, M., Rose, R., Ruiz, S., S. Sanders, W., Saverly, G., Scherer, S., Scott, G., Shatman, S., Shen, H., Shetty, V., Shvartsbeyn, A., Sisson, I., Sitter, C., D., Smaj, D., Sneed, A., Sodergren, E., Song, X., Z., Sorrelle, R., Sosa, J., Steimle, M., Strong, R., Sutton, A., Svatek, A., Tabors, P., Taylor, C., Taylor, T., Thomas, N., Thomas, S., Tingey, A., Trejos, Z., Umali, K., Vadas, R., Vera, V., Villalana, D., Waldron, L., Walker, B., Wang, J., Wang, O., Wang, S., Warren, J., Warren, R., Wei, X., White, F., Williams, G., Willson, R., Wleczek, R., Wodden, H., Wootley, K., Wright, D., Wright, R., Wu, J., Yakub, S., Yen, T., Yoon, L., Yoon, V., Yu, F., Zhang, J., Zhou, J., Zhou, X., Zhao, S., Zhu, D., von Weinstock, G., Weiss, R., Smith, D., R., Holt, R., A., Smith, H., O., Unpublished

# REFERENCE

2 (bases 1 to 232344)  
Mortley, K.C.  
Direct Submission  
Submitted (19-FEB-2002) Human Genome Sequencing Center, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA  
3 (bases 1 to 232344)  
Rat Genome Sequencing Consortium.  
Direct Submission  
Submitted (19-NOV-2002) Human Genome Sequencing Center, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA

# REFERENCE

AUTHORS

TITLE

JOURNAL

# COMMENT

On Nov 19, 2002 this sequence version replaced gi:23602292. The sequence in this assembly is a combination of BAC based reads and whole genome shotgun sequencing reads assembled using Atlas (<http://www.hgsc.bcm.tmc.edu/projects/rat/>). Each contig described in the feature table below represents a scaffold in the Atlas assembly (a 'contig-scaffold'). Within each contig-scaffold, individual sequence contigs are ordered and oriented, and separated by sized gaps filled with Ns to the estimated size. The sequence may extend beyond the ends of the clone and there may be sequence contigs within a contig-scaffold that consist entirely of whole genome shotgun sequence reads. Both end sequences and whole genome shotgun sequence only contigs will be indicated in the feature table.

Center: Baylor College of Medicine  
Center code: BCM  
Web site: <http://www.hgsc.bcm.tmc.edu/>  
Contact: hgsc-help@bcm.tmc.edu  
Project Information  
Center project name: GOOCG  
Center clone name: CH230-22601

Summary Statistics  
Assembly program: Phrap; version 0.990329  
Consensus quality: 22543 bases at least Q40  
Consensus quality: 22608 bases at least Q30  
Estimated insert size: 225765; sum-of-contigs estimation  
Quality coverage: 7x in Q20 bases; sum-of-contigs estimation

NOTE: Estimated insert size may differ from sequence length  
(see [http://www.hgsc.bcm.tmc.edu/docs/genbank\\_draft\\_data.html](http://www.hgsc.bcm.tmc.edu/docs/genbank_draft_data.html)).  
NOTE: This is a 'working draft' sequence. It currently consists of 3 contigs. The true order of the pieces is not known and their order in this sequence record is arbitrary. Gaps between the contigs are represented as runs of N, but the exact sizes of the gaps are unknown. This record will be updated with the finished sequence as soon as it is available and the accession number will be preserved.

1 226162: contig of 226162 bp in length  
226163 226262: gap of unknown length  
226263 230757: contig of 4495 bp in length  
230758 230857: gap of unknown length  
230858 232344: contig of 1487 bp in length.

# FEATURES

source

misc\_feature

misc\_feature

misc\_feature

1..232344  
/organism="Rattus norvegicus"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:10115"  
/clone="CH230-22601"  
1..1538  
/note="wgs\_end\_extension  
clone\_end:77"  
1589..2718  
/note="wgs\_end\_extension  
clone\_end:77"  
4907..5729  
/note="clone boundary  
clone\_end:77"  
site:  
end\_sequence:B2103653"

TITLE

JOURNAL

```

misc_feature      222851..224016
                  /note="wgs_contig"
misc_feature      224067..226162
                  /note="wgs_contig"
misc_feature      226263..227570
                  /note="wgs_contig"
misc_feature      227922..230757
                  /note="wgs_contig"

ORIGIN
Query Match      32.2%; Score 19; DB 2; Length 232344;
Best Local Similarity 100.0%; Pred. No. 5.8;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Q# 4 CTGAAGAACTGCTTGACA 22
Db 191901 CTGAAGAACTGCTTGACA 191919

RESULT 7
LOCUS AC128608/c
DEFINITION Rattus norvegicus clone CH230-320L21, ** SEQUENCING IN PROGRESS
ACCESSION AC128608
VERSION AC128608.2 GI:22856092
KEYWORDS HTG; HTGS PHASE1; HTGS DRAFT; HTGS_ENRICHED.
SOURCE Rattus norvegicus (Norway rat)
ORGANISM Rattus norvegicus
          Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
          Rattus.
          1 (bases 1 to 246787)
          Muzny,D,Marle, Metzker,M,Lee, Abramzon,S, Adams,C, Alder,J,
          Allen,C, Allen,H, Alshrooke,S, Amin,A, Argulano,D,
          Ayalebechi,V, Aoyagi,A, Ayodeji,M, Baca,B, Baden,H,
          Baldwin,D, Bandaranaike,D, Barber,M, Barnstead,M, Benahmed,F,
          Bisswal,K, Blair,J, Blankenburg,K, Blyth,P, Brown,M,
          Bryant,N, Buhay,C, Burch,P, Burrell,K, Calderon,E,
          Cardenas,V, Carter,K, Cavazos,I, Cessat,H, Center,A,
          Chacko,J, Chavez,D, Chen,G, Chen,R, Chen,Y, Chen,Z, Chu,J,
          Cleveland,C, Cockrell,R, Cox,C, Coyle,M, Cree,A, D'Souza,L,
          Davila,M,L, Davis,C, Davy-Carroll,L, De Anda,C, Dederich,D,
          Delgado,O, Denson,S, Deramo,C, Ding,Y, Dinh,H, Divya,K,
          Diaper,H, Dugan-Rocha,S, Dunn,A, Durbin,K, Duval,B, Evans,K,
          Egan,A, Escotto,M, Eugene,C, Evans,C,A, Falis,T, Fan,G,
          Fernandez,S, Finley,M, Flagg,N, Forbes,L, Foster,M, Foster,P,
          Fraser,C,M, Gabisi,A, Ganta,R, Garcia,A, Garner,T, Garza,N,
          Gebregregis,E, Geel,K, Gill,R, Grady,M, Guert,M, Guevara,W,
          Gunaratne,P, Haaland,W, Hamill,C, Hamilton,C, Hamilton,K,
          Harvey,Y, Havlak,P, Hawes,A, Henderson,N, Hernandez,J,
          Hernandez,R, Hines,S, Hladun,S,L, Hodgson,A, Hogues,M,
          Hollins,B, Howells,S, Hulik,S, Hume,J, Idlebird,D, Jackson,A,
          Karpathy,S, Kelly,S, Kelly,S, Khan,Z, King,J, Kovac,C,
          Jackson,L, Jacob,L, Jiang,H, Johnson,B, Johnson,R, Jolivet,A,
          Kowis,C, Kraft,C,L, Lepow,H, Levan,J, Lewis,L, Li,Z, Liu,J,
          Liu,J, Liu,W, Liu,Y, London,P, Longacre,S, Lopez,J,
          Lorensueta,L, Louisedge,H, Lozano,R,J, Lu,X, Ma,J,
          Maheshwari,M, Mahindaratne,M, Mahmoud,M, Malloy,K, Mangum,A,
          Mangum,B, Mapua,P, Martin,K, Martin,R, Martinez,E,
          Mahoney,S, McLeod,M,P, McNeill,T,Z, Meenen,E,
          Milosavljevic,A, Miner,G, Minja,E, Montemayor,J, Moore,S,
          Morgan,M, Morris,K, Morris,S, Mundasa,M, Murphy,M, Nair,T,
          Nankervis,C, Neal,D, Newton,N, Nguyen,N, Norris,S,
          Nwackelamleh,O, Okunolu,G, Olarunpusogun,A, Pal,S, Parks,K,
          Pasternak,S, Paul,H, Perez,A, Perez,L, Pfannkuch,C,
          Plopper,F, Poindexter,A, Popovic,D, Prims,E, Pu,L,
          Puazo,M, Quinroz,J, Rachlin,E, Reeves,K, Reiter,M,A, Reigh,R,
          Relliy,B, Relliy,M, Ren,Y, Reuter,M, Richards,S, Riggs,F,
          Rivers,C, Rodkey,T, Rojas,A, Rose,M, Rose,R, Ruiz,S,
          Sanders,W, Savary,G, Scherer,S, Scott,G, Shatman,S, Shen,H,
          Shetty,J, Shvartsbeyn,A, Sisson,I, Sitter,C,D, Smaiz,D,
          Sneed,A, Sodergren,E, Song,X,Z, Sorelle,R, Sosa,J,

```

```

TITLE
JOURNAL
REFERENCE
AUTHORS
Worley,K.C.
TITLE
JOURNAL
REFERENCE
AUTHORS
JOURNAL
COMMENT
The sequence in this assembly is a combination of BAC based reads
and whole genome shotgun sequencing reads assembled using Atlas
(http://www.hgsc.bcm.tmc.edu/projects/rat/). As a result, the
sequence may extend beyond the ends of the clone and there may be
contigs that consist entirely of whole genome shotgun sequence
reads. Both end sequences and whole genome shotgun sequence only
contigs will be indicated in the feature table.
----- Genome Center
Center: Baylor College of Medicine
Center code: BCM
Web site: http://www.hgsc.bcm.tmc.edu/
Contact: hgsc-help@bcm.tmc.edu
----- Project Information
Center project name: GYIN
Center clone name: CH230-320L21
----- Summary Statistics
Assembly program: Phrap; version 0.990329
Consensus quality: 219698 bases at least Q40
Consensus quality: 223003 bases at least Q30
Consensus quality: 224973 bases at least Q20
Estimated insert size: 239001; sum-of-contigs estimation
Quality coverage: 4x in Q20 bases; sum-of-contigs estimation
----- NOTE: Estimated insert size may differ from sequence length
* (see http://www.hgsc.bcm.tmc.edu/docs/genbankdraft_data.html).
* NOTE: This is a 'working draft' sequence. It currently
* consists of 2 contigs. The true order of the pieces
* is not known and their order in this sequence record is
* arbitrary. Gaps between the contigs are represented as
* runs of N, but the exact sizes of the gaps are unknown.
* This record will be updated with the finished sequence
* as soon as it is available and the accession number will
* be preserved.
* 1 245086: contig of 245086 bp in length
* 245087 245186: gap of unknown length
* 245187 246787: contig of 1601 bp in length.
Location/Qualifiers
1..246787
/organism="Rattus norvegicus"
/mol_type="genomic DNA"
/db_xref="taxon:10116"
/clone="CH230-320L21"
1..1472
/note="wgs_contig"
54443..56179
/note="wgs_contig"
241917..243271
/note="wgs_contig"
243322..245086

```

ORIGIN /note="wgs\_contig"

Query Match 32.2%; Score 19; DB 2; Length 246787;  
Best Local Similarity 100.0%; Pred. No. 5.8;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 CTGAAGAACTGGTTGACA 22  
DB 210071 CTGAAGAACTGGTTGACA 210053

RESULT 8

LOCUS A13577 215 bp DNA PAT 31-DEC-1993  
DEFINITION IGF-II gene.  
ACCESSION A13577  
VERSION A13577.1 GI:491682  
KEYWORDS  
SOURCE  
ORGANISM  
synthetic construct  
artificial sequences.

REFERENCE 1 (bases 1 to 215)  
AUTHORS Nygren,P.A., Abrahamson,L. and Uhlen,M.  
TITLE A recombinant fusion protein, its use and a recombinant vector  
JOURNAL Patent: EP 0333691-A 1 20-SEP-1989;  
CEMU BIOTECHNIK AB

FEATURES  
source  
1..215  
location/Qualifiers  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"

gene  
7..213  
/gene="IGF II"  
7..213  
/gene="IGF II"  
/codon\_start=1  
/transl\_table=11  
/protein\_id="CA401122.1"  
/db\_xref="GI:491683"  
/translation="MAVRPSETLGGELVDTLQFVCGDGRGFYFSRPSRINRRSGIV  
EECCFRSCDIALLETYCATPAKSE"

ORIGIN

Query Match 30.5%; Score 18; DB 6; Length 215;  
Best Local Similarity 100.0%; Pred. No. 25;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 11 AACTGTTGACACCTGC 28  
DB 44 AACTGTTGACACCTGC 61

RESULT 9  
LOCUS A13578 215 bp DNA PAT 31-DEC-1993  
DEFINITION IGF-II gene.  
ACCESSION A13578  
VERSION A13578.1 GI:489637  
KEYWORDS  
SOURCE  
ORGANISM  
synthetic construct  
artificial sequences.  
1 (bases 1 to 215)  
REFERENCE 1 (bases 1 to 215)  
AUTHORS Nygren,P.A., Abrahamson,L. and Uhlen,M.  
TITLE A recombinant fusion protein, its use and a recombinant vector  
JOURNAL Patent: EP 0333691-A 2 20-SEP-1989;  
CEMU BIOTECHNIK AB

FEATURES  
source  
1..215  
location/Qualifiers  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"

ORIGIN

Query Match 30.5%; Score 18; DB 6; Length 215;  
Best Local Similarity 100.0%; Pred. No. 25;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 11 AACTGTTGACACCTGC 28  
DB 176 AACTGTTGACACCTGC 159

RESULT 10

LOCUS SYNBLRG 220 bp DNA SYN 27-APR-1993  
DEFINITION Artificial bovine insulin-like growth factor 2 gene, complete cds.  
ACCESSION M60420  
VERSION M60420.1 GI:208029  
KEYWORDS insulin-like growth factor II.  
SOURCE  
ORGANISM  
synthetic construct  
artificial sequences.  
1 (bases 1 to 220)  
REFERENCE 1 (bases 1 to 220)  
AUTHORS Easton,A.M., Gierse,J.K., Seetharam,R., Klein,B.K. and Kotts,C.E.  
TITLE Production of bovine insulin-like growth factor 2 (BIGF2) in  
JOURNAL Escherichia coli  
Gene 101 (2), 291-295 (1991)  
MEDLINE 91276286  
PubMed 2055493

COMMENT Original source text: Synthetic DNA.  
FEATURES  
source  
1..220  
location/Qualifiers  
/organism="synthetic construct"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630"

CDS

7..216  
/note="bovine"  
/codon\_start=1  
/transl\_table=11  
/product="insulin-like growth factor 2"  
/protein\_id="AA72971.1"  
/db\_xref="GI:208030"  
/translation="MAVRPSETLGGELVDTLQFVCGDGRGFYFSRPSRINRRSGI  
VECCFRSCDIALLETYCATPAKSE"

ORIGIN

Query Match 30.5%; Score 18; DB 12; Length 220;  
Best Local Similarity 100.0%; Pred. No. 25;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 11 AACTGTTGACACCTGC 28  
DB 47 AACTGTTGACACCTGC 64

RESULT 11  
LOCUS AK073198 1234 bp mRNA PLN 24-JUL-2003  
DEFINITION Oryza sativa (japonica cultivar-group) cDNA clone:J03022115, full  
insert sequence.  
ACCESSION AK073198  
VERSION AK073198.1 GI:32983221  
KEYWORDS FLI\_CDNA; CAP trapper.  
SOURCE Oryza sativa (japonica cultivar-group)  
ORGANISM Oryza sativa (japonica cultivar-group)  
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;  
Ehrhartoideae; Oryzaceae; Oryza.

REFERENCE 1  
AUTHORS The Rice Full-Length cDNA Consortium, National Institute of  
Agrobiological Sciences Rice Full-Length cDNA Project Team,  
Kikuchi,S., Satoh,K., Nagata,T., Kawagashira,N., Doi,K.,  
Kishimoto,N., Yasaki,U., Ishikawa,M., Yamada,H., Ooka,H., Hotpa,T.,  
Kojima,K., Namiki,T., Ohneda,E., Yahagi,W., Suzuki,K., Li,C.,

Chen, K., Shishiki, T., Foundation of Advancement of International Science Genome Sequencing & Analysis Group, Otsu, Y., Murakami, K., Iida, Y., Sugano, S., Fujimura, T., Suzuki, Y., Tsunoda, Y., Kurosaki, T., Kodama, T., Masuda, H., Kobayashi, M., Xie, Q., Lu, M., Narikawa, R., Sugiyama, A., Mizuno, K., Yokomizo, S., Nishikawa, J., Ikeda, R., Ishibiki, J., Kawamata, M., Yoshimura, A., Mura, J., Kusumegi, T., Oka, M., Ryu, R., Ueda, M., Matsubara, K., RIKEN, Kawai, J., Carninci, P., Adachi, J., Aizawa, K., Arakawa, T., Fukuda, S., Hara, A., Hashidume, W., Hayatsu, N., Imocani, K., Ishii, Y., Itoh, M., Kagawa, I., Kondo, S., Kono, H., Miyazaki, A., Otsu, Y., Ota, Y., Saito, R., Sasaki, D., Sato, K., Shibata, K., Shinagawa, A., Shiraki, T., Yoshino, M., and Hayashizaki, Y.

Collection, mapping, and annotation of over 28,000 cDNA clones from japonica rice

JOURNAL  
MEDLINE  
PUBMED  
REFERENCE  
AUTHORS

Science 301 (5631), 376-379 (2003)

22752273

12869764

2 (bases 1 to 1234)

Adachi, J., Aizawa, K., Akimura, T., Arakawa, T., Carninci, P., Doi, K., Fujimura, T., Fukuda, S., Hanagaki, T., Hara, A., Hashidume, W., Hayashida, K., Hayashizaki, Y., Hayatsu, N., Hiramoto, K., Hiraoka, T., Hori, F., Hotta, T., Iida, Y., Ikeda, R., Imamura, K., Imocani, K., Ishibiki, J., Ishii, Y., Ishikawa, M., Itoh, M., Kaga, T., Kanagawa, S., Katoh, H., Kawagashira, N., Kawai, J., Kawamata, M., Kikuchi, S., Kishikawa-Hirozane, T., Kishimoto, N., Kobayashi, M., Kodama, T., Kojima, K., Kojima, Y., Kondo, S., Kono, H., Kouda, M., Koya, S., Kurihara, C., Kurosaki, T., Kusumegi, T., Li, C., Lu, M., Masuda, H., Matsubara, K., Matsuyama, T., Minai, J., Miyazaki, A., Mizuno, K., Murakami, K., Murata, M., Nagata, T., Nakamura, M., Namiki, T., Narikawa, R., Nishikawa, J., Nishikawa, Y., Nishikawa, M., Nishikawa, R., Ohneda, E., Ohno, M., Ohtsuki, K., Oka, M., Ooka, H., Otsu, Y., Ota, Y., Otsu, Y., Otsu, Y., Saito, R., Saito, H., Sakai, C., Sakai, K., Sakazume, N., Sano, H., Sasaki, D., Sato, K., Satoh, K., Satoh, K., Shibata, K., Shiraga, A., Shiraki, T., Shishiki, T., Sogabe, Y., Sugano, S., Sugiyama, A., Suzuki, K., Suzuki, Y., Tagami, M., Tagami, T., Tanaka, Y., Tagawa, A., Takahashi, F., Takaku-Akaiwa, S., Tanaka, T., Tomaru, A., Toyai, T., Tsunoda, Y., Ueda, M., Waki, K., Xie, Q., Yahagi, W., Yamada, H., Yamamoto, M., Yasunishi, A., Yazaki, J., Yokomizo, S., and Yoshimura, A.

TITLE  
JOURNAL  
COMMENT

Direct Submission  
Submitted (05-DEC-2001) Shoshi Kikuchi, National Institute of Agricultural Sciences, Department of Molecular Genetics, Head of Laboratory of Gene Expression, 2-1-2 Kannondai, Tsukuba, Ibaraki 305-8602, Japan (E-mail:skikuchi@nias.affrc.go.jp, Tel:81-29-838-7007, Fax:81-29-838-7007)

This clone is one of the 28K full-length cDNA clones from japonica rice.

URL: [http://cdna01.dna.affrc.go.jp/cDNA/NIAS\\_Rice\\_Full-Length\\_cDNA\\_Project\\_Team\\_Kikuchi\\_S\\_Satoh\\_K\\_Nagata\\_T\\_Kawagashira\\_N\\_Doi\\_K\\_Kishimoto\\_N\\_Yazaki\\_J\\_Ishikawa\\_M\\_Yamada\\_H\\_Ooka\\_H\\_Hotta\\_I\\_Kojima\\_K\\_Namiki\\_T\\_Ohneda\\_E\\_Yahagi\\_W\\_Suzuki\\_K\\_Li\\_C\\_Ohtsuki\\_K\\_Shishiki\\_T\\_and\\_Yasunishi\\_A](http://cdna01.dna.affrc.go.jp/cDNA/NIAS_Rice_Full-Length_cDNA_Project_Team_Kikuchi_S_Satoh_K_Nagata_T_Kawagashira_N_Doi_K_Kishimoto_N_Yazaki_J_Ishikawa_M_Yamada_H_Ooka_H_Hotta_I_Kojima_K_Namiki_T_Ohneda_E_Yahagi_W_Suzuki_K_Li_C_Ohtsuki_K_Shishiki_T_and_Yasunishi_A)

FAIS Genome Sequencing & Analysis Group, Otsu, Y., Iida, Y., Fujimura, T., Ikeda, R., Ishibiki, J., Kawamata, M., Kobayashi, M., Kogawa, T., Kurosaki, T., Kusumegi, T., Lu, M., Masuda, H., Mura, J., Mizuno, K., Narikawa, R., Nishikawa, J., Oka, M., Ryu, R., Sugano, S., Sugiyama, A., Suzuki, Y., Tsunoda, Y., Ueda, M., Xie, Q., Yokomizo, S., Yoshimura, A., Matsubara, K., and Murakami, K.

Genome Exploration Research Group in Riken Genomic Sciences Center and Genome Science Laboratory in Riken: Adachi, J., Aizawa, K., Akimura, T., Arakawa, T., Carninci, P., Fukuda, S., Hanagaki, T., Hara, A., Hashidume, W., Hayatsu, N., Imocani, K., Itoh, M., Kaga, I., Kondo, S., Kono, H., Miyazaki, A., Otsu, Y., Ota, Y., Saito, R., Sasaki, D., Sato, K., Shibata, K., Shinagawa, A., Shiraki, T., Sogabe, Y., Tagami, M., Tagami, T., Tanaka, Y., Tagawa, A., Takahashi, F., Takaku-Akaiwa, S., Tanaka, T., Tomaru, A., Toyai, T., Waki, K., Yasunishi, A., and Hayashizaki, Y.

FEATURES  
source

location/Qualifiers  
1..1234  
/organism="Oryza sativa (japonica cultivar-group)"  
/mol\_type="mRNA"  
/cultivar="Nipponbare"  
/db\_xref="taxon:39947"  
/clone="J033022115"

ORIGIN

Query Match 30.5%; Score 18; DB 8; Length 1234;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 660 CTGGTTGACACCCCTGCCG 643

13 CTGGTTGACACCCCTGCCG 30

CTGGTTGACACCCCTGCCG 643

RESULT 12  
AK461306/c  
LOCUS  
DEFINITION  
Sequence 235 from Patent WO0198480.  
ACCESSION  
AK461306  
VERSION  
AK461306.1 GI:21726514  
KEYWORDS  
SOURCE  
ORGANISM  
Arabidopsis thaliana (thale cress)  
Arabidopsis thaliana  
Eubryotia Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosid; eurosids II; Brassicales; Brassicaceae; Arabidopsids.

REFERENCE  
1 Budworth, P., Brown, D., Chang, H.S., Zhu, T., Han, B., Wang, X. and Cooper, B.  
Promoters for regulation of plant gene expression  
Patent: WO 0198480-A 235 27-DEC-2001;  
Syngenta Participations AG (CH)  
location/Qualifiers  
1..2004  
/organism="Arabidopsis thaliana"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:3702"

TITLE  
JOURNAL  
FEATURES  
source

ORIGIN

Query Match 30.5%; Score 18; DB 6; Length 2004;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 389 GCGAAGACCGCGTGATC 372

30 GCGAAGACCGCGTGATC 47

389 GCGAAGACCGCGTGATC 372

RESULT 13  
AK065797  
LOCUS  
DEFINITION  
Oryza sativa (japonica cultivar-group) cDNA clone:J013041K05, full insert sequence.  
ACCESSION  
AK065797  
VERSION  
AK065797.1 GI:32975815  
KEYWORDS  
FLI cDNA; CAP trapper.  
SOURCE  
Oryza sativa (japonica cultivar-group)  
Oryza sativa (japonica cultivar-group)  
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Euphorbiaceae; Oryzae; Oryza.

REFERENCE  
1 The Rice Full-Length cDNA Consortium, National Institute of Agricultural Sciences Rice Full-Length cDNA Project Team,  
Kikuchi, S., Satoh, K., Nagata, T., Kawagashira, N., Doi, K., Kishimoto, N., Yazaki, J., Ishikawa, M., Yamada, H., Ooka, H., Hotta, I., Kojima, K., Namiki, T., Ohneda, E., Yahagi, W., Suzuki, K., Li, C., Ohtsuki, K., Shishiki, T., Foundation of Advancement of International Science Genome Sequencing & Analysis Group, Otsu, Y., Murakami, K.,







gene  
CDS

/gene="trpg"  
4589..5165  
/gene="trpg"  
/codon\_start=1  
/transl\_table=11  
/product="anthranilate synthetase beta-subunit"  
/protein\_id="AA080553.1"  
/db\_xref="GI:151631"

gene  
CDS

/gene="trpg"  
5195..6244  
/gene="trpg"  
/codon\_start=1  
/transl\_table=11  
/product="phosphoribosyl transferase"  
/protein\_id="AA080554.1"  
/db\_xref="GI:1052829"

gene  
CDS

/gene="trpc"  
6241..7074  
/gene="trpc"  
/codon\_start=1  
/transl\_table=11  
/product="indoleglycerol phosphate synthetase"  
/protein\_id="AAB06555.1"  
/db\_xref="GI:1052830"

Query Match      30.5%; Score 18; DB 1; Length 7419;  
Best Local Similarity: 100.0%; Pred. No. 23;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Dy    19    GACACCCTCCCGCACAAA    36  
|||||  
Db    388    GACACCCCTCCCGGAGAA    405

RESULT 15  
LOCUS AC004625  
DEFINITION Arabidopsis thaliana chromosome 2 clone T26J13 map C1C11C08,  
complete sequence.  
VERSION AC004625  
KEYWORDS GI:20197200  
SOURCE HTG.  
ORGANISM Arabidopsis thaliana (thale cress)  
Eukaryote; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;  
rosids; eurosoids II; Brassicales; Brassicaceae; Arabidopsids.  
REFERENCE 1 (bases 1 to 42499)  
Rounseley,S.D., Lin,X., Ketchum,K.A., Crosby,M.L., Brandon,R.C.,  
Sykes,S.M., Kail,S., Mason,T.M., Kerlavage,A.R., Adams,M.D.,  
Somerville,C.R. and Venter,J.C.

JOURNAL REFERENCE  
Unpublished  
(bases 1 to 42499)

AUTHORS	Llin,X.
TITLE	Direct Submission
JOURNAL	Submitted (09-MAR-2000) The Institute for Genomic Research, 9712 Medical Center Dr., Rockville, MD 20850, USA
REFERENCE	3 (bases 1 to 4249)
AUTHORS	Town,C.D. and Kaul,S.
TITLE	Direct Submission
JOURNAL	Submitted (27-FEB-2002) The Institute for Genomic Research, 9712 Medical Center Dr., Rockville, MD 20850, USA, cdow@tigr.org
COMMENT	On Apr 18, 2002 this sequence version replaced gi:6599247.
FEATURES	Location/Qualifiers 1..4249 /organism="Arabidopsis thaliana" /mol_type="genomic DNA" /cultivar="Columbia" /db_xref="taxon:3702" /chromosome="2" /map="C1C1C08" /clone="T26J13" complement(1..5112) /note="overlap with BAC clone F13H10 (AC005662:1..5112)."
misc_feature	gene
gene	2683..3649 /gene="At2g41430" /note="synonym: T26J13.2; identical to GB D30719; supported by full length cDNA: Ceres: 31388" join(2683..2727,2957..3312,3400..3649) /gene="At2g41430" join(2973..3312,3400..3551) /gene="At2g41430" codon_start=1 /product="ERD15 protein" /protein_id="AAC3728.1" /db_xref="GI:3241941" /trans-action="MAWSGRSTLNPDAPLFLPAVQVEDFSEMMQLVTSTWYR DYMSIOCGDFGNDGENENGCHIDVADLLPSPDPDEDDFDFAEPFOGEFE GRMYQQAPDSRGFGKNGEMTKYSGNRSRSIVEDAKYAERKAKNGRNAAARNLIH QPR" qpr="4440..10934 /gene="At2g41440" /note="synonym: T26J13.3; predicted by genSCAN" join(4440..4488,4522..4676,4989..5123,5491..5528,5605..5701,5791..5832,6102..6175,6573..6615,6634..6777,6869..7010,7136..7268,8763..8916,9258..9300,9378..9516..9615,9739..9789,10210..10289,10327..10421,10852..>10934) /gene="At2g41440" join(4440..4488,4522..4676,4989..5123,5491..5528,5605..5701,5791..5832,6102..6175,6573..6615,6634..6777,6869..7010,7136..7268,8763..8916,9258..9300,9378..9516..9615,9739..9789,10210..10289,10327..10421,10852..10934) /gene="At2g41440" translational /product="unknown protein" /protein_id="AAC3729.1" /db_xref="GI:3241942" translation="MAPKRASPVQSLSYEINSDGNSCYLIFLDVITRLQMWTR ISVPNPDKAFKSNFTTOSQWKRTIGRSIRPFGERGRSDIEEARKSNODER ALOPIRLDOOLREKEVERILLIKMTGKEDIVSFTEILALOSHMDVRSVLQCKR VEEAEAPRHOKKEAHHDAGMRGVLPVKCFSSASUGROEDNGEAPALQMGREKQESSEIOPFDKLMLFNRRNKGRELBMGTSLIHICILRALRIALIOCKGRC EHRMONGELSPGVRIIMTMLTLPCVDFTFSPOESSSDSIISGSACGRHPDNPEF EPTSLIELSRMGGRITMKYKGRBDLTCTKYRELCDYGGRSGLIIIDRDRPHRDLE EAVSENENLRKLRLTRATCGRDDLTPELLSLKSHQQTALLIVCOETKIOLK EDWMGRLDLSOLOEFERRNAESPMLIEYRWLMKSADVSTFLFMVCFLLLEVKTLD RRMNRGLDVGVADEFFFGFYVVSDDRLLTIIVF"
CDS	repeat_region 8133..8176 /rpt_family="AT_rich" repeat_region 8261..8300 /rpt_family="AT_rich" repeat_region Complement(8423..8633) /rpt_family="AT_rich" repeat_region Complement(8550..8611)



GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

CM nucleic - nucleic search, using sw model

Run on: December 22, 2004, 19:14:28 ; Search time 208.235 Seconds  
(without alignments)  
1487.336 Million cell updates/sec

Title: US-09-898-616A-3

Perfect score: 59

Sequence: 1 cagctgaagaactggtgtgta.....cgtgacatcatcataactg 59

Scoring table: OLIGO\_NUC  
Gapop 60.0 , Gapext 60.0

Searched: 4134886 seqs, 2624710521 residues

Word size : 0

Total number of hits satisfying chosen parameters: 8269772

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Listing first 45 summaries

Database : N\_Geneseq\_23Sep04:\*

1: geneseqn1980a:\*\n2: geneseqn1990a:\*\n3: geneseqn2000a:\*\n4: geneseqn2001a:\*\n5: geneseqn2001b:\*\n6: geneseqn2002a:\*\n7: geneseqn2002b:\*\n8: geneseqn2003a:\*\n9: geneseqn2003b:\*\n10: geneseqn2003c:\*\n11: geneseqn2003d:\*\n12: geneseqn2004a:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	59	100.0	59	ABZ58372	ABZ58372 Human ute
2	59	100.0	59	ADL27628	ADL27628 Recombina
3	37	62.7	59	ABZ58375	ABZ58375 Human ute
4	37	62.7	59	ADL27631	ADL27631 Recombina
5	18	30.5	215	AAW90906	AAW90906 Synthetic
6	17	28.8	195	ABK76145	ABK76145 Bacillus
7	17	28.8	993	ADCC24050	ADCC24050 DNA seque
8	17	28.8	993	ADH36151	ADH36151 Chemical
9	17	28.8	993	ADG93852	ADG93852 Nitriase
10	17	28.8	993	ADL62449	ADL62449 DNA encod
11	17	28.8	993	ADL64570	ADL64570 DNA encod
12	17	28.8	3530	ABU08480	ABU08480 Drosophila
13	17	28.8	5568	ABX08140	ABX08140 S. pneumo
14	17	28.8	5568	ADM91810	ADM91810 S. pneumo
15	17	28.8	14736	AAV52304	AAV52304 Streptoco
16	17	28.8	62598	ABZ58374	ABZ58374 Human ute
17	17	28.8	60	ABZ58374	Continuation (22 o
18	16	27.1	60	ADL27630	ADL27630 Recombina
19	16	27.1	311	ADL01419	ADL01419 Human rep
20	16	27.1	377	ABX55377	ABX55377 Bovine ES
21	16	27.1	603	ABD04549	ABD04549 Pseudomon

C 22	16	27.1	639	10	ADB69621	ADB69621 C. neofo
C 23	16	27.1	659	3	AAFO8058	AAFO8058 Fusarium
C 24	16	27.1	667	6	ABQ75940	ABQ75940 CHD activ
C 25	16	27.1	743	10	ADB69260	ADB69260 C. neofo
C 26	16	27.1	933	11	ABD02206	ABD02206 Pseudomon
C 27	16	27.1	1346	5	AAST7383	AAST7383 DNA encod
C 28	16	27.1	1769	6	ABN98233	ABN98233 Arabidops
C 29	16	27.1	2142	11	ABD02265	ABD02265 Pseudomon
C 30	16	27.1	2658	5	AAST90260	AAST90260 DNA encod
C 31	16	27.1	2658	5	AAST94408	AAST94408 DNA encod
C 32	16	27.1	2658	5	AAST73288	AAST73288 DNA encod
C 33	16	27.1	2659	5	AAST88462	AAST88462 DNA encod
C 34	16	27.1	2743	10	ADB68899	ADB68899 C. neofo
C 35	16	27.1	2874	8	ACAL8781	ACAL8781 Prokaryot
C 36	16	27.1	3056	3	AACT4758	AACT4758 Arabidops
C 37	16	27.1	3108	4	ABL24046	ABL24046 Drosophila
C 38	16	27.1	3163	10	ADZ5034	ADZ5034 Plant gro
C 39	16	27.1	4221	12	ADOS7346	ADOS7346 DNA encod
C 40	16	27.1	5603	3	AACT5314	AACT5314 Human act
C 41	16	27.1	6564	3	ABLI2539	ABLI2539 Human act
C 42	16	27.1	10327	4	ABLI2538	ABLI2538 Drosophila
C 43	16	27.1	11204	3	AACT5339	AACT5339 Human act
C 44	16	27.1	11204	6	ABST7286	ABST7286 DNA encod
C 45	16	27.1	21469	4	AAK89568	AAK89568 Human dig

## ALIGNMENTS

RESULT 1  
ABZ58372  
ID ABZ58372 standard; DNA; 59 BP.  
XX  
AC ABZ58372;  
XX  
DT 28-APR-2003 (first entry)  
XX  
DE Human uteroglobin synthetic gene oligonucleotide 3.  
XX  
KW Human; uteroglobin; respiratory distress; antiinflammatory; antifibrotic;  
KW antiinflammatory; antiasthmatic; nephroretropic; antithrombotic;  
KW antithrombotic; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
OS  
PN WO2003003979-A2.  
XX  
PD 16-JAN-2003.  
XX  
PF 02-JUL-2002; 2002WO-US020836.  
XX  
PR 02-JUL-2001; 2001US-00898616.  
XX  
PA (CLAR-) CLARAGEN INC.  
XX  
PI Pilon AL, Welch RE;  
XX  
DR WPI, 2003-221527/21.  
XX  
PT Bacterial expression system for producing recombinant human uteroglobin  
PT for treating inflammatory and fibrotic conditions, comprises a synthetic  
PT gene which codes for human uteroglobin.  
XX  
PS Claim 1, Page 33; 127pp; English.  
XX  
CC The present sequence is that of oligonucleotide 3, which was used in the  
CC construction of a synthetic gene for the production of human uteroglobin  
CC (hug) in bacteria. Oligonucleotides 1-4 (see ABZ58370-73) were used to  
CC assemble the coding strand and oligonucleotides 5-8 (see ABZ58374-77) the  
CC complementary strand. The gene was assembled by annealing and ligation of  
CC the oligonucleotides. Because mature native hug has glutamic acid at its  
CC N-terminus, an initiator methionine was added to the N-terminus, and

CC codon usage was optimised for expression in bacteria. In an example from  
CC the invention, the synthetic gene was cloned into plasmid pCG12 (see  
CC AB258378) and recombinant rhUG (see ABP72259) was produced in *Escherichia*  
CC coli strain CG12. The invention relates generally to the production of  
CC recombinant rhUG by bacterial expression, protein purification and scaled-  
CC up production according to current good manufacturing practices. The  
CC recombinant rhUG is useful for the treatment of inflammatory and fibrotic  
CC conditions, such as neonatal respiratory distress syndrome and  
CC bronchopulmonary dysplasia. It may also be used to treat conditions  
CC associated with elevated phospholipase A2 levels such as pancreatitis,  
CC acute renal failure, rheumatoid arthritis and asthma  
CC  
XX  
SO Sequence 59 BP; 19 A; 17 C; 13 G; 10 T; 0 U; 0 Other;  
Query Match 100.0%; Score 59; DB 9; Length 59;  
Best Local Similarity 100.0%; Pred. No. 7.3e-22;  
Matches 59; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Dy 1 CAGCTGAAGAACTGTTGACACCTGCGCGAGAAACCGGTGATTCATCAATAAATG 59  
Db 1 CAGCTGAAGAACTGTTGACACCTGCGCGAGAAACCGGTGATTCATCAATAAATG 59  
RESULT 2  
ADL27628  
ID ADL27628 standard; DNA; 59 BP.  
XX  
AC ADL27628;  
XX  
DT 20-MAY-2004 (first entry)  
XX  
DE Recombinant human uteroglobin, rhUG, coding oligonucleotide #3.  
XX  
XX Human; ss; recombinant human uteroglobin, rhUG;  
XX bacterial expression system; rhUG master cell bank;  
XX rhUG research seed bank; anti-inflammatory; secretory phospholipase A2;  
XX fibronectin; respiratory distress; inflammation; fibrotic disease.  
XX  
XX Homo sapiens.  
XX Synthetic.  
XX  
XX US2003207795-A1.  
XX  
XX 06-NOV-2003.  
XX  
XX 02-JUL-2002; 2002US-00187498.  
XX  
XX 28-MAY-1997; 97US-00864357.  
XX  
XX 02-JUL-2001; 2001US-00898616.  
XX  
XX (PILON) PILON A L.  
XX (WELCH) WELCH R W.  
XX  
XX Pilon AL, Welch RW;  
XX  
XX WPI; 2004-051527/05.  
XX  
XX Bacterial expression system for production of recombinant human  
XX uteroglobin comprising synthetic gene or human cDNA sequence which codes  
XX for human uteroglobin.  
XX  
XX Claim 1; SEQ ID NO 3; 64bp; English.  
XX  
XX The invention relates to a bacterial expression system for the production  
XX of recombinant human uteroglobin (rhUG), comprising a synthetic gene or  
XX human cDNA sequence which codes for human UG, constructed from the  
XX oligonucleotides appearing as ADL27626-ADL27629, and which further  
XX comprises Met-Ala-Ala at the N-terminus of the sequence. Also included  
XX are producing an rhUG master cell bank (comprising inoculating a suitable  
XX incubating broth with an aliquot portion of a rhUG research seed bank to  
XX form a bacterial culture, incubating the bacterial culture, adding a  
XX cryoprotective to the bacterial culture to form a cryopreserved  
XX solution, transferring a portion of the cryopreserved solution to a

CC cryovial and storing the cryovial at a temperature below -60 degrees C),  
CC expressing rhUG (comprising providing a production seed cell bank culture  
CC comprising an expression vector capable of expressing rhUG, inoculating a  
CC broth medium with the production seed cell bank culture to form an  
CC inoculum, incubating the bacterial culture formed in step (b),  
CC inoculating a large scale fermenter with the inoculum formed from the  
CC step (c) to form a fermentation culture, incubating the fermentation  
CC culture within the large scale fermenter, adding an induction agent to  
CC the fermentation culture to induce the expression of rhUG and harvesting  
CC the above fermentation culture), purifying rhUG, determining the potency  
CC of rhUG in a sample, measuring in vitro anti-inflammatory effect arising  
CC from inhibition or blocking of secretory phospholipase A2 enzymes by  
CC rhUG, measuring in vitro binding of rhUG to fibronectin, determining the  
CC purity of rhUG, and a pharmaceutical composition comprising a purified  
CC rhUG and a carrier or diluent. The bacterial expression system is useful  
CC for producing a rhUG research seed bank or a pharmaceutical grade rhUG  
CC drug substance. rhUG is safe to administer to a patient in respiratory  
CC distress. The rhUG is useful for treating inflammation and fibrotic  
CC diseases. The present sequence is a coding strand oligonucleotide used to  
CC construct the synthetic rhUG gene.  
CC  
XX  
SO Sequence 59 BP; 19 A; 17 C; 13 G; 10 T; 0 U; 0 Other;  
Query Match 100.0%; Score 59; DB 15; Length 59;  
Best Local Similarity 100.0%; Pred. No. 7.3e-22;  
Matches 59; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Dy 1 CAGCTGAAGAACTGTTGACACCTGCGCGAGAAACCGGTGATTCATCAATAAATG 59  
Db 1 CAGCTGAAGAACTGTTGACACCTGCGCGAGAAACCGGTGATTCATCAATAAATG 59  
RESULT 3  
ABZ58375/c  
ID ABZ58375 standard; DNA; 59 BP.  
XX  
AC ABZ58375;  
XX  
DT 28-APR-2003 (first entry)  
XX  
DE Human uteroglobin synthetic gene oligonucleotide 6.  
XX  
XX Human; uteroglobin; respiratory distress; anti-inflammatory; antifibrotic;  
XX anti-inflammatory; antiaesthetic; nephrotoxic; antirheumatic;  
XX antiarthritic; ss.  
XX  
XX Homo sapiens.  
XX Synthetic.  
XX  
XX WO2003003979-A2.  
XX  
XX 16-JAN-2003.  
XX  
XX 02-JUL-2002; 2002WO-US020836.  
XX  
XX 02-JUL-2001; 2001US-00898616.  
XX  
XX (CLAR-) CLARAGEN INC.  
XX  
XX Pilon AL, Welch RE;  
XX  
XX WPI; 2003-221527/21.  
XX  
XX Bacterial expression system for producing recombinant human uteroglobin  
XX for treating inflammatory and fibrotic conditions, comprises a synthetic  
XX gene which codes for human uteroglobin.  
XX  
XX Example 1; Page 33; 127bp; English.  
XX  
XX The present sequence is that of oligonucleotide 6, which was used in the  
XX construction of a synthetic gene for the production of human uteroglobin  
XX (rhUG) in bacteria. Oligonucleotides 1-4 (see ABZ58370-73) were used to  
XX assemble the coding strand and oligonucleotides 5-8 (see ABZ58374-77) the

complementary strand. The gene was assembled by annealing and ligation of the oligonucleotides. Because mature native rhug has glutamic acid at its N-terminus, an initiator methionine was added to the N-terminus, and codon usage was optimized for expression in bacteria. In an example from the invention, the synthetic gene was cloned into plasmid pCG12 (see AB253378) and recombinant rhug (see ABP72259) was produced in *Escherichia coli* strain CG12. The invention relates generally to the production of recombinant rhug by bacterial expression, protein purification and scaled-up production according to current good manufacturing practices. The recombinant rhug is useful for the treatment of inflammatory and fibrotic conditions, such as neonatal respiratory distress syndrome and bronchopulmonary dysplasia. It may also be used to treat conditions associated with elevated phospholipase A2 levels such as pancreatitis, acute renal failure, rheumatoid arthritis and asthma.

Sequence 59 BP; 9 A; 17 C; 15 G; 18 T; 0 U; 0 Other;

Query Match 62.7%; Score 37; DB 9; Length 59;  
Best Local Similarity 100.0%; Pred. No. 4.9e-10;  
Matches 37; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 CAGCTGAAGAAACTGGTTGACACCCCTGCCGCAAGAAC 37  
37 CAGCTGAAGAAACTGGTTGACACCCCTGCCGCAAGAAC 1

RESULT 4  
ADL27631/C  
ID ADL27631 standard; DNA; 59 BP.  
XX  
XX ADL27631:  
XX  
XX 20-MAY-2004 (first entry)  
XX  
DE Recombinant human uteroglobin, rhug, non-coding oligonucleotide #2.  
XX  
XX Human; ss; recombinant human uteroglobin, rhug;  
XX bacterial expression system; rhug master cell bank;  
XX rhug research seed bank; anti-inflammatory; secretory phospholipase A 2;  
XX fibronectin; respiratory distress; inflammation; fibrotic disease.  
XX  
XX Homo sapiens.  
XX Synthetic.  
XX  
XX US2003207795-A1.  
XX  
XX 06-NOV-2003.  
XX  
XX 02-JUL-2002; 2002US-00187498.  
XX  
XX 28-MAY-1997; 97US-00864357.  
XX PR 02-JUL-2001; 2001US-00898616.  
XX  
XX (PILO/) PILON A L.  
XX (WELC/) WELCH R W.  
XX  
XX Pilon AL, Welch RW;  
XX  
XX MPI; 2004-051527/05.  
XX  
XX Bacterial expression system for production of recombinant human  
XX uteroglobin comprising synthetic gene or human cDNA sequence which codes  
XX for human uteroglobin.  
XX  
XX Example 1; SEQ ID NO 6; 64bp; English.  
XX  
XX The invention relates to a bacterial expression system for the production  
XX of recombinant human uteroglobin (rhug), comprising a synthetic gene or  
XX human cDNA sequence which codes for human uteroglobin, constructed from the  
XX oligonucleotides appearing as ADL27626-ADL27629, and which further  
XX comprises Met-Ala-Ala at the N-terminus of the sequence. Also included  
XX are producing an rhug master cell bank (comprising inoculating a suitable  
XX incubating broth with an aliquot portion of a rhug research seed bank to

form a bacterial culture, incubating the bacterial culture, adding a cryoprotective to the bacterial culture to form a cryopreserved solution, transferring a portion of the cryopreserved solution to a cryovial and storing the cryovial at a temperature below -60 degrees C),  
XX expressing rhug (comprising providing a production seed cell bank culture  
XX comprising an expression vector capable of expressing rhug; inoculating a  
XX broth medium with the production seed cell bank culture to form an  
XX inoculum, incubating the bacterial culture formed in step (b),  
XX inoculating a large scale fermenter with the inoculum formed from the  
XX step (c) to form a fermentation culture, incubating the fermentation  
XX culture within the large scale fermenter, adding an induction agent to  
XX the fermentation culture to induce the expression of rhug and harvesting  
XX the above fermentation culture), purifying rhug, determining the potency  
XX of rhug in a sample, measuring in vitro anti-inflammatory effect arising  
XX from inhibition or blocking of secretory phospholipase A 2 enzymes by  
XX rhug, measuring in vitro binding of rhug to fibronectin, determining the  
XX purity of rhug, and a pharmaceutical composition comprising a purified  
XX rhug and a carrier or diluent. The bacterial expression system is useful  
XX for producing a rhug research seed bank or a pharmaceutical grade rhug  
XX drug substance. rhug is safe to administer to a patient in respiratory  
XX distress. The rhug is useful for treating inflammation and fibrotic  
XX diseases. The present sequence is a non-coding strand oligonucleotide  
XX used to construct the synthetic rhug gene.

Sequence 59 BP; 9 A; 17 C; 15 G; 18 T; 0 U; 0 Other;

Query Match 62.7%; Score 37; DB 12; Length 59;  
Best Local Similarity 100.0%; Pred. No. 4.9e-10;  
Matches 37; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 CAGCTGAAGAAACTGGTTGACACCCCTGCCGCAAGAAC 37  
37 CAGCTGAAGAAACTGGTTGACACCCCTGCCGCAAGAAC 1

RESULT 5  
AAN90906  
ID AAN90906 standard; DNA; 215 BP.  
XX  
XX AAN90906:  
XX  
XX 25-MAR-2003 (revised)  
XX DT 26-JAN-1990 (first entry)  
XX  
XX Synthetic human IGF-II.  
XX  
XX Synthetic IGF-II; fusion protein.  
XX  
XX Homo sapiens.  
XX  
XX EP333691-A.  
XX PN 20-SEP-1989.  
XX  
XX 16-MAR-1989; 89EP-00850091.  
XX PF  
XX 17-MAR-1988; 88SE-00000981.  
XX PR  
XX (CEMU-) CEMU BIOTECHNIK AB.  
XX (SEMB-) SEM BIOTECHNIK AB.  
XX  
XX Nygren PA, Abrahamson L, Uhlen M,  
XX  
XX MPI; 1989-272436/38.  
XX DR P-PSDB; AAP91389.  
XX  
XX New recombinant fusion protein comprising desired protein - flanked by  
XX IGG-binding domain of staphylococcal protein A and albumin-binding domain  
XX of streptococcal protein G.  
XX  
XX Disclosure, Fig 1; 10pp; English.  
XX  
XX Synthetic IGF-II was constructed from 22 oligonucleotides. The gene was

CC designed with EcoRI and HindIII 5' and 3' cohesive ends resp. to  
CC facilitate cloning. An N-terminal methionine codon was included to allow  
CC cleavage of fusion proteins with CNBR to generate native IGF-II. A double  
CC TAA stop codon was incorporated at the 3' end. The gene was used to  
CC construct a fusion vector with DNA coding for an IgG-binding domain from  
CC staphylococcal protein A and an albumin-binding part of streptococcal  
CC protein G. (Updated on 25-MAR-2003 to correct PA field.)

XX Sequence 215 BP; 35 A; 55 C; 53 G; 72 T; 0 U; 0 Other;

Query Match 30.5%; Score 18; DB 1; Length 215;  
Best Local Similarity 100.0%; Pred. No. 8.4;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 11 AACTGTTGACACCCCTGC 28  
DB 44 AACTGTTGACACCCCTGC 61

RESULT 6  
ABK76145/c  
ID ABK76145 standard; DNA; 195 BP.

XX ABK76145;  
XX 13-AUG-2002 (first entry)

DE Bacillus licheniformis genomic sequence tag (GST) #3436.

XX Differential gene expression; genomic sequenced tag; GST;  
XX altered culture condition; environmental stress;  
XX physiological provocation; de.

OS Bacillus licheniformis.

XX WO200229113-A2.

XX 11-APR-2002.

XX 05-OCT-2001; 2001WO-US031437.

XX 06-OCT-2000; 2000US-00680598.

XX 27-MAR-2001; 2001US-0279526P.

XX (NOVO) NOVOSYNTHE BIOTECH INC.

XX (NOVO) NOVOSYNTHE AS.

XX Berka R, Clausen IG;

XX WPI; 2002-416684/44.

XX Monitoring differential expression of several genes in first Bacillus  
XX cell relative to expression of same genes in one or more second Bacillus  
XX cells, by using substrate containing Bacillus genomic sequenced tag  
XX array.

XX Claim 4; SEQ ID NO 3436; 200PP; English.

XX The invention describes a method of monitoring differential expression of  
XX genes in a first Bacillus cell relative to expression of the genes in  
XX other Bacillus cells, comprising hybridising labelled nucleic acid probes  
XX isolated from Bacillus cells to a substrate containing array of Bacillus  
XX genomic sequenced tags (GST), examining the array, and determining  
XX relative gene expression by an observed hybridisation reporter signal of  
XX a spot in the array. The method is useful for measuring the expression of  
XX genes in a first Bacillus cell relative to expression of the same genes  
XX in one or more second Bacillus cells. The method is useful for monitoring  
XX global expression of several genes from a Bacillus cell, discovering new  
XX genes, identifying possible functions of unknown open reading frames and  
XX monitoring gene copy number variation and stability. Monitoring changes  
XX in expression of genes may be used to provide a representation of the way  
XX in which Bacillus cells adapt to changes in culture conditions.  
XX environmental stress or other physiological provocation. Extensive follow

CC -up characterisation is unnecessary, when one spot on an array equals one  
CC gene or one open reading frame, since sequence information is available.  
CC This sequence represents a genomic sequence tag (GST) used in the method  
CC of the invention. Note: The sequence data for this patent did not form  
CC part of the printed specification, but was obtained in electronic format  
CC directly from WIPO at ftp.wipo.int/pub/published\_pct\_sequences

XX Sequence 195 BP; 34 A; 48 C; 56 G; 57 T; 0 U; 0 Other;

Query Match 28.8%; Score 17; DB 6; Length 195;  
Best Local Similarity 100.0%; Pred. No. 29;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 21 CACCTGCGCGCAGAAC 37  
DB 102 CACCTGCGCGCAGAAC 86

RESULT 7  
ADC24050/c  
ID ADC24050 standard; DNA; 993 BP.

XX ADC24050;

XX 16-DEC-2003 (first entry)

DE DNA sequence (SegID 317) encoding a nitrilase enzyme.

XX Gene; de; nitrilase; nitrile; cyanohydrin; ammonia; biocatalyst;  
XX emantomer; chiral medicine.

OS Unidentified.

XX WO2003000840-A2.

XX 03-JAN-2003.

XX 15-MAY-2002; 2002WO-US015983.

XX 21-JUN-2001; 2001US-0300189P.

XX 26-JUN-2001; 2001US-0309006P.

XX 22-JAN-2002; 2002US-0351336P.

XX (DIVE-) DIVERSA CORP.

XX (MADP/) MADDEN D.

XX Madder M, Desantis G, Chaplin JA, Weiner DP, Milan A, Chl E;

XX Short JM, Burk M;

XX WPI; 2003-201417/19.

XX P-PDB; ADC24051.

XX Novel nitrilase polypeptide, useful for making (R)- or (S)-ethyl-4-cyano-  
XX 3-hydroxybutyric acid or (R)- or (S)-mandelic acid or (S)- or (R)-phenyl  
XX lactic acid derivative and for producing pharmaceutical composition, and  
XX food additive.

XX Claim 1; SEQ ID NO 317; 560PP; English.

XX This invention relates to nitrilases and the nucleic acids that encode  
XX these enzymes thereof. Specifically, it refers to polypeptides that  
XX exhibit nitrilase activity, i.e. the ability to directly hydrolyse  
XX nitriles or cyanohydrins into their corresponding carboxylic acids and  
XX ammonia. Nitrilases have commercial utility as biocatalysts for use in  
XX the synthesis of enantiomerically pure aromatic and aliphatic amino  
XX acids, as well as hydroxy acids, which are important for the development  
XX of chiral medicines. Furthermore, the present invention describes  
XX nitrilases, isolated from mesophilic microorganisms, that have improved  
XX activity and stability at increased pH and temperature. They are also  
XX inexpensive, efficient catalysts, have broad substrate specificity and  
XX are capable of chiral differentiation. This polynucleotide is a DNA  
XX sequence that encodes a nitrilase enzyme of the invention.

SQL Sequence 993 BP, 188 A, 330 C, 305 G, 170 T, 0 U, 0 Other;

Query Match 28.8%; Score 17; DB 10; Length 993;

Best Local Similarity 100.0%; Pred. No. 30;

Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 37 CCGCGTGAATCCATCAT 53  
DB 860 CCGCGTGAATCCATCAT 844

# RESULT 8

ID ADH36151/c  
ADH36151 standard; DNA, 993 BP.

AC ADH36151;

DT 11-MAR-2004 (first entry)

DE Chemical process monitoring-related nitrilase gene sequence SegID317.

KW Chemical process monitoring; biochemical process monitoring; cyanide;

KW high throughput system; gene; ds.

OS Unidentified.

PN WO2003098187-A2.

PD 27-NOV-2003.

PF 15-MAY-2003; 2003WO-US015639.

PR 15-MAY-2002; 2002US-0380737P.

PA (DIVE-) DIVERSA CORP.

PI Weiner D, Chaplin JA, Chi E, Mian A, Desantis G, Burk M;

PI McQuaid J, Siege J;

DR WPI; 2004-142708/14.

DR P-PSDB; ADH36152.

PT Monitoring a chemical or biochemical process comprising providing a

PT reactant comprising a cyanide or a material that can be converted to

PT cyanide or a reactant that generates a cyanide or a material that can be

PT converted to cyanide.

PS Claim 74; SEQ ID NO 317; 277bp; English.

CC This invention relates to a novel method of monitoring chemical or

CC biochemical processes. The method involves providing a reactant

CC comprising cyanide (or a material that can be converted to a cyanide)

CC that generates as a reaction product cyanide or a material that can be

CC converted to cyanide and measuring the concentration of produced cyanide.

CC The method is useful for monitoring a chemical or biochemical process.

CC The method is effective for high throughput systems and is sufficiently

CC sensitive to detect a small amount of product. The present sequence is

CC that of a gene which encodes a nitrilase enzyme which can be used in the

CC method of the invention.

XX Sequence 993 BP, 188 A, 330 C, 305 G, 170 T, 0 U, 0 Other;

XX Query Match 28.8%; Score 17; DB 12; Length 993;

XX Best Local Similarity 100.0%; Pred. No. 30;

XX Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 37 CCGCGTGAATCCATCAT 53

DB 860 CCGCGTGAATCCATCAT 844

RESULT 9

ADG93852/c

ID ADG93852 standard; DNA, 993 BP.

AC ADG93852;

DT 11-MAR-2004 (first entry)

DE Nitrilase enzyme gene sequence SegID317.

KW nitrilase; nitrile; carboxylic acid; chemical process; pH; temperature;

KW enantioselective transformation; gene; ds.

OS Unidentified.

PN WO2003097810-A2.

PD 27-NOV-2003.

PF 15-MAY-2003; 2003WO-US015712.

PR 15-MAY-2002; 2002US-00146772.

PR 09-SEP-2002; 2002US-00241742.

PA (DIVE-) DIVERSA CORP.

PI Desantis G, Short JM, Burk M, Wong K, Farwell R, Chatman K;

PI WPI; 2004-090637/09.

DR P-PSDB; ADG93853.

PT New isolated or recombinant nucleic acid encoding a polypeptide having

PT nitrilase activity, useful for screening enantioselective transformation.

PS Claim 44; SEQ ID NO 317; 295bp; English.

CC This invention is related to a novel isolated or recombinant nucleic acid

CC encoding a protein having nitrilase activity. Nitrilases are capable of

CC converting nitrile's directly to carboxylic acids and have great

CC potential for use in industrial chemical processes. The isolated

CC nitrilase proteins of the invention have increased activity and stability

CC at increased pH and temperature when compared to those conventionally

CC used. In addition, the nucleic acid of the invention is useful for

CC screening enantioselective transformation. The present sequence is that

CC of a DNA sequence which encodes a nitrilase enzyme of the invention.

XX Sequence 993 BP, 188 A, 330 C, 305 G, 170 T, 0 U, 0 Other;

XX Query Match 28.8%; Score 17; DB 12; Length 993;

XX Best Local Similarity 100.0%; Pred. No. 30;

XX Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 37 CCGCGTGAATCCATCAT 53

DB 860 CCGCGTGAATCCATCAT 844

RESULT 10

AD162449/c

ID AD162449 standard; DNA, 993 BP.

AC AD162449;

DT 22-APR-2004 (first entry)

DE DNA encoding nitrilase polypeptide #159.

KW Altorvastatin; (R)-ethyl 4-cyano-3-hydroxybutyrate;

KW (R)-ethyl 4-cyano-3-hydroxybutyric acid; epichlorohydrin;

KW 3-hydroxyglutaronitrile; 3-hydroxyglutaronitrile;

KW 4-cyano-3-hydroxybutyric acid; ethyl-4-cyano-3-hydroxybutyric acid;

KW mixed hyperlipidaemia; homozygous familial hypercholesterolaemia;

KW antihypertensive; gene; ds.

OS Unidentified.



XX WO2003106415-A2.  
PN  
XX  
PD 24-DEC-2003.  
PP  
PX 13-JUN-2003; 2003MO-US018640.  
PY  
PR 13-JUN-2002; 2002US-0389317P.  
PS 28-JUN-2002; 2002US-0392944P.  
PT  
PA (DIVE-) DIVERSA CORP.  
PI Burk M., Desantis G., Morgan B., Zhu Z;  
PJ WPI; 2004-090821/09.  
PK P-PADB; ADI62450.  
PL  
PM Preparation of atorvastatin comprises catalytic conversion of 3-hydroxyglutaronitrile by polypeptide with nitrilase activity, converting obtained 4-cyano-3-hydroxybutyric acid to ethyl-4-cyano-3-hydroxybutyric acid and forming atorvastatin.

Claim 46; SEQ ID NO 317; 253pp; English.

The present invention relates to a method for preparing an atorvastatin intermediate known as (R)-ethyl 4-cyano-3-hydroxybutyrate ((R)-ethyl 4-cyano-3-hydroxybutyric acid). The method comprises optionally converting chloroethanol or equivalent to 3-hydroxyglutaronitrile, catalytic conversion of 3-hydroxyglutaronitrile or equivalent to 4-cyano-3-hydroxybutyric acid with a polypeptide having nitrilase activity, converting 4-cyano-3-hydroxybutyric acid to ethyl-4-cyano-3-hydroxybutyric acid, and converting this to (R)-ethyl 4-cyano-3-hydroxybutyrate. The method involves whole cell processes, cell lysate process, "one pot" processes, and "multi-pot" processes using a variety of parameters. Atorvastatin is used, in conjunction with dietary restriction, in the management of hyperlipidaemia, including hypercholesterolaemia, mixed dyslipidaemia and homozygous familial hypercholesterolaemia. The present sequence encodes a nitrilase polypeptide obtained from an environmental sample.

Sequence 993 BP; 188 A; 330 C; 305 G; 170 T; 0 U; 0 Other;

Query Match 28.8%; Score 17; DB 12; Length 993;  
Best Local Similarity 100.0%; Pred.No. 30;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 37 CCGGCGAATCATCAT 53  
DB 860 CCGGCGAATCATCAT 844

RESULT 11  
ADI64570/c  
ID ADI64570 standard; DNA; 993 BP.  
AC ADI64570;  
DT 22-APR-2004 (first entry)  
DE DNA encoding nitrilase seq id 159.  
E  
F  
G (R)-ethyl 4-cyano-3-hydroxybutyric acid; nitrile hydrolysis;  
H carboxylic acid; cyanohydrin moiety hydrolysis;  
I aminonitrile moiety hydrolysis; chiral alpha-hydroxy acid molecule;  
J chiral amino acid molecule; (S)-ethyl 4-cyano-3-hydroxybutyric acid;  
K (R)-mandelic acid; (S)-mandelic acid; (S)-phenyl lactic acid derivative;  
L (R)-phenyl lactic acid derivative; % enantiomeric excess;  
M % diastereomeric excess; food additive; drug intermediate; ds; nitrilase;  
N gene.  
O  
P Unidentified.  
Q  
R US2004014195-A1.  
S  
T  
U  
V  
W  
X  
Y  
Z  
aa  
ab  
ac  
ad  
ae  
af  
ag  
ah  
ai  
aj  
ak  
al  
am  
an  
ao  
ap  
aq  
ar  
as  
at  
au  
av  
aw  
ax  
ay  
az  
ba  
bb  
bc  
bd  
be  
bf  
bg  
bh  
bi  
bj  
bk  
bl  
bm  
bn  
bo  
bp  
bq  
br  
bs  
bt  
bu  
bv  
bw  
bx  
by  
bz  
ca  
cb  
cc  
cd  
ce  
cf  
cg  
ch  
ci  
cj  
ck  
cl  
cm  
cn  
co  
cp  
cq  
cr  
cs  
ct  
cu  
cv  
cw  
cx  
cy  
cz  
da  
db  
dc  
dd  
de  
df  
dg  
dh  
di  
dj  
dk  
dl  
dm  
dn  
do  
dp  
dq  
dr  
ds  
dt  
du  
dv  
dw  
dx  
dy  
dz  
ea  
eb  
ec  
ed  
ee  
ef  
eg  
eh  
ei  
ej  
ek  
el  
em  
en  
eo  
ep  
eq  
er  
es  
et  
eu  
ev  
ew  
ex  
ey  
ez  
fa  
fb  
fc  
fd  
fe  
ff  
fg  
fh  
fi  
fj  
fk  
fl  
fm  
fn  
fo  
fp  
fq  
fr  
fs  
ft  
fu  
fv  
fw  
fx  
fy  
fz  
ga  
gb  
gc  
gd  
ge  
gf  
gg  
gh  
gi  
gj  
gk  
gl  
gm  
gn  
go  
gp  
gq  
gr  
gs  
gt  
gu  
gv  
gw  
gx  
gy  
gz  
ha  
hb  
hc  
hd  
he  
hf  
hg  
hh  
hi  
hj  
hk  
hl  
hm  
hn  
ho  
hp  
hq  
hr  
hs  
ht  
hu  
hv  
hw  
hx  
hy  
hz  
ia  
ib  
ic  
id  
ie  
if  
ig  
ih  
ii  
ij  
ik  
il  
im  
in  
io  
ip  
iq  
ir  
is  
it  
iu  
iv  
iw  
ix  
iy  
iz  
ja  
jb  
jc  
jd  
je  
jf  
jg  
jh  
ji  
jj  
jk  
jl  
jm  
jn  
jo  
jp  
jq  
jr  
js  
jt  
ju  
jv  
jw  
jx  
jy  
jz  
ka  
kb  
kc  
kd  
ke  
kf  
kg  
kh  
ki  
kj  
kk  
kl  
km  
kn  
ko  
kp  
kq  
kr  
ks  
kt  
ku  
kv  
kw  
kx  
ky  
kz  
la  
lb  
lc  
ld  
le  
lf  
lg  
lh  
li  
lj  
lk  
ll  
lm  
ln  
lo  
lp  
lq  
lr  
ls  
lt  
lu  
lv  
lw  
lx  
ly  
lz  
ma  
mb  
mc  
md  
me  
mf  
mg  
mh  
mi  
mj  
mk  
ml  
mm  
mn  
mo  
mp  
mq  
mr  
ms  
mt  
mu  
mv  
mw  
mx  
my  
mz  
na  
nb  
nc  
nd  
ne  
nf  
ng  
nh  
ni  
nj  
nk  
nl  
nm  
nn  
no  
np  
nq  
nr  
ns  
nt  
nu  
nv  
nw  
nx  
ny  
nz  
oa  
ob  
oc  
od  
oe  
of  
og  
oh  
oi  
oj  
ok  
ol  
om  
on  
oo  
op  
oq  
or  
os  
ot  
ou  
ov  
ow  
ox  
oy  
oz  
pa  
pb  
pc  
pd  
pe  
pf  
pg  
ph  
pi  
pj  
pk  
pl  
pm  
pn  
po  
pp  
pq  
pr  
ps  
pt  
pu  
pv  
pw  
px  
py  
pz  
qa  
qb  
qc  
qd  
qe  
qf  
qg  
qh  
qi  
qj  
qk  
ql  
qm  
qn  
qo  
qp  
qq  
qr  
qs  
qt  
qu  
qv  
qw  
qx  
qy  
qz  
ra  
rb  
rc  
rd  
re  
rf  
rg  
rh  
ri  
rj  
rk  
rl  
rm  
rn  
ro  
rp  
rq  
rr  
rs  
rt  
ru  
rv  
rw  
rx  
ry  
rz  
sa  
sb  
sc  
sd  
se  
sf  
sg  
sh  
si  
sj  
sk  
sl  
sm  
sn  
so  
sp  
sq  
sr  
ss  
st  
su  
sv  
sw  
sx  
sy  
sz  
ta  
tb  
tc  
td  
te  
tf  
tg  
th  
ti  
tj  
tk  
tl  
tm  
tn  
to  
tp  
tq  
tr  
ts  
tt  
tu  
tv  
tw  
tx  
ty  
tz  
ua  
ub  
uc  
ud  
ue  
uf  
ug  
uh  
ui  
uj  
uk  
ul  
um  
un  
uo  
up  
uq  
ur  
us  
ut  
uu  
uv  
uw  
ux  
uy  
uz  
va  
vb  
vc  
vd  
ve  
vf  
vg  
vh  
vi  
vj  
vk  
vl  
vm  
vn  
vo  
vp  
vq  
vr  
vs  
vt  
vu  
vv  
vw  
vx  
vy  
vz  
wa  
wb  
wc  
wd  
we  
wf  
wg  
wh  
wi  
wj  
wk  
wl  
wm  
wn  
wo  
wp  
wq  
wr  
ws  
wt  
wu  
wv  
ww  
wx  
wy  
wz  
xa  
xb  
xc  
xd  
xe  
xf  
xg  
xh  
xi  
xj  
xk  
xl  
xm  
xn  
xo  
xp  
xq  
xr  
xs  
xt  
xu  
xv  
xw  
xx  
xy  
xz  
ya  
yb  
yc  
yd  
ye  
yf  
yg  
yh  
yi  
yj  
yk  
yl  
ym  
yn  
yo  
yp  
yq  
yr  
ys  
yt  
yu  
yv  
yw  
yx  
yy  
yz  
za  
zb  
zc  
zd  
ze  
zf  
zg  
zh  
zi  
zj  
zk  
zl  
zm  
zn  
zo  
zp  
zq  
zr  
zs  
zt  
zu  
zv  
zw  
zx  
zy  
zz

PX	22-JAN-2004.
XX	
PF	15-MAY-2003; 2003US-00440523.
XX	
XX	29-DEC-1999; 99US-0173609P.
FR	07-DEC-2000; 2000US-0254418F.
PR	28-DEC-2000; 2000US-00751289.
PR	21-JUN-2001; 2001US-0300189P.
PR	30-JUL-2001; 2001US-0309006P.
PR	22-JAN-2002; 2002US-0351336P.
PR	15-MAY-2002; 2002US-00146772.
PR	09-SEP-2002; 2002US-00241742.
XX	
PA	(DIVE-) DIVERSA CORP.
PI	Dessantis G, Short JM, Burk MJ, Wong K, Farwell R, Chatman K;
PI	WPI; 2004-121569/12.
DR	P-PDB; ADI64571.
XX	
PT	Novel isolated or recombinant polypeptide having nitrilase activity,
PT	useful in production of food additives.
XX	
PS	Claim 1; Seq ID NO 317; 105bp; English.
XX	
CC	The invention describes an isolated or recombinant polypeptide (I)
CC	comprising amino acids having a sequence at least 50 % identical to a
CC	sequence (S1) available in electronic form (EC) from the following web
CC	site: ftp.seqdata.uspro.gov/sequence.html?docid=2004014195, or its
CC	variant(s), having one or more mutations at residue 55 lys, Gly or Glu, at
CC	residue 60 glutamic acid, at residue 111 ser, their combinations or
CC	fragments. (I) is useful for: producing an (R)-ethyl 4-cyano-3-
CC	hydroxybutyric acid; hydrolysing a nitrile to a carboxylic acid;
CC	hydrolysing cyanohydrin moiety or an ammonium salt moiety; producing a
CC	chiral alpha-hydroxy acid molecule or a chiral amino acid molecule;
CC	producing an (S)-ethyl 4-cyano-3-hydroxybutyric acid; producing an (R)-
CC	mandelic acid or (S)-mandelic acid; producing (S)-phenyl lactic acid
CC	derivative or an (R)-phenyl lactic acid derivative; modifying a molecule
CC	and for identifying a modified and enantiomeric excess or % diastereomic
CC	for monitoring or determining & enantiomeric excess or % diastereomic
CC	excess. (I) is useful in the production of food additives and drug
CC	intermediates. This sequence encodes a nitrilase of the invention.
SO	
SQ	Sequence 993 BP; 188 A; 330 C; 305 G; 170 T; 0 U; 0 Other;
Query Match	28.8%; Score 17; DB 12; Length 993;
Best Local Similarity	100.0%; Pred. No 30;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	37 CCGCGTGATTCATCAT 53       
Db	860 CCGCGTGATTCATCAT 844
RESULT 12	
ABL08480	ABL08480 standard; cDNA; 3530 BP.
XX	
AC	ABL08480;
XX	
DT	26-MAR-2002 (first entry)
DE	Drosophila melanogaster expressed polymucleotide SEQ ID NO 19922.
XX	
KX	Drosophila; developmental biology; cell signalling; insecticide;
KW	pharmaceutical; gene; ss.
XX	
OS	Drosophila melanogaster.
XX	
EN	MO200171042-A2.
XX	
PD	27-SEP-2001.



```

XX 23-MAR-2001; 2001WO-US009231.
PF 23-MAR-2000; 2000US-0191637P.
PR 11-JUL-2000; 2000US-00614150.
XX
XX (PEKE ) PE CORP NY.
XX
XX Venter JC, Adams M, Li PWD, Myers EW;
XX MPI: 2001-655686/75.
XX P-PSDB; ABB64377.
XX
XX New isolated nucleic acid detection reagent for detecting 1000 or more
XX PT genes from Drosophila and for elucidating cell signaling and cell-cell
XX PR interactions.
XX
XX Claim 1; SEQ ID NO 19922; 21pp + Sequence Listing; English.
XX
XX The invention relates to an isolated nucleic acid detection reagent
XX CC capable of detecting 1000 or more genes from Drosophila. The invention is
XX CC useful in developmental biology and in elucidating cell signaling and
XX CC cell-cell interactions in higher eukaryotes for the development of
XX CC insecticides, therapeutics and pharmaceutical drugs. The invention
XX CC discloses genomic DNA sequences (AB16176-AB130511), expressed DNA
XX CC sequences (AB101840-AB16175) and the encoded proteins (AB57737-
XX CC AB572072). The sequence data for this patent did not form part of the
XX CC printed specification, but was obtained in electronic format directly
XX CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 3530 BP; 1121 A; 634 C; 690 G; 1085 T; 0 U; 0 Other;
XX
XX Query Match 28.8%; Score 17; DB 4; Length 3530;
XX Best Local Similarity 100.0%; Pred. No. 32;
XX Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 4 CTGAGAAACTGCTTGA 20
XX Db 1786 CTGAGAAACTGCTTGA 1802
XX
XX RESULT 13
XX ABX08140/C
XX ID ABX08140 standard; DNA; 5568 BP.
XX
XX ABX08140;
XX
XX 27-OCT-2003 (revised)
XX DT 11-FEB-2003 (first entry)
XX
XX S. pneumoniae type 4 strain coding region #2428.
XX DE
XX Gene; ds; bacterial meningitis; pneumonia; sepsis; otitis media;
XX KW ear infection; antiinflammatory; antibacterial; immunostimulant;
XX KW auditory; respiratory; gene therapy; vaccine.
XX
XX Streptococcus pneumoniae; type 4 strain.
XX OS
XX WO200277021-A2.
XX PN
XX
XX 03-OCT-2002.
XX PD
XX 27-MAR-2002; 2002WO-IB002163.
XX PF
XX 27-MAR-2001; 2001GB-00007658.
XX PR
XX (CHIR-) CHIRON SPA.
XX PA (GENO-) INST GENOMIC RES.
XX PI
XX Massignani V, Tettelin H, Fraser C;
XX DR MPI: 2003-040579/03.
XX P-PSDB; AB028477.

```

```

XX New proteins and nucleic acid molecules from Streptococcus pneumoniae,
XX PT useful as medicaments for treating or preventing a disease or infection
XX PR due to Streptococcus bacteria, such as pneumonia, sepsis, otitis media or
XX PT ear infection.
XX
XX Claim 6; SEQ ID NO 4855; 56pp; English.
XX
XX The invention relates to a protein comprising or having at least 50%
XX CC identity to any of the 2469 amino acid sequences, identified in the
XX CC specification (available on a computer readable format), or its fragment,
XX CC expressed from 2469 of 2469 identified DNA coding regions from the
XX CC Streptococcus pneumoniae type 4 strain genomic sequence appearing as
XX CC AB56454. Also included are an antibody which binds one of the proteins,
XX CC treating a patient by administering the protein, DNA or antibody (in a
XX CC composition), a kit comprising first and second primers, which are the
XX CC nucleic acid cited above or fragments between nucleotides 8-100 of a
XX CC sequence not defined in the specification, for amplifying a target
XX CC sequence contained within a Streptococcus nucleic acid sequence, where
XX CC the first primer is substantially complementary to the target sequence
XX CC and the second primer is substantially complementary to the complement of
XX CC the target sequence, and where the parts of the primers having
XX CC substantial complementarity define the terminal of the target sequence to
XX CC be amplified, assay comprising contacting a test compound with the
XX CC protein, and determining whether the test compound binds to the protein
XX CC and a Streptococcus pneumoniae bacterium, where one or more genes
XX CC encoding the proteins has been rendered inactive. The proteins, nucleic
XX CC acid molecules, antibody and compositions are useful as medicaments for
XX CC treating or preventing a disease or infection due to Streptococcus
XX CC bacteria, particularly S. pneumoniae, such as pneumonia, sepsis, otitis
XX CC media or ear infection. They are also useful in developing vaccines,
XX CC diagnostics and antibiotics. The methods are useful for identifying
XX CC immunodominant proteins. The present sequence is one of the 2469
XX CC identified coding regions from the genomic sequence. Note: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format directly from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences. (Updated on 27-OCT-2003 to
XX CC standardise OS field)
XX
XX Sequence 5568 BP; 2066 A; 873 C; 1182 G; 1447 T; 0 U; 0 Other;
XX
XX Query Match 28.8%; Score 17; DB 10; Length 5568;
XX Best Local Similarity 100.0%; Pred. No. 32;
XX Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 42 TGAATCCATCATTAAC 58
XX Db 4309 TGAATCCATCATTAAC 4293
XX
XX RESULT 14
XX ADM91810/C
XX ID ADM91810 standard; DNA; 5568 BP.
XX
XX ADM91810;
XX
XX 03-JUN-2004 (first entry)
XX DT
XX S pneumoniae antigenic protein-encoding gene sequence Segd7.
XX DE
XX antibacterial; gene therapy; Streptococcus pneumoniae infection;
XX KW antigenic; gene; ds.
XX KW
XX Streptococcus pneumoniae.
XX OS
XX WO2004020609-A2.
XX PN
XX 11-MAR-2004.
XX PD
XX 02-SEP-2003; 2003WO-US027401.
XX PF
XX 30-AUG-2002; 2002US-0407082P.
XX PR
XX

```

PA (TUFT) UNIV TUFTS.  
XX  
PI Camilla A, Hava DL,  
XX  
DR WPI; 2004-239189/22.  
DR P-PSDS; ADM92047.  
XX  
PT New Streptococcus pneumoniae nucleic acid molecules, useful for  
PT diagnosing, treating and preventing active infections of Streptococcus  
PT pneumoniae.  
XX  
PS Claim 1; SEQ ID NO 7; 123bp; English.  
XX  
CC This invention relates to novel isolated Streptococcus pneumoniae nucleic  
CC acid molecules and the antigenic polypeptides encoded by them. The  
CC invention may be useful for the production of compounds with an  
CC antibacterial activity or for gene therapy. The nucleic acid molecules,  
CC compositions and methods disclosed are useful for treating Streptococcus  
CC pneumoniae infection. The present sequence is that of an S pneumoniae  
CC gene of the invention.  
XX  
SQ Sequence 5568 BP; 2066 A; 873 C; 1182 G; 1447 T; 0 U; 0 Other;  
XX  
Query Match 28.8%; Score 17; DB 12; Length 5568;  
Best Local Similarity 100.0%; Pred. No. 32;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 42 TGAATCATCATTAACCT 58  
DB 4309 TGAATCATCATTAACCT 4293  
RESULT 15  
AAVS2304/c  
ID AAVS2304 standard; DNA; 14736 BP.  
XX  
AC AAVS2304;  
XX  
DT 23-OCT-1998 (first entry)  
XX  
DE Streptococcus pneumoniae genome fragment SEQ ID NO:171.  
XX  
KM Streptococcus pneumoniae; S. pneumoniae; genome; diagnosis; assay;  
KM computer readable medium; vaccine; pharmaceutical composition; ds.  
XX  
OS Streptococcus pneumoniae.  
XX  
PN MO9818931-A2.  
XX  
PD 07-MAY-1998.  
XX  
PP 30-OCT-1997; 97MO-US019588.  
XX  
PR 31-OCT-1996; 96US-0029960P.  
XX  
PA (HUMA-) HUMAN GENOME SCI INC.  
XX  
PI Kunsch CA, Choi GH, Dillon PJ, Rosen CA, Barash SC, Fannon M;  
PI Dougherty BA;  
XX  
DR WPI; 1998-272225/24.  
XX  
PT Computer-readable medium with recorded Streptococcus pneumoniae  
PT polynucleotide sequences - useful in diagnostic kits and assays, and  
PT pharmaceutical compositions and vaccines for Streptococcus pneumoniae.  
XX  
PS Claim 1; Page 1085-1094; 1409bp; English.  
XX  
CC The present invention describes a computer readable medium which has the  
CC nucleotide sequences SEQ ID NO:1 to 391 (AAVS2134 to AAVS2524) recorded  
CC on it, or a representative fragment or a sequence at least 95% identical  
CC to SEQ ID NO: 1 to 391. The nucleotide sequences depicted in SEQ ID NO:1  
CC to 391 (AAVS2134 to AAVS2524) are genomic fragments from Streptococcus

CC pneumoniae. The present invention also describes an isolated nucleic acid  
CC molecule encoding a homologue of any of the fragments of the S.pneumoniae  
CC genome (SEQ ID NO:1 to 391) where the nucleic acid molecule is produced  
CC by a process comprising: (a) screening a genomic DNA library using as a  
CC probe a target sequence defined by any of the sequences in SEQ ID NO:1 to  
CC 391, identifying members of the library which contain sequences that  
CC hybridize to the target sequence and isolating the nucleic acid molecules  
CC from the members; or (b) isolating mRNA, DNA or cDNA produced from an  
CC organism, amplifying nucleic acid molecules whose nucleotide sequence is  
CC homologous to amplification primers derived from the fragment of the S.  
CC pneumoniae genome to prime the amplification and isolating the amplified  
CC sequences. The computer readable medium can be used in a computer-based  
CC system for identifying fragments of the S. pneumoniae genome of  
CC commercial importance, or expression modulating fragments of the S.  
CC pneumoniae genome. Products from the present invention can be used in  
CC diagnosis kits and assays, and pharmaceutical compositions and vaccines  
CC for S. pneumoniae  
XX  
SQ Sequence 14736 BP; 4665 A; 2568 C; 3255 G; 4247 T; 0 U; 1 Other;  
XX  
Query Match 28.8%; Score 17; DB 2; Length 14736;  
Best Local Similarity 100.0%; Pred. No. 33;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 42 TGAATCATCATTAACCT 58  
DB 13144 TGAATCATCATTAACCT 13128  
Search completed: December 22, 2004, 22:44:17  
Job time : 213.485 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 22, 2004, 22:08:48 / Search time 47.5204 Seconds

(without alignments)  
882.496 Million cell updates/sec

Title: US-09-898-616A-3

Perfect score: 59

Sequence: 1 cagctgaagaacacgtgtga.....cgtgaacatcataaactg 59

Scoring table: OLIGO NUC  
Gapop 60.0, Gapext 60.0

Searched: 824507 seqs, 355394441 residues

Word size: 0

Total number of hits satisfying chosen parameters: 1649014

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Listing first 45 summaries

Database: Issued Patents NA.\*  
1: /cgn2\_6/ptodata/1/ina/5A.COMB.seq.\*  
2: /cgn2\_6/ptodata/1/ina/5B.COMB.seq.\*  
3: /cgn2\_6/ptodata/1/ina/6A.COMB.seq.\*  
4: /cgn2\_6/ptodata/1/ina/6B.COMB.seq.\*  
5: /cgn2\_6/ptodata/1/ina/PTCUTS.COMB.seq.\*  
6: /cgn2\_6/ptodata/1/ina/backfileseq.seq.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	59	100.0	59	US-08-864-357F-8	Sequence 8, Appl
2	37	62.7	59	US-08-864-357F-11	Sequence 11, Appl
3	17	28.8	14736	US-08-961-527F-171	Sequence 171, Appl
4	16	27.1	60	US-08-864-357F-10	Sequence 10, Appl
5	16	27.1	603	US-09-252-991A-3153	Sequence 3153, App
6	16	27.1	933	US-09-252-991A-8153	Sequence 8153, App
7	16	27.1	2142	US-09-252-991A-8153	Sequence 8153, App
8	15	25.4	309	US-09-489-039A-1471	Sequence 1471, App
9	15	25.4	342	US-09-252-991A-3202	Sequence 3202, App
10	15	25.4	369	US-09-489-039A-1498	Sequence 1498, App
11	15	25.4	484	US-09-270-767-7800	Sequence 2802, App
12	15	25.4	484	US-09-270-767-7800	Sequence 2802, App
13	15	25.4	516	US-09-270-767-7800	Sequence 1781, App
14	15	25.4	516	US-09-270-767-7800	Sequence 1781, App
15	15	25.4	525	US-09-489-039A-1476	Sequence 1476, App
16	15	25.4	525	US-09-489-039A-1476	Sequence 1476, App
17	15	25.4	768	US-09-270-767-29574	Sequence 29574, A
18	15	25.4	807	US-09-248-796A-4201	Sequence 4201, App
19	15	25.4	987	US-09-252-991A-3011	Sequence 3011, App
20	15	25.4	1092	US-09-543-681A-3011	Sequence 3011, App
21	15	25.4	1296	US-09-270-767-13572	Sequence 13572, App
22	15	25.4	1334	US-08-629-643A-4	Sequence 4, Appl
23	15	25.4	1534	US-09-155-884-4	Sequence 4, Appl
24	15	25.4	1605	US-09-807-802A-16	Sequence 16, Appl
25	15	25.4	1632	US-09-252-991A-3113	Sequence 3113, App
26	15	25.4	1743	US-09-252-991A-2863	Sequence 2863, App
27	15	25.4	1800	US-09-807-802A-14	Sequence 14, Appl
	15	25.4	2211	US-09-807-802A-12	Sequence 12, Appl

28	15	25.4	3000	US-09-705-267A-18	Sequence 18, Appl
29	15	25.4	4718	US-09-807-802A-1	Sequence 1, Appl
30	15	25.4	6727	US-08-629-643A-5	Sequence 5, Appl
31	15	25.4	6727	US-08-629-643A-5	Sequence 5, Appl
32	15	25.4	6727	US-08-629-643A-5	Sequence 5, Appl
33	15	25.4	7447	US-10-216-870-11	Sequence 11, Appl
34	15	25.4	9347	US-10-204-708-35	Sequence 35, Appl
35	15	25.4	10480	US-09-732-615-13	Sequence 13, Appl
36	15	25.4	10480	US-10-273-051-13	Sequence 13, Appl
37	15	25.4	35100	US-08-770-379-18	Sequence 18, Appl
38	15	25.4	35100	US-08-757-669A-18	Sequence 18, Appl
39	15	25.4	35100	US-08-230-571A-18	Sequence 18, Appl
40	15	25.4	786431	US-09-751-389-3	Sequence 3, Appl
41	15	25.4	1830121	US-09-557-884-1	Sequence 1, Appl
42	15	25.4	1830121	US-09-643-990A-1	Sequence 1, Appl
43	15	25.4	1830121	US-10-329-960-1	Sequence 1, Appl
44	15	25.4	1830121	US-09-671-117-817	Sequence 817, App
45	14	23.7	133	PCT-US96-0561A-7	Sequence 7, Appl

## ALIGNMENTS

RESULT 1  
US-08-864-357F-8  
Sequence 8, Application US/08864357F  
Patent No. 6255281  
GENERAL INFORMATION:  
APPLICANT: Claragen, Inc. & NIH  
TITLE OF INVENTION: Use of Recombinant Human Uteroglobulin in Treatment of Inflammato  
FILE REFERENCE: 116142/2  
CURRENT APPLICATION NUMBER: US/08/864,357F  
CURRENT FILING DATE: 1997-05-28  
NUMBER OF SEQ ID NOS: 22  
SOFTWARE: Patent version 3.0  
SEQ ID NO: 8  
LENGTH: 59  
TYPE: DNA  
ORGANISM: artificial  
FEATURE:  
OTHER INFORMATION: primer sequence  
US-08-864-357F-8

Query Match 100.0%; Score 59; DB 3; Length 59;  
Best Local Similarity 100.0%; Pred. No. 5.5e-24;  
Matches 59; Conservativity 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGCTGAAGAAGACGTGTGACACCCGCGGAGAAACGGGTGAATCCATCAATAACTG 59  
DB 1 CAGCTGAAGAAGACGTGTGACACCCGCGGAGAAACGGGTGAATCCATCAATAACTG 59

RESULT 2  
US-08-864-357F-11/C  
Sequence 11, Application US/08864357F  
Patent No. 6255281  
GENERAL INFORMATION:  
APPLICANT: Claragen, Inc. & NIH  
TITLE OF INVENTION: Use of Recombinant Human Uteroglobulin in Treatment of Inflammato  
FILE REFERENCE: 116142/2  
CURRENT APPLICATION NUMBER: US/08/864,357F  
CURRENT FILING DATE: 1997-05-28  
NUMBER OF SEQ ID NOS: 22  
SOFTWARE: Patent version 3.0  
SEQ ID NO: 11  
LENGTH: 59  
TYPE: DNA  
ORGANISM: artificial  
FEATURE:  
OTHER INFORMATION: primer sequence  
US-08-864-357F-11

Query Match 62.7%; Score 37; DB 3; Length 59;  
Best Local Similarity 100.0%; Pred. No. 1.2e-11;  
Matches 37; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CY 1 CAGCTGAAGAACTGGTTGACCCCTGCCGAGAAC 37  
DB 37 CAGCTGAAGAACTGGTTGACCCCTGCCGAGAAC 1

## RESULT 3

US-08-961-527-171/C  
Sequence 171, Application US/08961527  
Patent No. 6420135  
GENERAL INFORMATION:  
APPLICANT: Charles Kunsch  
TITLE OF INVENTION: Streptococcus pneumoniae Polynucleotides and Sequences  
NUMBER OF SEQUENCES: 391  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Human Genome Sciences, Inc.  
STREET: 9410 Key West Avenue  
CITY: Rockville  
STATE: Maryland  
COUNTRY: USA  
ZIP: 20850  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette, 3.50 inch, 1.4MB storage  
OPERATING SYSTEM: MSDOS version 6.2  
SOFTWARE: ASCII text  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/961,527  
FILING DATE:  
CLASSIFICATION: 424  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER:  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: Brookes, A. Anders  
REGISTRATION NUMBER: 36,373  
REFERENCE/DOCKET NUMBER: PB340P1  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (301) 309-8504  
TELEFAX: (301) 309-8512  
INFORMATION FOR SEQ ID NO: 171:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 14736 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: double  
TOPOLOGY: linear  
US-08-961-527-171

Query Match 28.8%; Score 17; DB 4; Length 14736;  
Best Local Similarity 100.0%; Pred. No. 2.7;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CY 42 TGAATCATCATTAAC 58  
DB 13144 TGAATCATCATTAAC 13128

RESULT 4  
US-08-864-357F-10/C  
Sequence 10, Application US/08864357F  
Patent No. 6255281  
GENERAL INFORMATION:  
APPLICANT: Clargen, Inc. & NIH  
TITLE OF INVENTION: Use of Recombinant Human Uteroglobulin in Treatment of Inflammato

FILE REFERENCE: 1.6142/2  
CURRENT APPLICATION NUMBER: US/08/864,357F  
CURRENT FILING DATE: 1997-05-28  
NUMBER OF SEQ ID NOS: 22

SOFTWARE: PatentIn version 3.0

SEQ ID NO 10  
LENGTH: 60  
TYPE: DNA  
ORGANISM: artificial  
FEATURE:  
OTHER INFORMATION: primer sequence  
US-08-864-357F-10

Query Match 27.1%; Score 16; DB 3; Length 60;  
Best Local Similarity 100.0%; Pred. No. 7.6;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CY 38 CCGGTGAATCATCAT 53  
DB 60 CCGGTGAATCATCAT 45

## RESULT 5

US-09-252-991A-3153/C  
Sequence 3153, Application US/09252991A  
Patent No. 6551795  
GENERAL INFORMATION:  
APPLICANT: Marc J. Rubenfield et al.  
TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS  
FILE REFERENCE: 107196.136  
CURRENT APPLICATION NUMBER: US/09/252,991A  
CURRENT FILING DATE: 1999-02-18  
PRIOR APPLICATION NUMBER: US 60/074,788  
PRIOR FILING DATE: 1998-02-18  
PRIOR APPLICATION NUMBER: US 60/094,190  
PRIOR FILING DATE: 1998-07-27  
NUMBER OF SEQ ID NOS: 33142  
SEQ ID NO 3153  
LENGTH: 603  
TYPE: DNA  
ORGANISM: Pseudomonas aeruginosa  
US-09-252-991A-3153

Query Match 27.1%; Score 16; DB 4; Length 603;  
Best Local Similarity 100.0%; Pred. No. 8.4;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CY 24 CCTGCCGCGAAGACCG 39  
DB 465 CCTGCCGCGAAGACCG 450

## RESULT 6

US-09-252-991A-810  
Sequence 810, Application US/09252991A  
Patent No. 6551795  
GENERAL INFORMATION:  
APPLICANT: Marc J. Rubenfield et al.  
TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS  
FILE REFERENCE: 107196.136  
CURRENT APPLICATION NUMBER: US/09/252,991A  
CURRENT FILING DATE: 1999-02-18  
PRIOR APPLICATION NUMBER: US 60/074,788  
PRIOR FILING DATE: 1998-02-18  
PRIOR APPLICATION NUMBER: US 60/094,190  
PRIOR FILING DATE: 1998-07-27  
NUMBER OF SEQ ID NOS: 33142  
SEQ ID NO 810  
LENGTH: 933  
TYPE: DNA  
ORGANISM: Pseudomonas aeruginosa  
US-09-252-991A-810

Query Match 27.1%; Score 16; DB 4; Length 933;  
Best Local Similarity 100.0%; Pred. No. 8.5;

Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 18 TCACACCTGGCGGAG 33  
 |||||  
 Db 564 TCACACCTGGCGGAG 579

RESULT 7  
 US-09-252-991A-869/c  
 ; Sequence 869, Application US/09252991A  
 ; Patent No. 6551795  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Marc J. Rubenfield et al.  
 ; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS  
 ; FILE REFERENCE: 107196.136  
 ; CURRENT APPLICATION NUMBER: US/09/252,991A  
 ; CURRENT FILING DATE: 1999-02-18  
 ; PRIOR APPLICATION NUMBER: US 60/074,788  
 ; PRIOR FILING DATE: 1998-02-18  
 ; PRIOR APPLICATION NUMBER: US 60/094,190  
 ; PRIOR FILING DATE: 1998-07-27  
 ; NUMBER OF SEQ ID NOS: 33142  
 ; SEQ ID NO 869  
 ; LENGTH: 2142  
 ; TYPE: DNA  
 ; ORGANISM: Pseudomonas aeruginosa  
 US-09-252-991A-869

Query Match  
 Best Local Similarity 100.0%; Pred. No. 8.9;  
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 18 TCACACCTGGCGGAG 33  
 |||||  
 Db 1639 TCACACCTGGCGGAG 1624

RESULT 8  
 US-09-489-039A-1471  
 ; Sequence 1471, Application US/09489039A  
 ; Patent No. 6610836  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Gary Breton et al.  
 ; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO KLEBSIELLA  
 ; FILE REFERENCE: 2709.2004001  
 ; CURRENT APPLICATION NUMBER: US/09/489,039A  
 ; CURRENT FILING DATE: 2000-01-27  
 ; PRIOR APPLICATION NUMBER: US 60/117,747  
 ; PRIOR FILING DATE: 1999-01-29  
 ; NUMBER OF SEQ ID NOS: 14342  
 ; SEQ ID NO 1471  
 ; LENGTH: 309  
 ; TYPE: DNA  
 ; ORGANISM: Klebsiella pneumoniae  
 US-09-489-039A-1471

Query Match  
 Best Local Similarity 100.0%; Pred. No. 30;  
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 3 GCTGAAGAACTGCT 17  
 |||||  
 Db 237 GCTGAAGAACTGCT 251

RESULT 9  
 US-09-252-991A-3202  
 ; Sequence 3202, Application US/09252991A  
 ; Patent No. 6551795  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Marc J. Rubenfield et al.

;; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS  
 ;; FILE REFERENCE: 107196.136  
 ;; CURRENT APPLICATION NUMBER: US/09/252,991A  
 ;; CURRENT FILING DATE: 1999-02-18  
 ;; PRIOR APPLICATION NUMBER: US 60/074,788  
 ;; PRIOR FILING DATE: 1998-02-18  
 ;; PRIOR APPLICATION NUMBER: US 60/094,190  
 ;; PRIOR FILING DATE: 1998-07-27  
 ;; NUMBER OF SEQ ID NOS: 33142  
 ;; SEQ ID NO 3202  
 ;; LENGTH: 342  
 ;; TYPE: DNA  
 ;; ORGANISM: Pseudomonas aeruginosa  
 US-09-252-991A-3202

Query Match  
 Best Local Similarity 100.0%; Pred. No. 30;  
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 21 CACCTGGCGGAGAA 35  
 |||||  
 Db 2 CACCTGGCGGAGAA 16

RESULT 10  
 US-09-489-039A-1498/c  
 ; Sequence 1498, Application US/09489039A  
 ; Patent No. 6610836  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Gary Breton et al.  
 ; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO KLEBSIELLA  
 ; FILE REFERENCE: 2709.2004001  
 ; CURRENT APPLICATION NUMBER: US/09/489,039A  
 ; CURRENT FILING DATE: 2000-01-27  
 ; PRIOR APPLICATION NUMBER: US 60/117,747  
 ; PRIOR FILING DATE: 1999-01-29  
 ; NUMBER OF SEQ ID NOS: 14342  
 ; SEQ ID NO 1498  
 ; LENGTH: 369  
 ; TYPE: DNA  
 ; ORGANISM: Klebsiella pneumoniae  
 US-09-489-039A-1498

Query Match  
 Best Local Similarity 100.0%; Pred. No. 30;  
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 3 GCTGAAGAACTGCT 17  
 |||||  
 Db 124 GCTGAAGAACTGCT 110

RESULT 11  
 US-09-270-767-7800/c  
 ; Sequence 7800, Application US/09270767  
 ; Patent No. 6703491  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Homburger et al.  
 ; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster  
 ; FILE REFERENCE: File Reference: 7326-094  
 ; CURRENT APPLICATION NUMBER: US/09/270,767  
 ; CURRENT FILING DATE: 1999-03-17  
 ; NUMBER OF SEQ ID NOS: 62517  
 ; SOFTWARE: Patent In Ver. 2.0  
 ; SEQ ID NO 7800  
 ; LENGTH: 484  
 ; TYPE: DNA  
 ; ORGANISM: Drosophila melanogaster  
 US-09-270-767-7800

Query Match  
 Best Local Similarity 100.0%; Pred. No. 30;  
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 3 GCTGAAGAACTGCT 17  
 |||||  
 Db 124 GCTGAAGAACTGCT 110

Best Local Similarity 100.0%; Pred. No. 30;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CAGCTGAAGAACTG 15  
Db 366 CAGCTGAAGAACTG 352

RESULT 12  
US-09-270-767-23082/c  
Sequence 23082, Application US/09270767  
Patent No. 6703491  
GENERAL INFORMATION:  
APPLICANT: Homburger et al.  
TITLE OF INVENTION: Nucleic acids and proteins of *Drosophila melanogaster*  
FILE REFERENCE: File Reference: 7326-094  
CURRENT FILING DATE: 1999-03-17  
NUMBER OF SEQ ID NOS: 62517  
SOFTWARE: Patentin Ver. 2.0  
SEQ ID NO 23082  
LENGTH: 484  
TYPE: DNA  
ORGANISM: *Drosophila melanogaster*  
US-09-270-767-23082

Query Match 25.4%; Score 15; DB 4; Length 484;  
Best Local Similarity 100.0%; Pred. No. 30;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGCTGAAGAACTG 15  
Db 366 CAGCTGAAGAACTG 352

RESULT 13  
US-09-270-767-1781/c  
Sequence 1781, Application US/09270767  
Patent No. 6703491  
GENERAL INFORMATION:  
APPLICANT: Homburger et al.  
TITLE OF INVENTION: Nucleic acids and proteins of *Drosophila melanogaster*  
FILE REFERENCE: File Reference: 7326-094  
CURRENT FILING DATE: 1999-03-17  
NUMBER OF SEQ ID NOS: 62517  
SOFTWARE: Patentin Ver. 2.0  
SEQ ID NO 1781  
LENGTH: 516  
TYPE: DNA  
ORGANISM: *Drosophila melanogaster*  
US-09-270-767-1781

Query Match 25.4%; Score 15; DB 4; Length 516;  
Best Local Similarity 100.0%; Pred. No. 30;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGCTGAAGAACTG 15  
Db 432 CAGCTGAAGAACTG 418

RESULT 14  
US-09-270-767-17063/c  
Sequence 17063, Application US/09270767  
Patent No. 6703491  
GENERAL INFORMATION:  
APPLICANT: Homburger et al.  
TITLE OF INVENTION: Nucleic acids and proteins of *Drosophila melanogaster*  
FILE REFERENCE: File Reference: 7326-094  
CURRENT FILING DATE: 1999-03-17  
NUMBER OF SEQ ID NOS: 62517

SOFTWARE: Patentin Ver. 2.0  
SEQ ID NO 17063  
LENGTH: 516  
TYPE: DNA  
ORGANISM: *Drosophila melanogaster*  
US-09-270-767-17063

Query Match 25.4%; Score 15; DB 4; Length 516;  
Best Local Similarity 100.0%; Pred. No. 30;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGCTGAAGAACTG 15  
Db 432 CAGCTGAAGAACTG 418

RESULT 15  
US-09-489-039A-1476/c  
Sequence 1476, Application US/09489039A  
Patent No. 6610836  
GENERAL INFORMATION:  
APPLICANT: Gary Bretton et al.  
TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO *KLEBSIELLA*  
FILE REFERENCE: 2703.2004001  
CURRENT FILING DATE: 2000-01-27  
PRIOR APPLICATION NUMBER: US 60/117,747  
PRIOR FILING DATE: 1999-01-29  
NUMBER OF SEQ ID NOS: 14342  
SEQ ID NO 1476  
LENGTH: 525  
TYPE: DNA  
ORGANISM: *Klebsiella pneumoniae*  
US-09-489-039A-1476

Query Match 25.4%; Score 15; DB 4; Length 525;  
Best Local Similarity 100.0%; Pred. No. 30;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 GCTGAAGAACTGCT 17  
Db 444 GCTGAAGAACTGCT 430

Search completed: December 23, 2004, 01:33:42  
Job time : 53.5204 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 22, 2004, 23:36:53 ; Search time 827.066 Seconds  
(without alignments)  
397.214 Million cell updates/sec

Title: US-09-898-616A-3

Perfect score: 59  
1 cagctgaagaactggttga.....cgtcaatcattatcattg 59

Scoring table: OLIGO NUC  
Gapop 60.0, Gapext 60.0

Searched: 4105333 seqs, 2784095677 residues

Word size: 0

Total number of hits satisfying chosen parameters: 8210666

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Listing first 45 summaries

Database:

Published Applications NA:  
1: /cgn2\_6/ptodata/1/pubpna/US07\_PUBCOMB.seq:\*  
2: /cgn2\_6/ptodata/1/pubpna/PCT\_NEW\_PUB.seq:\*  
3: /cgn2\_6/ptodata/1/pubpna/US06\_NEW\_PUB.seq:\*  
4: /cgn2\_6/ptodata/1/pubpna/US06\_PUBCOMB.seq:\*  
5: /cgn2\_6/ptodata/1/pubpna/US07\_NEW\_PUB.seq:\*  
6: /cgn2\_6/ptodata/1/pubpna/PCUS\_PUBCOMB.seq:\*  
7: /cgn2\_6/ptodata/1/pubpna/US08\_NEW\_PUB.seq:\*  
8: /cgn2\_6/ptodata/1/pubpna/US08\_PUBCOMB.seq:\*  
9: /cgn2\_6/ptodata/1/pubpna/US09\_PUBCOMB.seq:\*  
10: /cgn2\_6/ptodata/1/pubpna/US09B\_PUBCOMB.seq:\*  
11: /cgn2\_6/ptodata/1/pubpna/US09C\_PUBCOMB.seq:\*  
12: /cgn2\_6/ptodata/1/pubpna/US09\_NEW\_PUB.seq:\*  
13: /cgn2\_6/ptodata/1/pubpna/US10\_PUBCOMB.seq:\*  
14: /cgn2\_6/ptodata/1/pubpna/US10B\_PUBCOMB.seq:\*  
15: /cgn2\_6/ptodata/1/pubpna/US10C\_PUBCOMB.seq:\*  
16: /cgn2\_6/ptodata/1/pubpna/US10D\_PUBCOMB.seq:\*  
17: /cgn2\_6/ptodata/1/pubpna/US10E\_PUBCOMB.seq:\*  
18: /cgn2\_6/ptodata/1/pubpna/US10\_NEW\_PUB.seq:\*  
19: /cgn2\_6/ptodata/1/pubpna/US11\_NEW\_PUB.seq:\*  
20: /cgn2\_6/ptodata/1/pubpna/US60\_NEW\_PUB.seq:\*  
21: /cgn2\_6/ptodata/1/pubpna/US60\_PUBCOMB.seq:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysts of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length DB	ID	Description
1	59	100.0	59	9	US-09-861-688-8
2	59	100.0	59	9	US-09-898-616A-3
3	59	100.0	59	15	US-10-187-498A-3
4	59	100.0	59	16	US-10-647-371-7
5	37	62.7	59	9	US-09-861-688-11
6	37	62.7	59	10	US-09-898-616A-6
7	37	62.7	59	15	US-10-187-498A-6
8	37	62.7	59	16	US-10-647-371-10
9	19	32.2	757	17	US-10-437-963-89235
10	18	30.5	1490	17	US-10-437-963-89235
11	18	30.5	1152	17	US-10-437-963-89235
12	18	30.5	2004	9	US-09-867-576-235

13	18	30.5	2134	17	US-10-437-963-74313	Sequence 74313, A
C 14	17	28.8	195	9	US-09-974-300-3436	Sequence 3436, Ap
C 15	17	28.8	520	13	US-10-027-632-51350	Sequence 51350, A
C 16	17	28.8	520	15	US-10-027-632-51350	Sequence 51350, A
C 17	17	28.8	549	13	US-10-027-632-71225	Sequence 71225, A
C 18	17	28.8	549	13	US-10-027-632-71225	Sequence 71225, A
C 19	17	28.8	549	15	US-10-027-632-71225	Sequence 71225, A
C 20	17	28.8	549	15	US-10-027-632-71225	Sequence 71225, A
C 21	17	28.8	868	13	US-10-027-632-72285	Sequence 72285, A
C 22	17	28.8	868	15	US-10-027-632-72285	Sequence 72285, A
C 23	17	28.8	993	15	US-10-146-742-317	Sequence 317, App
C 24	17	28.8	993	16	US-10-241-742-317	Sequence 317, App
C 25	17	28.8	993	16	US-10-440-503-317	Sequence 317, App
C 26	17	28.8	993	16	US-10-461-925-317	Sequence 317, App
C 27	17	28.8	993	16	US-10-461-925-317	Sequence 317, App
C 28	17	28.8	1000	16	US-10-425-114-16587	Sequence 16587, A
C 29	17	28.8	1130	18	US-10-425-115-153378	Sequence 153378, A
C 30	17	28.8	14736	8	US-08-961-527-171	Sequence 171, App
C 31	17	28.8	14736	16	US-10-158-844-171	Sequence 171, App
C 32	17	28.8	59475	17	US-10-332-686-166	Sequence 166, App
C 33	16	27.1	60	9	US-09-861-688-10	Sequence 10, Appl
C 34	16	27.1	60	10	US-09-898-616A-5	Sequence 5, Appl
C 35	16	27.1	60	15	US-10-187-498A-5	Sequence 5, Appl
C 36	16	27.1	60	16	US-10-647-371-9	Sequence 9, Appl
C 37	16	27.1	311	10	US-09-764-891-1420	Sequence 1420, Ap
C 38	16	27.1	373	16	US-10-424-599-11255	Sequence 11255, A
C 39	16	27.1	455	9	US-09-983-965-5306	Sequence 5306, Ap
C 40	16	27.1	457	18	US-10-425-115-115741	Sequence 115741, A
C 41	16	27.1	547	16	US-10-424-599-35982	Sequence 35982, A
C 42	16	27.1	639	18	US-10-320-797-2026	Sequence 2026, Ap
C 43	16	27.1	659	16	US-10-653-047-581	Sequence 581, App
C 44	16	27.1	667	13	US-10-005-057A-34	Sequence 34, Appl
C 45	16	27.1	667	16	US-10-675-072A-37	Sequence 37, Appl

#### ALIGNMENTS

RESULT 1  
US-09-861-688-8  
Sequence 8, Appl  
Patent No. US20020173460A1  
GENERAL INFORMATION:  
APPLICANT: Clargen, Inc. & NIH  
TITLE OF INVENTION: Use of Recombinant Human Uteroglobin in Treatment of  
TITLE OF INVENTION: Inflammatory and  
FILE REFERENCE: 116142/2  
CURRENT APPLICATION NUMBER: US/09/861,688  
CURRENT FILING DATE: 2001-05-21  
PRIOR APPLICATION NUMBER: 08/864,357  
NUMBER OF SEQ ID NOS: 22  
SOFTWARE: Patent version 3.0  
SEQ ID NO 8  
LENGTH: 59  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: primer sequence  
US-09-861-688-8

Query Match 100.0%; Score 59; DB 9; Length 59;  
Best Local Similarity 100.0%; Pred. No. 1.7e-23;  
Matches 59; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy 1 CAGCTGAAGAAGTGTGACACCCCTCCAGAAACCGGTGATCATCAATCAATG 59  
Db 1 CAGCTGAAGAAGTGTGACACCCCTCCAGAAACCGGTGATCATCAATCAATG 59

RESULT 2  
US-09-898-616A-3

```
Sequence 3, Application US/09898616A
Publication No. US20030109429A1
GENERAL INFORMATION:
APPLICANT: Clargen Inc.
APPLICANT: Pilon, Aprile L
APPLICANT: Welch, Richard W
TITLE OF INVENTION: Method for the Production of Purified rhug for the Treatment of
FILE REFERENCE: 116142/00170
CURRENT APPLICATION NUMBER: US/09/898,616A
PRIOR FILING DATE: 2002-10-15
PRIOR APPLICATION NUMBER: US 08/864,357
NUMBER OF SEQ ID NOS: 10
SOFTWARE: Patentin version 3.1
SEQ ID NO 3
LENGTH: 59
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte
FEATURE:
OTHER INFORMATION: d sequence maximized for expression in E. coli.
NAME/KEY: misc feature
OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte
US-09-898-616A-3

Query Match 100.0%; Score 59; DB 10; Length 59;
Best Local Similarity 100.0%; Pred. No. 1.7e-23;
Matches 59; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy 1 CAGCTGAAGAACTGGTTGACACCCCTGCCGAGAAACCGCGTGAATCATCATTAACCTG 59
Db 1 CAGCTGAAGAACTGGTTGACACCCCTGCCGAGAAACCGCGTGAATCATCATTAACCTG 59

RESULT 3
US-10-187-498A-3
Sequence 3, Application US/10187498A
Publication No. US20030207925A1
GENERAL INFORMATION:
APPLICANT: Clargen Inc.
APPLICANT: Pilon, Aprile L
APPLICANT: Welch, Richard W
TITLE OF INVENTION: Method for the Production of Purified rhug for the Treatment of
FILE REFERENCE: 116142/00260
CURRENT APPLICATION NUMBER: US/10/187,498A
PRIOR FILING DATE: 2001-07-02
PRIOR APPLICATION NUMBER: US 08/864,357
NUMBER OF SEQ ID NOS: 10
SOFTWARE: Patentin version 3.1
SEQ ID NO 3
LENGTH: 59
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte
FEATURE:
OTHER INFORMATION: d sequence maximized for expression in E. coli.
NAME/KEY: misc feature
OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte
US-10-187-498A-3

Query Match 100.0%; Score 59; DB 15; Length 59;
Best Local Similarity 100.0%; Pred. No. 1.7e-23;
Matches 59; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy 1 CAGCTGAAGAACTGGTTGACACCCCTGCCGAGAAACCGCGTGAATCATCATTAACCTG 59
Db 1 CAGCTGAAGAACTGGTTGACACCCCTGCCGAGAAACCGCGTGAATCATCATTAACCTG 59
```

```
Db 1 CAGCTGAAGAACTGGTTGACACCCCTGCCGAGAAACCGCGTGAATCATCATTAACCTG 59

RESULT 4
US-10-647-371-7
Sequence 7, Application US/10647371
Publication No. US20040047857A1
GENERAL INFORMATION:
APPLICANT: Clargen, Inc. & NIH
TITLE OF INVENTION: Use of Recombinant Human Uteroglobulin in Treatment of Inflammatory
FILE REFERENCE: 116142-85
CURRENT APPLICATION NUMBER: US/10/647,371
PRIOR FILING DATE: 2003-08-25
PRIOR APPLICATION NUMBER: 09/549,926
NUMBER OF SEQ ID NOS: 12
SOFTWARE: Patentin version 3.2
SEQ ID NO 7
LENGTH: 59
TYPE: DNA
ORGANISM: Artificial
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: primer sequence
US-10-647-371-7

Query Match 100.0%; Score 59; DB 15; Length 59;
Best Local Similarity 100.0%; Pred. No. 1.7e-23;
Matches 59; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy 1 CAGCTGAAGAACTGGTTGACACCCCTGCCGAGAAACCGCGTGAATCATCATTAACCTG 59
Db 1 CAGCTGAAGAACTGGTTGACACCCCTGCCGAGAAACCGCGTGAATCATCATTAACCTG 59

RESULT 5
US-09-861-688-11/c
Sequence 11, Application US/09861688
Patent No. US20020173460A1
GENERAL INFORMATION:
APPLICANT: Clargen, Inc. & NIH
TITLE OF INVENTION: Use of Recombinant Human Uteroglobulin in Treatment of
FILE REFERENCE: 116142/2
CURRENT APPLICATION NUMBER: US/09/861,688
PRIOR FILING DATE: 2001-05-21
PRIOR APPLICATION NUMBER: 08/864,357
NUMBER OF SEQ ID NOS: 22
SOFTWARE: Patentin version 3.0
SEQ ID NO 11
LENGTH: 59
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: primer sequence
US-09-861-688-11

Query Match 62.7%; Score 37; DB 9; Length 59;
Best Local Similarity 100.0%; Pred. No. 5.4e-11;
Matches 37; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy 1 CAGCTGAAGAACTGGTTGACACCCCTGCCGAGAAAC 37
Db 37 CAGCTGAAGAACTGGTTGACACCCCTGCCGAGAAAC 1

RESULT 6
US-09-898-616A-6/c
Sequence 6, Application US/09898616A
Publication No. US20030109429A1
GENERAL INFORMATION:
```



```
APPLICANT: Clargen Inc.
APPLICANT: Pilon, April L
APPLICANT: Welch, Richard W
TITLE OF INVENTION: Method for the Production of Purified rhug for the Treatment of
FILE REFERENCE: 116142/00170
CURRENT APPLICATION NUMBER: US/09/898,616A
CURRENT FILING DATE: 2002-10-15
PRIOR APPLICATION NUMBER: US 08/864,357
PRIOR FILING DATE: 1997-05-28
NUMBER OF SEQ ID NOS: 10
SOFTWARE: PatentIn version 3.1
SEQ ID NO 6
LENGTH: 59
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte
FEATURE:
OTHER INFORMATION: d sequence maximized for expression in E. coli.
NAME/KEY: misc.feature
OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte
OTHER INFORMATION: d sequence maximized for expression in E. coli.
US-09-898-616A-6
```

```
Query Match 62.7%; Score 37; DB 10; Length 59;
Best Local Similarity 100.0%; Pred. No. 5,4e-11;
Matches 37; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 CAGCTGAAGAAACTGTTGACACCCCTGCGCAGAAAC 37
DB 37 CAGCTGAAGAAACTGTTGACACCCCTGCGCAGAAAC 1
```

```
RESULT 7
US-10-187-498A-6/c
Sequence 6, Application US/10187498A
Publication No. US2003020795A1
GENERAL INFORMATION:
APPLICANT: Clargen Inc.
APPLICANT: Pilon, April L
APPLICANT: Welch, Richard W
TITLE OF INVENTION: Method for the Production of Purified rhug for the Treatment of
FILE REFERENCE: 116142/00260
CURRENT APPLICATION NUMBER: US/10/187,498A
CURRENT FILING DATE: 2001-07-02
PRIOR APPLICATION NUMBER: US 08/864,357
PRIOR FILING DATE: 1997-05-28
NUMBER OF SEQ ID NOS: 10
SOFTWARE: PatentIn version 3.1
SEQ ID NO 6
LENGTH: 59
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte
FEATURE:
OTHER INFORMATION: d sequence maximized for expression in E. coli.
NAME/KEY: misc.feature
OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte
OTHER INFORMATION: d sequence maximized for expression in E. coli.
US-10-187-498A-6
```

```
Query Match 62.7%; Score 37; DB 15; Length 59;
Best Local Similarity 100.0%; Pred. No. 5,4e-11;
Matches 37; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 CAGCTGAAGAAACTGTTGACACCCCTGCGCAGAAAC 37
DB 37 CAGCTGAAGAAACTGTTGACACCCCTGCGCAGAAAC 1
```

```
RESULT 8
US-10-647-371-10/c
Sequence 10, Application US/10647371
Publication No. US20040047857A1
GENERAL INFORMATION:
APPLICANT: Clargen, Inc. & NIH
TITLE OF INVENTION: Use of Recombinant Human Uteroglobulin in Treatment of Inflammatory
FILE REFERENCE: 116142-85
CURRENT APPLICATION NUMBER: US/10/647,371
CURRENT FILING DATE: 2003-08-25
PRIOR APPLICATION NUMBER: 09/549,926
PRIOR FILING DATE: 2000-04-14
NUMBER OF SEQ ID NOS: 12
SOFTWARE: PatentIn version 3.2
SEQ ID NO 10
LENGTH: 59
TYPE: DNA
ORGANISM: Artificial
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: primer sequence
US-10-647-371-10
```

```
Query Match 62.7%; Score 37; DB 16; Length 59;
Best Local Similarity 100.0%; Pred. No. 5,4e-11;
Matches 37; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 CAGCTGAAGAAACTGTTGACACCCCTGCGCAGAAAC 37
DB 37 CAGCTGAAGAAACTGTTGACACCCCTGCGCAGAAAC 1
```

```
RESULT 9
US-10-437-963-89235
Sequence 89235, Application US/10437963
Publication No. US20040123343A1
GENERAL INFORMATION:
APPLICANT: La Rosa, Thomas J.
APPLICANT: Kovalic, David K.
APPLICANT: Zhou, Yihua
APPLICANT: Cao, Yongwei
APPLICANT: Wu, Wei
APPLICANT: Boukharov, Andrey A.
APPLICANT: Barbazuk, Brad
APPLICANT: Li, Ping
TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
FILE REFERENCE: 38-21(53221)B
CURRENT APPLICATION NUMBER: US/10/437,963
CURRENT FILING DATE: 2003-05-14
NUMBER OF SEQ ID NOS: 204966
SEQ ID NO 89235
LENGTH: 757
TYPE: DNA
ORGANISM: Oryza sativa
FEATURE:
OTHER INFORMATION: Clone ID: PAT_MRT4530_88009C.1
US-10-437-963-89235
```

```
Query Match 32.2%; Score 19; DB 17; Length 757;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2 AGCTGAAGAAACTGTTGA 20
DB 207 AGCTGAAGAAACTGTTGA 225
```

```
RESULT 10
US-10-437-963-65306/c
Sequence 65306, Application US/10437963
Publication No. US20040123343A1
GENERAL INFORMATION:
```

APPLICANT: La Rosa, Thomas J.  
APPLICANT: Kovalic, David K.  
APPLICANT: Zhou, Yinhua  
APPLICANT: Cao, Yongwei  
APPLICANT: Wu, Wei  
APPLICANT: Boukharov, Andrey A.  
APPLICANT: Barbazuk, Brad  
APPLICANT: Li, Ping  
TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With  
FILE REFERENCE: 38-21(53221)B  
CURRENT APPLICATION NUMBER: US/10/437,963  
CURRENT FILING DATE: 2003-05-14  
NUMBER OF SEQ ID NOS: 204966  
SEQ ID NO 65306  
LENGTH: 490  
TYPE: DNA  
ORGANISM: Oryza sativa  
FEATURE:  
OTHER INFORMATION: Clone ID: PAT\_MRT4530\_66367C.1  
US-10-437-963-65306

Query Match 30.5%; Score 18; DB 17; Length 490;  
Best Local Similarity 100.0%; Pred. No. 3.8;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 CTGGTGCACACCTGCGC 30  
DB 335 CTGGTGCACACCTGCGC 318

RESULT 11  
US-10-437-963-65308/c  
Sequence 65308, Application US/10437963  
Publication No. US20040123343A1  
GENERAL INFORMATION:  
APPLICANT: La Rosa, Thomas J.  
APPLICANT: Kovalic, David K.  
APPLICANT: Zhou, Yinhua  
APPLICANT: Cao, Yongwei  
APPLICANT: Wu, Wei  
APPLICANT: Boukharov, Andrey A.  
APPLICANT: Barbazuk, Brad  
APPLICANT: Li, Ping  
TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With  
FILE REFERENCE: 38-21(53221)B  
CURRENT APPLICATION NUMBER: US/10/437,963  
CURRENT FILING DATE: 2003-05-14  
NUMBER OF SEQ ID NOS: 204966  
SEQ ID NO 65308  
LENGTH: 1152  
TYPE: DNA  
ORGANISM: Oryza sativa  
FEATURE:  
OTHER INFORMATION: Clone ID: PAT\_MRT4530\_66369C.1  
US-10-437-963-65308

Query Match 30.5%; Score 18; DB 17; Length 1152;  
Best Local Similarity 100.0%; Pred. No. 4;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 CTGGTGCACACCTGCGC 30  
DB 668 CTGGTGCACACCTGCGC 651

RESULT 12  
US-09-887-576-235/c  
Sequence 235, Application US/09887576  
Patent No. US20020144047A1  
GENERAL INFORMATION:  
APPLICANT: Budworth, P.

APPLICANT: Brown, D.  
APPLICANT: Chang, H.  
APPLICANT: Zhu, T.  
APPLICANT: Han, B.  
APPLICANT: Wang, X.  
APPLICANT: Cooper, Bret  
TITLE OF INVENTION: Promoters for regulation of plant expression  
FILE REFERENCE: 1360.001US1  
CURRENT APPLICATION NUMBER: US/09/887,576  
CURRENT FILING DATE: 2001-06-25  
PRIOR APPLICATION NUMBER: US 60/213,848  
PRIOR FILING DATE: 2000-06-23  
PRIOR APPLICATION NUMBER: US 60/214,087  
PRIOR FILING DATE: 2000-06-23  
PRIOR APPLICATION NUMBER: US 60/258,692  
PRIOR FILING DATE: 2000-12-29  
NUMBER OF SEQ ID NOS: 875  
SOFTWARE: FastSeq for Windows Version 4.0  
SEQ ID NO 235  
LENGTH: 2004  
TYPE: DNA  
ORGANISM: Arabidopsis thaliana  
US-09-887-576-235

Query Match 30.5%; Score 18; DB 9; Length 2004;  
Best Local Similarity 100.0%; Pred. No. 4.1;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 30 GCAGAAACCGCGTGAATC 47  
DB 389 GCAGAAACCGCGTGAATC 372

RESULT 13  
US-10-437-963-74313  
Sequence 74313, Application US/10437963  
Publication No. US20040123343A1  
GENERAL INFORMATION:  
APPLICANT: La Rosa, Thomas J.  
APPLICANT: Kovalic, David K.  
APPLICANT: Zhou, Yinhua  
APPLICANT: Cao, Yongwei  
APPLICANT: Wu, Wei  
APPLICANT: Boukharov, Andrey A.  
APPLICANT: Barbazuk, Brad  
APPLICANT: Li, Ping  
TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With  
FILE REFERENCE: 38-21(53221)B  
CURRENT APPLICATION NUMBER: US/10/437,963  
CURRENT FILING DATE: 2003-05-14  
NUMBER OF SEQ ID NOS: 204966  
SEQ ID NO 74313  
LENGTH: 2134  
TYPE: DNA  
ORGANISM: Oryza sativa  
FEATURE:  
OTHER INFORMATION: Clone ID: PAT\_MRT4530\_74510C.1  
US-10-437-963-74313

Query Match 30.5%; Score 18; DB 17; Length 2134;  
Best Local Similarity 100.0%; Pred. No. 4.1;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 GCTGAAGAACTGTTGA 20  
DB 1728 GCTGAAGAACTGTTGA 1745

RESULT 14  
US-09-974-300-3436/c  
Sequence 3436, Application US/09974300  
Patent No. US20020146721A1

```

: GENERAL INFORMATION:
: APPLICANT: Bekra, Randy M.
: APPLICANT: Clausen, Ib Groth
: TITLE OF INVENTION: Methods For Monitoring Multiple Gene
: TITLE OF INVENTION: Expression
: FILE REFERENCE: 10085, 500-US
: CURRENT APPLICATION NUMBER: US/09/974,300
: PRIOR FILING DATE: 2001-10-05
: PRIOR APPLICATION NUMBER: 09/680,558
: PRIOR FILING DATE: 2000-10-06
: PRIOR APPLICATION NUMBER: 60/279,526
: PRIOR FILING DATE: 2001-03-27
: NUMBER OF SEQ ID NOS: 8481
: SOFTWARE: PasteSeq for Windows Version 4.0
: SEQ ID NO 3496
: LENGTH: 195
: TYPE: DNA
: ORGANISM: Bacillus licheniformis
: US-09-974-300-3436

```

Query Match	28.8%;	Score 17;	DB 9;	Length 195;
Best Local Similarity	100.0%;	Pred. No. 13;		
Matches 17; Conservative	0;	Mismatches	0;	Indels 0; Gaps 0;

QY	21	CACCCTGCCGCAAGAAC	37
D5	102	CACCTGTCCGCAGAATC	86

```

RESULT 15
US-10-027-632-51350/c
: Sequence 51350, Application US/10027632.
: Publication No. US20020195371A1
GENERAL INFORMATION:
APPLICANT: Wang, David G.
TITLE OF INVENTION: Identification and Mapping of Single Nucleotide
: Polymorphisms in the Human Genome
FILE REFERENCE: 108627.129
CURRENT APPLICATION NUMBER: US/10/027,632
CURRENT FILING DATE: 2002-04-30
PRIORITY APPLICATION NUMBER: US 60/216,006
PRIORITY FILING DATE: 2000-07-12
PRIORITY APPLICATION NUMBER: US 60/198,676
PRIORITY FILING DATE: 2000-04-20
PRIORITY APPLICATION NUMBER: US 60/193,483
PRIORITY FILING DATE: 2000-03-29
PRIORITY APPLICATION NUMBER: US 60/185,218
PRIORITY FILING DATE: 2000-02-24
PRIORITY APPLICATION NUMBER: US 60/167,363
PRIORITY FILING DATE: 1999-11-23
PRIORITY APPLICATION NUMBER: US 60/156,358
PRIORITY FILING DATE: 1999-09-28
PRIORITY APPLICATION NUMBER: US 60/146,002
PRIORITY FILING DATE: 1999-08-03
NUMBER OF SEQ ID NOS: 325720
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 51350
LENGTH: 520
TYPE: DNA
ORGANISM: Human
US-10-027-632-51350

```

Query Match	28.8%	Score 17;	DB 13;	Length 520;
Best Local Similarity	100.0%	Pred. NO. 14;		
Matches 17;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;

QY 5 TGAAGAACTGGTTGAC 21  
|||  
Db 106 TGAAGAACTGGTTGAC 90

**This Page Blank (uspto)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 22, 2004, 19:17:58 ; Search time 523.357 Seconds  
(without alignments)  
3343.258 Million cell updates/sec

Title: US-09-898-616A-4

Sequence: 1 atggaagaatgcctcagctcagctgtgcaactaag 37

Scoring table: OLIGO\_NUC  
Gapop 60.0 , Gapext 60.0

Searched: 4526729 seqs, 23644849745 residues

Word size : 0

Total number of hits satisfying chosen parameters: 9053458

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Listing first 45 summaries

Database : GenEmbl:

1: gb\_da:\*  
2: gb\_hhg:\*  
3: gb\_in:\*  
4: gb\_om:\*  
5: gb\_ov:\*  
6: gb\_pat:\*  
7: gb\_ph:\*  
8: gb\_pl:\*  
9: gb\_pr:\*  
10: gb\_ro:\*  
11: gb\_sts:\*  
12: gb\_sy:\*  
13: gb\_un:\*  
14: gb\_vl:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match Length	ID	Description
1	37	100.0	37	ARI60918 Sequence
2	37	100.0	60	ARI60919 Sequence
3	37	100.0	60	ARI60919 Sequence
4	19	51.4	96850	ACI02518.3
5	19	51.4	110000	AC092450_5
6	19	51.4	143233	ACI02189
7	19	51.4	157842	AC092825
8	18	48.6	163834	AL691449 Human DNA
9	18	48.6	167082	AP001503
10	18	48.6	168813	AP000555 Homo sapi
11	18	48.6	169230	AP000555 Homo sapi
12	18	48.6	172921	AP002454 Mus muscu
13	18	48.6	17056	AP002454 Homo sapi
14	18	48.6	180851	AC091843 Homo sapi
15	18	48.6	181211	AP001904 Homo sapi
16	18	48.6	186110	ACI36510 Pan trogl
17	18	48.6	204136	AL831776 Mouse DNA
18	18	48.6	213552	ACI010928 Homo sapi
19	18	48.6	222545	ACI09051 Rattus no
19	18	48.6	228081	ACI15237 Rattus no

C 20	17	45.9	2997	9	AKI27463	Homo sapi
C 21	17	45.9	105856	9	AC015669	Homo sapi
C 22	17	45.9	120817	2	ACI36057	Rattus no
C 23	17	45.9	149951	9	AC004970	Homo sapi
C 24	17	45.9	156008	9	AL353093	Human DNA
C 25	17	45.9	168602	2	ACI24099	Mus muscu
C 26	17	45.9	171112	9	AC016866	Homo sapi
C 27	17	45.9	181936	2	AL360090	Homo sapi
C 28	17	45.9	185472	2	ACI28825	Rattus no
C 29	17	45.9	201725	2	AL591706	Homo sapi
C 30	17	45.9	206075	2	ACI18511	Rattus no
C 31	17	45.9	209380	10	ACI33186	Mus muscu
C 32	17	45.9	222162	10	ACI09281	Mus muscu
C 33	17	45.9	224326	2	ACI29414	Rattus no
C 34	17	45.9	235965	2	ACI22659	Rattus no
C 35	17	45.9	239924	2	ACI11266	Rattus no
C 36	17	45.9	240418	2	ACI28419	Rattus no
C 37	17	45.9	243598	2	ACI42076	Rattus no
C 38	17	45.9	243640	2	ACI08571	Rattus no
C 39	17	45.9	275059	2	ACI20776	Rattus no
C 40	16	43.2	666	11	BV047886	Xenopus 1
C 41	16	43.2	1240	5	AF414086	Xenopus 1
C 42	16	43.2	2420	5	CTD243835	Xenopus 1
C 43	16	43.2	12282	1	AE010462	Fusobacte
C 44	16	43.2	34667	5	EX571693	Carp DNA
C 45	16	43.2	38490	9	AP001236	Homo sapi

## ALIGNMENTS

RESULT 1	ARI60918	Sequence 9 from patent US 6255281.	37 bp	DNA	linear	PAT 17-OCT-2001
LOCUS	ARI60918					
DEFINITION	ARI60918					
ACCESSION	ARI60918.1	GI:16225987				
VERSION						
KEYWORDS						
SOURCE	Unknown.					
ORGANISM	Unclassified.					
REFERENCE	1 (bases 1 to 37)					
AUTHORS	Pilon,A.L., Mukherjee,A.B. and Zhang,Z.					
TITLE	Use of recombinant human uteroglobin in treatment of inflammatory					
FEATURES	and fibrotic conditions					
JOURNAL	Patent: US 6255281-A 9/03-JUL-2001;					
LOCUS	Location/Qualifiers					
FEATURES	1..37					
SOURCE	/organism="unknown"					
ORIGIN	/mol_type="unassigned DNA"					

Query Match	100.0%	Score 37;	DB 6;	Length 37;
Best Local Similarity	100.0%	Pred. No. 9.7e-12;		
Matches	37;	Conservative	0;	Mismatches 0;
				Indels 0;
				Gaps 0;
Qy	1	ATGGAAGAATGCTCAGCTCAGCTGCACTAG 37		
Db	1	ATGGAAGAATGCTCAGCTCAGCTGCACTAG 37		
RESULT 2	ARI60919/c	Sequence 10 from patent US 6255281.	60 bp	DNA
LOCUS	ARI60919			
DEFINITION	ARI60919			
ACCESSION	ARI60919.1	GI:16225990		
VERSION				
KEYWORDS				
SOURCE	Unknown.			
ORGANISM	Unclassified.			
REFERENCE	1 (bases 1 to 60)			
AUTHORS	Pilon,A.L., Mukherjee,A.B. and Zhang,Z.			

TITLE Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions  
 JOURNAL Patent: US 6255281-A 10 03-JUL-2001;  
 FEATURES Location/Qualifiers  
 source 1..60  
 /organism="unknown"  
 /mol\_type="unassigned DNA"

## ORIGIN

Query Match 100.0%; Score 37; DB 6; Length 60;  
 Best Local Similarity 100.0%; Pred. No. 9.4e-12;  
 Matches 37; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATGAGAGAGATGCTAGCTAGCTGTGCAACTAG 37  
 DB 37 ATGAGAGAGATGCTAGCTAGCTGTGCAACTAG 1

RESULT 3  
 AC102518\_3/c  
 WCOMMENT  
 Sequence split into 4 fragments LOCUS AC102518 Accession AC102518

Fragment Name Begin End  
 AC102518\_0 1 110000  
 AC102518\_1 100001 210000  
 AC102518\_2 200001 310000  
 AC102518\_3 300001 396850  
 Continuation (4 of 4) of AC102518 from base 300001 (AC102518 Mus musculus chromosome 8 c

Query Match 51.4%; Score 19; DB 2; Length 96850;  
 Best Local Similarity 100.0%; Pred. No. 0.76;  
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 14 CTCAGCTAGGCTGTGCAA 32  
 DB 22796 CTCAGCTAGGCTGTGCAA 22778

RESULT 4  
 AC092450\_5  
 WCOMMENT  
 Sequence split into 8 fragments LOCUS AC092450 Accession AC092450

Fragment Name Begin End  
 AC092450\_0 1 110000  
 AC092450\_1 100001 210000  
 AC092450\_2 200001 310000  
 AC092450\_3 300001 410000  
 AC092450\_4 400001 510000  
 AC092450\_5 500001 610000  
 AC092450\_6 600001 710000  
 AC092450\_7 700001 727300  
 Continuation (6 of 8) of AC092450 from base 500001 (AC092450 Homo sapiens chromosome 12

Query Match 51.4%; Score 19; DB 2; Length 110000;  
 Best Local Similarity 100.0%; Pred. No. 0.75;  
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 14 CTCAGCTAGGCTGTGCAA 32  
 DB 17216 CTCAGCTAGGCTGTGCAA 17234

RESULT 5  
 AC102189/c  
 LOCUS AC102189 143233 bp DNA linear HTG 16-JUL-2003  
 DEFINITION Mus musculus clone RP24-21607, WORKING DRAFT SEQUENCE, 12 unordered  
 places.

AC102189  
 AC102189.3 GI:32813512  
 HTG: HTGS PHASE1; HTGS DRAFT; HTGS\_FULLTOP.  
 KEYWORDS Mus musculus (house mouse)  
 SOURCE Mus musculus  
 ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

REFERENCE  
 AUTHORS  
 TITLE  
 JOURNAL  
 REFERENCE  
 AUTHORS  
 1 (bases 1 to 143233)  
 Birren, B., Nusbaum, C., and Lander, E.  
 Mus musculus, clone RP24-21607  
 Unpublished  
 2 (bases 1 to 143233)  
 Birren, B., Linton, L., Nusbaum, C., Lander, E., Ali, A., Allen, N.,

Anderson, S., Barna, N., Baerlein, V., Boguslavsky, L., Boukhalter, B.,  
 Brown, A., Camarata, J., Campopiano, A., Chang, J., Chazaro, B.,  
 Choepel, Y., Collangelo, M., Collins, A., Collymore, A., Cook, A.,  
 Cooke, P., Dearellano, K., Dewar, K., Diaz, J. S., Dodge, S., Faro, S.,  
 Ferreira, P., Fitzhugh, W., Gage, D., Galagan, J., Gardyna, S.,  
 Ginde, S., Gord, S., Goyette, M., Graham, L., Grand-Pierre, N.,  
 Hagos, B., Heaford, A., Horton, L., Hulme, W., Iliev, I., Johnson, R.,  
 Jones, C., Kamat, A., Karatas, A., Kells, C., Laroque, K.,  
 Lamarez, R., Landers, T., Lehotzky, T., Levine, R., Liu, G.,  
 Maclean, C., Macdonald, P., Major, J., Margus, N., Mathews, C.,  
 McCarthy, M., McEwan, P., McKernan, K., McPheters, R., Meldrum, J.,  
 Menus, L., Minova, T., Mlenga, V., Murphy, T., Naylor, J., Nguyen, C.,  
 Norbu, C., Norman, C. H., O'Connor, T., O'Donnell, P., O'Neill, D.,  
 Oliver, J., Peterson, K., Phunkhang, P., Pierre, N., Pollara, V.,  
 Raymond, C., Retta, R., Rieback, M., Riley, R., Rise, C., Rogov, P.,  
 Roman, J., Rosetti, M., Roy, A., Santos, R., Schauer, S., Schupbach, R.,  
 Seaman, S., Severy, P., Spencer, B., Strange-Thomann, N., Stojanovic, N.,  
 Strause, N., Subramanian, A., Talamas, J., Teefaye, S., Theodore, J.,  
 Topham, K., Travers, W., Travis, N., Triggillo, J., Vassiliev, H.,  
 Viel, R., Vo, A., Wilson, B., Wu, X., Wyman, D., Ye, W. J., Young, G.,  
 Zainoun, J., Zembek, L., Zimmer, A. and Zody, M.  
 Direct Submission

TITLE  
 JOURNAL  
 REFERENCE  
 AUTHORS  
 Submitted (23-NOV-2001) Whitehead Institute/MIT Center for Genome  
 Research, 320 Charles Street, Cambridge, MA 02141, USA  
 3 (bases 1 to 143233)

Birren, B., Nusbaum, C., Lander, E., Abouliell, A., Allen, N.,  
 Anderson, M., Arachchi, H. M., Barna, N., Baerlein, V., Bloom, T.,  
 Boguslavsky, L., Boukhalter, B., Camarata, J., Chang, J., Choepel, Y.,  
 Collymore, A., Cook, A., Cooke, P., Corum, B., Dearellano, K.,  
 Diaz, J. S., Dodge, S., Dooley, K., Dorris, L., Erickson, J., Faro, S.,  
 Ferreira, P., Fitzhugh, W., Gage, D., Galagan, J., Gardyna, S.,  
 Graham, L., Grand-Pierre, N., Hafer, N., Hascopian, D., Hagos, B.,  
 Hall, J., Horton, L., Hulme, W., Iliev, I., Johnson, R., Jones, C.,  
 Kamat, A., Karatas, A., Kells, C., Landers, T., Levine, R.,  
 Lindblad-Toh, K., Liu, X., Liu, A., Vachit, R., Maclean, C.,  
 Macdonald, P., Major, J., Manning, J., Mathews, C., McCarthy, M.,  
 Meldrum, J., Menus, L., Minova, T., Mlenga, V., Murphy, T., Naylor, J.,  
 Nguyen, C., Nicol, R., Norbu, C., O'Connor, T., O'Donnell, P.,  
 O'Neill, D., Oliver, J., Peterson, K., Phunkhang, P., Pierre, N.,  
 Rachupka, A., Ramsamy, U., Raymond, C., Retta, R., Rise, C., Rogov, P.,  
 Roman, J., Schauer, S., Schupbach, R., Seaman, S., Severy, P., Smith, C.,  
 Spencer, B., Strange-Thomann, N., Stojanovic, N., Stubbs, M.,  
 Talamas, J., Teefaye, S., Theodore, J., Topham, K., Travers, W.,  
 Vassiliev, H., Venkataraman, V. S., Viel, R., Vo, A., Wilson, B., Wu, X.,  
 Wyman, D., Young, G., Zainoun, J., Zembek, L., Zimmer, A. and Zody, M.  
 Direct Submission

TITLE  
 JOURNAL  
 REFERENCE  
 Submitted (16-JUL-2003) Whitehead Institute/MIT Center for Genome  
 Research, 320 Charles Street, Cambridge, MA 02141, USA  
 On Jul 16, 2003 this sequence version replaced gi:22381210.

All repeats were identified using RepeatMasker:  
 Smit, A.F.A. & Green, P. (1996-1997) RepeatMasker.html  
 http://ftp.genome.washington.edu/RM/RepeatMasker.html

Genome Center  
 Center: Whitehead Institute/MIT Center for Genome Research  
 Center code: WIRB  
 Web site: http://www-seq.wi.mit.edu  
 Contact: sequence\_submissions@genome.wi.mit.edu

Project Information  
 Center project name: 216-J-7  
 Center clone name: 118187

Summary Statistics  
 Sequencing vector: Plasmid; n/a; 100% of reads  
 Chemistry: Dye-terminator Big Dye; 100% of reads  
 Assembly program: Phrap; version 0.960731  
 Consensus quality: 139726 bases at least Q40  
 Consensus quality: 14319 bases at least Q30

Consensus quality: 141907 bases at least Q20  
Insert size: 13300; agarose-fp  
Insert size: 14213; sum-of-ctnigs  
Quality coverage: 10.7 in Q20 bases; agarose-fp  
Quality coverage: 10.0 in Q20 bases; sum-of-ctnigs

NOTE: This is a 'working draft' sequence. It currently consists of 12 contigs. The true order of the pieces is not known and their order in this sequence record is arbitrary. Gaps between the contigs are represented as runs of N, but the exact sizes of the gaps are unknown. This record will be updated with the finished sequence as soon as it is available and the accession number will be preserved.

1 10232: contig of 10232 bp in length  
10233 10332: gap of 100 bp  
10333 11435: contig of 1103 bp in length  
11436 11535: gap of 100 bp  
11536 12833: contig of 1298 bp in length  
12834 12933: gap of 100 bp  
12934 15356: contig of 2423 bp in length  
15357 15457: gap of 100 bp  
15457 17667: contig of 2210 bp in length  
17667 20013: contig of 2247 bp in length  
20013 20114: gap of 100 bp  
20114 23551: contig of 3438 bp in length  
23551 23652: gap of 100 bp  
23652 27915: contig of 4164 bp in length  
27915 36443: contig of 8528 bp in length  
36443 36544: gap of 100 bp  
36544 46767: contig of 10224 bp in length  
46767 46868: gap of 100 bp  
46868 66890: contig of 20023 bp in length  
66890 66991: gap of 100 bp  
66991 143233: contig of 76243 bp in length.

## FEATURES

source

1.143233  
/organism="Mus musculus"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:10090"  
/clone\_1b="RP24-216J7"  
1.10232  
/note="assembly\_fragment  
clone\_end:SP6  
vector\_side:left"  
10333.11435  
/note="assembly\_fragment"  
11536.12833  
/note="assembly\_fragment"  
12934.15356  
/note="assembly\_fragment"  
15457.17667  
/note="assembly\_fragment"  
17667.20013  
/note="assembly\_fragment"  
20013.20114  
/note="assembly\_fragment"  
20114.23551  
/note="assembly\_fragment"  
23551.23652  
/note="assembly\_fragment"  
23652.27915  
/note="assembly\_fragment"  
27915.36443  
/note="assembly\_fragment"  
36443.36544  
/note="assembly\_fragment"  
36544.46767  
/note="assembly\_fragment"  
46767.46868  
/note="assembly\_fragment"  
46868.66890  
/note="assembly\_fragment"  
66890.66991  
/note="assembly\_fragment"

## ORIGIN

Query Match

51.4%; Score 19; DB 2; length 143233;

Best Local Similarity 100.0%; Pred. NO. 0.74;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 14 CTCAGCTAGCCTGTGCAA 32  
Db 105062 CTCAGCTAGCCTGTGCAA 105044

## RESULT 6

AC092825/c

LOCUS

DEFINITION

AC092825

VERSION

AC092825.5

KEYWORDS

HTG.

SOURCE

ORGANISM

REFERENCE

AUTHORS

Muzny, D.M., Adams, C., Aiello-Duda, B., Altman, F.R., Allen, C., Alsprouk, S.L., Amaratunga, H.C., Are, J.R., Ayala, M., Banks, T., Barbata, J., Benton, J., Bimonte, K., Blankenburg, K., Bonin, D., Bouck, J., Bowie, S., Brileva, M., Brown, E., Brown, M., Bryant, N.P., Buhay, C., Burch, P., Burkett, C., Burrell, K.L., Byrd, N.C., Carron, T.F., Carter, M., Cavazos, S.R., Chacko, V., Chavez, D., Chen, G., Chen, R., Chen, Z., Chowdhury, I., Christopoulos, C., Cleveland, C.D., Cox, C., Coyle, M.D., Dathorne, S.R., David, R., Davila, M.L., Davis, C., Davy-Carroll, L., Dederich, D.A., Delaney, K.R., Delgado, O., Denn, A.L., Ding, Y., Dinh, H.H., Douthwaite, K.J., Draper, H., Dugan-Rocha, S., Durbin, K.J., Earhart, C., Edgar, D., Edwards, C.C., Elhaj, C., Escotte, M., Falls, T., Ferraguto, D., Flagg, N., Ford, J., Foster, P., Frantz, P., Gabisi, A., Gao, V., Garcia, A., Garner, T., Garza, N., Gill, R., Gorell, J.H., Guevara, M., Gunathne, P., Hale, S., Hamilton, K., Harris, C., Harris, K., Hart, M., Havlak, P., Hawes, A., He, X., Hernandez, J., Hernandez, O., Hodgson, A., Hognes, M., Hollway, C., Hollins, B., Homs, F., Howard, S., Huber, J., Hulyk, S., Hume, J., Jackson, L.E., Jacobson, B., Jia, Y., Johnson, R., Jolyvet, S., Jondah, S., Karlson, E., Kelly, S., Khan, U., King, U., Korvah, J., Kovar, C., Kratovic, J., Kuresh, A., Landry, N., Leal, B., Lewis, L.C., Lewis, J., Li, J., Li, J., Lichtarge, O., Liu, C., Liu, W., Louisedge, H., Lozano, R.J., Lu, X., Lucier, A., Lucier, R., Luna, R., Ma, J., Maheshwari, M., Mapa, P., Martin, R., Martindale, A., Martinez, E., Massey, B., Mahoney, E., McLeod, M.P., Meador, M., Mel, G., Metzker, M., Miner, G., Miner, Z., Mitchell, T., Mohabat, K., Moore, S., Morgan, M., Moorish, T., Morris, S., Moser, M., Neal, D., Nelson, D., Newton, J., Newton, N., Nguyen, A., Nguyen, N., Nguyen, N., Nickerson, E., Nwokoko, S., Ogun, M., Okwuonu, G., Ogunyemi, N., Oviedo, R., Pace, A., Payton, B., Peery, J., Perez, L., Peters, L., Pickens, R., Primus, E., Pu, L.L., Quiles, M., Rer, Y., Rivers, M., Rojas, A., Rojibokan, I., Rolfe, M., Ruiz, S., Saverly, G., Scheer, S., Scott, G., Shen, H., Shoshitani, N., Sisson, I., Sodergren, E., Sonaike, T., Sparks, A., Stanley, H., Stone, H., Sutton, A., Svatek, A., Tabore, P., Tamerisa, A., Tamerisa, K., Tang, H., Tansey, J., Taylor, C., Taylor, T., Teliford, B., Thomas, N., Thomas, S., Usmani, K., Vaequez, L., Vera, V., Villalón, D., Vinson, R., Wang, O., Wang, S., Ward-Moore, S., Warren, R., Washington, C., Watlington, S., Williams, G., Williamson, A., Wlezyk, R., Wooden, S., Worley, K., Wu, C., Wu, Y., Wu, Y.F., Zhou, J., Zorilla, S., Naylor, S.L., Weinstock, G. and Gibbs, R.

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

## JOURNAL

Submitted (09-MAY-2002) Human Genome Sequencing Center, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA  
4 (bases 1 to 157842)

## REFERENCE

## AUTHORS

## TITLE

## JOURNAL

Worley, K.C.

Submitted (22-MAY-2002) Human Genome Sequencing Center, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA  
On May 22, 2002 this sequence version replaced gi:20279217.  
INFORMATION: <http://www.hgsc.bcm.tmc.edu/> or email [gc-help@bcm.tmc.edu](mailto:gc-help@bcm.tmc.edu)

## COMMENT

CLONE LENGTH: This sequence does not necessarily represent the entire insert of this clone. Overlapping regions of clones are only sequenced and submitted once, so the sequence for the remainder of the insert may be found in the record for the adjacent clones. Overlapping clones are noted at the beginning and end of the Features listing.

## ANNOTATION OF FEATURES:

STS are identified using ePCR (Genome Res. 7:541-550) searches of a local database that includes entries from dbSTS, GDB, and local mapping efforts.

Repeats are identified using RepeatMasker (A. Smit and P. Green, unpublished) for Human and Mouse sequences. Genes and Region of sequence similarity are identified by BLAST (Nuc. Acids Res. 25:3389-3402) similarity (expect < 1e-34) to the EST and cDNA sequences. Genes demonstrate at least two exons flanked by consensus splice sites that maintained sequence continuity across the splice junctions. Sequences that are not identical matches are annotated as similar.

SEQUENCING READ COVERAGE: Sequencing is completed to a minimum standard of double strand coverage with a minimum of 2 clones and 2 reads with no ambiguities or 2 chemistries with a minimum of 2 clones and 3 reads with no ambiguities. If the sequence quality for a region does not meet this standard, it will be indicated in the annotation as Low Coverage.

QUALITY OF INDIVIDUAL BASES: This sequence meets stringent quality standards - estimated error rate less than 1 per 10,000 bases. Reports of lowest quality individual bases and measures of base quality are listed below. Description of the metrics can be found at URL: <http://gc.bcm.tmc.edu:8088/quality.info/genbank.annotation.html>.

## QUALSTAT-REPORT.

## FEATURES

## SOURCE

Location/Qualifiers  
1. 157842  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
/chromosome="3"  
/clone="RP11-171G7"  
163..204  
/rpt\_family="AT-rich"  
complement(206..514)  
/rpt\_family="AluY"  
581..811  
/rpt\_family="Charlie2"  
1005..1307  
/rpt\_family="MLT2E"  
complement(1308..1371)  
/rpt\_family="MER109"  
2801..3030  
/standard\_name="81156"  
2824..2892  
/rpt\_family="TCTA)n"  
2893..2924  
/rpt\_family="(CA)n"  
complement(3582..3979)  
/rpt\_family="MSTRB"

repeat\_region 4295..4334  
/rpt\_family="AT-rich"  
complement(7020..7227)  
repeat\_region  
/rpt\_family="MER101"  
10026..10204  
/rpt\_family="(TA)n"  
11515..11546  
/rpt\_family="AT-rich"  
complement(11596..11904)  
repeat\_region  
/rpt\_family="AluX"  
complement(15095..15165)  
/rpt\_family="T199er1"  
15770..15789  
/rpt\_family="(T)n"  
complement(15793)  
repeat\_region  
/rpt\_family="L1HS"  
17161..17338  
/standard\_name="61535"  
18421..18480  
/rpt\_family="L2"  
complement(21210..21359)  
repeat\_region  
/rpt\_family="L1"  
23843..24385  
/rpt\_family="MER1A"  
complement(24743..24873)  
repeat\_region  
/rpt\_family="L1M3a"  
complement(25825..25997)  
/rpt\_family="L1M3a"  
26400..26421  
/rpt\_family="AT-rich"  
complement(26586..26814)  
repeat\_region  
/rpt\_family="L2"  
27101..27277  
/standard\_name="150162"  
complement(27621..28060)  
repeat\_region  
/rpt\_family="L2"  
28243..28408  
/rpt\_family="MIR"  
28577..28697  
/rpt\_family="L2"  
30613..30633  
/rpt\_family="AT-rich"  
complement(31014..31089)  
repeat\_region  
/rpt\_family="MIR"  
complement(32739..32905)  
/rpt\_family="MT111"  
33642..33933  
/rpt\_family="AluSg"  
34226..34535  
/rpt\_family="AluX"  
35570..35756  
/rpt\_family="MIR"  
36998..37030  
/rpt\_family="(TA)n"  
37096..37118  
/rpt\_family="(TTTG)n"  
37242..37285  
/rpt\_family="(TTTG)n"  
41336..41383  
/rpt\_family="MIR"  
41727..41775  
/rpt\_family="AT-rich"  
42867..43150  
/rpt\_family="AluJo"

Query Match 51.4%; Score 19; DB 9; Length 157842;  
Best Local Similarity 100.0%; Pred. No. 0.73;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
14 CTCAGCTAGCGCTGCA 32  
DB 117040 CTCAGCTAGCGCTGCA 117022



RESULT 7  
 LOCUS AL691449 163934 bp DNA linear PRI 21-JAN-2003  
 DEFINITION Human DNA sequence from clone RP11-558F24 on chromosome 1, complete sequence.  
 ACCESSION AL691449  
 VERSION AL691449.2 GI:27817297  
 KEYWORDS HTG  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 REFERENCE 1 (bases 1 to 163934)  
 AUTHORS Matthews, N.  
 TITLE Direct Submission  
 JOURNAL Submitted (21-JAN-2003) Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK. E-mail enquiries: humquerry@sanger.ac.uk  
 On Jan 21, 2003 this sequence version replaced gi:27803162.  
 COMMENT ----- Genome Center  
 Center: Wellcome Trust Sanger Institute  
 Center code: SC  
 Web site: <http://www.sanger.ac.uk>  
 Contact: humquerry@sanger.ac.uk

During sequence assembly data is compared from overlapping clones. Where differences are found these are annotated as variations together with a note of the overlapping clone name. Note that the variation annotation may not be found in the sequence submission corresponding to the overlapping clone, as we submit sequences with only a small overlap as described above.  
 This sequence was finished as follows unless otherwise noted: all regions were either double-stranded or sequenced with an alternate chemistry or covered by high quality data (i.e., phred quality > 30); an attempt was made to resolve all sequencing problems, such as compressions and repeats; all regions were covered by at least one plasmid subclone or more than one M13 subclone; and the assembly was confirmed by restriction digest, except on the rare occasion of the clone being a YAC.  
 The following abbreviations are used to associate primary accession numbers given in the feature table with their source databases: EMBL, SW, SWISSPROT, Tr, TREMBL, Wp, WORMPEP; information on the WORMPEP database can be found at [http://www.sanger.ac.uk/Projects/C\\_elegans/wormpep](http://www.sanger.ac.uk/Projects/C_elegans/wormpep). This sequence was generated from part of bacterial clone contigs of human chromosome 1, constructed by the Sanger Centre Chromosome 1 Mapping Group. Further information can be found at <http://www.sanger.ac.uk/HGP/Chr1>  
 RP11-558F24 is from the library RP11-11.2 constructed by the group of Pletier de Jong. For further details see <http://www.chori.org/bacpac/home.htm>  
 VECTOR: pBACe3.6.

FEATURES  
 source location/Qualifiers  
 1..163934  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 /chromosome="1"  
 /clone="RP11-558F24"  
 /clone\_11b="RP11-11.2"

Query Match 48.6%; Score 18; DB 9; Length 163934;  
 Best Local Similarity 100.0%; Pred. No. 3;  
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CAGCTAGAGCTGTGCAAC 33  
 |||||  
 DB 44909 CAGCTAGAGCTGTGCAAC 44926

RESULT 8

AP001903  
 LOCUS AP001903 167082 bp DNA linear HTG 30-MAY-2000  
 DEFINITION Homo sapiens chromosome 18 clone RP11-719K4 map 18q21, WORKING DRAFT SEQUENCE, 26 unordered pieces.  
 ACCESSION AP001903  
 VERSION AP001903.2 GI:8117554  
 KEYWORDS HTG; HTGS PHASE1; HTGS\_DRAFT.  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 REFERENCE 1 (bases 1 to 167082)  
 AUTHORS Hattori, M., Ishii, K., Toyoda, A., Taylor, T. D., Hong-Seog, P., Fujiyama, A., Yada, T., Totoki, Y., Watanabe, H. and Sakaki, Y.  
 TITLE Direct Submission  
 JOURNAL Published Only in Database (2000)  
 2 (bases 1 to 167082)  
 Hattori, M., Ishii, K., Toyoda, A., Taylor, T. D., Hong-Seog, P., Fujiyama, A., Yada, T., Totoki, Y., Watanabe, H. and Sakaki, Y.  
 Direct Submission  
 Submitted (24-APR-2000) Masahira Hattori, The Institute of Physical and Chemical Research (RIKEN), Genomic Sciences Center (GSC), Kitasato Univ., 1-15-1 Kitasato, Sagami-hara, Kanagawa 228-8555, Japan (E-mail: hattori@gsc.riken.go.jp, [uri.hattori@hgp.gsc.riken.go.jp](mailto:uri.hattori@hgp.gsc.riken.go.jp), Tel:81-42-778-9923, Fax:81-42-778-9924)  
 On May 30, 2003 this sequence version replaced gi:7649790.  
 COMMENT ----- Genome Center  
 Center: RIKEN Genomic Sciences Center (GSC)  
 Center code: RIKEN  
 Web site: <http://hgp.gsc.riken.go.jp/>  
 Contact: hattori@gsc.riken.go.jp  
 ----- Project Information  
 Center project name: HumDrat18  
 Center clone name: RP11-719K4  
 ----- Summary Statistics  
 Sequencing vector: PCR products; 100% of reads  
 Chemistry: Dye-terminator ET-amersham; 100% of reads  
 Assembly program: Phrap; version 0.990329  
 Consensus quality: 153234 bases at least Q40  
 Consensus quality: 159520 bases at least Q30  
 Consensus quality: 162786 bases at least Q20  
 Insert size: 164582; sum-of-contigs  
 Quality coverage: 5.73x in Q20 bases; sum-of-contigs

NOTE: This is a 'working draft' sequence. It currently consists of 26 contigs. The true order of the pieces is not known and their order in this sequence record is arbitrary. Gaps between the contigs are represented as runs N, but the exact sizes of the gaps are unknown. This record will be updated with the finished sequence as soon as it is available and the accession number will be preserved

1	22433 contig of	22433 bp in length
22534	45017 contig of	22443 bp in length
45118	59868 contig of	14751 bp in length
59969	71793 contig of	11925 bp in length
71894	81974 contig of	10081 bp in length
82075	91440 contig of	9366 bp in length
91541	98433 contig of	6893 bp in length
98534	104713 contig of	6180 bp in length
104814	108664 contig of	3851 bp in length
108765	113626 contig of	4862 bp in length
113727	120106 contig of	6380 bp in length
120207	125002 contig of	4766 bp in length
125103	129865 contig of	4763 bp in length
129166	133126 contig of	3361 bp in length
133427	138379 contig of	4393 bp in length
138480	142887 contig of	4408 bp in length
142988	146547 contig of	3560 bp in length
146648	149630 contig of	3663 bp in length
149631	152938 contig of	3308 bp in length
153039	155117 contig of	2073 bp in length
155212	157376 contig of	2185 bp in length

157477 160277 contig of 2801 bp in length  
 160378 162841 contig of 2464 bp in length  
 162942 164597 contig of 1656 bp in length  
 164598 166310 contig of 1613 bp in length  
 166411 167082 contig of 672 bp in length

Sequence updated (26-May-2000).

\* NOTE: This is a 'working draft' sequence. It currently consists of 26 contigs. The true order of the pieces is not known and their order in this sequence record is arbitrary. Gaps between the contigs are represented as runs of N, but the exact sizes of the gaps are unknown. This record will be updated with the finished sequence as soon as it is available and the accession number will be preserved.

1 22433: contig of 22433 bp in length  
 22434 22533: gap of 100 bp  
 22534 45017: contig of 22484 bp in length  
 45018 45117: gap of 100 bp  
 45118 59668: contig of 14751 bp in length  
 59669 59689: gap of 100 bp  
 59690 71793: contig of 11825 bp in length  
 71794 71894: gap of 100 bp  
 71895 81974: contig of 10081 bp in length  
 81975 91440: contig of 9366 bp in length  
 91441 91540: gap of 100 bp  
 91541 98433: contig of 6883 bp in length  
 98434 98533: gap of 100 bp  
 98534 104713: contig of 6180 bp in length  
 104714 104813: gap of 100 bp  
 104814 108664: contig of 3851 bp in length  
 108665 108764: gap of 100 bp  
 108765 113726: contig of 4862 bp in length  
 113727 113727: gap of 100 bp  
 113728 120106: contig of 6380 bp in length  
 120107 120206: gap of 100 bp  
 120207 125002: contig of 4756 bp in length  
 125003 125102: gap of 100 bp  
 125103 129865: contig of 4763 bp in length  
 129866 129965: gap of 100 bp  
 129966 133326: contig of 3361 bp in length  
 133327 133426: gap of 100 bp  
 133427 138379: contig of 4953 bp in length  
 138380 138479: gap of 100 bp  
 138480 142887: contig of 4408 bp in length  
 142888 142987: gap of 100 bp  
 142988 146547: contig of 3560 bp in length  
 146548 146647: gap of 100 bp  
 146648 149530: contig of 2883 bp in length  
 149531 149630: gap of 100 bp  
 149631 152938: contig of 3308 bp in length  
 152939 153038: gap of 100 bp  
 153039 153111: contig of 2073 bp in length  
 153112 155211: gap of 100 bp  
 155212 157376: contig of 2165 bp in length  
 157377 157476: gap of 100 bp  
 157477 160277: contig of 2801 bp in length  
 160278 160377: gap of 100 bp  
 160378 162841: contig of 2464 bp in length  
 162842 162942: gap of 100 bp  
 162943 164597: contig of 1656 bp in length  
 164598 166310: contig of 1613 bp in length  
 166311 166411: gap of 100 bp  
 166411 167082: contig of 672 bp in length.

## FEATURES

1 .167082  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 /chromosome="18"  
 /map="18q21"  
 /clone="RP11-719K4"

misc\_feature 1..22433  
 /note="assembly\_fragment"  
 misc\_feature 22534..45017  
 /note="assembly\_fragment"  
 misc\_feature 45118..59668  
 /note="assembly\_fragment"  
 misc\_feature 59669..71793  
 /note="assembly\_fragment"  
 misc\_feature 71894..81974  
 /note="assembly\_fragment clone\_end:77 vector\_side:right"  
 misc\_feature 82075..91440  
 /note="assembly\_fragment"  
 misc\_feature 91541..98433  
 /note="assembly\_fragment"  
 misc\_feature 98534..104713  
 /note="assembly\_fragment"  
 misc\_feature 104814..108664  
 /note="assembly\_fragment"  
 misc\_feature 108765..113726  
 /note="assembly\_fragment"  
 misc\_feature 113727..120106  
 /note="assembly\_fragment"  
 misc\_feature 120207..125002  
 /note="assembly\_fragment"  
 misc\_feature 125103..129865  
 /note="assembly\_fragment"  
 misc\_feature 129966..133326  
 /note="assembly\_fragment"  
 misc\_feature 133427..138379  
 /note="assembly\_fragment"  
 misc\_feature 138480..142887  
 /note="assembly\_fragment"  
 misc\_feature 142988..146547  
 /note="assembly\_fragment"  
 misc\_feature 146648..149530  
 /note="assembly\_fragment"  
 misc\_feature 149631..152938  
 /note="assembly\_fragment"  
 misc\_feature 153039..155211  
 /note="assembly\_fragment"  
 misc\_feature 155212..157376  
 /note="assembly\_fragment"  
 misc\_feature 157477..160277  
 /note="assembly\_fragment"  
 misc\_feature 160378..162841  
 /note="assembly\_fragment"  
 misc\_feature 162942..164597  
 /note="assembly\_fragment"  
 misc\_feature 164698..166310  
 /note="assembly\_fragment"  
 misc\_feature 166411..167082  
 /note="assembly\_fragment clone\_end:86 vector\_side:left"

## ORIGIN

Query Match 48.6%; Score 18; DB 2; Length 167082;  
 Best Local Similarity 100.0%; Pred. No. 3;  
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CAGCTAGCCTGTGCAAC 33

DB 70348 CAGCTAGCCTGTGCAAC 70365

## RESULT 9

AP000555 168813 bp DNA linear PRI 01-OCN-1999  
 LOCUS Homo sapiens genomic DNA, chromosome 22q11.2, BCL2 region,  
 DEFINITION clone:RB1027C11.

AP000555 168813 bp DNA linear PRI 01-OCN-1999

VERSION AP000555.1 GI:5931541

KEYWORDS Homo sapiens (human)

SOURCE Homo sapiens

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE 1 (bases 1 to 168813)

AUTHORS Shimizu,N.

TITLE Human DNA sequence from clone KB1027C11 on chromosome 22q11.2

JOURNAL Published Only in Database (1999)

REFERENCE 2 (bases 1 to 168813)

AUTHORS Shimizu,N.

TITLE Direct Submission

JOURNAL Submitted (22-SEP-1999) Nobuyoshi Shimizu, Keio University, School of Medicine, Molecular Biology, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-0016, Japan (E-mail:nshimizu@med.keio.ac.jp, Tel:81-3-3351-2370, Fax:81-3-3351-2370)

COMMENT This is a complete sequence of the insert of KB1027C11 clone. The proximal adjacent clone is KB665H9(ACC.#AP000554) with 586-bp overlapping. The distal adjacent clone is N109G12 (ACC.#D86995) with 24893-bp overlapping.

FEATURES

source Location/Qualifiers

1..168813

/organism="Homo sapiens"

/mol\_type="genomic DNA"

/db\_xref="taxon:9606"

/chromosome="22"

/map="22q11.2"

/clone="KB1027C11"

/cell\_line="FUB14-14"

/cell\_type="pre-pro-B cell"

/clone\_lib="Keio BAC library"

3880..4003

/evidence=not experimental

/rpt\_family="MIR"

complement(6409..6701)

/evidence=not experimental

/rpt\_family="AluYb8"

complement(6814..6961)

/evidence=not experimental

/rpt\_family="FRAM"

7486..7518

/evidence=not experimental

/rpt\_family="AT-rich"

7839..8175

/evidence=not experimental

/rpt\_family="AluSx"

8454..8739

/evidence=not experimental

/rpt\_family="AluYc"

8742..9041

/evidence=not experimental

/rpt\_family="AluSc"

complement(9240..9538)

/evidence=not experimental

/rpt\_family="AluSg"

complement(9542..9833)

/evidence=not experimental

/rpt\_family="AluSx"

complement(9940..10107)

/evidence=not experimental

/rpt\_family="AluYc"

complement(11679..11889)

/evidence=not experimental

/rpt\_family="AluY"

12877..13181

/evidence=not experimental

/rpt\_family="AluY"

complement(131910..14225)

/evidence=not experimental

/rpt\_family="AluYc"

complement(14232..14525)

/evidence=not experimental

/rpt\_family="AluSg"

complement(14797..14847)

/evidence=not experimental

/rpt\_family="Char11a1"

repeat\_region complement(14860..15262)

repeat\_region /evidence=not experimental

repeat\_region /rpt\_family="Char11a1"

15643..15859

/evidence=not experimental

/rpt\_family="L2"

complement(15899..16209)

/evidence=not experimental

/rpt\_family="AluYb"

16465..16486

/evidence=not experimental

/rpt\_family="AT-rich"

16492..16803

/evidence=not experimental

/rpt\_family="AluY"

16818..17049

/evidence=not experimental

/rpt\_family="AluYc"

17247..17332

/evidence=not experimental

/rpt\_family="MLT1K"

17851..17998

/evidence=not experimental

/rpt\_family="L2"

complement(18114..18236)

/evidence=not experimental

/rpt\_family="MIR"

complement(18503..18635)

/evidence=not experimental

/rpt\_family="AluM4"

complement(18851..18934)

/evidence=not experimental

/rpt\_family="L1P4"

19285..19356

/evidence=not experimental

/rpt\_family="L2"

19391..19697

/evidence=not experimental

/rpt\_family="AluSc"

19708..19987

/evidence=not experimental

/rpt\_family="AluSg"

19988..20022

/evidence=not experimental

/rpt\_family="TAAAn"

20035..20363

/evidence=not experimental

/rpt\_family="AluYc"

20358..20711

/evidence=not experimental

/rpt\_family="MLT1H"

20807..21027

/evidence=not experimental

/rpt\_family="AluYb"

21028..21062

/evidence=not experimental

/rpt\_family="AluY"

complement(21074..21375)

/evidence=not experimental

/rpt\_family="AluYc"

complement(21472..21611)

/evidence=not experimental

/rpt\_family="AluSg/x"

complement(21612..21623)

/evidence=not experimental

/rpt\_family="AluY"

21624..21643

/evidence=not experimental

/rpt\_family="TAAAn"

complement(21644..21913)

/evidence=not experimental

/rpt\_family="AluY"

21914..22185

/evidence=not\_experimental  
 /rpt family="AluUb"  
 repeat\_region 22190..22505  
 /evidence=not\_experimental  
 /rpt family="AluSg"  
 repeat\_region 22510..22812  
 /evidence=not\_experimental  
 /rpt family="AluUb"  
 repeat\_region 22872..23141  
 /evidence=not\_experimental  
 /rpt family="AluSg1"  
 repeat\_region 23261..23563  
 /evidence=not\_experimental  
 /rpt family="AluUb"  
 repeat\_region 23741..24077  
 /evidence=not\_experimental  
 /rpt family="AluUb"  
 repeat\_region 24095..24405  
 /evidence=not\_experimental  
 /rpt family="AluY"  
 repeat\_region 24715..24774  
 /evidence=not\_experimental  
 /rpt family="CATATA)n"  
 repeat\_region 24915..25015  
 /evidence=not\_experimental  
 /rpt family="AT rich"  
 repeat\_region 25077..25132  
 /evidence=not\_experimental  
 /rpt family="MUTID"  
 repeat\_region 25191..25245  
 /evidence=not\_experimental  
 /rpt family="MER66A"  
 repeat\_region 25556..25720  
 /evidence=not\_experimental  
 /rpt family="LIM4"  
 repeat\_region 25717..26058  
 /evidence=not\_experimental  
 /rpt family="LIME1"  
 repeat\_region 26150..26446  
 /evidence=not\_experimental  
 /rpt family="AluSx"  
 repeat\_region 27486..27783  
 /evidence=not\_experimental  
 /rpt family="AluSx"  
 repeat\_region 27982..28268  
 /evidence=not\_experimental

Query Match 48.6%; Score 18; DB 9; Length 168813;  
 Best Local Similarity 100.0%; Pred. No. 3;  
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 16 CAGCTAGCCTGTGCAC 33  
 Db 73695 CAGCTAGCCTGTGCAC 73712

RESULT 10  
 AC102275 169230 bp DNA linear HTG 23-APR-2003  
 LOCUS  
 DEFINITION Mus musculus clone RP24-290E7, WORKING DRAFT SEQUENCE, 40 unordered  
 pieces.  
 AC102275  
 VERSION AC102275.2 GT:30017900  
 KEYWORDS HTG; HTGS\_PHASE1; HTGS\_DRAFT.  
 SOURCE Mus musculus (house mouse)  
 ORGANISM Mus musculus  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 REFERENCE 1 (bases 1 to 169230)  
 AUTHORS Birren, B., Nusbaum, C. and Lander, E.  
 TITLE Mus musculus, clone RP24-290E7  
 JOURNAL  
 REFERENCE 2 (bases 1 to 169230)

## AUTHORS

Birren, B., Linton, J., Nusbaum, C., Lander, E., Ali, A., Allen, N.,  
 Anderson, S., Barna, N., Bastien, V., Boguslavsky, L., Bouckgalter, B.,  
 Brown, A., Camarata, J., Campopiano, A., Chang, J., Chararo, B.,  
 Chopel, Y., Colangelo, M., Collins, S., Collymore, A., Cook, A.,  
 Cooke, P., Dearrellano, K., Dewar, K., Diaz, J. S., Dodge, S., Fero, S.,  
 Ferreira, P., Fitzhugh, M., Gage, D., Galgan, J., Gardyna, S.,  
 Ginde, S., Gora, S., Goyette, M., Graham, L., Grand-Pierre, N.,  
 Hagos, B., Heatford, A., Horton, L., Hulme, W., Iliev, I., Johnson, R.,  
 Jones, C., Kamat, A., Karatas, A., Kells, C., Lacroque, R.,  
 Lamazares, R., Landers, T., Lehoczy, J., Levine, R., Lu, G.,  
 Maclean, C., Macdonald, P., Major, J., Margulis, N., Matthews, C.,  
 McCarthy, M., McEwan, P., McKernan, K., McPheters, R., Melnick, C.,  
 Menus, L., Mihova, T., Mlenka, V., Murphy, T., Naylor, J., Nguyen, C.,  
 Norbu, C., Norman, C. H., O'Connor, T., O'Donnell, P., O'Neill, D.,  
 Oliver, J., Peterson, K., Phunkhang, P., Pierre, N., Pollara, V.,  
 Raymond, C., Retta, R., Rieback, M., Riley, R., Rise, C., Rogov, P.,  
 Roman, J., Rosetti, M., Roy, A., Santos, R., Schauer, S., Schupack, R.,  
 Seaman, S., Severy, P., Spencer, B., Stange-Thomann, N., Stojanovic, N.,  
 Strauss, K., Subramanian, A., Talamas, J., Tesfaye, S., Theodore, J.,  
 Topham, K., Travers, M., Travis, N., Trigilio, J., Vassiliev, H.,  
 Viel, R., Vo, A., Wilson, B., Wu, X., Wyman, D., Ye, W. J., Young, G.,  
 Zainoun, J., Zembek, L., Zimmer, A. and Zody, M.

## TITLE

## JOURNAL

REFERENCE  
AUTHORS

Direct Submission  
 Submitted (23-NOV-2001) Whitehead Institute/MIT Center for Genome  
 Research, 320 Charles Street, Cambridge, MA 02141, USA  
 3 (bases 1 to 169230)  
 Birren, B., Nusbaum, C., Lander, E., Abouelell, A., Allen, N.,  
 Anderson, S., Arachchi, H. M., Barna, N., Bastien, V., Bloom, T.,  
 Boguslavsky, L., Bouckgalter, B., Camarata, J., Chang, J., Chopel, Y.,  
 Collymore, A., Cook, A., Cooke, P., Corum, B., Dearrellano, K.,  
 Diaz, J. S., Dodge, S., Dooley, K., Dorris, L., Erickson, J., Fero, S.,  
 Ferreira, P., Fitzhugh, M., Gage, D., Galagan, J., Gardyna, S.,  
 Graham, L., Grand-Pierre, N., Hage, N., Hagopian, D., Hagos, B.,  
 Hall, J., Horton, L., Hulme, W., Iliev, I., Johnson, R., Jones, C.,  
 Kamat, A., Karatas, A., Kells, C., Landers, T., Levine, R.,  
 Lindblad-Toh, K., Liu, G., Lui, A., Mabbitt, R., Maclean, C.,  
 Macdonald, P., Major, J., Manning, J., Matthews, C., McCarthy, M.,  
 Melnick, C., Menus, L., Mihova, T., Mlenka, V., Murphy, T., Naylor, J.,  
 Nguyen, C., Nicol, R., Norbu, C., O'Connor, T., O'Donnell, P.,  
 O'Neill, D., Oliver, J., Peterson, K., Phunkhang, P., Pierre, N.,  
 Rachupka, A., Ramasamy, V., Raymond, C., Retta, R., Rise, C., Rogov, P.,  
 Roman, J., Schauer, S., Schupack, R., Seaman, S., Severy, P., Smith, C.,  
 Spencer, B., Stange-Thomann, N., Stojanovic, N., Stubbbs, M.,  
 Talamas, J., Tesfaye, S., Theodore, J., Topham, K., Travers, M.,  
 Vassiliev, H., Venkataraman, V. S., Viel, R., Vo, A., Wilson, B., Wu, X.,  
 Wyman, D., Young, G., Zainoun, J., Zembek, L., Zimmer, A. and Zody, M.  
 Direct Submission  
 Submitted (23-APR-2003) Whitehead Institute/MIT Center for Genome  
 Research, 320 Charles Street, Cambridge, MA 02141, USA  
 On Apr 17, 2003 this sequence version replaced gi:17061361.  
 All repeats were identified using RepeatMasker:  
 Smit, A. F. A. & Green, P. (1996-1997)  
 http://ftp.genome.washington.edu/RM/RepeatMasker.html

TITLE  
JOURNAL  
COMMENT

Center: Whitehead Institute/ MIT Center for Genome Research

Center code: WIBR

Web site: <http://www-seq.wi.mit.edu>

Contact: [sequence\\_submissions@genome.wi.mit.edu](mailto:sequence_submissions@genome.wi.mit.edu)

Project Information

Center project name: L18289

Center clone name: 290\_E\_7

\* NOTE: This is a 'working draft' sequence. It currently  
 \* consists of 40 contigs. The true order of the pieces  
 \* is not known and their order in this sequence record is  
 \* arbitrary. Gaps between the contigs are represented as  
 \* runs of N, but the exact sizes of the gaps are unknown.  
 \* This record will be updated with the finished sequence  
 \* as soon as it is available and the accession number will  
 \* be preserved.  
 \* 1 121664: contig of 121664 bp in length  
 \* 121665 121764: gap of 100 bp  
 \* 121765 122426: contig of 662 bp in length

```

* 122427 122526: gap of 100 bp
* 122527 123632: contig of 106 bp in length
* 123633 123732: gap of 100 bp
* 123733 124478: contig of 746 bp in length
* 124479 124578: gap of 100 bp
* 124579 125233: contig of 655 bp in length
* 125234 125333: gap of 100 bp
* 125334 126116: contig of 1083 bp in length
* 126117 126516: gap of 100 bp
* 126517 127253: contig of 737 bp in length
* 127254 128020: contig of 667 bp in length
* 128021 128121: gap of 100 bp
* 128122 128805: contig of 685 bp in length
* 128806 129774: gap of 100 bp
* 129775 129806: contig of 869 bp in length
* 129807 129874: gap of 100 bp
* 129875 130556: contig of 682 bp in length
* 130557 130656: gap of 100 bp
* 130657 131603: contig of 947 bp in length
* 131604 131703: gap of 100 bp
* 131704 132737: contig of 1034 bp in length
* 132738 132837: gap of 100 bp
* 132838 133498: contig of 661 bp in length
* 133499 133598: gap of 100 bp
* 133599 134340: contig of 742 bp in length
* 134341 134440: gap of 100 bp
* 134441 135339: contig of 899 bp in length
* 135340 135439: gap of 100 bp
* 135440 136302: contig of 863 bp in length
* 136303 136402: gap of 100 bp
* 136403 137116: contig of 714 bp in length
* 137117 137216: gap of 100 bp
* 137217 137842: contig of 626 bp in length
* 137843 137942: gap of 100 bp
* 137943 139264: contig of 1322 bp in length
* 139265 139364: gap of 100 bp
* 139365 140707: contig of 1343 bp in length
* 140708 140807: gap of 100 bp
* 140808 141956: contig of 1149 bp in length
* 141957 142056: gap of 100 bp
* 142057 142855: contig of 799 bp in length
* 142856 142955: gap of 100 bp
* 142956 143957: contig of 1002 bp in length
* 143958 144057: gap of 100 bp
* 144058 144736: contig of 679 bp in length
* 144737 144836: gap of 100 bp
* 144837 146268: contig of 1432 bp in length
* 146269 146368: gap of 100 bp
* 146369 147694: contig of 1326 bp in length
* 147695 147794: gap of 100 bp
* 147795 148673: contig of 879 bp in length
* 148674 148773: gap of 100 bp
* 148774 149716: contig of 943 bp in length
* 149717 149816: gap of 100 bp
* 149817 150915: contig of 1099 bp in length
* 150916 151015: gap of 100 bp
* 151016 152223: contig of 1208 bp in length
* 152224 152323: gap of 100 bp
* 152324 153902: contig of 1579 bp in length
* 153903 154002: gap of 100 bp
* 154003 155546: contig of 1544 bp in length
* 155447 155646: gap of 100 bp
* 155647 156697: contig of 1051 bp in length
* 156698 156797: gap of 100 bp
* 156798 158478: contig of 1681 bp in length
* 158479 158578: gap of 100 bp
* 158579 159753: contig of 1175 bp in length
* 159754 159853: gap of 100 bp
* 159854 161008: contig of 1155 bp in length
* 161009 161108: gap of 100 bp
* 161109 162235: contig of 1127 bp in length
* 162236 162335: gap of 100 bp

```

## FEATURES

```

* 162336 163344: contig of 1009 bp in length
* 163345 163444: gap of 100 bp
* 163445 169230: contig of 5786 bp in length.
Location/Qualifiers
1..169230
/organism="Mus musculus"
/mol_type="genomic DNA"
/db_xref="taxon:10090"
/clone_id="RP24-290E7"
/clone_id="RPC1-24 Male Mouse BAC"
1..121664
/note="assembly_fragment"
clone end:SP6
vector side:left"
121765..122426
/note="assembly_fragment"
122527..123632
/note="assembly_fragment"
123733..124478
/note="assembly_fragment"
124579..125233
/note="assembly_fragment"
125334..126116
/note="assembly_fragment"
126117..127253
/note="assembly_fragment"
127354..128020
/note="assembly_fragment"
128121..128805
/note="assembly_fragment"
128906..129774
/note="assembly_fragment"
129875..130556
/note="assembly_fragment"
130657..131603
/note="assembly_fragment"
131704..132737
/note="assembly_fragment"
132838..133498

```

## Query Match

Best Local Similarity 100.0%; Pred. No. 3;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY

```

11 TCGCTCAGCTAGCCTGT 28
|||||
Db 65094 TCGCTCAGCTAGCCTGT 65111

```

## RESULT 11

AP002454

LOCUS Homo sapiens chromosome 18 clone RP11-819K4 map 18q21, WORKING

DEFINITION

DRAFT SEQUENCE, 29 unordered pieces.

ACCESSION

AP002454.1 GI:8307758

VERSION

HTG\_PHASE1; HTGS\_DRAFT.

KEYWORDS

Homo sapiens (human)

SOURCE

Homo sapiens

ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE

1 (bases 1 to 172921) Taylor, T.D., Hong-Seog, P., Hattori, M., Ishii, K., Toyoda, A., Totoroki, Y., Watanabe, H. and Sakaki, Y.

TITLE

Fujiyama, A., Yada, T., Totoroki, Y., Watanabe, H. and Sakaki, Y.

JOURNAL

Published Only in Database (2000)

REFERENCES

2 (bases 1 to 172921) Taylor, T.D., Hong-Seog, P., Hattori, M., Ishii, K., Toyoda, A., Totoroki, Y., Watanabe, H. and Sakaki, Y.

AUTHORS

Fujiyama, A., Yada, T., Totoroki, Y., Watanabe, H. and Sakaki, Y.

TITLE

Direct Submission

JOURNAL

Submitted (02-JUN-2000) Masahira Hattori, The Institute of Physical and Chemical Research (RIKEN), Genomic Sciences Center (GSC), Kitasato Univ., 1-15-1 Kitasato, Sagamihara, Kanagawa 228-8535,



misc\_feature 88367.95348  
 /note="assembly\_fragment"  
 misc\_feature 95449.101895  
 /note="assembly\_fragment"  
 misc\_feature 101996.107285  
 /note="assembly\_fragment"  
 misc\_feature 107386.113439  
 /note="assembly\_fragment"  
 misc\_feature 113540.120229  
 /note="assembly\_fragment"  
 misc\_feature 120330.126155  
 /note="assembly\_fragment"  
 misc\_feature 126256.132039  
 /note="assembly\_fragment"  
 misc\_feature 132130.136178  
 /note="assembly\_fragment"  
 misc\_feature 136279.140578  
 /note="assembly\_fragment"  
 misc\_feature 140679.144357  
 /note="assembly\_fragment"  
 misc\_feature 144458.147973  
 /note="assembly\_fragment"  
 misc\_feature 148074.151415  
 /note="assembly\_fragment"  
 misc\_feature 151516.155725  
 /note="assembly\_fragment"  
 misc\_feature 155826.158863  
 /note="assembly\_fragment"  
 misc\_feature 158964.161765  
 /note="assembly\_fragment"  
 misc\_feature 161866.164392  
 /note="assembly\_fragment"

Query Match 48.6% Score 18; DB 2; Length 172921;  
 Best Local Similarity 100.0%; Pred. No. 3;  
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CAGCTACCTGTGCAC 33  
 DB 34753 CAGCTACCTGTGCAC 34770

RESULT 12  
 LOCUS AC091843/c 177056 bp DNA linear PRI 27-FEB-2002  
 DEFINITION Homo sapiens chromosome 5 clone CTD-2185023, complete sequence.  
 ACCESSION AC091843  
 VERSION AC091843.3 GI:18958638  
 KEYWORDS HTG.  
 SOURCE Homo sapiens (human)  
 ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 REFERENCE 1 (bases 1 to 177056)  
 AUTHORS DOE Joint Genome Institute and Stanford Human Genome Center.  
 TITLE Direct Submission  
 JOURNAL Unpublished  
 REFERENCE 2 (bases 1 to 177056)  
 AUTHORS DOE Joint Genome Institute.  
 TITLE Direct Submission  
 JOURNAL Submitted (09-JUN-2001) Production Sequencing Facility, DOE Joint  
 Genome Institute, 2800 Mitchell Drive, Walnut Creek, CA 94598, USA  
 3 (bases 1 to 177056)  
 REFERENCE DOE Joint Genome Institute and Stanford Human Genome Center.  
 TITLE Direct Submission  
 JOURNAL Submitted (27-FEB-2002) DOE Joint Genome Institute, 2800 Mitchell  
 Drive, Walnut Creek, CA 94598, USA  
 On Feb 27, 2002 this sequence version replaced gi:15290412.  
 COMMENT Draft Sequence Produced by DOE Joint Genome Institute  
 www.jgi.doe.gov  
 www.jgi.doe.gov  
 Finishing Completed at Stanford Human Genome Center  
 www-shgc.stanford.edu  
 Quality: Phrap Quality >=40 100% of sequence;

FEATURES  
 source  
 location/Qualifiers  
 1. 177056  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 /chromosome="5"  
 /clone="CTD-2185023"

Query Match 48.6% Score 18; DB 9; Length 177056;  
 Best Local Similarity 100.0%; Pred. No. 3;  
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CAGCTACCTGTGCAC 33  
 DB 14662 CAGCTACCTGTGCAC 14645

RESULT 13  
 LOCUS AC090210/c 180851 bp DNA linear HTG 27-MAR-2003  
 DEFINITION Homo sapiens chromosome 18 clone RP11-720N18 map 18.  
 ACCESSION AC090210  
 VERSION AC090210.4 GI:15290848  
 KEYWORDS HTG; HTGS PHASE2; HTGS\_FULFILL; HTGS\_CANCELLED.  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 REFERENCE 1 (bases 1 to 180851)  
 AUTHORS Birren, B., Linton, L., Nusbaum, C. and Landry, E.  
 TITLE Direct Submission  
 JOURNAL Unpublished  
 REFERENCE 2 (bases 1 to 180851)  
 AUTHORS Birren, B., Linton, L., Nusbaum, C., Landry, E., Allen, N., Anderson, S.,  
 Berra, N., Baetien, V., Boguslavsky, L., Bouckgalter, B., Brown, A.,  
 Camarata, J., Campopiano, A., Choepel, Y., Colangelo, M., Collins, S.,  
 Collymore, A., Cooke, P., Dearlano, K., Dewar, K., Diaz, D., S.,  
 Dodge, S., Faro, S., Ferreira, P., Fitzhugh, W., Gage, D., Galagan, J.,  
 Gardina, S., Ginde, S., Goyette, M., Graham, M., Grand-Pierre, N.,  
 Hages, B., Heaford, A., Horton, L., Hulme, W., Iliev, I., Johnson, R.,  
 Jones, C., Karatas, A., Labrecque, K., Lamazares, R., Landers, T.,  
 Lehoczy, J., Levine, R., Liu, G., Maclean, C., Macdonald, P.,  
 Marquis, N., Mathews, C., McCarthy, M., McEwan, P., McKernan, K.,  
 McPheters, R., Melidim, J., Meneus, L., Minova, T., Menga, V.,  
 Murphy, T., Naylor, J., Nguyen, C., Norbu, C., Norman, C. H.,  
 O'Connor, T., O'Donnell, P., O'Neill, D., Oliver, J., Peterson, K.,  
 Phunkhang, P., Piere, N., Pollara, V., Raymond, C., Retta, R.,  
 Rieback, M., Riley, R., Rise, C., Rogov, P., Roman, J., Rosetti, M.,  
 Roy, A., Santos, R., Schauer, S., Schupack, R., Seaman, S., Severy, P.,  
 Sougnier, C., Spencer, B., Strange-Thomann, N., Stojanovic, N.,  
 Strauss, N., Subramanian, A., Talmas, J., Tesfaye, S., Theodore, J.,  
 Travers, M., Travis, N., Triggillo, J., Vassiliev, H., Veli, R., Vo, A.,  
 Wilson, B., Wu, X., Wyman, D., Ye, W. J., Young, G., Zainum, J.,  
 Zembek, L., Zimmer, A. and Zody, M.  
 TITLE Direct Submission  
 JOURNAL Submitted (17-FEB-2001) Whitehead Institute/MIT Center for Genome  
 Research, 320 Charles Street, Cambridge, MA 02141, USA  
 3 (bases 1 to 180851)  
 REFERENCE Birren, B., Linton, L., Nusbaum, C., Landry, E., Allen, N.,  
 Anderson, S., Berra, N., Baetien, V., Boguslavsky, L., Bouckgalter, B.,  
 Brown, A., Camarata, J., Campopiano, A., Chang, J., Chazaro, B.,  
 Choepel, Y., Colangelo, M., Collins, S., Collymore, A., Cook, A.,  
 Cooke, P., Dearlano, K., Dewar, K., Diaz, J. S., Dodge, S., Faro, S.,  
 Ferreira, P., Fitzhugh, W., Gage, D., Galagan, J., Gardina, S.,  
 Ginde, S., Goyette, M., Graham, M., Grand-Pierre, N.,  
 Hages, B., Heaford, A., Horton, L., Hulme, W., Iliev, I., Johnson, R.,  
 Jones, C., Karatas, A., Labrecque, K., Lamazares, R., Landers, T.,  
 Lehoczy, J., Levine, R., Liu, G., Maclean, C., Macdonald, P.,  
 Marquis, N., Mathews, C., McCarthy, M., McEwan, P., McKernan, K.,  
 McPheters, R., Melidim, J., Meneus, L., Minova, T., Menga, V.,  
 Murphy, T., Naylor, J., Nguyen, C., Norbu, C., Norman, C. H.,  
 O'Connor, T., O'Donnell, P., O'Neill, D., Oliver, J., Peterson, K.,  
 Phunkhang, P., Piere, N., Pollara, V., Raymond, C., Retta, R.,  
 Rieback, M., Riley, R., Rise, C., Rogov, P., Roman, J., Rosetti, M.,  
 Roy, A., Santos, R., Schauer, S., Schupack, R., Seaman, S., Severy, P.,  
 Sougnier, C., Spencer, B., Strange-Thomann, N., Stojanovic, N.,  
 Strauss, N., Subramanian, A., Talmas, J., Tesfaye, S., Theodore, J.,  
 Travers, M., Travis, N., Triggillo, J., Vassiliev, H., Veli, R., Vo, A.,  
 Wilson, B., Wu, X., Wyman, D., Ye, W. J., Young, G., Zainum, J.,  
 Zembek, L., Zimmer, A. and Zody, M.

Norbu, C., Norman, C.H., O'Connor, T., O'Donnell, P., O'Neill, D.,  
 Oliver, J., Peterson, K., Phukhang, P., Pierre, N., Pollara, V.,  
 Raymond, C., Rella, R., Rieback, M., Riley, R., Rise, C., Rogov, P.,  
 Roman, J., Rosetti, M., Roy, A., Santos, R., Schauer, S., Schupbach, R.,  
 Saman, S., Severy, P., Spencer, B., Stange-Thomann, N., Stojanovic, N.,  
 Straus, N., Subramanian, A., Talamas, D., Testa, S., Theodore, T.,  
 Tophan, K., Travers, M., Travis, N., Trigg, J., Vasilev, H.,  
 Viel, R., Vo, A., Wilson, B., Wu, X., Wyman, D., Ye, W.J., Young, G.,  
 Zainoun, J., Zembek, L., Zimmer, A., and Zody, M.  
 Direct Submission  
 Submitted (27-MAR-2003) Whitehead Institute/MIT Center for Genome  
 Research, 320 Charles Street, Cambridge, MA 02141, USA  
 On Aug 26, 2001 this sequence version replaced gi:14192981.  
 All repeats were identified using RepeatMasker:  
 Smit, A.F.A. & Green, P. (1996-1997)  
<http://ftp.genome.washington.edu/M/RepeatMasker.html>

Center: Whitehead Institute/ MIT Center for Genome Research

Center code: WIBR

Web site: <http://www-seq.wi.mit.edu>

Contact: [submissions@genome.wi.mit.edu](mailto:submissions@genome.wi.mit.edu)

Project Information

Center project name: L1223

Center clone name: 720\_N\_18

\* NOTE: This is a 'working draft' sequence. It currently  
 \* consists of 1 contigs. Gaps between the contigs  
 \* are represented as runs of N. The order of the pieces  
 \* is believed to be correct as given, however the sizes  
 \* of the gaps between them are based on estimates that have  
 \* provided by the submitter.  
 \* This sequence will be replaced  
 \* by the finished sequence as soon as it is available and  
 \* the accession number will be preserved.  
 \* 180851: contig of 180851 bp in length.

Location/Qualifiers

1. 180851

/organism="Homo sapiens"

/mol\_type="genomic DNA"

/db\_xref="taxon:9606"

/chromosome="18"

/map="18"

/clone="RP11-720N18"

/clone\_1b="RP11-720N18 Human Male BAC"

## ORIGIN

Query Match

Best Local Similarity 100.0%; Pred. No. 3;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

16 CAGCTAGCCTGTGCAC 33

DB 33216 CAGCTAGCCTGTGCAC 33199

## RESULT 14

AP001904/c

LOCUS

Homo sapiens chromosome 18 clone RP11-720N18 map 18g21, WORKING

DEFINITION

DRAFT SEQUENCE, 15 unordered pieces.

AP001904

AP001904.2 GI:8117555

HTG; HTGS PHASE1; HTGS\_DRAFT.

SOURCE

Homo sapiens (human)

ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

1 (bases 1 to 181211)

Hattori, M., Ishii, K., Toyoda, A., Taylor, T.D., Hong-Seog, P.,

Fujiyama, A., Yada, T., Totoki, Y., Watanabe, H. and Sakaki, Y.

Homosapiens 181,211 genomic DNA of 18g21

Published only in Database (2000)

2 (bases 1 to 181211)

## AUTHORS

TITLE

JOURNAL

## COMMENT

Hattori, M., Ishii, K., Toyoda, A., Taylor, T.D., Hong-Seog, P.,  
 Fujiyama, A., Yada, T., Totoki, Y., Watanabe, H. and Sakaki, Y.  
 Direct Submission  
 Submitted (24-APR-2000) Masahira Hattori, The Institute of Physical  
 and Chemical Research (RIKEN), Genomic Sciences Center (GSC),  
 Kitasato Univ., 1-15-1 Kitasato, Sagami-hara, Kanagawa 228-8555,  
 Japan (E-mail: [hattori@gsc.riken.go.jp](mailto:hattori@gsc.riken.go.jp)),  
 URL: <http://hgp.gsc.riken.go.jp/>, Tel: 81-42-778-9923,  
 Fax: 81-42-778-9924  
 On May 30, 2000 this sequence version replaced gi:7649791.  
 ----- Genome Center  
 Center: RIKEN Genomic Sciences Center (GSC)  
 Center code: RIKEN  
 Web site: <http://hgp.gsc.riken.go.jp/>  
 Contact: [hattori@gsc.riken.go.jp](mailto:hattori@gsc.riken.go.jp)  
 ----- Project Information  
 Center project name: Hummapfl8  
 Center clone name: RP11-720N18

----- Summary Statistics  
 Sequencing vector: PCR products; 100% of reads  
 Chemistry: Dye-terminator ET-amersham; 100% of reads  
 Assembly program: Phrap; version 0.990329  
 Consensus quality: 171968 bases at least Q40  
 Consensus quality: 176258 bases at least Q30  
 Consensus quality: 177945 bases at least Q20  
 Insert size: 179811; sum-of-contigs  
 Quality coverage: 5.94x in Q20 bases; sum-of-contigs

NOTE: This is a 'working draft' sequence. It currently consists of  
 15 contigs. The true order of the pieces is not known and their  
 order in this sequence record is arbitrary. Gaps between the  
 contigs are represented as runs N, but the exact sizes of the gaps  
 are unknown. This record will be updated with the finished sequence  
 as soon as it is available and the accession number will be  
 preserved.

1 33300 contig of 33300 bp in length  
 33401 54981 contig of 21581 bp in length  
 55082 73468 contig of 18387 bp in length  
 73569 94430 contig of 20862 bp in length  
 94531 113614 contig of 19084 bp in length  
 113715 123984 contig of 10270 bp in length  
 124085 137815 contig of 13721 bp in length  
 137916 147429 contig of 9514 bp in length  
 147530 154898 contig of 7369 bp in length  
 154999 162210 contig of 7212 bp in length  
 162311 168580 contig of 6270 bp in length  
 168681 175531 contig of 2851 bp in length  
 175632 175227 contig of 3356 bp in length  
 175328 178652 contig of 3325 bp in length  
 178753 181211 contig of 2459 bp in length

Sequence updated (26-May-2000).  
 NOTE: This is a 'working draft' sequence. It currently  
 consists of 15 contigs. The true order of the pieces  
 is not known and their order in this sequence record is  
 arbitrary. Gaps between the contigs are represented as  
 runs of N, but the exact sizes of the gaps are unknown.  
 This record will be updated with the finished sequence  
 as soon as it is available and the accession number will  
 be preserved.

1 33300: contig of 33300 bp in length  
 33301 33400: gap of 100 bp  
 33401 54981: contig of 21581 bp in length  
 54982 55081: gap of 100 bp  
 55082 73468: contig of 18387 bp in length  
 73469 73568: gap of 100 bp  
 73569 94430: contig of 20862 bp in length  
 94431 94530: gap of 100 bp  
 94531 113614: contig of 19084 bp in length  
 113615 113714: gap of 100 bp  
 113715 123984: contig of 10270 bp in length  
 123985 124084: gap of 100 bp  
 124085 137815: contig of 13721 bp in length  
 137816 137915: gap of 100 bp



```

* 137916 147429: contig of 9514 bp in length
* 147430 147529: gap of 100 bp
* 147530 154898: contig of 7369 bp in length
* 154899 154998: gap of 100 bp
* 154999 162210: contig of 7212 bp in length
* 162211 162310: gap of 100 bp
* 162311 168580: contig of 6270 bp in length
* 168581 168680: gap of 100 bp
* 168681 171531: contig of 2851 bp in length
* 171532 171631: gap of 100 bp
* 171632 175227: contig of 3596 bp in length
* 175228 175327: gap of 100 bp
* 175328 178652: contig of 3325 bp in length
* 178653 178753: gap of 100 bp
* 178753 181211: contig of 2459 bp in length.

```

```

FEATURES
source
1. 181211
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/chromosome="18"
/map="18q21"
/clone="RP11-720N18"
1. 33300
/misc_feature
/feature="assembly_fragment"
33401..54981
/feature="assembly_fragment"
55082..73468
/misc_feature
/feature="assembly_fragment clone_end:SP6 vector_side:right"
73569..94430
/misc_feature
/feature="assembly_fragment"
94531..113614
/misc_feature
/feature="assembly_fragment"
113715..123984
/misc_feature
/feature="assembly_fragment"
124085..137815
/misc_feature
/feature="assembly_fragment"
137916..147429
/misc_feature
/feature="assembly_fragment"
147530..154898
/misc_feature
/feature="assembly_fragment clone_end:RT vector_side:right"
154999..162210
/misc_feature
/feature="assembly_fragment"
162311..168580
/misc_feature
/feature="assembly_fragment"
168681..171531
/misc_feature
/feature="assembly_fragment"
171632..175227
/misc_feature
/feature="assembly_fragment"
175328..178652
/misc_feature
/feature="assembly_fragment"
178753..181211
/feature="assembly_fragment"

```

## ORIGIN

```

Query Match 48.6%; Score 18; DB 2; Length 181211;
Best Local Similarity 100.0%; Pred. No. 3;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 16 CAGCTTAGCCTGTGCAAC 33
DB 180151 CAGCTTAGCCTGTGCAAC 180134

```

```

RESULT 15
AC136510
LOCUS AC136510 186110 bp DNA linear HTG 18-MAR-2004
DEFINITION Pan troglodytes clone rp43-27n3, WORKING DRAFT SEQUENCE, 6 ordered
pieces.
ACCESSION AC136510
VERSION AC136510.17 GI:45544719
KEYWORDS HTG; HTGS PHASE2; HTGS DRAFT.
SOURCE Pan troglodytes (chimpanzee)

```

```

ORGANISM Pan troglodytes
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Pan.
REFERENCE
AUTHORS Lau,C.C.Y. and Roe,B.A.
TITLE 1 (bases 1 to 186110)
JOURNAL Pan troglodytes BAC clone rp43-27n3
REFERENCE
AUTHORS Lau,C.C.Y. and Roe,B.A.
TITLE 2 (bases 1 to 186110)
JOURNAL Direct Submmission
REFERENCE
AUTHORS Lau,C.C.Y. and Roe,B.A.
TITLE Submitted (05-NOV-2002) Department Of Chemistry And Biochemistry,
The University Of Oklahoma, 620 Parrington Oval, Room 208, Norman,
OK 73019, USA
REFERENCE
AUTHORS Lau,C.C.Y. and Roe,B.A.
TITLE 3 (bases 1 to 186110)
JOURNAL Direct Submmission

```

## COMMENT

```

Submitted (18-MAR-2004) Department Of Chemistry And Biochemistry,
The University Of Oklahoma, 620 Parrington Oval, Room 208, Norman,
OK 73019, USA
On Mar 18, 2004 this sequence version replaced gi:45476613.
----- Genome Center
Center: Department Of Chemistry And Biochemistry
The University Of Oklahoma
Center code:DOXNOR

```

```

* NOTE: This is a 'working draft' sequence. It currently
* consists of 6 contigs. Gaps between the contigs
* are represented as runs of N. The order of the pieces
* is believed to be correct as given, however the sizes
* of the gaps between them are based on estimates that have
* provided by the submittor.
* This sequence will be replaced
* by the finished sequence as soon as it is available and
* the accession number will be preserved.
1 76466: contig of 76466 bp in length
76467 76566: gap of unknown length
76567 82125: contig of 5559 bp in length
82126 82225: gap of unknown length
82226 92187: contig of 9962 bp in length
92188 92288: gap of unknown length
92289 94597: contig of 2310 bp in length
94598 94697: gap of unknown length
94698 112016: contig of 17319 bp in length
112017 112116: gap of unknown length
112117 186110: contig of 73994 bp in length.

```

## FEATURES

```

source
1. 186110
/organism="Pan troglodytes"
/mol_type="genomic DNA"
/db_xref="taxon:9598"
/clone="rp43-27n3"
/clone_lib="RPCI - 43 Male Chimpanzee BAC Library"

```

## ORIGIN

```

Query Match 48.6%; Score 18; DB 2; Length 186110;
Best Local Similarity 100.0%; Pred. No. 3;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 16 CAGCTTAGCCTGTGCAAC 33
DB 36383 CAGCTTAGCCTGTGCAAC 36400

```

```

Search completed: December 22, 2004, 23:36:46
Job time : 531.357 secs

```

**This Page Blank (uspto)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd

OM nucleic - nucleic search, using sw model

Run on: December 22, 2004, 19:14:28 ; Search time 130.588 Seconds  
(without alignments)  
1487.336 Million cell updates/sec

Title:	US-09-898-616A-4
Perfect score:	37
Sequence:	1 atggaagaatcgctcagtcctagcctgtgcaactaag 37

Scoring table: OLIGO NUC  
Gapop 60.0 , Gapext 60.0

Searched: 4134886 seqs, 2624710521 residues

Word size : 0

Total number of hits satisfying chosen parameters: 8269772

```
Minimum DB seq length: 0
Maximum DB seq length: 20000000000
```

Post-processing: Listing first 45 summaries

Database : N\_Geneseq\_23Sep04:\*

```

1:  gensesegqr1980s: *
2:  gensesegqr1990s: *
3:  gensesegqr2000s: *
4:  gensesegqr2001as: *
5:  gensesegqr2001bs: *
6:  gensesegqr2002as: *
7:  gensesegqr2002bs: *
8:  gensesegqr2003as: *
9:  gensesegqr2003bs: *
10: gensesegqr2003cs: *
11: gensesegqr2004as: *
12: gensesegqr2004bs: *

```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query	Length	DB	ID	Description
1	37	100.0	37	9	ABZ58373	ABZ58373 Human ute
2	37	100.0	37	12	ADL276229	ADL276229 Recombinational
3	37	100.0	60	9	ABZ58374	ABZ58374 Human ute
4	37	100.0	60	12	ADL27630	ADL27630 Recombinational
5	16	43.2	698	4	AAK69658	AAK69658 Human imm
6	16	43.2	699	4	AAK69659	AAK69659 Human imm
7	16	43.2	699	4	AAK69660	AAK69660 Human imm
8	15	40.5	477	9	ACH14100	ACH14100 Human adu
9	15	40.5	621	4	AAI92367	AAI92367 Human pol
10	15	40.5	675	10	ADB35086	ADB35086 Mouse mit
11	15	40.5	1043	2	AAZ24882	AAZ24882 Human sec
12	15	40.5	1089	2	AAK37460	AAK37460 Human sec
13	15	40.5	1601	3	AAK28524	AAK28524 Human opi
14	15	40.5	1786	10	ADD44906	ADD44906 Rat gene
15	15	40.5	2289	3	AAK48556	AAK48556 Human opi
16	15	40.5	2290	3	AAK48552	AAK48552 Human opi
17	15	40.5	2348	3	AAK48555	AAK48555 Human opi
18	15	40.5	2408	3	AAK48523	AAK48523 Human opi
19	15	40.5	2409	4	AAH17441	AAH17441 Human cdn
20	15	40.5	2423	10	ADD14783	ADD14783 Human strc
21	15	40.5	3460	10	ADZ56935	ADZ56935 Rat gene

22	15	40.5	3715	8	ADAI5021	Mutrine an
22	15	40.5	4065	8	ADAI6913	Human pho
24	15	40.5	8003	6	ABR99404	B. mori t
25	15	40.5	13660	4	AA199126	Human exc
26	15	40.5	13660	4	AAK81002	Human imm
27	15	40.5	13660	4	AAK67807	Human imm
28	15	40.5	13660	5	AAI63476	Human kid
29	15	40.5	16122	4	AA522808	AA522808
30	15	40.5	16341	4	AA523002	DNA encod
31	15	40.5	28001	12	AD136729	Genomic L
32	15	40.5	28001	12	AD136730	Genomic L
33	15	40.5	28001	12	ADM93169	Human KOX
34	15	40.5	28001	12	ADM93170	Human KOX
35	15	40.5	78025	8	ABQ77404	Human SEL
36	15	40.5	153170	12	AD017382	Adq17382
37	15	40.5	183610	8	ACF62736	Cancer ba
38	15	40.5	183610	8	ADB20851	MRP1 base
39	15	40.5	183610	10	ADB87940	Human UtrG
40	15	40.5	183610	10	ADB56923	Human MRP1
41	15	40.5	183610	10	ADB92114	Human MDR
42	15	40.5	186591	8	ACF62750	Cancer ba
43	15	40.5	186591	8	ADB20869	MRP1 base
44	15	40.5	186591	10	ADB87958	Human UtrG
45	15	40.5	186591	10	ADB96941	Human MDR1

## ALIGNMENTS

	RESULT
XX	1
XX	ID ABZ58373
XX	ABZ58373 standard; DNA; 37 BP.
XX	AZ58373;
DT	28-APR-2003 (first entry)
DE	Human uteroglobin synthetic gene oligonucleotide 4.
XX	Human; uteroglobin; respiratory distress; antiinflammatory; antifibrotic
KW	antiinflammation; antiasthmatic; nephrotoxic; antipneumatic;
KW	antiarthritic; ss.
OS	Homo sapiens.
OS	Synthetic.
EN	MO2003003979-AZ.
FD	16-JAN-2003.
PF	02-JUL-2002; 2002WO-US020836.
PR	02-JUL-2001; 2001US-00898616.
PA	(CLAR-) CLARAGEN INC.
PI	Pilon AL, Welch RE;
DR	WPI; 2003-221527/21.
XX	Bacterial expression system for producing recombinant human uteroglobin
PT	for treating inflammatory and fibrotic conditions, comprises a synthetic
PT	gene which codes for human uteroglobin.
PS	Claim 1; Page 33; 127BP; English.
XX	The present sequence is that of oligonucleotide 4, which was used in the
CC	construction of a synthetic gene for the production of human uteroglobin
CC	(hUG) in bacteria. Oligonucleotides 1-4' (see ABZ58370-73) were used to
CC	assemble the coding strand and oligonucleotides 5-8' (see ABZ58374-77) the
CC	complementary strand. The gene was assembled by annealing and ligation of
CC	the oligonucleotides. Because mature native hUG has glutamic acid at its
CC	N-terminus, an initiator methionine was added to the N-terminus, and

CC codon usage was optimised for expression in bacteria. In an example from  
CC the invention, the synthetic gene was cloned into plasmid pC312 (see  
CC AB258378) and recombinant rhUG (see AB272259) was produced in *Escherichia*  
CC coli strain CG12. The invention relates generally to the production of  
CC recombinant rhUG by bacterial expression, protein purification and scaled-  
CC up production according to current good manufacturing practices. The  
CC recombinant rhUG is useful for the treatment of inflammatory and fibrotic  
CC conditions, such as neonatal respiratory distress syndrome and  
CC bronchopulmonary dysplasia. It may also be used to treat conditions  
CC associated with elevated phospholipase A2 levels such as pancreatitis,  
CC acute renal failure, rheumatoid arthritis and asthma.

SO Sequence 37 BP; 11 A; 8 C; 10 G; 8 T; 0 U; 0 Other;

Query Match 100.0%; Score 37; DB 9; Length 37;  
Best Local Similarity 100.0%; Pred. No. 4.8e-11;  
Matches 37; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATGAGAGAGATCGCTCAGTCTAGCCTGTGCACACTAG 37  
1 ATGAGAGAGATCGCTCAGTCTAGCCTGTGCACACTAG 37

Db 1 ATGAGAGAGATCGCTCAGTCTAGCCTGTGCACACTAG 37

RESULT 2  
ID ADL27629 standard; DNA; 37 BP.  
XX ADL27629;  
AC ADL27629;  
XX 20-MAY-2004 (first entry)  
DT  
XX  
DE Recombinant human uteroglobin, rhUG, coding oligonucleotide #4.  
XX  
KM Human; ss; recombinant human uteroglobin, rhUG;  
KM bacterial expression system; rhUG master cell bank;  
KM rhUG research seed bank; anti-inflammatory; secretory phospholipase A 2;  
KM fibronectin; respiratory distress; inflammation; fibrotic disease.  
XX  
OS Homo sapiens.  
OS Synthetic.  
OS  
XX US2003207795-A1.  
PN  
XX  
PD 06-NOV-2003.  
XX  
PE 02-JUL-2002; 2002US-00187498.  
XX  
PR 28-MAY-1997; 97US-00864357.  
PR 02-JUL-2001; 2001US-00898616.  
XX  
XX (PILON) PILON A L.  
XX (WELCH) WELCH R W.  
XX  
XX Pilon AL, Welch RW;  
XX  
XX WPI; 2004-051527/05.  
XX  
XX Bacterial expression system for production of recombinant human  
PT uteroglobin comprising synthetic gene or human cDNA sequence which codes  
PT for human uteroglobin.  
XX  
XX  
PS Claim 1; SEQ ID NO 4; 64bp; English.

CC The invention relates to a bacterial expression system for the production  
CC of recombinant human uteroglobin (rhUG), comprising a synthetic gene or  
CC human cDNA sequence which codes for human rhUG, constructed from the  
CC oligonucleotides appearing as ADL27626-ADL27629, and which further  
CC comprises Met-Ala-Ala at the N-terminus of the sequence. Also included  
CC are producing an rhUG master cell bank (comprising inoculating a suitable  
CC incubating broth with an aliquot portion of a rhUG research seed bank to  
CC form a bacterial culture, incubating the bacterial culture, adding a  
CC cryoprotective to the bacterial culture to form a cryopreserved  
CC solution, transferring a portion of the cryopreserved solution to a

CC cryovial and storing the cryovial at a temperature below -60 degrees C),  
CC expressing rhUG (comprising providing a production seed cell bank culture  
CC comprising an expression vector capable of expressing rhUG, inoculating a  
CC broth medium with the production seed cell bank culture to form an  
CC inoculum, incubating the bacterial culture formed in step (b) from the  
CC inoculating a large scale fermenter with the inoculum formed from the  
CC step (c) to form a fermentation culture, adding an induction agent to  
CC the fermentation culture to induce the expression of rhUG and harvesting  
CC the above fermentation culture), purifying rhUG, determining the potency  
CC of rhUG in a sample, measuring in vitro anti-inflammatory effect arising  
CC from inhibition or blocking of secretory phospholipase A 2 enzymes by  
CC rhUG, measuring in vitro binding of rhUG to fibronectin, determining the  
CC purity of rhUG, and a pharmaceutical composition comprising a purified  
CC rhUG and a carrier or diluent. The bacterial expression system is useful  
CC for producing a rhUG research seed bank or a pharmaceutical grade rhUG  
CC drug substance. The rhUG is safe to administer to a patient in respiratory  
CC distress. The rhUG is useful for treating inflammation and fibrotic  
CC diseases. The present sequence is a coding strand oligonucleotide used to  
CC construct the synthetic rhUG gene.

SO Sequence 37 BP; 11 A; 8 C; 10 G; 8 T; 0 U; 0 Other;

Query Match 100.0%; Score 37; DB 12; Length 37;  
Best Local Similarity 100.0%; Pred. No. 4.8e-11;  
Matches 37; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATGAGAGAGATCGCTCAGTCTAGCCTGTGCACACTAG 37  
1 ATGAGAGAGATCGCTCAGTCTAGCCTGTGCACACTAG 37

Db 1 ATGAGAGAGATCGCTCAGTCTAGCCTGTGCACACTAG 37

RESULT 3  
ID AB258374/c  
XX AB258374 standard; DNA; 60 BP.  
XX  
AC AB258374;  
XX  
DT 28-APR-2003 (first entry)  
XX  
DE Human uteroglobin synthetic gene oligonucleotide 5.  
XX  
KM Human; uteroglobin; respiratory distress; anti-inflammatory; antifibrotic;  
KM anti-inflammatory; antiaesthetic; nephrotropic; antithematic;  
KM antiaesthetic; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
OS  
XX WO2003003979-A2.  
PN  
XX  
PD 16-JAN-2003.  
XX  
PE 02-JUL-2002; 2002MO-US020836.  
XX  
PR 02-JUL-2001; 2001US-00898616.  
XX  
XX (CLAR-) CLARAGEN INC.  
XX  
XX Pilon AL, Welch RE;  
XX  
XX WPI; 2003-221527/21.  
XX  
XX Bacterial expression system for producing recombinant human uteroglobin  
PT for treating inflammatory and fibrotic conditions, comprises a synthetic  
PT gene which codes for human uteroglobin.  
XX  
XX  
PS Example 1; Page 33; 127bp; English.

CC The present sequence is that of oligonucleotide 5, which was used in the  
CC construction of a synthetic gene for the production of human uteroglobin  
CC (rhUG) in bacteria. Oligonucleotides 1-4 (see AB258370-73) were used to  
CC assemble the coding strand and oligonucleotides 5-8 (see AB258374-77) the

complementary strand. The gene was assembled by annealing and ligation of the oligonucleotides. Because mature hUG has glutamic acid at its N-terminus, an initiator methionine was added to the N-terminus, and the codon usage was optimised for expression in bacteria. In an example from the invention, the synthetic gene was cloned into plasmid pCG12 (see ABZ68378), and recombinant hUG (see ABP72259) was produced in *Escherichia coli* strain CG12. The invention relates generally to the production of recombinant hUG by bacterial expression, protein purification and scaled-up production according to current good manufacturing practices. The recombinant hUG is useful for the treatment of inflammatory and fibrotic conditions, such as neonatal respiratory distress syndrome and bronchopulmonary dysplasia. It may also be used to treat conditions associated with elevated phospholipase A2 levels such as pancreatitis, acute renal failure, rheumatoid arthritis and asthma.

Sequence 60 BP; 13 A; 14 C; 15 G; 18 T; 0 U; 0 Other;

Query Match 100.0%; Score 37; DB 9; Length 60;  
Best Local Similarity 100.0%; Pred. No. 4.8e-11;  
Matches 37; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 ATGAGAGATCGCTCAGCTTACGCTGTGCACTTAAG 37  
37 ATGAGAGATCGCTCAGCTTACGCTGTGCACTTAAG 1

RESULT 4  
ADL27630/C  
ID ADL27630 standard; DNA; 60 BP.  
XX  
XX ADL27630;  
XX  
XX 20-MAY-2004 (first entry)  
XX  
DE Recombinant human uteroglobin, rhUG, non-coding oligonucleotide #1.  
XX  
XX Human; 6S; recombinant human uteroglobin; rhUG;  
XX bacterial expression system; rhUG master cell bank;  
XX rhUG research seed bank; anti-inflammatory; secretory phospholipase A 2;  
XX fibronectin; respiratory distress; inflammation; fibrotic disease.  
XX  
XX Homo sapiens.  
XX Synthetic.  
XX  
XX US2003207795-A1.  
XX  
XX 06-NOV-2003.  
XX  
XX 02-JUL-2002; 2002US-00187498.  
XX  
XX 28-MAY-1997; 97US-00864357.  
XX  
XX 02-JUL-2001; 2001US-00898616.  
XX  
XX (PILO/) PILON A L.  
XX (WELC/) WELCH R W.  
XX  
XX Pilon AL, Welch RW;  
XX  
XX WPI; 2004-051527/05.  
XX  
XX Bacterial expression system for production of recombinant human  
XX uteroglobin comprising synthetic gene or human cDNA sequence which codes  
XX for human uteroglobin.  
XX  
XX Example 1; SEQ ID NO 5; 64bp; English.  
XX  
XX The invention relates to a bacterial expression system for the production  
XX of recombinant human uteroglobin (rhUG), comprising a synthetic gene or  
XX human cDNA sequence which codes for human UG, constructed from the  
XX oligonucleotides appearing as ADL27626-ADL27629, and which further  
XX comprises Met-Ala-Ala at the N-terminus of the sequence. Also included  
XX are producing an rhUG master cell bank (comprising inoculating a suitable  
XX incubating broth with an aliquot portion of a rhUG research seed bank to

form a bacterial culture, incubating the bacterial culture, adding a cryoprotective to the bacterial culture to form a cryopreserved solution, transferring a portion of the cryopreserved solution to a cryovial and storing the cryovial at a temperature below -60 degrees C), expressing rhUG (comprising providing a production seed cell bank culture comprising an expression vector capable of expressing rhUG, inoculating a broth medium with the production seed cell bank culture to form an inoculum, incubating the bacterial culture formed in step (b), inoculating a large scale fermenter with the inoculum formed from the step (c) to form a fermentation culture, incubating the fermentation culture within the large scale fermenter, adding an induction agent to the fermentation culture to induce the expression of rhUG and harvesting the above fermentation culture), purifying rhUG, determining the potency of rhUG in a sample, measuring in vitro anti-inflammatory effect arising from inhibition or blocking of secretory phospholipase A 2 enzymes by rhUG, measuring in vitro binding of rhUG to fibronectin, determining the purity of rhUG, and a pharmaceutical composition comprising a purified rhUG and a carrier or diluent. The bacterial expression system is useful for producing a rhUG research seed bank or a pharmaceutical grade rhUG drug substance. rhUG is safe to administer to a patient in respiratory distress. The rhUG is useful for treating inflammation and fibrotic diseases. The present sequence is a non-coding strand oligonucleotide used to construct the synthetic rhUG gene.

Sequence 60 BP; 13 A; 14 C; 15 G; 18 T; 0 U; 0 Other;

Query Match 100.0%; Score 37; DB 12; Length 60;  
Best Local Similarity 100.0%; Pred. No. 4.8e-11;  
Matches 37; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 ATGAGAGATCGCTCAGCTTACGCTGTGCACTTAAG 37  
37 ATGAGAGATCGCTCAGCTTACGCTGTGCACTTAAG 1

RESULT 5  
AAK69658/C  
ID AAK69658 standard; DNA; 698 BP.  
XX  
XX AAK69658;  
XX  
XX 06-NOV-2001 (first entry)  
XX  
XX Human immune/haematopoietic antigen genomic sequence SEQ ID NO:24470.  
XX  
XX Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;  
XX cytostatic; gene therapy; vaccine; metastasis; ds.  
XX  
XX Homo sapiens.  
XX  
XX WO200157182-A2.  
XX  
XX 09-AUG-2001.  
XX  
XX 17-JAN-2001; 2001WO-US001354.  
XX  
XX 31-JAN-2000; 2000US-0179065P.  
XX  
XX 04-FEB-2000; 2000US-0180628P.  
XX  
XX 24-FEB-2000; 2000US-0184664P.  
XX  
XX 02-MAR-2000; 2000US-0186350P.  
XX  
XX 16-MAR-2000; 2000US-0189874P.  
XX  
XX 17-MAR-2000; 2000US-0190076P.  
XX  
XX 18-APR-2000; 2000US-0198123P.  
XX  
XX 19-MAY-2000; 2000US-0205515P.  
XX  
XX 07-JUN-2000; 2000US-0209467P.  
XX  
XX 28-JUN-2000; 2000US-0214886P.  
XX  
XX 30-JUN-2000; 2000US-0215135P.  
XX  
XX 07-JUL-2000; 2000US-0216647P.  
XX  
XX 07-JUL-2000; 2000US-0216880P.  
XX  
XX 11-JUL-2000; 2000US-0217487P.  
XX  
XX 11-JUL-2000; 2000US-0217496P.  
XX  
XX 14-JUL-2000; 2000US-0218290P.  
XX  
XX 26-JUL-2000; 2000US-0220963P.



CC sequences from the present invention. AAK54942 to AAK54950 and AAK82169  
CC represent sequences used in the exemplification of the present invention  
XX  
SQ Sequence 698 BP; 270 A; 116 C; 107 G; 205 T; 0 U; 0 Other;

Query Match 43.2%; Score 16; DB 4; Length 698;  
Best Local Similarity 100.0%; Pred. No. 30;  
Matches 16; Conservative 0; Mismatches 0; Gaps 0;

QY 17 AGCTAGCCTGTGCA 32  
Db 664 AGCTAGCCTGTGCA 649

RESULT 6  
AAK69659/c  
ID AAK69659 standard; DNA; 699 BP.

AC AAK69659;

DT 06-NOV-2001 (first entry)

XX Human immune/haematopoietic antigen genomic sequence SEQ ID NO:24471.

XX Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;  
KW cytostatic; gene therapy; vaccine; metastasis; ds.

OS Homo sapiens.

XX WO200157182-A2.

XX 09-AUG-2001.

PD 17-JAN-2001; 2001WO-US001354.

XX 31-JAN-2000; 2000US-0179065P.

PR 04-FEB-2000; 2000US-0180628P.

PR 24-FEB-2000; 2000US-0184684P.

PR 02-MAR-2000; 2000US-0186350P.

PR 16-MAR-2000; 2000US-0189874P.

PR 17-MAR-2000; 2000US-0190076P.

PR 18-APR-2000; 2000US-0198123P.

PR 19-MAY-2000; 2000US-0205515P.

PR 07-JUN-2000; 2000US-0209457P.

PR 28-JUN-2000; 2000US-0214888P.

PR 30-JUN-2000; 2000US-0215135P.

PR 07-JUL-2000; 2000US-0216880P.

PR 11-JUL-2000; 2000US-0217487P.

PR 14-JUL-2000; 2000US-0218290P.

PR 26-JUL-2000; 2000US-0220963P.

PR 26-JUL-2000; 2000US-0220963P.

PR 14-AUG-2000; 2000US-0224518P.

PR 14-AUG-2000; 2000US-0224518P.

PR 14-AUG-2000; 2000US-0225213P.

PR 14-AUG-2000; 2000US-0225213P.

PR 14-AUG-2000; 2000US-0225213P.

PR 14-AUG-2000; 2000US-0225213P.

PR 01-SEP-2000; 2000US-0229344P.

PR 01-SEP-2000; 2000US-0229345P.

PR 05-SEP-2000; 2000US-0229509P.

PR 05-SEP-2000; 2000US-0229513P.

PR 06-SEP-2000; 2000US-0230437P.

PR 06-SEP-2000; 2000US-0230438P.

PR 08-SEP-2000; 2000US-0231242P.

PR 08-SEP-2000; 2000US-0231243P.

PR 08-SEP-2000; 2000US-0231244P.

PR 08-SEP-2000; 2000US-0231413P.

PR 08-SEP-2000; 2000US-0231414P.

PR 08-SEP-2000; 2000US-0232080P.

PR 08-SEP-2000; 2000US-0232081P.

PR 12-SEP-2000; 2000US-0231958P.

PR 14-SEP-2000; 2000US-0232377P.

PR 14-SEP-2000; 2000US-0232398P.

PR 14-SEP-2000; 2000US-0232399P.

PR 14-SEP-2000; 2000US-0232400P.

PR 14-SEP-2000; 2000US-0232401P.

PR 14-SEP-2000; 2000US-0233063P.

PR 14-SEP-2000; 2000US-0233064P.

PR 14-SEP-2000; 2000US-0233065P.

PR 21-SEP-2000; 2000US-0234223P.

PR 21-SEP-2000; 2000US-0234274P.

PR 25-SEP-2000; 2000US-0234937P.

PR 25-SEP-2000; 2000US-0234938P.

PR 26-SEP-2000; 2000US-0235484P.

PR 27-SEP-2000; 2000US-0235836P.

PR 29-SEP-2000; 2000US-0236327P.

PR 29-SEP-2000; 2000US-0236367P.

PR 29-SEP-2000; 2000US-0236369P.

PR 29-SEP-2000; 2000US-0236369P.

PR 29-SEP-2000; 2000US-0236370P.

PR 02-OCT-2000; 2000US-0236802P.

PR 02-OCT-2000; 2000US-0237037P.

PR 02-OCT-2000; 2000US-0237038P.

PR 02-OCT-2000; 2000US-0237039P.

PR 02-OCT-2000; 2000US-0237040P.

PR 13-OCT-2000; 2000US-0239935P.

PR 13-OCT-2000; 2000US-0239937P.

PR 20-OCT-2000; 2000US-0240960P.

PR 20-OCT-2000; 2000US-0241221P.

PR 20-OCT-2000; 2000US-0241785P.

PR 20-OCT-2000; 2000US-0241786P.

PR 20-OCT-2000; 2000US-0241787P.

PR 20-OCT-2000; 2000US-0241808P.

PR 20-OCT-2000; 2000US-0241809P.

PR 01-NOV-2000; 2000US-0244617P.

PR 01-NOV-2000; 2000US-0244617P.

PR 08-NOV-2000; 2000US-0246475P.

PR 08-NOV-2000; 2000US-0246476P.

PR 08-NOV-2000; 2000US-0246477P.

PR 08-NOV-2000; 2000US-0246532P.

PR 08-NOV-2000; 2000US-0246533P.

PR 08-NOV-2000; 2000US-0246533P.

PR 08-NOV-2000; 2000US-0246534P.

PR 08-NOV-2000; 2000US-0246535P.

PR 08-NOV-2000; 2000US-0246536P.

PR 08-NOV-2000; 2000US-0246537P.

PR 08-NOV-2000; 2000US-0246538P.

PR 08-NOV-2000; 2000US-0246539P.

PR 08-NOV-2000; 2000US-0246539P.

PR 17-NOV-2000; 2000US-0249210P.

PR 17-NOV-2000; 2000US-0249211P.

PR 17-NOV-2000; 2000US-0249212P.

PR 17-NOV-2000; 2000US-0249212P.

PR 17-NOV-2000; 2000US-0249213P.

PR 17-NOV-2000; 2000US-0249213P.





```

PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234222P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234979P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0234998P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 13-OCT-2000; 2000US-0239355P.
PR 13-OCT-2000; 2000US-0239379P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 01-NOV-2000; 2000US-0244826P.
PR 08-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0244747P.
PR 08-NOV-2000; 2000US-0244752P.
PR 08-NOV-2000; 2000US-0244766P.
PR 08-NOV-2000; 2000US-0244777P.
PR 08-NOV-2000; 2000US-0244785P.
PR 08-NOV-2000; 2000US-0245232P.
PR 08-NOV-2000; 2000US-0245234P.
PR 08-NOV-2000; 2000US-0245252P.
PR 08-NOV-2000; 2000US-0245253P.
PR 08-NOV-2000; 2000US-0245277P.
PR 08-NOV-2000; 2000US-0245282P.
PR 08-NOV-2000; 2000US-0245328P.
PR 08-NOV-2000; 2000US-0246039P.
PR 08-NOV-2000; 2000US-0246101P.
PR 08-NOV-2000; 2000US-0246113P.
PR 17-NOV-2000; 2000US-0248207P.
PR 17-NOV-2000; 2000US-0248208P.
PR 17-NOV-2000; 2000US-0248209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249298P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251855P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.

```

```

PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Rosen CA, Barash SC, Ruben SM;
XX WPI, 2001-483426/52.
XX
XX Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
XX useful for preventing, diagnosing and/or treating cancers and metastasis.
XX
XX Disclosure, SEQ ID NO 24472; 3071bp + Sequence Listing, English.
XX
XX AAK54991 to AAK64702 encode the human immune/hematopoietic antigen (I)
XX amino acid sequences given in AAK62170 to AAK61921. (I) have cytostatic
XX activity, and can be used in gene therapy and vaccine production. (I)
XX proteins and polynucleotides may be used in the prevention, diagnosis and
XX treatment of diseases associated with inappropriate (I) expression. For
XX example, they may be used to treat disorders associated with decreased
XX expression by rectifying mutations or deletions in a patient's genome
XX that affect the activity of (I) by expressing inactive proteins or to
XX supplement the patient's own production of (I). Additionally, (I)
XX polynucleotides may be used to produce the secreted (I), by inserting the
XX nucleic acids into a host cell and culturing the cell to express the
XX protein. (I) proteins and polynucleotides may be used to prevent,
XX diagnose and treat immune/hematopoietic-related diseases, especially
XX cancer and cancer metastases of hematopoietic-derived cells. AAK64703
XX to AAK67694 represent human immune/hematopoietic antigen genomic
XX sequences from the present invention. AAK54942 to AAK54950 and AAK62169
XX represent sequences used in the exemplification of the present invention
XX
XX Sequence 699 BP; 270 A; 115 C; 107 G; 207 T; 0 U; 0 Other;
XX
XX Query Match 43.2%; Score 16; DB 4; Length 699;
XX Best Local Similarity 100.0%; Pred. No. 30;
XX Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 17 AGTCTAGCCTGTGCA 32
XX |||||
XX DB 665 AGTCTAGCCTGTGCA 650
XX
XX RESULT 8
XX ACH14100
XX ID ACH14100 standard; cDNA; 477 BP.
XX
XX ACH14100;
XX
XX AC 13-OCT-2003 (first entry)
XX
XX DT 13-OCT-2003 (first entry)
XX
XX DE Human adult brain cDNA #1312.
XX
XX XX Human, ss; sequencing by hybridisation. SM; expressed sequence tag; EST;
XX KM genome mapping; biodiversity; genetic disorder.
XX
XX OS Homo sapiens.
XX
XX PN US2003073623-A1.
XX
XX XX 17-APR-2003.
XX
XX PD 30-JUL-2001; 2001US-00918995.
XX
XX PF 30-JUL-2001; 2001US-00918995.
XX
XX PR 30-JUL-2001; 2001US-00918995.
XX
XX XX (DRMA/) DRMANAC R T.
XX PA (LABA/) LABAT I.
XX PA (STRAC/) STRACHE-CRAIN B.
XX PA (DICK/) DICKSON M C.
XX (JONE/) JONES L W.
XX

```

XX Drmanac RT, Labat I, Scache-Crain B, Dickson MC, Jones LW;  
 PI WPI; 2003-615964/58.  
 XX  
 PT New polynucleotide sequences obtained from various cDNA libraries, useful  
 PT as hybridization probes, as oligomers for PCR, for chromosome and gene  
 PT mapping, in the recombinant production of protein, or in generating  
 PT antisense DNA or RNA.  
 PS Claim 1: SEQ ID NO 1312; 44bp; English.  
 CC The invention relates to an isolated polynucleotide comprising any one of  
 CC 38043 cDNA sequences, appearing as ACh12789-ACH5081, whose sequence was  
 CC determined by the technique of SBH (sequencing by hybridisation). Also  
 CC included is a purified polypeptide comprising a sequence corresponding to  
 CC a reading frame of the novel polynucleotide. The nucleic acid sequences  
 CC are useful in diagnostics as expressed sequence tags (EST) for  
 CC identifying expressed genes or for physical mapping of the human genome,  
 CC in forensics, in assessing biodiversity, or in identifying mutations  
 CC responsible for genetic disorders and other traits. The nucleotide  
 CC sequences are also useful as hybridisation probes, as oligomers for PCR,  
 CC for chromosome and gene mapping, in the recombinant production of  
 CC protein, or in generating antisense DNA or RNA. The purified polypeptide  
 CC is useful for generating antibodies specific for it. The present sequence  
 CC is one of the 38043 isolated cDNA/EST sequences. Note: The sequence data  
 CC for this patent did not form part of the printed specification, but was  
 CC obtained in electronic format directly from USPTO at  
 CC seqdata.uspto.gov/sequence.html?DocID=20030073623  
 CC  
 SQ Sequence 477 BP; 101 A; 116 C; 194 G; 52 T; 0 U; 14 Other;  
 XX  
 Query Match 40.5%; Score 15; DB 9; Length 477;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;  
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 2 TGGAGAGATCGCTC 16  
 Db 305 TGGAGAGATCGCTC 319  
 XX  
 RESULT 9  
 AA192367  
 ID AA192367 standard; cDNA; 621 BP.  
 XX  
 AC AA192367;  
 XX  
 DT 06-NOV-2001 (first entry)  
 XX  
 DE Human polynucleotide SEQ ID NO 12427.  
 XX  
 KW Human; cytokine; cell proliferation; cell differentiation; gene therapy;  
 KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;  
 KW tissue growth factor; immunomodulatory; cancer; leukaemia;  
 KW nervous system disorders; arthritis; inflammation; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PA WO200164835-A2.  
 XX  
 PI 07-SEP-2001.  
 XX  
 PD 26-FEB-2001; 2001WO-US004927.  
 XX  
 PF 28-FEB-2000; 2000US-00515126.  
 XX  
 PR 18-MAY-2000; 2000US-00577409.  
 XX  
 PA (HYSE-) HYSEQ INC.  
 XX  
 PI Tang YT, Liu C, Drmanac RT;  
 XX  
 DR WPI; 2001-514838/56.  
 DR P-PSDB; AAC12436.

XX  
 PT Isolated nucleic acids and polypeptides, useful for preventing diagnosing  
 PT and treating e.g. leukemia, inflammation and immune disorders.  
 XX  
 PS Claim 1: SEQ ID NO 12427; 1399bp + Sequence listing; English.  
 CC The invention relates to human polynucleotides (AA19941-AA19841) and  
 CC the encoded proteins (AA00010-AA01310) that exhibit activity relating to  
 CC cytokine, cell proliferation or cell differentiation or which may induce  
 CC production of other cytokines in other cell populations. The  
 CC polynucleotides and polypeptides are useful in gene therapy, vaccines or  
 CC peptide therapy. The polypeptides have various cytokine-like activities,  
 CC e.g. stem cell growth factor activity, haematopoietic regulatory  
 CC activity, tissue growth factor activity, immunomodulatory activity and  
 CC activity/inhibin activity and may be useful in the diagnosis and/or  
 CC treatment of cancer, leukaemia, nervous system disorders, arthritis and  
 CC inflammation. Note: The sequence data for this patent did not form part  
 CC of the printed specification, but was obtained in electronic format  
 CC directly from WIPO at ftp.wipo.int/pub/published\_pct\_sequences  
 CC  
 SQ Sequence 621 BP; 152 A; 162 C; 137 G; 168 T; 0 U; 2 Other;  
 XX  
 Query Match 40.5%; Score 15; DB 4; Length 621;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;  
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 19 TCTAGCCTGTGCAC 33  
 Db 113 TCTAGCCTGTGCAC 127  
 XX  
 RESULT 10  
 ADD35086  
 ID ADD35086 standard; DNA; 675 BP.  
 XX  
 AC ADD35086;  
 XX  
 DT 15-JAN-2004 (first entry)  
 XX  
 DE Mouse mitochondrial DNA sequence SEQ ID NO:2866.  
 XX  
 KW ds; mouse; array; mitochondrial; hybridisation; energy metabolism;  
 KW mitochondrial disease; oxidative phosphorylation dysfunction;  
 KW oxidative stress; apoptosis; aging.  
 XX  
 OS Mus musculus.  
 XX  
 PA WO2003020220-A2.  
 XX  
 PI 13-MAR-2003.  
 XX  
 PD 30-AUG-2002; 2002WO-US027886.  
 XX  
 PF 30-AUG-2001; 2001US-0316323P.  
 XX  
 PR 31-AUG-2001; 2001CA-02356540.  
 XX  
 PA (UYEM-) UNIV EMORY.  
 XX  
 PI Wallace DC, Levy S, Kerstann K, Procaccio V;  
 XX  
 DR WPI; 2003-300821/29.  
 XX  
 PT Array containing probes for genes involved in mitochondrial biology,  
 PT useful for determining mitochondrial biology gene expression profiles for  
 PT use in diagnosing pathologies and identifying biochemical pathways.  
 XX  
 PS Claim 2: SEQ ID NO 2866; 201bp; English.  
 CC The invention relates to a novel array comprising at least two isolated  
 CC nucleotide molecules, each molecule having a sequence capable of uniquely  
 CC hybridising to a nucleic acid molecule which is an expression product of  
 CC a gene involved in mitochondrial biology. The array comprises two or more  
 CC isolated nucleic acid molecules or spots, each molecule having a sequence

CC chosen from sequence of 994 human probes and 2046 mouse probes. An array  
CC of the invention is useful for determining an expression profile of a  
CC mouse or human sample containing nucleic acid, by contacting the array  
CC with the sample under conditions allowing selective hybridization, and  
CC measuring hybridization of nucleic acid in the sample to the array to  
CC produce an expression profile. The array is also useful for determining  
CC an expression profile of a first labeled sample containing nucleic acid  
CC relative to a second, differently labeled sample containing nucleic  
CC acid. The second sample is a reference or a standard. An array is useful  
CC for determining an expression profile diagnostic of an energy-metabolism-  
CC related physiological condition. An array of the invention is useful for  
CC determining mitochondrial biology gene expression profiles of organisms,  
CC such as human, mice and closely related species, tissue and organs of  
CC such organisms, which are useful for determining expression profiles  
CC diagnostic of energy metabolism-related physiological conditions,  
CC diagnosing such physiological conditions, identifying biochemical  
CC pathways, genes, and mutations involved in such physiological conditions,  
CC identifying therapeutic agents useful for preventing and/or treating such  
CC physiological conditions, evaluating and/or monitoring the efficacy of  
CC such therapies, and creating and identifying animal models of human  
CC energy metabolism-related physiological conditions. An array is also  
CC useful for defining expression signatures or profiles for mitochondrial  
CC diseases, as well as distinguishing clinical disorders that result from  
CC oxidative phosphorylation (OXPHOS) dysfunction, oxidative stress,  
CC apoptosis and aging. An array of the invention contains probes of genes  
CC not previously recognised to participate in mitochondrial biology. The  
CC sequences shown in A033224-A033260 represent murine mitochondrial DNA  
CC clones used to make the probe of the invention. Some sequences are not  
CC present, these are SEQ ID NOs 295, 1174, 1213, 1700, 1728, 1730, 1905,  
CC 1906, 2408 and 2643.

CC Sequence 675 BP; 173 A; 142 C; 129 G; 221 T; 0 U; 0 Other;

CC Query Match 40.5%; Score 15; DB 10; Length 675;

CC Best Local Similarity 100.0%; Pred. No. 1.1e+02; Indels 0; Gaps 0;

CC Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CC 15 TCAGCTGACCTGCTG 29

CC 301 TCAGCTGACCTGCTG 315

CC RESULT 11  
CC AA224882/C  
CC ID AA224882 standard; DNA; 1043 BP.

CC AA224882;

CC 02-DEC-1999 (first entry)

CC Human secreted protein gene 72 clone H86GA29.

CC Human; secreted protein; fusion protein; gene therapy; protein therapy;  
CC diagnosis; tissue; cancer; tumour; neurodegenerative disorder; leukemia;  
CC developmental abnormality; foetal deficiency; blood; allergy; renal; ds;  
CC immune system; asthma; lymphocytic disease; brain; hepatic; lymphoma;  
CC inflammation; ischaemic shock; Alzheimer's disease; osteoclast; AIDS;  
CC cognitive disorder; schizophrenia; prostate; obesity; osteoclast; thymus;  
CC osteoporosis; arthritis; testis; lung; thyroiditis; thyroid; digestion;  
CC endocrine; metabolism; regulation; malabsorption; gastritis; neoplasm.

CC Homo sapiens.

CC MO9947540-A1.

CC 23-SEP-1999.

CC 18-MAR-1999; 99WO-US005894.

CC 19-MAR-1999; 98US-0078563P.

CC 19-MAR-1999; 98US-0078563P.

CC 19-MAR-1999; 98US-0078573P.

CC 19-MAR-1999; 98US-0078574P.

PR 19-MAR-1998; 98US-0078576P.  
PR 19-MAR-1998; 98US-0078577P.  
PR 19-MAR-1998; 98US-0078578P.  
PR 19-MAR-1998; 98US-0078579P.  
PR 19-MAR-1998; 98US-0078581P.  
PR 01-APR-1998; 98US-0080312P.  
PR 01-APR-1998; 98US-0080313P.  
PR 01-APR-1998; 98US-0080314P.

PA (HUMA-) HUMAN GENOME SCI INC.

PI Ruben SM, Ni U, Rosen CA, Yu G, Young PE, Feng P, Soppet DR;

PI Wei Y, Endress GA, Duan RD, Kyaw H, Edner R, Lafleur DM, Olsen HS,

PI Shi Y, Moore PA;

DR WPI; 1999-562050/47.

DR P-FSDB; AAY41379.

PT New isolated human genes, useful for diagnosis and treatment of e.g.

PT cancers, neurological disorders, immune diseases, inflammation or blood

PT disorders.

PS Claim 1; Page 341; 484p; English.

CC This sequence represents a nucleic acid molecule which encodes a secreted  
CC human protein. The gene number, and the clone it is derived from, are  
CC detailed in the descriptor line. The gene can be used to generate fusion  
CC proteins by linking to the gene to a human immunoglobulin Fc portion  
CC (e.g. AA224882) for increasing the stability of the fused protein as  
CC compared to the human protein only. The invention relates to 95 novel  
CC genes and their fragments (nucleic acid sequences: AA224811-224907; amino  
CC acid sequences AAY41308-Y41404) which are useful for preventing, treating  
CC or ameliorating medical conditions e.g. by protein or gene therapy. Also,  
CC pathological conditions can be diagnosed by determining the amount of the  
CC new polypeptides in a sample or by determining the presence of mutations  
CC in the new polynucleotides. Specific uses are described for each of the  
CC 95 polynucleotides, based on which tissues they are most highly expressed  
CC in (see AA224811 for described uses)

CC Sequence 1043 BP; 281 A; 236 C; 291 G; 235 T; 0 U; 0 Other;

CC Query Match 40.5%; Score 15; DB 2; Length 1043;

CC Best Local Similarity 100.0%; Pred. No. 1.1e+02; Indels 0; Gaps 0;

CC Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CC 19 TCTAGCCCTGTCACAC 33

CC 597 TCTAGCCCTGTCACAC 583

CC RESULT 12  
CC AA37460  
CC ID AA37460 standard; cDNA; 1089 BP.

CC AA37460;

CC 06-JUL-1999 (first entry)

CC Human secreted protein cDNA fragment containing gene 10.

CC Human; secreted protein; treatment; prevention; protein therapy; AIDS;  
CC gene therapy; diagnosis; cancer; tumour; neurodegenerative disorder;  
CC developmental abnormality; foetal deficiency; blood disorder; leukemia;  
CC immune system disease; autoimmune disease; hepatic disease; lymphoma;  
CC renal disease; inflammation; allergy; Alzheimer's disease; schizophrenia;  
CC cognitive disorder; prostate disease; skeletal; cardiac; muscle disorder;  
CC pulmonary disorder; transplant rejection; osteoclast; osteoporosis;  
CC arthritis; malignancy; digestive; endocrine; infection; ss.

CC Homo sapiens.

CC WO9918208-A1.

```

PD 15-APR-1999.
XX
PF 01-OCT-1998; 98MO-US020775.
XX
PR 02-OCT-1997; 97US-0060833P.
PR 02-OCT-1997; 97US-0060836P.
PR 02-OCT-1997; 97US-0060837P.
PR 02-OCT-1997; 97US-0060838P.
PR 02-OCT-1997; 97US-0060839P.
PR 02-OCT-1997; 97US-0060843P.
PR 02-OCT-1997; 97US-0060862P.
PR 02-OCT-1997; 97US-0060866P.
PR 02-OCT-1997; 97US-0060874P.
PR 02-OCT-1997; 97US-0060880P.
PR 02-OCT-1997; 97US-0060884P.
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Duan DR, Florence KA, Rosen CA, Ruben SM, Greene JM, Young P,
PI Ferrie AM, Yu G, Janat F, Ni J, Carter KC, Endress GA, Feng P,
PI Latleur DM, Shi Y;
XX
DR WPI; 1999-264022/22.
DR P-PSDB; AAY07861.
XX
PT New isolated human genes and the secreted polypeptides they encode.
XX
PS Claim 1a; Page 232-233; 368pp; English.
XX
CC This invention describes novel isolated human genes and the secreted
CC proteins they encode. The products of the invention are useful for
CC preventing, treating or ameliorating medical conditions, e.g. by protein
CC or gene therapy. Also pathological conditions can be diagnosed by
CC determining the amount of the new polypeptides in a sample or by
CC determining the presence of mutations in the new polynucleotides.
CC Specific uses are described for each of the 101 polynucleotides, based on
CC which tissues they are most highly expressed in, and include developing
CC products for the diagnosis or treatment of cancer, tumours,
CC neurodegenerative disorders, developmental abnormalities and fetal
CC deficiencies, blood disorders, leukemias, diseases of the immune system,
CC autoimmune diseases, hepatic and renal disease, lymphomas, inflammation,
CC allergies, Alzheimer's and cognitive disorders, pulmonary disorders,
CC disease, skeletal or cardiac muscle disorders, primary disorders,
CC osteoporosis, rejection, disorders involving osteoclasts such as
CC osteopetrosis, arthritis or malignancies, digestive/endocrine disorders,
CC infections and AIDS. The human secreted proteins of the invention are
CC represented in AAY07852-Y07993 and the encoding nucleic acids are
CC represented in AAX37451-X37552
XX
SQ Sequence 1089 BP; 367 A; 202 C; 240 G; 279 T; 0 U; 1 Other;
XX
Query Match 40.5%; Score 15; DB 2; Length 1089;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3 GGAGAGATCGCTCA 17
DB 14 GGAGAGATCGCTCA 28
XX
RESULT 13
AAA28524
ID AAA28524 standard; cDNA; 1601 BP.
XX
AC AAA28524;
XX
DT 29-AUG-2000 (first entry)
XX
DE Human opioid growth factor receptor cDNA spliced version 1.
XX
KW OGR; opioid growth factor receptor; growth inhibitor; proliferative;
KW cytoskeletal; vulnary; gene therapy; antagonist; chromosome 20q13.3; ss.
XX

```

```

OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT 5' UTR 1..33
FT CDS /tag= a
FT CDS 34..1419
FT 3' UTR /tag= b
FT /product= "Opioid_growth_factor_receptor"
FT /tag= c
XX
EN MO200026340-A2.
XX
PD 11-MAY-2000.
XX
PF 02-NOV-1999; 99MO-US025802.
XX
PR 03-NOV-1998; 98US-0106879P.
XX
PA (PENN-) PENN STATE RES FOUND.
XX
PI Zagon IS, McLaughlin PJ, Verderame MF;
XX
PI WPI; 2000-365594/31.
XX
DR P-PSDB; AAY92810.
XX
PT New cDNA encoding rat and human opioid growth factor receptors which
PT modulate cell growth, useful for treating cancer.
XX
PS Claim 1; Page 82-83; 91pp; English.
XX
CC Primers generated from rat opioid growth factor receptor (OGFR) cDNA were
CC used to clone a fragment of the human OGFR cDNA. The complete sequence of
CC human OGFR was assembled with a combination of 3' and 5' RACE. 5' RACE
CC consistently yielded a single species of cDNA, while the 3' RACE revealed
CC extensive alternative splicing. The alternate splice forms were missing
CC the imperfect repeats or differed in the number of imperfect repeats. The
CC human OGFR gene chromosomal location was determined by FISH as 20q13.3.
CC OGFR proteins, nucleic acid molecules, antibodies, transformed cells and
CC expression vector are useful for detecting expression or levels of an
CC OGFR in a tissue. OGFR nucleic acids can be used to inhibit growth of
CC cells in vitro. The antisense sequences and antibodies can be used to
CC promote growth of cells in vitro. Cell growth can be promoted by
CC interfering with the OGFR ligand-receptor system, especially where a
CC subject suffers from a tissue wound. Treating cancer comprises enhancing
CC the function of the OGFR ligand-receptor system in cancerous cells of a
CC patient or administering the OGFR nucleic acid to the patient
XX
SQ Sequence 1601 BP; 322 A; 485 C; 558 G; 236 T; 0 U; 0 Other;
XX
Query Match 40.5%; Score 15; DB 3; Length 1601;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2 TGGAGAGATCGCTC 16
DB 1253 TGGAGAGATCGCTC 1267
XX
RESULT 14
ADD44906/c
ID ADD44906 standard; DNA; 1756 BP.
XX
AC ADD44906;
XX
DT 29-JAN-2004 (first entry)
XX
DE Rat gene Y15054, SEQ ID NO 10337.
XX
KW Rat; ds; gene; pain; neuronal tissue; gene therapy;
KW spinal segmental nerve injury; chronic constriction injury; CCI;
KW spared nerve injury; SNI; Chung.
XX

```

OS Rattus norvegicus.  
 XX  
 XX WO2003016475-A2.  
 XX  
 PD 27-FEB-2003.  
 XX  
 PF 14-AUG-2002; 2002WO-US025765.  
 XX  
 XX 14-AUG-2001; 2001US-0312147P.  
 PR 01-NOV-2001; 2001US-0346382P.  
 PR 26-NOV-2001; 2001US-0333347P.  
 XX  
 PA (GHEO) GEN HOSPITAL CORP.  
 PA (PARB) BAYER AG.  
 FI Woolf C, D'urso D, Befort K, Costigan M;  
 XX WPI; 2003-268312/26.  
 DR GENBANK; Y15054.  
 XX  
 PT New composition comprising two or more isolated polypeptides, useful for  
 XX preparing a medicament for treating pain in an animal.  
 XX  
 PS Claim 1; Page: 1017P; English.

XX The invention discloses a composition comprising two or more isolated rat  
 CC or human polynucleotides or a polynucleotide which represents a fragment,  
 CC derivative or allelic variation of the nucleic acid sequence. Also  
 CC claimed are a vector comprising the novel polynucleotide, a host cell  
 CC comprising the vector, a method for identifying a nucleotide sequence  
 CC which is differentially regulated in an animal subjected to pain and a  
 CC kit to perform the method, an array, a method for identifying an agent  
 CC that increases or decreases the expression of the polynucleotide sequence  
 CC that is differentially expressed in neuronal tissue of a first animal  
 CC subjected to pain, a method for identifying a compound which regulates  
 CC the expression of a polynucleotide sequence which is differentially  
 CC expressed in an animal subjected to pain, a method for identifying a  
 CC compound that regulates the activity of one or more of the  
 CC polynucleotides, a method for producing a pharmaceutical composition, a  
 CC method for identifying a compound or small molecule that regulates the  
 CC activity in an animal of one or more of the polypeptides given in the  
 CC specification, a method for identifying a compound useful in treating  
 CC pain and a pharmaceutical composition comprising the one or more  
 CC polypeptides or their antibodies. The polynucleotide or the compound that  
 CC modulates its activity is useful for preparing a medicament for treating  
 CC pain (e.g. spinal segmental nerve injury (Chung), chronic constriction  
 CC injury (CCI) and spared nerve injury (SNI)) in an animal (e.g. gene  
 CC therapy). The sequence presented is a rat DNA (shown in Table 2 of the  
 CC specification) which encodes one of the polypeptides of the invention  
 CC which is differentially expressed during pain. Note: The sequence data  
 CC for this patent did not form part of the printed specification, but was  
 CC obtained in electronic form directly from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences.

SO Sequence 1756 BP; 355 A; 543 C; 484 G; 374 T; 0 U; 0 Other;

Query Match 40.5%; Score 15; DB 10; Length 1756;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 GCTCAGCTAGCCTG 27  
 DB 402 GCTCAGCTAGCCTG 388

RESULT 15  
 AAA28526  
 ID AAA28526 standard; cDNA; 2289 BP.  
 XX  
 AC AAA28526;  
 XX  
 DT 29-AUG-2000 (first entry)  
 XX

DE Human opioid growth factor receptor cDNA spliced version 7.  
 XX  
 XX OGRF, opioid growth factor receptor; growth inhibitor; proliferative;  
 KM cytostatic; vulnerary, gene therapy; antagonist; chromosome 20q13.3; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 XX Key Location/Qualifiers  
 FH 1..33  
 FT 5'UTR /tag= a  
 FT CDS 34..2007 /tag= b  
 FT /product= "Opioid\_growth\_factor\_receptor"  
 FT 2008..2289  
 FT 3'UTR /tag= c  
 XX  
 XX WO200026340-A2.  
 XX  
 XX 11-MAY-2000.  
 XX  
 XX 02-NOV-1999; 99WO-US025802.  
 XX  
 XX 03-NOV-1998; 98US-0106879P.  
 XX  
 XX (PENN-) PENN STATE RES FOUND.  
 XX  
 XX Zagon IS, McLaughlin PJ, Verderame MF;  
 XX WPI; 2000-365594/31.  
 XX P-PDB; AA92812.

PT New cDNA encoding rat and human opioid growth factor receptors which  
 PT modulate cell growth, useful for treating cancer.  
 XX  
 PS Claim 1; Page 87-89; 91pp; English.

CC Primers generated from rat opioid growth factor receptor (OGRF) cDNA were  
 CC used to clone a fragment of the human OGRF cDNA. The complete sequence of  
 CC human OGRF was assembled with a combination of 3' and 5' RACE. 5' RACE  
 CC consistently yielded a single species of cDNA, while the 3' RACE revealed  
 CC extensive alternative splicing. The alternate splice forms were missing  
 CC the imperfect repeats or differed in the number of imperfect repeats. The  
 CC human OGRF gene chromosomal location was determined by FISH as 20q13.3.  
 CC OGRF proteins, nucleic acid molecules, antibodies, transformed cells and  
 CC expression vector are useful for detecting expression or levels of an  
 CC OGRF in a tissue. OGRF nucleic acids can be used to inhibit growth of  
 CC cells in vitro. The antisense sequences and antibodies can be used to  
 CC promote growth of cells in vitro. Cell growth can be promoted by  
 CC interfering with the OGRF ligand-receptor system, especially where a  
 CC subject suffers from a tissue wound. Treating cancer comprises enhancing  
 CC the function of the OGRF ligand-receptor system in cancerous cells of a  
 CC patient or administering the OGRF nucleic acid to the patient

SO Sequence 2289 BP; 470 A; 714 C; 809 G; 296 T; 0 U; 0 Other;

Query Match 40.5%; Score 15; DB 3; Length 2289;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 TGGAGAGATGCTC 16  
 DB 1253 TGGAGAGATGCTC 1267

Search completed: December 22, 2004, 22:44:23  
 Job time : 136.838 secs

This Page Blank (uspio)

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Comugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 22, 2004, 22:08:48 ; Search time 29.8009 Seconds  
(without alignments)  
882.496 Million cell updates/sec

Title: US-09-898-616A-4

Perfect score: 37  
Sequence: 1 atgagagaagatcgctcagctcgtcgaactaag 37

Scoring table: OLIGO\_NUC  
Gapop 60.0, Gapext 60.0

Searched: 824507 seqs, 355394441 residues

Word size: 0

Total number of hits satisfying chosen parameters: 1649014

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Listing first 45 summaries

Database: Issued Patents NA.\*

1: /cgn2\_6/ptodata/1/ina/5A.COMB.seq.\*  
2: /cgn2\_6/ptodata/1/ina/5B.COMB.seq.\*  
3: /cgn2\_6/ptodata/1/ina/6A.COMB.seq.\*  
4: /cgn2\_6/ptodata/1/ina/6B.COMB.seq.\*  
5: /cgn2\_6/ptodata/1/ina/PCUTS.COMB.seq.\*  
6: /cgn2\_6/ptodata/1/ina/backfile1.seq.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	37	100.0	37	US-08-864-357F-9	Sequence 9, Appl
2	37	100.0	60	US-08-864-357F-10	Sequence 10, Appl
3	15	40.5	3715	US-09-234-245-1	Sequence 1, Appl
4	14	37.8	283	US-08-760-534A-5	Sequence 5, Appl
5	14	37.8	283	US-09-336-757-5	Sequence 5, Appl
6	14	37.8	341	US-09-513-999C-3565	Sequence 3565, Ap
7	14	37.8	422	US-09-621-976-12461	Sequence 12461, A
8	14	37.8	553	US-08-463-115-26	Sequence 26, Appl
9	14	37.8	553	US-08-465-388-26	Sequence 26, Appl
10	14	37.8	715	US-08-463-115-18	Sequence 18, Appl
11	14	37.8	715	US-08-465-388-18	Sequence 18, Appl
12	14	37.8	1374	US-09-253-991A-5999	Sequence 5999, Ap
13	14	37.8	1540	US-08-463-115-2	Sequence 2, Appl
14	14	37.8	1540	US-08-465-388-2	Sequence 2, Appl
15	14	37.8	1899	US-09-253-991A-6306	Sequence 6306, Ap
16	14	37.8	2196	US-09-799-461-298	Sequence 298, App
17	14	37.8	2196	US-08-472-217-3	Sequence 3, Appl
18	14	37.8	2196	US-08-760-534A-3	Sequence 3, Appl
19	14	37.8	2196	US-09-336-757-3	Sequence 3, Appl
20	14	37.8	2895	US-09-556-877-171	Sequence 171, App
21	14	37.8	2895	US-09-620-412C-171	Sequence 171, App
22	14	37.8	2895	US-09-598-419-171	Sequence 171, App
23	14	37.8	2934	US-09-556-877-183	Sequence 183, App
24	14	37.8	2934	US-09-620-412C-183	Sequence 183, App
25	14	37.8	2934	US-09-598-419-183	Sequence 183, App
26	14	37.8	4000	US-09-780-049-18	Sequence 18, Appl
27	14	37.8	72604	US-09-268-992-7	Sequence 7, Appl

C 28	14	37.8	72604	3	US-09-657-474-7	Sequence 7, Appl
C 29	14	37.8	1830121	4	US-09-557-884-1	Sequence 1, Appl
C 30	14	37.8	1830121	4	US-09-643-990A-1	Sequence 1, Appl
C 31	14	37.8	1830121	4	US-10-329-960-1	Sequence 1, Appl
C 32	14	37.8	4403765	3	US-09-103-840A-2	Sequence 2, Appl
C 33	14	37.8	4411529	3	US-09-103-840A-1	Sequence 1, Appl
C 34	13	35.1	271	4	US-09-313-294A-695	Sequence 695, App
C 35	13	35.1	289	4	US-08-651-155B-12	Sequence 12, Appl
C 36	13	35.1	289	4	US-09-194-036B-12	Sequence 12, Appl
C 37	13	35.1	297	4	US-09-252-991A-8030	Sequence 8030, Ap
C 38	13	35.1	301	4	US-09-270-767-2113	Sequence 2113, Ap
C 39	13	35.1	301	4	US-09-270-767-17395	Sequence 17395, A
C 40	13	35.1	342	4	US-10-101-464A-147	Sequence 147, App
C 41	13	35.1	348	3	US-08-844-059-3	Sequence 3, Appl
C 42	13	35.1	348	3	US-09-431-202-3	Sequence 3, Appl
C 43	13	35.1	369	4	US-09-270-767-14734	Sequence 14734, A
C 44	13	35.1	410	4	US-09-221-017B-273	Sequence 273, App
C 45	13	35.1	423	4	US-09-252-991A-11388	Sequence 11388, A

#### ALIGNMENTS

```

RESULT 1
US-08-864-357F-9
; Sequence 9, Application US/08864357F
; Patent No. 6255281
; GENERAL INFORMATION:
; APPLICANT: Clagen, Inc. & NIH
; TITLE OF INVENTION: Use of Recombinant Human Uteroglobulin in Treatment of Inflammato
; FILE REFERENCE: 116142/2
; CURRENT APPLICATION NUMBER: US/08/864,357F
; CURRENT FILING DATE: 1997-05-28
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9
; LENGTH: 37
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: primer sequence
US-08-864-357F-9
Query Match      100.0%; Score 37; DB 3; Length 37;
Best Local Similarity 100.0%; Pred. No. 2.2e-12;
Matches 37; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      1 ATGAGAGAAGATCGCTCAGTCTAGCCTGTGCACTAAG 37
DB      1 ATGAGAGAAGATCGCTCAGTCTAGCCTGTGCACTAAG 37
RESULT 2
US-08-864-357F-10/c
; Sequence 10, Application US/08864357F
; Patent No. 6255281
; GENERAL INFORMATION:
; APPLICANT: Clagen, Inc. & NIH
; TITLE OF INVENTION: Use of Recombinant Human Uteroglobulin in Treatment of Inflammato
; FILE REFERENCE: 116142/2
; CURRENT APPLICATION NUMBER: US/08/864,357F
; CURRENT FILING DATE: 1997-05-28
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 10
; LENGTH: 60
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: primer sequence
US-08-864-357F-10

```





MOLECULE TYPE: CDNA  
US-09-336-757-5

Query Match 37.8%; Score 14; DB 4; Length 283;  
Best Local Similarity 100.0%; Pred. No. 43;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 15 TCAGCTAGCCTGT 28  
DB 269 TCAGCTAGCCTGT 256

RESULT 6  
US-09-513-999C-3565/C  
Sequence 3565, Application US/09513999C  
Patent No. 6783961  
GENERAL INFORMATION:  
APPLICANT: Dumas Milne Edwards, J.B.  
APPLICANT: Duclet, A.  
APPLICANT: Giordano, J.Y.  
TITLE OF INVENTION: Expressed Sequence Tags and Encoded Human Proteins.  
Patent No. 6783961  
FILE REFERENCE: 59 US2, REG  
CURRENT APPLICATION NUMBER: US/09/513, 999C  
CURRENT FILING DATE: 2000-02-24  
PRIOR APPLICATION NUMBER: US 60/122,487  
PRIOR FILING DATE: 1999-02-26  
NUMBER OF SEQ ID NOS: 36681  
SOFTWARE: Patent.pm  
SEQ ID NO 3565  
LENGTH: 341  
TYPE: DNA  
ORGANISM: Homo sapiens  
FEATURE:  
NAME/KEY: CDS  
LOCATION: 22..339  
US-09-513-999C-3565

Query Match 37.8%; Score 14; DB 4; Length 341;  
Best Local Similarity 100.0%; Pred. No. 43;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CAGCTAGCCTGTG 29  
DB 111 CAGCTAGCCTGTG 98

RESULT 7  
US-09-621-976-12461  
Sequence 12461, Application US/09621976  
Patent No. 6639063  
GENERAL INFORMATION:  
APPLICANT: Dumas Milne Edwards, J.B.  
APPLICANT: Gobert, S.  
APPLICANT: Giordano, J.Y.  
TITLE OF INVENTION: ESTs and Encoded Human Proteins.  
FILE REFERENCE: GENSET, 054PR2  
CURRENT APPLICATION NUMBER: US/09/621, 976  
CURRENT FILING DATE: 2000-07-21  
NUMBER OF SEQ ID NOS: 19335  
SOFTWARE: Patent.pm  
SEQ ID NO 12461  
LENGTH: 422  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-621-976-12461

Query Match 37.8%; Score 14; DB 4; Length 422;  
Best Local Similarity 100.0%; Pred. No. 43;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 20 TCAGCCTGTGCAAC 33  
DB 111 TCAGCCTGTGCAAC 33

DB 354 TCAGCCTGTGCAAC 367

RESULT 8  
US-08-463-115-26  
Sequence 26, Application US/08463115  
Patent No. 5703221  
GENERAL INFORMATION:  
APPLICANT: WILLIAM JOHN MARTIN  
TITLE OF INVENTION: ISOLATED STEALTH VIRUSES  
TITLE OF INVENTION: AND RELATED VACCINES  
NUMBER OF SEQUENCES: 104  
CORRESPONDENCE ADDRESS:  
ADDRESS: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066

COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FastSeq Version 1.5  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/463,115  
FILING DATE: June 5, 1995  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
PRIOR APPLICATION DATA: including application  
PRIOR APPLICATION DATA: described below:  
APPLICATION NUMBER: 08/157,811  
FILING DATE: No. 5703221member 23, 1993  
APPLICATION NUMBER: 07/887,502  
FILING DATE: May 22, 1992  
APPLICATION NUMBER: 07/704,814  
FILING DATE: May 23, 1991  
APPLICATION NUMBER: 07/763,039  
FILING DATE: September 20, 1991  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 213/301  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 26:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 553 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
FEATURE:  
OTHER INFORMATION:

US-08-463-115-26

Query Match 37.8%; Score 14; DB 1; Length 553;  
Best Local Similarity 100.0%; Pred. No. 43;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 19 TCAGCCTGTGCAA 32  
DB 310 TCAGCCTGTGCAA 323

RESULT 9  
US-08-465-388-26  
Sequence 26, Application US/08465388  
Patent No. 5753468  
GENERAL INFORMATION:

APPLICANT: WILLIAM JOHN MARTIN  
TITLE OF INVENTION: ISOLATED STEALTH VIRUSES  
NUMBER OF SEQUENCES: 104  
CORRESPONDENCE ADDRESSES:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FastSeq Version 1.5  
CURRENT APPLICATION DATA:  
FILING DATE: June 5, 1995  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
PRIOR APPLICATION DATA: including application  
PRIOR APPLICATION DATA: described below:  
APPLICATION NUMBER: 08/157,811  
FILING DATE: No. 5753488ember 23, 1993  
APPLICATION NUMBER: 07/887,502  
FILING DATE: May 22, 1992  
APPLICATION NUMBER: 07/704,814  
FILING DATE: May 23, 1991  
APPLICATION NUMBER: 07/763,039  
FILING DATE: September 20, 1991  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 213/300  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 26:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 553 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
FEATURE:  
OTHER INFORMATION:  
US-08-465-388-26

Query Match 37.8%; Score 14; DB 1; Length 553;  
Best Local Similarity 100.0%; Pred. No. 43;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 19 TCTAGCCTGTGCA 32  
DB 310 TCTAGCCTGTGCA 323

RESULT 10  
US-08-463-115-18  
Sequence 18, Application US/08463115  
Patent No. 5703221  
GENERAL INFORMATION:  
APPLICANT: WILLIAM JOHN MARTIN  
TITLE OF INVENTION: ISOLATED STEALTH VIRUSES  
NUMBER OF SEQUENCES: 104  
CORRESPONDENCE ADDRESSES:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible

CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FastSeq Version 1.5  
CURRENT APPLICATION DATA:  
FILING DATE: June 5, 1995  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
PRIOR APPLICATION DATA: including application  
PRIOR APPLICATION DATA: described below:  
APPLICATION NUMBER: 08/157,811  
FILING DATE: No. 5703221ember 23, 1993  
APPLICATION NUMBER: 07/887,502  
FILING DATE: May 22, 1992  
APPLICATION NUMBER: 07/704,814  
FILING DATE: May 23, 1991  
APPLICATION NUMBER: 07/763,039  
FILING DATE: September 20, 1991  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 213/301  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 18:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 715 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
FEATURE:  
OTHER INFORMATION:  
US-08-463-115-18

Query Match 37.8%; Score 14; DB 1; Length 715;  
Best Local Similarity 100.0%; Pred. No. 43;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 19 TCTAGCCTGTGCA 32  
DB 325 TCTAGCCTGTGCA 338

RESULT 11  
US-08-465-388-18  
Sequence 18, Application US/08465388  
Patent No. 5753468  
GENERAL INFORMATION:  
APPLICANT: WILLIAM JOHN MARTIN  
TITLE OF INVENTION: ISOLATED STEALTH VIRUSES  
NUMBER OF SEQUENCES: 104  
CORRESPONDENCE ADDRESSES:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FastSeq Version 1.5  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/465,388  
FILING DATE: June 5, 1995  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA: including application  
PRIOR APPLICATION DATA: described below:  
APPLICATION NUMBER: 08/157,811  
FILING DATE: No. 5753488ember 23, 1993  
APPLICATION NUMBER: 07/887,502  
FILING DATE: May 22, 1992  
APPLICATION NUMBER: 07/704,814  
FILING DATE: May 23, 1991  
APPLICATION NUMBER: 07/763,039  
FILING DATE: September 20, 1991  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 213/300  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 18:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 715 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
FEATURE:  
OTHER INFORMATION:  
US-08-465-388-18

Query Match 37.8%; Score 14; DB 1; Length 715;  
Best Local Similarity 100.0%; Pred. No. 43;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 19 TCTAGCCTGTGCA 32  
DB 325 TCTAGCCTGTGCA 338

RESULT 12  
US-09-252-991A-5999/c  
Sequence 5999, Application US/09252991A  
PATENT No. 6551795  
GENERAL INFORMATION:  
APPLICANT: Marc J. Rubenstein et al.  
TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS  
FILE REFERENCE: 107196.116  
CURRENT APPLICATION NUMBER: US/09/252,991A  
PRIOR FILING DATE: 1999-02-18  
PRIOR APPLICATION NUMBER: US 60/074,788  
PRIOR FILING DATE: 1998-02-18  
PRIOR APPLICATION NUMBER: US 60/094,190  
PRIOR FILING DATE: 1998-07-27  
NUMBER OF SEQ ID NOS: 33142  
SEQ ID NO 5999  
LENGTH: 1374  
TYPE: DNA  
ORGANISM: Pseudomonas aeruginosa  
US-09-252-991A-5999

Query Match 37.8%; Score 14; DB 4; Length 1374;  
Best Local Similarity 100.0%; Pred. No. 43;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 GAGAAGATGCTCA 17  
DB 78 GAGAAGATGCTCA 65

RESULT 13  
US-08-463-115-2  
Sequence 2, Application US/08463115  
PATENT No. 5703221  
GENERAL INFORMATION:  
APPLICANT: WILLIAM JOHN MARTIN  
TITLE OF INVENTION: ISOLATED STEALTH VIRUSES  
NUMBER OF SEQUENCES: 104  
CORRESPONDENCE ADDRESS:  
ADDRESSER: Lyon & Lyon  
STREET: 633 West Fifth Street  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FastSeq Version 1.5  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/463,115  
FILING DATE: June 5, 1995  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA: including application  
PRIOR APPLICATION DATA: described below:  
APPLICATION NUMBER: 08/157,811  
FILING DATE: No. 5703221ember 23, 1993  
APPLICATION NUMBER: 07/887,502  
FILING DATE: May 22, 1992  
APPLICATION NUMBER: 07/704,814  
FILING DATE: May 23, 1991  
APPLICATION NUMBER: 07/763,039  
FILING DATE: September 20, 1991  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 213/301  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 2:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1540 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-463-115-2

Query Match 37.8%; Score 14; DB 1; Length 1540;  
Best Local Similarity 100.0%; Pred. No. 43;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 19 TCTAGCCTGTGCA 32  
DB 997 TCTAGCCTGTGCA 1010

RESULT 14  
US-08-465-388-2  
Sequence 2, Application US/08465388  
PATENT No. 5753488  
GENERAL INFORMATION:  
APPLICANT: WILLIAM JOHN MARTIN  
TITLE OF INVENTION: ISOLATED STEALTH VIRUSES  
TITLE OF INVENTION: AND RELATED VACCINES

NUMBER OF SEQUENCES: 104  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: Lyon & Lyon  
 STREET: 633 West Fifth Street  
 CITY: Los Angeles  
 STATE: California  
 COUNTRY: U.S.A.  
 ZIP: 90071-2066  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
 MEDIUM TYPE: Storage  
 COMPUTER: IBM Compatible  
 OPERATING SYSTEM: IBM P.C. DOS 5.0  
 SOFTWARE: Fastseq Version 1.5  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/08/465,388  
 FILING DATE: June 5, 1995  
 CLASSIFICATION: 435  
 PRIOR APPLICATION DATA:  
 PRIOR APPLICATION DATA: including application  
 PRIOR APPLICATION DATA: described below:  
 APPLICATION NUMBER: 08/157,811  
 FILING DATE: No. 57534888, 23, 1993  
 APPLICATION NUMBER: 07/887,502  
 FILING DATE: May 22, 1992  
 APPLICATION NUMBER: 07/7704,814  
 FILING DATE: May 23, 1991  
 APPLICATION NUMBER: 07/763,039  
 FILING DATE: September 20, 1991  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Maiburg, Richard J.  
 REGISTRATION NUMBER: 32,327  
 REFERENCE/DOCKET NUMBER: 213/300  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: (213) 489-1600  
 TELEFAX: (213) 955-0440  
 TELEX: 67-3510  
 INFORMATION FOR SEQ ID NO: 2:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 1540 base pairs  
 TYPE: nucleic acid  
 STRANDEDNESS: single  
 TOPOLOGY: linear  
 US-08-465-388-2

Query Match 37.8%; Score 14; DB 1; Length 1540;  
 Best Local Similarity 100.0%; Pred. No. 43;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 19 TCTAGCCTGTGCA 32  
 |||||  
 Db 997 TCTAGCCTGTGCA 1010

RESULT 15  
 US-09-252-991A-6306  
 Sequence 6306, Application US/09252991A  
 Patent No. 6531795  
 GENERAL INFORMATION:  
 APPLICANT: Marc J. Rubenfield et al.  
 TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS  
 TITLE OF INVENTION: AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS  
 FILE REFERENCE: 107196.136  
 CURRENT APPLICATION NUMBER: US/09/252,991A  
 CURRENT FILING DATE: 1999-02-18  
 PRIOR APPLICATION NUMBER: US 60/074,788  
 PRIOR FILING DATE: 1998-02-18  
 PRIOR APPLICATION NUMBER: US 60/094,190  
 PRIOR FILING DATE: 1998-07-27  
 NUMBER OF SEQ ID NOS: 33142  
 SEQ ID NO 6306  
 LENGTH: 1899

TYPE: DNA  
 ORGANISM: Pseudomonas aeruginosa  
 US-09-252-991A-6306  
 Query Match 37.8%; Score 14; DB 4; Length 1899;  
 Best Local Similarity 100.0%; Pred. No. 43;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 GAGAGATCGCTCA 17  
 |||||  
 Db 1534 GAGAGATCGCTCA 1547

Search completed: December 23, 2004, 01:33:53  
 Job time: 40.8009 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 22, 2004, 23:36:53 ; Search time 518.67 Seconds

(without alignments)  
397.214 Million cell updates/sec

Title: US-09-898-616A-4

Perfect score: 37

Sequence: 1 atgagaagatcgtcctcgtcgtcgtcgaactaag 37

Scoring table: OLIGO\_NUC  
Gapop 60.0 , Gapext 60.0

Searched: 4105333 seqs, 2784095677 residues

Word size: 0

Total number of hits satisfying chosen parameters: 8210666

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Listing first 45 summaries

Database: Published Applications NA:

1: /cgn2\_6/ptodata/1/pubpna/US07\_PUBCOMB.seq:\*  
2: /cgn2\_6/ptodata/1/pubpna/PCT\_NEW\_PUB.seq:\*  
3: /cgn2\_6/ptodata/1/pubpna/US06\_NEW\_PUB.seq:\*  
4: /cgn2\_6/ptodata/1/pubpna/US06\_PUBCOMB.seq:\*  
5: /cgn2\_6/ptodata/1/pubpna/US07\_NEW\_PUB.seq:\*  
6: /cgn2\_6/ptodata/1/pubpna/PCTUS\_PUBCOMB.seq:\*  
7: /cgn2\_6/ptodata/1/pubpna/US08\_NEW\_PUB.seq:\*  
8: /cgn2\_6/ptodata/1/pubpna/US08\_PUBCOMB.seq:\*  
9: /cgn2\_6/ptodata/1/pubpna/US09\_PUBCOMB.seq:\*  
10: /cgn2\_6/ptodata/1/pubpna/US09B\_PUBCOMB.seq:\*  
11: /cgn2\_6/ptodata/1/pubpna/US09C\_PUBCOMB.seq:\*  
12: /cgn2\_6/ptodata/1/pubpna/US09\_NEW\_PUB.seq:\*  
13: /cgn2\_6/ptodata/1/pubpna/US10\_PUBCOMB.seq:\*  
14: /cgn2\_6/ptodata/1/pubpna/US10B\_PUBCOMB.seq:\*  
15: /cgn2\_6/ptodata/1/pubpna/US10C\_PUBCOMB.seq:\*  
16: /cgn2\_6/ptodata/1/pubpna/US10D\_PUBCOMB.seq:\*  
17: /cgn2\_6/ptodata/1/pubpna/US10E\_PUBCOMB.seq:\*  
18: /cgn2\_6/ptodata/1/pubpna/US10F\_PUBCOMB.seq:\*  
19: /cgn2\_6/ptodata/1/pubpna/US11\_NEW\_PUB.seq:\*  
20: /cgn2\_6/ptodata/1/pubpna/US60\_NEW\_PUB.seq:\*  
21: /cgn2\_6/ptodata/1/pubpna/US60\_PUBCOMB.seq:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	37	100.0	37	9 US-09-861-688-9	Sequence 9, Appl1
2	37	100.0	37	15 US-09-898-616A-4	Sequence 4, Appl1
3	37	100.0	37	15 US-10-187-498A-4	Sequence 4, Appl1
4	37	100.0	37	16 US-10-647-971-8	Sequence 8, Appl1
5	37	100.0	60	9 US-09-861-688-10	Sequence 10, Appl1
6	37	100.0	60	15 US-09-898-616A-5	Sequence 5, Appl1
7	37	100.0	60	15 US-10-187-498A-5	Sequence 5, Appl1
8	37	100.0	60	15 US-10-647-971-9	Sequence 9, Appl1
9	16	43.2	33706	13 US-10-087-192-1750	Sequence 1750, Ap
10	16	43.2	78268	13 US-10-087-192-742	Sequence 742, Ap
11	15	40.5	261	18 US-10-674-124A-5867	Sequence 5867, Ap
12	15	40.5	389	16 US-10-424-599-75149	Sequence 75149, A

## ALIGNMENTS

13	15	40.5	477	10	US-09-918-995-1312	Sequence 1312, Ap
14	15	40.5	574	13	US-10-027-632-131785	Sequence 131785, Ap
15	15	40.5	574	13	US-10-027-632-131786	Sequence 131786, Ap
16	15	40.5	574	13	US-10-027-632-131785	Sequence 131785, Ap
17	15	40.5	574	13	US-10-027-632-131786	Sequence 131786, Ap
18	15	40.5	679	16	US-10-424-599-82560	Sequence 82560, A
19	15	40.5	686	16	US-10-424-599-109965	Sequence 109965, A
20	15	40.5	727	18	US-10-425-115-90184	Sequence 90184, A
21	15	40.5	1043	16	US-09-397-945-82	Sequence 82, Appl1
22	15	40.5	1043	16	US-10-653-599-82	Sequence 82, Appl1
23	15	40.5	1089	15	US-10-195-730-20	Sequence 20, Appl1
24	15	40.5	1089	17	US-10-799-747-20	Sequence 20, Appl1
25	15	40.5	1224	17	US-10-437-963-94846	Sequence 94846, A
26	15	40.5	1436	17	US-10-437-963-46892	Sequence 46892, A
27	15	40.5	1946	17	US-10-767-701-14898	Sequence 14898, A
28	15	40.5	2201	10	US-09-791-254-4	Sequence 4, Appl1
29	15	40.5	2814	17	US-10-437-963-94851	Sequence 94851, A
30	15	40.5	2823	17	US-10-437-963-94806	Sequence 94806, A
31	15	40.5	2835	17	US-10-437-963-94776	Sequence 94776, A
32	15	40.5	2889	17	US-10-437-963-94807	Sequence 94807, A
33	15	40.5	2952	17	US-10-437-963-94766	Sequence 94766, A
34	15	40.5	3366	17	US-10-437-963-94707	Sequence 94707, A
35	15	40.5	3396	17	US-10-437-963-94769	Sequence 94769, A
36	15	40.5	3414	17	US-10-437-963-94802	Sequence 94802, A
37	15	40.5	3501	17	US-10-437-963-94774	Sequence 94774, A
38	15	40.5	3558	17	US-10-437-963-94702	Sequence 94702, A
39	15	40.5	3561	17	US-10-437-963-94836	Sequence 94836, A
40	15	40.5	3591	17	US-10-437-963-94843	Sequence 94843, A
41	15	40.5	3618	17	US-10-437-963-94841	Sequence 94841, A
42	15	40.5	3677	17	US-10-437-963-94855	Sequence 94855, A
43	15	40.5	3687	17	US-10-437-963-47011	Sequence 47011, A
44	15	40.5	3711	17	US-10-437-963-94812	Sequence 94812, A
45	15	40.5	4065	10	US-09-791-254-1	Sequence 1, Appl1

RESULT 1  
US-09-861-688-9  
Sequence 9, Application US/09861688  
Patent No. US20020173460A1  
GENERAL INFORMATION:  
APPLICANT: Clargen, Inc. & NIH  
TITLE OF INVENTION: Use of Recombinant Human Uteroglobulin in Treatment of  
TITLE OF INVENTION: Fibrotic Conditions  
FILE REFERENCE: 116142/2  
CURRENT APPLICATION NUMBER: US/09/861,688  
CURRENT FILING DATE: 2001-05-21  
PRIOR APPLICATION NUMBER: 08/864,357  
PRIOR FILING DATE: 1997-05-28  
NUMBER OF SEQ ID NOS: 22  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 9  
LENGTH: 37  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: primer sequence  
US-09-861-688-9

Query Match 100.0%, Score 37, DB 9, Length 37,  
Best Local Similarity 100.0%, Pred. No. 1.3e-12,  
Matches 37, Conservative 0, Mismatches 0, Indels 0, Gaps 0;

1 ATGAGAAGATCGCTCAGTCTAGCCTGTGCAACTAAG 37  
1 ATGAGAAGATCGCTCAGTCTAGCCTGTGCAACTAAG 37  
DB  
RESULT 2  
US-09-898-616A-4



APPLICANT: Claragen Inc.  
 APPLICANT: Pilon, Richard L.  
 TITLE OF INVENTION: Method for the Production of Purified rhug for the Treatment of  
 TITLE OF INVENTION: Inflammation and Fibrotic Conditions  
 FILE REFERENCE: 116142/00170  
 CURRENT APPLICATION NUMBER: US/09/898, 616A  
 CURRENT FILING DATE: 2002-10-15  
 PRIOR APPLICATION NUMBER: US 08/864,357  
 PRIOR FILING DATE: 1997-05-28  
 NUMBER OF SEQ ID NOS: 10  
 SOFTWARE: PatentIn version 3.1  
 SEQ ID NO 5  
 LENGTH: 60  
 TYPE: DNA  
 ORGANISM: Artificial Sequence  
 FEATURE:  
 OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte  
 OTHER INFORMATION: d sequence maximized for expression in E. coli.  
 NAME/KEY: misc.feature  
 OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte  
 OTHER INFORMATION: d sequence maximized for expression in E. coli.  
 US-09-898-616A-5

Query Match 100.0%; Score 37; DB 10; Length 60;  
 Best Local Similarity 100.0%; Pred. No. 1.3e-12;  
 Matches 37; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATGAGAGAGATCGCTCAGCTAGCCTGTGCACTAG 37  
 DB 37 ATGAGAGAGATCGCTCAGCTAGCCTGTGCACTAG 1

RESULT 7  
 US-10-187-498A-5/c  
 Sequence 5, Application US/10187498A  
 Publication No. US2003020795A1  
 GENERAL INFORMATION:  
 APPLICANT: Claragen Inc.  
 APPLICANT: Pilon, Richard L.  
 APPLICANT: Melch, Richard W.  
 TITLE OF INVENTION: Method for the Production of Purified rhug for the Treatment of  
 TITLE OF INVENTION: Inflammation and Fibrotic Conditions  
 FILE REFERENCE: 116142/00260  
 CURRENT APPLICATION NUMBER: US/10/187,498A  
 CURRENT FILING DATE: 2001-07-02  
 PRIOR APPLICATION NUMBER: US 08/864,357  
 PRIOR FILING DATE: 1997-05-28  
 NUMBER OF SEQ ID NOS: 10  
 SOFTWARE: PatentIn version 3.1  
 SEQ ID NO 5  
 LENGTH: 60  
 TYPE: DNA  
 ORGANISM: Artificial Sequence  
 FEATURE:  
 OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte  
 OTHER INFORMATION: d sequence maximized for expression in E. coli.  
 NAME/KEY: misc.feature  
 OTHER INFORMATION: Original amino acid sequence obtained from cDNA. Current submitte  
 OTHER INFORMATION: d sequence maximized for expression in E. coli.  
 US-10-187-498A-5

Query Match 100.0%; Score 37; DB 15; Length 60;  
 Best Local Similarity 100.0%; Pred. No. 1.3e-12;  
 Matches 37; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATGAGAGAGATCGCTCAGCTAGCCTGTGCACTAG 37  
 DB 37 ATGAGAGAGATCGCTCAGCTAGCCTGTGCACTAG 1

RESULT 8  
 US-10-647-371-9/c  
 Sequence 9, Application US/10647371  
 Publication No. US20040047857A1  
 GENERAL INFORMATION:  
 APPLICANT: Claragen, Inc. & NIH  
 TITLE OF INVENTION: Use of Recombinant Human Uteroglobulin in Treatment of Inflammatory  
 TITLE OF INVENTION: and Fibrotic Conditions  
 FILE REFERENCE: 116142-85  
 CURRENT APPLICATION NUMBER: US/10/647,371  
 CURRENT FILING DATE: 2003-08-25  
 PRIOR APPLICATION NUMBER: 09/549,926  
 PRIOR FILING DATE: 2000-04-14  
 NUMBER OF SEQ ID NOS: 12  
 SOFTWARE: PatentIn version 3.2  
 SEQ ID NO 9  
 LENGTH: 60  
 TYPE: DNA  
 ORGANISM: Artificial  
 FEATURE:  
 OTHER INFORMATION: Description of Artificial Sequence: primer sequence  
 US-10-647-371-9

Query Match 100.0%; Score 37; DB 16; Length 60;  
 Best Local Similarity 100.0%; Pred. No. 1.3e-12;  
 Matches 37; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATGAGAGAGATCGCTCAGCTAGCCTGTGCACTAG 37  
 DB 37 ATGAGAGAGATCGCTCAGCTAGCCTGTGCACTAG 1

RESULT 9  
 US-10-087-192-1750  
 Sequence 1750, Application US/10087192  
 Publication No. US20020182586A1  
 GENERAL INFORMATION:  
 APPLICANT: Morris, David W.  
 APPLICANT: Engelhard, Eric K.  
 TITLE OF INVENTION: NOVEL COMPOSITIONS AND METHODS FOR  
 TITLE OF INVENTION: CANCER  
 FILE REFERENCE: 528452000122  
 CURRENT APPLICATION NUMBER: US/10/087,192  
 CURRENT FILING DATE: 2002-03-01  
 PRIOR APPLICATION NUMBER: US 09/747,377  
 PRIOR FILING DATE: 2000-12-22  
 PRIOR APPLICATION NUMBER: US 09/798,586  
 PRIOR FILING DATE: 2001-03-02  
 NUMBER OF SEQ ID NOS: 2059  
 SOFTWARE: FastSeq for Windows Version 4.0  
 SEQ ID NO 1750  
 LENGTH: 32706  
 TYPE: DNA  
 ORGANISM: Homo sapiens  
 US-10-087-192-1750

Query Match 43.2%; Score 16; DB 13; Length 32706;  
 Best Local Similarity 100.0%; Pred. No. 7.4; Indels 0; Gaps 0;  
 Matches 16; Conservative 0; Mismatches 0;

QY 19 TCTAGCCTGTGCACT 34  
 DB 7293 TCTAGCCTGTGCACT 7308

RESULT 10  
 US-10-087-192-742/c  
 Sequence 742, Application US/10087192  
 Publication No. US20020182586A1  
 GENERAL INFORMATION:  
 APPLICANT: Morris, David W.  
 APPLICANT: Engelhard, Eric K.  
 TITLE OF INVENTION: NOVEL COMPOSITIONS AND METHODS FOR

TITLE OF INVENTION: CANCER  
FILE REFERENCE: 529452000122  
CURRENT APPLICATION NUMBER: US/10/087,132  
CURRENT FILING DATE: 2002-03-01  
PRIOR APPLICATION NUMBER: US 09/747,377  
PRIOR FILING DATE: 2000-12-22  
PRIOR APPLICATION NUMBER: US 09/798,586  
PRIOR FILING DATE: 2001-03-02  
NUMBER OF SEQ ID NOS: 2059  
SOFTWARE: FastSeq for Windows Version 4.0  
SEQ ID NO 742  
LENGTH: 78268  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-10-087-192-742

Query Match 43.2%; Score 16; DB 13; Length 78268;  
Best Local Similarity 100.0%; Pred. No. 7.2;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 GCTGAGTCTGCTGT 28  
DB 29223 GCTGAGTCTGCTGT 29208

RESULT 11  
US-10-674-124A-5867/C  
Sequence 5867, Application US/10674124A  
Publication No. US2004019797A1  
GENERAL INFORMATION:  
APPLICANT: INOKO, Hidetoshi  
APPLICANT: TAMURA, Gen  
TITLE OF INVENTION: GENE MAPPING METHOD USING MICROSATELLITE  
FILE REFERENCE: ORIN-003CIP  
CURRENT APPLICATION NUMBER: US/10/674,124A  
CURRENT FILING DATE: 2003-09-26  
PRIOR APPLICATION NUMBER: 10/257,511  
PRIOR FILING DATE: 2003-03-07  
PRIOR APPLICATION NUMBER: PCT/JP00/07621  
PRIOR FILING DATE: 2000-10-30  
PRIOR APPLICATION NUMBER: JP2000-112699  
PRIOR FILING DATE: 2000-04-13  
PRIOR APPLICATION NUMBER: JP2002-327516  
PRIOR FILING DATE: 2002-09-28  
PRIOR APPLICATION NUMBER: JP2002-383869  
PRIOR FILING DATE: 2002-12-09  
NUMBER OF SEQ ID NOS: 27110  
SEQ ID NO 5867  
LENGTH: 261  
TYPE: DNA  
ORGANISM: Homo sapiens  
FEATURE:  
OTHER INFORMATION: AC072028.5\_149909  
FEATURE:  
OTHER INFORMATION: Located on chromosome 3  
FEATURE:  
OTHER INFORMATION: Distance between a terminus base of telomere on  
OTHER INFORMATION: chromosomal short arm and 5'-terminus of this base  
FEATURE:  
OTHER INFORMATION: sequence : 147898939  
FEATURE:  
OTHER INFORMATION: Distance between 3'-terminus of neighbour sequence of  
OTHER INFORMATION: sequence listing upward to telomere on chromosomal short arm and  
OTHER INFORMATION: 5'-terminus of this base sequence : 110675  
US-10-674-124A-5867

Query Match 40.5%; Score 15; DB 18; Length 261;  
Best Local Similarity 100.0%; Pred. No. 36;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 19 TCTAGCCTGTGCAAC 33  
DB 240 TCTAGCCTGTGCAAC 226

RESULT 12  
US-10-424-599-75149/C  
Sequence 75149, Application US/10424599  
Publication No. US20040031072A1  
GENERAL INFORMATION:  
APPLICANT: La Rosa Thomas J  
APPLICANT: Kovalic David K  
APPLICANT: Zhou Yihua  
APPLICANT: Cao Yongwei  
TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With  
TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement  
FILE REFERENCE: 38-21(53223)B  
CURRENT APPLICATION NUMBER: US/10/424,599  
CURRENT FILING DATE: 2003-04-28  
NUMBER OF SEQ ID NOS: 285684  
SEQ ID NO 75149  
LENGTH: 389  
TYPE: DNA  
ORGANISM: Glycine max  
FEATURE:  
OTHER INFORMATION: Clone ID: PAT\_MRT3847\_38873C.1  
US-10-424-599-75149

Query Match 40.5%; Score 15; DB 16; Length 389;  
Best Local Similarity 100.0%; Pred. No. 35;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 15 TTAGCTTAGCTGTG 29  
DB 40 TTAGCTTAGCTGTG 26

RESULT 13  
US-09-918-995-1312  
Sequence 1312, Application US/09918995  
Publication No. US20030073623A1  
GENERAL INFORMATION:  
APPLICANT: Hyseq, Inc.  
TITLE OF INVENTION: NOVEL NUCLEIC ACID SEQUENCES OBTAINED  
TITLE OF INVENTION: FROM VARIOUS CDNA LIBRARIES  
FILE REFERENCE: 20411-756  
CURRENT APPLICATION NUMBER: US/09/918,995  
CURRENT FILING DATE: 2001-07-30  
PRIOR APPLICATION NUMBER: US/09/235,076  
PRIOR FILING DATE: 1999-01-20  
NUMBER OF SEQ ID NOS: 38054  
SOFTWARE: FastSeq for Windows Version 3.0  
SEQ ID NO 1312  
LENGTH: 477  
TYPE: DNA  
ORGANISM: Homo sapiens  
FEATURE:  
NAME/KEY: misc\_feature  
LOCATION: (1)...(477)  
OTHER INFORMATION: n = A,T,C or G  
US-09-918-995-1312

Query Match 40.5%; Score 15; DB 10; Length 477;  
Best Local Similarity 100.0%; Pred. No. 35;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 TGGAGAGATCGCTC 16  
DB 305 TGGAGAGATCGCTC 319

RESULT 14  
US-10-027-632-131785/C  
Sequence 131785, Application US/10027632  
Publication No. US20020198371A1  
GENERAL INFORMATION:



```

APPLICANT: Wang, David G.
TITLE OF INVENTION: Identification and Mapping of Single Nucleotide
FILE REFERENCE: 108827.129
CURRENT APPLICATION NUMBER: US/10/027,632
PRIOR FILING DATE: 2002-04-30
PRIOR APPLICATION NUMBER: US 60/218,006
PRIOR FILING DATE: 2000-07-12
PRIOR APPLICATION NUMBER: US 60/198,676
PRIOR FILING DATE: 2000-04-20
PRIOR APPLICATION NUMBER: US 60/193,483
PRIOR FILING DATE: 2000-03-29
PRIOR APPLICATION NUMBER: US 60/185,218
PRIOR FILING DATE: 2000-02-24
PRIOR APPLICATION NUMBER: US 60/167,363
PRIOR FILING DATE: 1999-11-23
PRIOR APPLICATION NUMBER: US 60/156,358
PRIOR FILING DATE: 1999-09-28
PRIOR APPLICATION NUMBER: US 60/146,002
PRIOR FILING DATE: 1999-08-09
NUMBER OF SEQ ID NOS: 325720
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO: 131785
LENGTH: 574
TYPE: DNA
ORGANISM: Human
US-10-027-632-131785

```

```

Query Match          40.5%; Score 15; DB 13; Length 574;
Best Local Similarity 100.0%; Pred. No. 35;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      18 GTCTAGCCTGTGCAA 32
         |||||
DB      40 GTCTAGCCTGTGCAA 26

```

```

RESULT 15
US-10-027-632-131786/c
Sequence 131786, Application US/10027632
Publication No. US20020198371A1
GENERAL INFORMATION:
APPLICANT: Wang, David G.
TITLE OF INVENTION: Identification and Mapping of Single Nucleotide
FILE REFERENCE: 108827.129
CURRENT APPLICATION NUMBER: US/10/027,632
PRIOR FILING DATE: 2002-04-30
PRIOR APPLICATION NUMBER: US 60/218,006
PRIOR FILING DATE: 2000-07-12
PRIOR APPLICATION NUMBER: US 60/198,676
PRIOR FILING DATE: 2000-04-20
PRIOR APPLICATION NUMBER: US 60/193,483
PRIOR FILING DATE: 2000-03-29
PRIOR APPLICATION NUMBER: US 60/185,218
PRIOR FILING DATE: 2000-02-24
PRIOR APPLICATION NUMBER: US 60/167,363
PRIOR FILING DATE: 1999-11-23
PRIOR APPLICATION NUMBER: US 60/156,358
PRIOR FILING DATE: 1999-09-28
PRIOR APPLICATION NUMBER: US 60/146,002
PRIOR FILING DATE: 1999-08-09
NUMBER OF SEQ ID NOS: 325720
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO: 131786
LENGTH: 574
TYPE: DNA
ORGANISM: Human
US-10-027-632-131786

```

```

Query Match          40.5%; Score 15; DB 13; Length 574;
Best Local Similarity 100.0%; Pred. No. 35;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      18 GTCTAGCCTGTGCAA 32
         |||||
DB      40 GTCTAGCCTGTGCAA 26

```

```

Search completed: December 23, 2004, 05:19:30
Job time : 520.67 secs

```

**This Page Blank (uspio)**